
<html lang="en"     class="pb-page"  data-request-id="ccefc872-6aa9-496e-a240-69dec7bd1087"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2019.62.issue-4;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.8b00990"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway" /></meta><meta name="dc.Creator" content="Tianyu  Wang" /></meta><meta name="dc.Creator" content="Xiaoxing  Wu" /></meta><meta name="dc.Creator" content="Changying  Guo" /></meta><meta name="dc.Creator" content="Kuojun  Zhang" /></meta><meta name="dc.Creator" content="Jinyi  Xu" /></meta><meta name="dc.Creator" content="Zheng  Li" /></meta><meta name="dc.Creator" content="Sheng  Jiang" /></meta><meta name="dc.Description" content="The clinical success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy. Currently, most drugs targeting this pathway are monoclonal antibodies. Sm..." /></meta><meta name="Description" content="The clinical success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy. Currently, most drugs targeting this pathway are monoclonal antibodies. Sm..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 24, 2018" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00990" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00990" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00990" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00990" /></link>
        
    
    

<title>Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00990" /></meta><meta property="og:title" content="Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0019.jpeg" /></meta><meta property="og:description" content="The clinical success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy. Currently, most drugs targeting this pathway are monoclonal antibodies. Small-molecule inhibitors as the alternative to monoclonal antibodies are expected to overcome the disadvantages of mAbs which include production difficulties and their long half-life. Recently, progress has been reported on anti-PD-1/PD-L1 small-molecule inhibitors. In this paper, we review the development of inhibitors targeting the PD-1/PD-L1 pathway, focusing mainly on peptide-based and nonpeptidic small-molecule inhibitors. The structures and the preclinical and clinical studies of several peptide-based small-molecule candidate compounds in clinical trials are discussed. We also illustrate the design strategies underlying reported nonpeptidic small-molecule inhibitors and provide insight into possible future exploration. Development of small-molecule drugs for anti-PD-1/PD-L1 activity with specific cancer applications is a promising and challenging prospect." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00990"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00990">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00990&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00990&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00990&amp;href=/doi/10.1021/acs.jmedchem.8b00990" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1715-1730</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00686" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b01092" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Tianyu Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tianyu Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tianyu++Wang">Tianyu Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoxing Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoxing Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoxing++Wu">Xiaoxing Wu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Changying Guo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Changying Guo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Changying++Guo">Changying Guo</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kuojun Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kuojun Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kuojun++Zhang">Kuojun Zhang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jinyi Xu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinyi Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinyi++Xu">Jinyi Xu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1961-0402" title="Orcid link">http://orcid.org/0000-0002-1961-0402</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zheng Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zheng Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Nanomedicine, Center for Bioenergetics, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zheng++Li">Zheng Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Sheng Jiang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sheng Jiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#f3999a929d94809bcab3949e929a9fdd909c9e"><span class="__cf_email__" data-cfemail="fa90939b949d8992c3ba9d979b9396d4999597">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sheng++Jiang">Sheng Jiang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4550-5024" title="Orcid link">http://orcid.org/0000-0002-4550-5024</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00990&amp;href=/doi/10.1021%2Facs.jmedchem.8b00990" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1715–1730</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 24, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>21 June 2018</li><li><span class="item_label"><b>Published</b> online</span>24 September 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 February 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00990" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00990</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1715%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTianyu%2BWang%252C%2BXiaoxing%2BWu%252C%2BChangying%2BGuo%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D4%26contentID%3Dacs.jmedchem.8b00990%26title%3DDevelopment%2Bof%2BInhibitors%2Bof%2Bthe%2BProgrammed%2BCell%2BDeath-1%252FProgrammed%2BCell%2BDeath-Ligand%2B1%2BSignaling%2BPathway%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1730%26publicationDate%3DFebruary%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00990"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6289</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">38</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00990" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tianyu&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Xiaoxing&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Changying&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Kuojun&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Jinyi&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Zheng&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Sheng&quot;,&quot;last_name&quot;:&quot;Jiang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;1715-1730&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00990&quot;},&quot;abstract&quot;:&quot;The clinical success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy. Currently, most drugs targeting this pathway are monoclonal antibodies. Small-molecule inhibitors as the alternative to monoclonal antibodies are expected to overcome the disadvantages of mAbs which include production difficulties and their long half-life. Recently, progress has been reported on anti-PD-1/PD-L1 small-molecule inhibitors. In this paper, we review the development of inhibitors targeting the PD-1/PD-L1 pathway, focusing mainly on peptide-based and nonpeptidic small-molecule inhibitors. The structures and the preclinical and clinical studies of several peptide-based small-molecule candidate compounds in clinical trials are discussed. We also illustrate the design strategies underlying reported nonpeptidic small-molecule inhibitors and provide insight into possible future exploration. Development of small-molecule drugs for anti-PD-1/PD-L1 activity with specific cancer applica&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00990&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00990" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00990&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00990" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00990&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00990" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00990&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00990&amp;href=/doi/10.1021/acs.jmedchem.8b00990" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00990" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00990" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00990%26sid%3Dliteratum%253Aachs%26pmid%3D30247903%26genre%3Darticle%26aulast%3DWang%26date%3D2019%26atitle%3DDevelopment%2Bof%2BInhibitors%2Bof%2Bthe%2BProgrammed%2BCell%2BDeath-1%252FProgrammed%2BCell%2BDeath-Ligand%2B1%2BSignaling%2BPathway%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D4%26spage%3D1715%26epage%3D1730%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/jmcmar.2019.62.issue-4/20190228/jmcmar.2019.62.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The clinical success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy. Currently, most drugs targeting this pathway are monoclonal antibodies. Small-molecule inhibitors as the alternative to monoclonal antibodies are expected to overcome the disadvantages of mAbs which include production difficulties and their long half-life. Recently, progress has been reported on anti-PD-1/PD-L1 small-molecule inhibitors. In this paper, we review the development of inhibitors targeting the PD-1/PD-L1 pathway, focusing mainly on peptide-based and nonpeptidic small-molecule inhibitors. The structures and the preclinical and clinical studies of several peptide-based small-molecule candidate compounds in clinical trials are discussed. We also illustrate the design strategies underlying reported nonpeptidic small-molecule inhibitors and provide insight into possible future exploration. Development of small-molecule drugs for anti-PD-1/PD-L1 activity with specific cancer applications is a promising and challenging prospect.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44682" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44682" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer immunotherapy, remanipulating the immune system for therapeutic treatment of cancer, has been pursued for over 100 years. In the early 20th century, Ehrlich first developed a chemical theory to explain the formation of antitoxins, or antibodies, which he described as “magic bullets” to fight the toxins released by the pathogens.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In 1950s, Burnet and Thomas introduced the concept of immunological surveillance with which the immune system can recognize and destroy somatic cells transformed by spontaneous mutations within the body and which provided a theoretical basis for cancer immunotherapy.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> The T-cell growth factor interleukin 2 (IL-2) was successfully identified in 1976, and patients with metastatic renal cancer and melanoma treated with high-dose IL-2 achieved effective cancer regression. The landmark discovery and trial of IL-2 demonstrated that immune manipulation can lead to cancer remission and contributed to the application of basic science knowledge of T cell regulation into the development of new cancer immunotherapy.<a onclick="showRef(event, 'ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6">(4−6)</a> With recent advances in immuno-oncology, from bench to bedside, many different types of cancer immunotherapy have been explored. These include monoclonal antibodies (mAbs),<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> cancer vaccines,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> adoptive T-cell therapy,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and immune checkpoint blockade.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13">(10−13)</a> Following the success of proof-of-concept clinical trials, cancer immunotherapy was highlighted as the breakthrough of the year in 2013 by the journal <i>Science</i>.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">The recent clinical success of immune checkpoint blockade in cancer patients has made it an important trend in the development of immunotherapeutic drugs. Under normal physiological conditions, immune checkpoints offer inhibitory signals to cause anergy or exhaustion in T cells for the maintenance of self-tolerance and protection of peripheral tissues from damage during immune responses.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> However, tumor cells can hijack certain immune-checkpoint pathways and evade immune surveillance by suppressing activation of the immune cells. Immune-checkpoint pathways are generally initiated by ligand–receptor interactions, and consequently, the blockade of immune checkpoints by specific inhibitors can reactivate the body’s antitumor immunity.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Cytotoxic T lymphocyte antigen-4 (CTLA-4) is the first immune-checkpoint receptor to have been clinically targeted, and this resulted in the approval in 2011 by the U.S. Food and Drug Administration (FDA) of ipilimumab, a mAb targeting CTLA-4, for the treatment of metastatic melanoma.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Encouraged by the approval of ipilimumab, other immune-checkpoint inhibitors are under active study. Among them, the blocker of programmed cell death-1 (PD-1, also known as CD279) and its ligands<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> exhibits a promising antitumor efficacy in clinical trials. Several anti-PD-1 mAb drugs, such as nivolumab and pembrolizumab, have been approved for the treatment of melanoma,<a onclick="showRef(event, 'ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22 ref23">(19−23)</a> and atezolizumab and durvalumab have been approved for the treatment of urothelial carcinoma.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Compared to CTLA-4, inhibition of PD-1 pathway has chronically stimulated state; therefore, anti-PD-1 drugs own increased antitumor activity and relatively favorable toxicity profile.<a onclick="showRef(event, 'ref22 ref26'); return false;" href="javascript:void(0);" class="ref ref22 ref26">(22,26)</a> Additionally, various promising immune checkpoints such as T cell membrane protein 3 (TIM3, also known as HAVcr2) and lymphocyte activation gene 3 (LAG3, also known as CD223) have been reported as potential targets with which to enhance antitumor immunity.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a></div><div class="NLM_p last">Currently the development of mAbs for the blockade of PD-1/PD-L1 has achieved great progress and relevant research has already been reviewed extensively and intensively.<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29−31)</a> Compared to mAbs, small-molecule drugs exhibit significant advantages such as the possibility of oral administration, stability, membrane permeability, and nonimmunogenicity. For this reason, the field of small-molecule inhibitors of immune checkpoint has attracted much research and many discussions, especially PD-1/PD-L1.<a onclick="showRef(event, 'ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34 ref35">(32−35)</a> We have been conducting research into the development of inhibitors targeting the PD-1/PD-L1 pathway, especially the peptide-based and nonpeptidic small-molecule inhibitors, as alternatives to mAbs. We are focused on small-molecule inhibitors and their design strategies to provide an insight into further exploration of anti-PD-1/PD-L1 small-molecule drugs for cancer immunotherapy. This paper is a review of the relevant research in this area.</div></div><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">An Overview of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43562" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43562" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As the member of an immunoglobulin (Ig) superfamily, the protein PD-1 is a homologue of CD28 consisting of 288 amino acids containing a single Ig-like variable domain and a cytoplasmic region. It has 21–33% sequence identity with CTLA-4 and CD28.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a> Structural and biophysical data show that, in contrast to CTLA-4 and other Ig family members that are disulfide-linked homodimers,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> PD-1 is monomeric both in solution and on the cell surface. PD-1 possesses an ectodomain with multiple loop structures and strands between the loops as shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Crystal structure of the extracellular domain (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2M2D">2M2D</a>) and structure-based sequence of human PD-1 (hPD-1).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As an immune-checkpoint receptor, PD-1 is expressed on a subset of thymocytes and upregulated on the surface of activated T cells, B cells, natural killer (NK) T cells, monocytes, and dendritic cells (DCs).<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> The functional role of PD-1 was initially determined to be induction of apoptosis. Because PD-1-deficient mice develop autoimmune diseases, it was thought that PD-1 might be crucial for the maintenance of immunologic homeostasis which maintains peripheral tolerance and prevents autoimmunity.<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> PD-1 expression is also considered as a marker for highly reactive tumor-specific T cells, and anti-PD-1 therapy has shown that the therapeutic responses were associated with PD-1 presenting on the surface of cytotoxic T cells in the tumor microenvironment.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><div class="NLM_p">Association of PD-1 with its ligands PD-L1 (also known as B7-H1 and CD274) and PD-L2 (also known as B7-DC and CD273) triggers an inhibitory pathway. As the member of the B7 family, PD-L1 is expressed in nonlymphoid organs and upregulated in response to activated T cells, antigen-presenting cells (APCs), and nonhematopoietic cells.<a onclick="showRef(event, 'ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46">(44−46)</a> The expression and function of PD-L2 are similar to those of PD-L1, and PD-L2 shares 34% identity with PD-L1. Both ligands have short cytoplasmic tails with an uncharacterized motif for signal transduction, suggesting that both ligands do not transduce any signal upon interaction with PD-1.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Engagement of PD-1 by PD-L1 impedes TCR signaling and CD28 co-stimulation and inhibits the activation of human T cells by anti-CD3.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> T cell receptor (TCR)-mediated proliferation and cytokine production by CD4 T cells are inhibited by engagement of PD-1 by PD-L2.<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48,49)</a> The interaction of PD-L1/PD-1 is similar to PD-L2/PD-1 with the affinities of <i>K</i><sub>D</sub> values as 10.4 and 11.3 nM, respectively, but striking differences were observed at the level of the association and dissociation characteristics.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a></div><div class="NLM_p">The aberrant expression of PD-L1 and PD-L2 in tumor cells impairs body’s antitumor immunity, resulting in the immune evasion of the tumor cells.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Many types of tumor cells and hematopoietic cells within the tumor microenvironment can upregulate the expression of PD-L1 by activating oncogenic pathways such as the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathway,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> the nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) pathway<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> (innate immune resistance) or in response to interferons (IFN), mostly IFN-γ, in the tumor microenvironment (adaptive immune resistance).<a onclick="showRef(event, 'ref10 ref55'); return false;" href="javascript:void(0);" class="ref ref10 ref55">(10,55)</a> In addition to its binding to PD-1, PD-L1 also inhibits T cell activation and cytokine production through its interaction with additional receptors such as B7-1.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> These findings suggest that the PD-1/PD-L1 pathway could be an ideal target with which to restore antitumor immunity and inhibitory approaches for cancer therapy (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref57 ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref57 ref58 ref59">(57−59)</a> On the other hand, the role of PD-L2 in tumor immunity remains unclear. Reportedly, PD-L2, but not PD-L1, elicits direct activating effects on dendritic cells, and this is thought to enhance immune responses. Because tumor cells barely upregulate the expression of PD-L2, few studies have focused on inhibitors targeting PD-L2 to block its interaction with PD-1. However, a study from the Merck Inc. showed that PD-L2 expression is independently associated with improved clinical response to the anti-PD-1/PD-L1 antibody pembrolizumab through high objective response rates and longer progression-free survival in patients with head and neck squamous cell carcinoma.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> The relevance to anti-PD-1 therapy suggests PD-L2 could provide clinical benefits in these patients.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Mechanism of the inhibition of the interaction between PD-1 and PD-L for cancer therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The structure of the full human PD-1/PD-L1 complex has been reported<a onclick="showRef(event, 'ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref61 ref62 ref63">(61−63)</a> and shows that the receptor–ligand interaction is mediated by residues of C’CFG strands within PD-1 and PD-L1. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, the interactions involve nonpolar residues (Val64, Ile126, Leu128, Ala132, Ile134) in the front sheet of PD-1 and those of the front sheet of PD-L1 (<sub>L</sub>Ile54, <sub>L</sub>Tyr56, <sub>L</sub>Met115, <sub>L</sub>Ala121, <sub>L</sub>Tyr123). This hydrophobic region is exposed to solvent on the antigen-binding site. Moreover, three major hot spots on the PD-L1 surface have been identified by Holak et al. (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B).<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> The first is a pocket composed of <sub>L</sub>Glu58, <sub>L</sub>Arg113, <sub>L</sub>Tyr123, which can accommodate an aromatic ring. The second hot spot is located nearby <sub>L</sub>Met115 and <sub>L</sub>Ala121 which can be filled by a branched aliphatic moiety. The third is an extended groove between <sub>L</sub>Asp122 and <sub>L</sub>Asp26 in which multiple hydrogen bonds could be anchored.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Crystal structure of the complex of hPD-1 (green ribbon)/hPD-L1 (blue ribbon) complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZQK">4ZQK</a>). (B) Three main hot spots (red circle) on the PD-L1 surface (gray). The first spot comprises Glu58, Arg113, and Tyr123. The second is formed by Met115 and Ala121. The third spot is composed of a shallow groove between Asp122 and Asp26. Residues interacted with PD-1 of PD-L1 are colored blue (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C3T">5C3T</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Inhibitors Targeting the PD-1/PD-L1 Pathway</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54766" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54766" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> mAbs Targeting the PD-1/PD-L1 Pathway</h3><div class="NLM_p">Since the clinical approval of rituximab and trastuzumab, antibody-based immunotherapy has become a significant field of research.<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a> Recently, promising clinical results of mAbs targeting the immune-checkpoint pathway including the PD-1/PD-L1 pathway have been obtained.<a onclick="showRef(event, 'ref6 ref30 ref35 ref66 ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref6 ref30 ref35 ref66 ref67 ref68">(6,30,35,66−68)</a><a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> lists the mAbs launched and in promising clinical trials targeting the PD-1/PD-L1 pathway. As described previously, both anti-PD-1 and anti-PD-L1 mAbs have shown promising antitumor activity in the treatment of melanoma, non-small-cell lung cancer (NSCLC), and urothelial carcinoma (UC).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. mAbs Currently Launched and in Promising Clinical Trials Targeting the PD-1/PD-L1 Pathway</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">generic name or code name</th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">organization</th><th class="colsep0 rowsep0" align="center">clinical indications<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">highest phase</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nivolumab</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Bristol-Myers Squibb/Ono</td><td class="colsep0 rowsep0" align="left">Unresectable melanoma (2014)</td><td class="colsep0 rowsep0" align="left">Launched 2014</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Squamous and nonsquamous NSCLC, advanced RCC (2015)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Classical Hodgkin’s lymphoma, renal cell carcinoma</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Recurrent or metastatic head and neck cancer (2016)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Unresectable or metastatic UC, HCC, metastatic CRC (2017)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pembrolizumab</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Merck</td><td class="colsep0 rowsep0" align="left">Unresectable or metastatic melanoma (2014)</td><td class="colsep0 rowsep0" align="left">Launched 2014</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NSCLC (2015)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Squamous head and neck cancer, metastatic NSCLC (2016)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CRC, classical Hodgkin’s lymphoma, gastric or GEJ adenocarcinoma (2017)</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">atezolizumab</td><td class="colsep0 rowsep0" align="left">PD-L1</td><td class="colsep0 rowsep0" align="left">Roche</td><td class="colsep0 rowsep0" align="left">Locally advanced or metastatic UC and NSCLC</td><td class="colsep0 rowsep0" align="left">Launched 2016</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">durvalumab</td><td class="colsep0 rowsep0" align="left">PD-L1</td><td class="colsep0 rowsep0" align="left">AstraZeneca</td><td class="colsep0 rowsep0" align="left">Locally advanced or metastatic UC (2017) and NSCLC (2018)</td><td class="colsep0 rowsep0" align="left">Launched 2017</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">avelumab</td><td class="colsep0 rowsep0" align="left">PD-L1</td><td class="colsep0 rowsep0" align="left">Merck/Pfizer</td><td class="colsep0 rowsep0" align="left">Metastatic Merkel cell carcinoma and locally advanced or metastatic UC</td><td class="colsep0 rowsep0" align="left">Launched 2017</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cemiplimab</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Sanofi/Regeneron</td><td class="colsep0 rowsep0" align="left">Metastatic CSCC, NSCLC, and second-line cervical cancer</td><td class="colsep0 rowsep0" align="left">Preregistered</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">camrelizumab</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Jiangsu Hengrui</td><td class="colsep0 rowsep0" align="left">Nonsquamous NSCLC and squamous esophageal carcinoma</td><td class="colsep0 rowsep0" align="left">Phase III</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IBI-308</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Innovent Biologics</td><td class="colsep0 rowsep0" align="left">NSCLC</td><td class="colsep0 rowsep0" align="left">Phase III</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tislelizumab</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">BeiGene</td><td class="colsep0 rowsep0" align="left">Unresectable HCC</td><td class="colsep0 rowsep0" align="left">Phase III</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">spartalizumab</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">Advanced melanoma</td><td class="colsep0 rowsep0" align="left">Phase III</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JNJ-63723283</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Janssen Research & Development</td><td class="colsep0 rowsep0" align="left">UC</td><td class="colsep0 rowsep0" align="left">Phase II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MGA-012</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Incyte/MacroGenics</td><td class="colsep0 rowsep0" align="left">Metastatic CRC, metastatic Merkel cell carcinoma</td><td class="colsep0 rowsep0" align="left">Phase II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AGEN-2034</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Agenus</td><td class="colsep0 rowsep0" align="left">Cervical cancer</td><td class="colsep0 rowsep0" align="left">Phase II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">M-7824</td><td class="colsep0 rowsep0" align="left">PD-L1/TGF-β</td><td class="colsep0 rowsep0" align="left">Merck</td><td class="colsep0 rowsep0" align="left">Advanced solid tumors</td><td class="colsep0 rowsep0" align="left">Phase II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CX-072</td><td class="colsep0 rowsep0" align="left">PD-L1</td><td class="colsep0 rowsep0" align="left">CytomX Therapeutics</td><td class="colsep0 rowsep0" align="left">Solid tumors, lymphomas</td><td class="colsep0 rowsep0" align="left">Phase II</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Sym-021</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Symphogen</td><td class="colsep0 rowsep0" align="left">Solid tumors, lymphomas</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LZM-009</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Livzon</td><td class="colsep0 rowsep0" align="left">Solid tumors</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BI-754091</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Boehringer Ingelheim</td><td class="colsep0 rowsep0" align="left">Solid tumors</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">XmAb-20717</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Xencor</td><td class="colsep0 rowsep0" align="left">Solid tumors</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PF-06801591</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">Solid tumors, lymphomas</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MGD-013</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">MacroGenics</td><td class="colsep0 rowsep0" align="left">Solid tumors, hematologic neoplasms</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TSR-042</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Tesaro/AnaptysBio</td><td class="colsep0 rowsep0" align="left">Solid tumors</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AMP-224</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">GlaxoSmithKline/MedImmune</td><td class="colsep0 rowsep0" align="left">CRC</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MSB-2311</td><td class="colsep0 rowsep0" align="left">PD-L1</td><td class="colsep0 rowsep0" align="left">MabSpace Biosciences</td><td class="colsep0 rowsep0" align="left">Solid tumors</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FS-118</td><td class="colsep0 rowsep0" align="left">PD-L1/LAG-3</td><td class="colsep0 rowsep0" align="left">F-star/Merck</td><td class="colsep0 rowsep0" align="left">Advanced cancer</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FAZ-053</td><td class="colsep0 rowsep0" align="left">PD-L1</td><td class="colsep0 rowsep0" align="left">Novartis</td><td class="colsep0 rowsep0" align="left">Advanced cancer</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KN-035</td><td class="colsep0 rowsep0" align="left">PD-L1</td><td class="colsep0 rowsep0" align="left">Suzhou Alphamab</td><td class="colsep0 rowsep0" align="left">Solid tumors</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LY-3300054</td><td class="colsep0 rowsep0" align="left">PD-L1</td><td class="colsep0 rowsep0" align="left">Lilly</td><td class="colsep0 rowsep0" align="left">Solid tumors</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">RCC, renal cell carcinoma; HCC, hepatocellular carcinoma; CRC, colorectal cancer; GEJ, gastroesophageal junction; CSCC, cutaneous squamous cell carcinoma.</p></div></div></div><div class="NLM_p last">So far, the available inhibitors of PD-1/PD-L1 pathway in clinical development are all mAbs. However, due to disadvantages such as their long half-life and unchecked immune response, mAbs targeting PD-1/PD-L1 pathway can lead to immune-related adverse events. These events can cause damage to normal organ systems and tissues and typically involve the skin, gastrointestinal, hepatic, pulmonary, and endocrine systems.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Moreover, lack of oral bioavailability, emergence of tumor resistance, and difficult and expensive production of the mAbs also limit their current clinical application.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The search for non-mAbs and low-molecular-weight inhibitors of PD-1/PD-L1 has thus become an active field. However, developing small-molecule protein–protein interaction (PPI) inhibitors is difficult due to the lack of small-molecule starting point and well-defined binding pockets.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Nevertheless, various small-molecule PPI inhibitors that have reached clinical development show that certain classes of PPI are amenable to small-molecule inhibition.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> And small-molecule inhibitors of PD-1/PD-L1 pathway have achieved substantial progress during the past few years.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Peptide-Based Inhibitors Targeting the PD-1/PD-L1 Pathway</h3><div class="NLM_p">Liu et al. from Tsinghua University developed the first proteolysis-resistant <span class="smallcaps smallerCapital">d</span>-peptide anti-PD-L1 antagonists.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> In their initial study, this group obtained a PD-L1 affinity peptide based on the technology of phase display, which used the ectodomain of PD-L1 expressed by <i>E. coli</i> for screening by a 12-mer peptide library displayed on M13 phage. The obtained peptide, FPNWSLRPMNQM, administered by hypodermic injection, has good affinity for PD-L1 and antitumor activity.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> However, due to its rapid degradation by proteolytic enzymes in the blood plasma, it failed to show any activity when administered by intraperitoneal injection. In order to overcome the stability problem and using the <span class="smallcaps smallerCapital">d</span>-version of the IgV domain of PD-L1 as bait, the optimized compound <sup>D</sup>PPA-1 which binds to PD-L1 with an affinity of 0.51 μM was investigated (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Flow cytometry experiments demonstrated that <sup>D</sup>PPA-1 can block PD-1/PD-L1 interaction at the cellular level. Tumor growth and survival experiments showed that <sup>D</sup>PPA-1 significantly inhibits the growth of implanted CT26 in mice and no loss of body weight was detected.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Amino Acid Sequences of <span class="smallcaps smallerCapital">d</span>-Peptide from PD-L1-Binding Phase and the Corresponding <i>K</i><sub>D</sub> Values</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">name</th><th class="colsep0 rowsep0" align="center">sequence</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>D</sub> (μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><sup>D</sup>PPA-1</td><td class="colsep0 rowsep0" align="left">NYSKPTDRQYHF</td><td class="colsep0 rowsep0" align="left">0.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><sup>D</sup>PPA-2</td><td class="colsep0 rowsep0" align="left">KHAHHTHNLRLP</td><td class="colsep0 rowsep0" align="left">1.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><sup>D</sup>PPA-3</td><td class="colsep0 rowsep0" align="left">AAKMDGHLHGGQ</td><td class="colsep0 rowsep0" align="left">NB<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><sup>D</sup>PPA-4</td><td class="colsep0 rowsep0" align="left">MRNRERYPKPYY</td><td class="colsep0 rowsep0" align="left">22.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><sup>D</sup>PPA-5</td><td class="colsep0 rowsep0" align="left">TLYQRPSTNLER</td><td class="colsep0 rowsep0" align="left">NB<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last"><i>K</i><sub>D</sub> values measured by surface plasmon resonance (SPR) spectroscopy.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">NB = no binding.</p></div></div></div><div class="NLM_p">Recently, Zhu et al. reported a peptide targeting PD-L1. TPP-1 whose amino acid sequence is SGQYASYHCWCWRDPGRSGGSK, which was screened and identified through a bacterial surface display method, binds to PD-L1 with an affinity of <i>K</i><sub>D</sub> = 94 nM.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Experiments with a xenograft mouse model using H460 cells and increased expression of IFN-γ and granzyme B indicated that TPP-1 could attenuate the inhibitory effect of PD-L1 on the T cells and reactivate T cells in vivo, inhibiting tumor growth.</div><div class="NLM_p">Li and co-workers at East China University of Science and Technology developed a computational method for de novo design of anti-PD-1 peptides with residues Y56, R113, A121, D122, and Y123 of PD-L1 as key anchors.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> The sequence and binding affinities to the PD-1 of four selected peptides are shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. The most potent of these, Ar5Y_4 (GN<b><u class="uu">W</u></b><u class="uu">DY</u>NSQ<u class="uu">R</u>AQL<u class="uu">Y</u>NQ), has a <i>K</i><sub>D</sub> value of 1.38 ± 0.39 μM. The SPR competitive binding assay and the production by T cells of IL-2 analyzed by an enzyme-linked immune sorbent assay (ELISA) indicated that Ar5Y_4 can inhibit the interaction of PD-1/PD-L1 and restore the suppressed function of Jurkat T cells.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Amino Acid Sequence, Purity, and Corresponding <i>K</i><sub>D</sub> Values of the Computational de Novo Peptides</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">name</th><th class="colsep0 rowsep0" align="center">sequence<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">purity (%)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>D</sub> (μM)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ar5Y_1</td><td class="colsep0 rowsep0" align="left">FN<b><u class="uu">W</u></b><u class="uu">DY</u>SWKSE<u class="uu">R</u>LKEA<u class="uu">Y</u>DL</td><td class="colsep0 rowsep0" align="left">96.66</td><td class="colsep0 rowsep0" align="left">3.39 ± 0.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ar5Y_2</td><td class="colsep0 rowsep0" align="left">FN<b><u class="uu">W</u></b><u class="uu">DY</u>SLEEL<u class="uu">R</u>EKAK<u class="uu">Y</u>K</td><td class="colsep0 rowsep0" align="left">95.80</td><td class="colsep0 rowsep0" align="left">3.14 ± 0.92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ar5Y_3</td><td class="colsep0 rowsep0" align="left">TE<b><u class="uu">K</u></b>DYRHGNI<u class="uu">R</u>MKLA<u class="uu">Y</u>DL</td><td class="colsep0 rowsep0" align="left">96.71</td><td class="colsep0 rowsep0" align="left">3.13 ± 0.45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ar5Y_4</td><td class="colsep0 rowsep0" align="left">GN<b><u class="uu">W</u></b><u class="uu">DY</u>NSQ<u class="uu">R</u>AQL<u class="uu">Y</u>NQ</td><td class="colsep0 rowsep0" align="left">98.24</td><td class="colsep0 rowsep0" align="left">1.38 ± 0.39</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Anchor residues are underlined, and residues corresponding to anchor residue A121 are in bold.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Determined by HPLC.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last"><i>K</i><sub><i>D</i></sub> value is shown as the mean ± SD from three independent experiments.</p></div></div></div><div class="NLM_p">Scientists from Aurigene, an Indian biotechnology company, developed several peptides or peptidomimetics as PD-1/PD-L1 pathway inhibitors. In 2014, Aurigene, together with Pierre Fabre Pharmaceuticals disclosed AUNP-12, a peptide based on the PD-1 ectodomain, which is highly effective in antagonizing PD-1 signaling with desirable in vivo exposure following subcutaneous administration. By analysis of the related patent,<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> the most possible structure of AUNP-12 appears to be compound <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), which shows the highest inhibition of tumor growth and metastasis in preclinical models of cancer and has a safer toxicological profile.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Possible structure of AUNP-12.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Small peptidomimetics have also been developed by Aurigene (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Compounds <b>2</b> and <b>3</b> are tripeptide or tetrapeptide peptidomimetics containing a hydrazine or urea linker<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77,78)</a> Compound <b>2</b> shows high inhibition of PD-L1 and PD-L2 (rescue of splenocyte effector function, with EC<sub>50</sub> = 30 and 40 nM, respectively) and significantly suppresses tumor growth. Compound <b>3</b> rescued anti-CD3/CD28-stimulated C57BL/6 mice with splenocyte proliferation in the presence of recombinant mouse ligand PD-L1 by 87% at 100 nM in carboxyfluorescein succinimidyl amino ester (CFSE) proliferation assays. CFSE is a dye that diffuses passively into cells and binds to intracellular proteins. Compound <b>4</b>, comprising a modified BC loop (amino acids 24–30 of the extracellular domain of hPD-1, sequence: SNTSESF), reduces lung metastasis by 64% in mice bearing melanoma B16F10 cancer cells.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Small peptidomimetics developed by Aurigene.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Cyclic peptidomimetic compounds were also disclosed by the same company (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> Compounds such as formula <b>5</b> have a -CO-(CH<sub>2</sub>)<sub>n</sub>-NH- or an amide bond as a linker and a further modified BC loop. Compound <b>6</b> induces mouse splenocyte proliferation in the presence of human breast MDA-MB-231 cancer cell lines overexpressing PD-L1 in CFSE assays and lung metastasis by 54% in mice bearing melanoma B16F10 cancer cells. Compounds <b>7</b> and <b>8</b> rescue anti-CD3/CD28-stimulated mice splenocyte proliferation in the presence of recombinant mouse ligand PD-L1 by 81% and 82%, respectively, at a concentration of 100 nM in CFSE proliferation assays.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cyclic peptidomimetic compounds developed by Aurigene. Formula <b>5</b>: L1 is selected from -CO-(CH<sub>2</sub>)<sub><i>n</i></sub>-NH-, -NH-(CH<sub>2</sub>)<sub><i>n</i></sub>-CO-, or an amide bond. Am1 and Am2 are amino acid residues. X is selected from Lys, Glu, or Ser. Y is selected from Glu, Gln, or Lys. Z is amino acid residues L2. L2: -NH-(CH<sub>2</sub>)<sub><i>n</i></sub>-CO- or absent.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Aurigene has also developed several macrocyclic peptidomimetic compounds.<a onclick="showRef(event, 'ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref82 ref83">(82,83)</a> Five such compounds were reported to rescue the anti-CD3/CD28-stimulated mouse splenocyte proliferation by up to 90% at a 100 nM concentration in the presence of recombinant mice ligand PD-L1 in CFSE assays (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). The peptidomimetics showing the highest inhibition were compounds <b>9</b> and <b>10</b> which rescued 95% and 94% splenocyte proliferation at 100 nM in the presence of PD-L1.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Macrocyclic peptidomimetic compounds developed by Aurigene.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since nivolumab was approved by the FDA for the treatment of unresectable melanoma, Bristol-Myers Squibb has developed non-mAbs inhibitors targeting the PD-1/PD-L1 pathway. A series of macrocyclic inhibitors containing 13–15 residues involved in the PD-1/PD-L1 interaction have been reported.<a onclick="showRef(event, 'ref84 ref85 ref86 ref87 ref88 ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref84 ref85 ref86 ref87 ref88 ref89 ref90">(84−90)</a></div><div class="NLM_p">BMS-986189, a macrocyclic peptide with a 45-residue N-methylated backbone with 14 amide bonds and 1 thioether bond, is a PD-L1 antagonist that entered a phase I clinical trial in 2016 for the treatment of severe sepsis. Although the full structure of BMS-986189 has not been disclosed, the patents indicate that formula <b>11</b> is a possible skeleton (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Compound <b>12</b> shows the highest binding affinity to PD-L1 using a PD-1/PD-L1 homogeneous time-resolved fluorescence (HTRF) binding assay.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Macrocyclic peptidomimetic compounds developed by BMS Company.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Holak and co-workers from Jagiellonian University have characterized three macrocyclic-peptide PD-1/PD-L1 antagonists that were later developed by Bristol-Myers Squibb (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Compounds <b>13</b> and <b>14</b> dose-dependently restore the activity of the TCR-responsive promoter under the control of overexpressed PD-1 with EC<sub>50</sub> values of 556 nM and 293 nM, respectively. In comparison, the immunomodulatory effects of the anti-PD-1 mAbs durvalumab and nivolumab were determined to have EC<sub>50</sub> values of 0.20 nM and 1.3 nM, respectively. Compound <b>15</b>, with EC<sub>50</sub> = 6.30 μM, was the least active. The cocrystal structures of <b>13</b> or <b>14</b> with PD-L1 demonstrate that no significant structural changes are induced within the PD-L1 receptor upon ligand binding. Analysis of the interactions of the residues of the therapeutic mAbs avelumab and peptides <b>13</b> and <b>14</b> shows that these peptides mimic about 37% of the PD-L1/mAbs interactions.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Three macrocyclic peptides PD-1/PD-L1 antagonists reported by Holak.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Nonpeptidic Small-Molecule Inhibitors Targeting the PD-1/PD-L1 Pathway</h3><div class="NLM_p">Sharpe and co-workers at Harvard University reported sulfonamides as inhibitors of PD-1/PD-L1.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> The activities of sulfamonomethoxine (<b>16</b>) and sulfamethizole (<b>17</b>) are >400 nM in rescuing PD-1 mediated inhibition of IFN-γ production (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Sulfonamides small-molecules inhibitors developed by Sharpe.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Using computer-aided drug design (CADD),<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Sun’s group from China Pharmaceutical University has identified isonicotinic acid derivatives as inhibitors of the interaction of PD-1 with PD-L1. Compound <b>18</b> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) provides 36% inhibition of the PD-1/PD-L1 binding at 10 μM in an HTRF binding assay.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Isonicotinic acid derivatives reported by Sun et al. and resorcinol derivatives developed by Li et al.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Li et al. from Beijing Institute of Pharmacology and Toxicology have developed resorcinol derivatives as immune-checkpoint inhibitors of the PD-1/PD-L1 interaction.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> Compound <b>19</b> inhibits the PD-1/PD-L1 interaction by 43% at 500 μM in the HTRF binding assay, and NMR spectroscopy suggests that the N atom (red) was supposed to interact with PD-1.</div><div class="NLM_p">Other than the aforementioned peptide-based anti-PD-1/PD-L1 inhibitors, the most promising candidates developed by Aurigene are CA-170 and CA-327. CA-170, co-developed by Curis, is a first-in-class, orally bioavailable, dual small-molecule inhibitor of PD-1 and a v-type immunoglobulin domain-containing suppressor of T-cell activation (VISTA), an immune checkpoint sharing structural similarity with PD-L1 and coexpressed with PD-L1 in specific tumor cells.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Preclinical ex vivo data show that CA-170 can induce effective proliferation and IFN-γ production by means of T cells that are specifically suppressed by PD-L1 or VISTA. In various in vivo tumor models, CA-170 shows antitumor effects similar to those of antibodies of PD-1 or VISTA. In 2016, Curis initiated the phase I trials of CA-170 for the treatment of advanced solid tumors and lymphomas and established that with a once daily oral dosing regimen, CA-170 has a safe toxicological profile. In the same year, Aurigene, in collaboration with Curis, reported CA-327 as an oral small-molecule antagonist targeting PD-L1 and the T-cell immunoglobulin and mucin domain containing protein-3 (TIM-3: an immune checkpoint coexpressed with PD-1 in certain T cells). CA-327 inhibits PD-L1 and TIM-3 with EC<sub>50</sub> values of 34 nM and 35 nM, respectively. Moreover, CA-327 shows no inhibition of other immune checkpoints such as CTLA-4 or VISTA, good PD modulation comparable to an anti-TIM3 antibody, and a combination of anti-PD-1 antibody and anti-TIM3 antibody properties. Currently CA-327 is undergoing IND-enabling studies.</div><div class="NLM_p">Aurigene and Curis have not revealed the structures of CA-170 and CA-327. On the basis of small peptidomimetics comprising a hydrazine and urea linker, Aurigene further developed a series of tripeptides or their derivatives comprising a core oxadiazole or thiadiazole with an amino acid side chain along with a hydrazine or urea linker at different sites. Specifically 1,2,4-oxadiazole/thiadiazole derivatives<a onclick="showRef(event, 'ref96 ref97 ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref96 ref97 ref98 ref99">(96−99)</a> and 1,3,4-oxadiazole/thiadiazole derivatives have been reported<a onclick="showRef(event, 'ref100 ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref100 ref101 ref102">(100−102)</a> as immunomodulators targeting PD-1 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). Compounds <b>20</b> and <b>21</b> rescue splenocyte proliferation 92% and 99% at 100 nM in the presence of PD-L1. In 2018, patents<a onclick="showRef(event, 'ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref103 ref104">(103,104)</a> from Aurigene shows that these oxadiazole/thiadiazole derivatives can also modulate the VISTA signaling pathway. Compound <b>22</b> rescues 99% IFN-γ release in a human peripheral blood mononuclear cell assay in the presence of VISTA. Compound <b>23</b> rescues splenocyte proliferation 97% at 100 nM in the presence of PD-L1 and rescues more than 70% IFN-γ release at 100 nM in the presence of VISTA. Besides the urea linker, compounds with amide or sulfonamide bonds as the linker were also disclosed by Aurigene.<a onclick="showRef(event, 'ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref105 ref106">(105,106)</a> Compounds <b>24</b> and <b>25</b> rescue 97% and 91% splenocyte proliferation at 100 nM in the presence of PD-L1.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. 1,2,4-Oxadiazole/thiadiazole and 1,3,4-oxadiazole/thiadiazole derivatives developed by Aurigene.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2018, Guangzhou Maxinovel Pharmaceuticals Company disclosed MAX-10129 as a novel, orally administrated, small-molecule inhibitor of PD-1/PD-L1 interaction. According to the patent,<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> a series of aromatic acetylene or ethylene compounds as PD-1/PD-L1 inhibitors have been developed by Guangzhou Maxinovel Pharmaceuticals. Compounds <b>26</b> and <b>27</b> (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), which have IC<sub>50</sub> values of 0.018 and 0.036 μM in the inhibition of interaction of PD-1 with PD-L1, are supposed to be the possible structure of MAX-10129. MAX-10129 displayed significant antitumor efficacy in MC-38 murine colorectal carcinoma model with dose dependency. Moreover, MAX-10129 demonstrated synergistic antitumor efficacy in different combinations with an anti-CTLA-4 antibody, epacadostat (IDO inhibitor), Celebrex (COX-2 inhibitor), and cisplatin, with a <i>p</i> value of the combo treatment group relative to the vehicle group of less than 0.05.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Aromatic ethylene compounds developed by the Guangzhou Maxinovel Pharmaceuticals Company.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Feng and co-workers from Institute of Materia Medica, Chinese Academy of Medical Sciences, reported a series of benzyl phenyl ether derivatives (<b>28</b>) as PD-1/PD-L1 inhibitors,<a onclick="showRef(event, 'ref108 ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref108 ref109 ref110">(108−110)</a> which can inhibit the interaction of PD-1 with PD-L1 with IC<sub>50</sub> values in the nanomolar range. Inhibition in the picomolar range was achieved with some substituted pyridine methylene derivatives. For example, compound <b>29</b> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) inhibits the PD-1/PD-L1 interaction with an IC<sub>50</sub> value of 0.08 pM.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Benzyl phenyl ether derivatives as PD-1/PD-L1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In recent years, the Incyte Corporation has disclosed many new small-molecule compounds that block the PD-1/PD-L1 interaction.<a onclick="showRef(event, 'ref111 ref112 ref113 ref114 ref115 ref116 ref117'); return false;" href="javascript:void(0);" class="ref ref111 ref112 ref113 ref114 ref115 ref116 ref117">(111−117)</a> Compounds such as <b>30</b> can inhibit the PD-1/PD-L1 interaction with IC<sub>50</sub> values of ≤100 nM in HTRF binding assays. Compounds <b>31</b>–<b>37</b> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) are described in different patents, and their IC<sub>50</sub> values are 100 nM or less.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Small-molecule compounds developed by Incyte Corporation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Besides mAbs and peptides, the Bristol-Myers Squibb company developed small-molecules as inhibitors of the PD-1/PD-L1 pathway. Two patents disclosed a series of triaromatic compounds (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A, <b>38</b>) that inhibit the PD-1/PD-L1 interaction.<a onclick="showRef(event, 'ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref118 ref119">(118,119)</a> Compounds <b>39</b> and <b>40</b> show IC<sub>50</sub> values of 0.146 and 0.018 μM, respectively, in HTRF binding assays. Studies by Holak et al. showed that based on the crystal structures and other biochemical data,<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> compounds <b>39</b> and <b>40</b> act by directly binding to PD-L1 rather than to PD-1 and PD-L2. The relative affinity of compounds <b>39</b> and <b>40</b> toward PD-L1 and PD-L2 was assessed using differential scanning fluorimetry. Compounds <b>39</b> and <b>40</b> stabilize the thermally induced unfolding of PD-L1 by 9.4 and 13 °C, respectively. However, neither <b>39</b> nor <b>40</b> significantly affects the melting temperature of PD-L2. The crystal structure of a complex of PD-L1 with <b>40</b>, shown in <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B, suggested that <b>40</b> inserts into the cylindrical, hydrophobic pocket at the PD-L1 dimer interface and induces dimerization of PD-L1. The distal phenyl ring within the biphenyl moiety creates a T-stacking interaction with <sub>A</sub>Tyr56. The phenylmethyl ring provides hydrophobic interactions with <sub>A</sub>Ala121 and <sub>B</sub>Met115, and the alkoxypyridine moiety creates π–π stacking with <sub>B</sub>Tyr56 and a number of polar interactions of chain A. The acetamide moiety of the <i>N</i>-(2-aminoethyl)acetamide group contributes a hydrogen bond to <sub>A</sub>Lys124. NMR data confirmed that <b>39</b> and <b>40</b> both can interrupt the PD-1/PD-L1 interaction at stoichiometric concentrations.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Triaromatic compounds developed by the BMS Company. (B) Crystal structure of PD-L1 (chain A, green; chain B, blue)/<b>40</b> (yellow) complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J89">5J89</a>). Hydrogen bond is shown in yellow dashed line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Holak et al. recently presented NMR and X-ray characterizations of <b>41</b> and <b>42</b> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>A), representatives of the two classes of anti-PD/PD-L1 inhibitors.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Ligand-induced chemical shift perturbations in the 2D HMQC spectra confirmed the interaction of <b>41</b> and <b>42</b> with PD-1. The X-ray crystal structures of compounds <b>41</b> and <b>42</b> complexed with PD-L1 show that <b>41</b> and <b>42</b> both bind to the dimeric PD-L1. The binding mode of the <b>41</b>/PD-L1 complex is similar to that of the <b>40</b>/PD-L1 complex. Compound <b>41</b> also locates itself in the cylindrical, hydrophobic pocket created at the interface of two monomers within the dimer. However, the ligand-binding mode of <b>42</b> (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>B), which contains a 2,3-dihydrobenzo[<i>b</i>][1,4]dioxine group, is different. The difluorophenyl ring of <b>42</b> provides interactions with <sub>A</sub>Ala121 through a long hydrogen bond and with <sub>A</sub>Tyr56, while the 2,3-dihydrobenzo[<i>b</i>][1,4]dioxine ring interacts with <sub>A</sub>Met115 and <sub>B</sub>Ala121. The methyl group on the phenyl ring has hydrophobic interactions with Met115 of chains A and B and with <sub>A</sub>Ala121. Additionally, the (<i>S</i>)-4-amino-3-hydroxybutyric acid moiety provides two hydrogen bonds, with <sub>A</sub>Thr20 and <sub>B</sub>Gln66. This structural difference also suggests that the ligand binding site of PD-L1 is more flexible.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (A) Anti-PD/PD-L1 inhibitors characterized by Holak et al. (B) Crystal structure of PD-L1 (chain A, blue; chain B, green)/<b>42</b> (yellow) complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5N2F">5N2F</a>). Hydrogen bonds is shown in yellow dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Scaffold <b>43</b> (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) is another small-molecule inhibitor of PD-1/PD-L1 targeting PD-1/PD-L1 disclosed by BMS company. Compounds <b>44</b>–<b>46</b>, taken from three patents,<a onclick="showRef(event, 'ref122 ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref122 ref123 ref124">(122−124)</a> are typical examples of compounds that can inhibit the PD-1/PD-L1 interaction with IC<sub>50</sub> values of <10 nM in HTRF binding assays. Moreover, according to studies by Holak et al.,<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> both compounds <b>44</b> and <b>45</b> present significantly improved cytotoxic properties and could successfully interfere with soluble PD-L1 interaction with PD-1 on T cells and induce the formation of PD-L1 dimers like other compounds tested by Holak et al. Compound <b>45</b> and its fragments were tested using <sup>1</sup>H–<sup>15</sup>N NMR method for the interaction with PD-L1. A two aromatic ring system is demonstrated as the minimal fragment essential for the PD-L1 binding.</div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Small-molecule inhibitors developed by the Bristol-Myers Squibb Company. The two aromatic ring system in the red cycle is the minimal fragment essential for the PD-L1 binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusion and Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64715" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64715" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Along with the rapid development of immune-checkpoint inhibitors, cancer immunotherapy has entered a new phase ripe with opportunity. The clinical application of anti-PD-1/PD-L1 mAbs such as nivolumab and pembrolizumab has demonstrated that immune-checkpoint inhibitors targeting the PD-1/PD-L1 pathway can be useful in cancer therapy. In comparison with CTLA-4, PD-1/PD-L1 checkpoint interaction occurs peripherally, whereas the CTLA-4/B7 interaction is centrally present in the lymphoid organs. Therefore, anti-PD-1/PD-L1 inhibitors may have the higher response rates and lower irAE.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">In recent years, more mAbs including combination therapy with other antitumor drugs like anti-CLTA-4 antibodies<a onclick="showRef(event, 'ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref126 ref127">(126,127)</a> will be approved in an attempt to improve the efficiency of anti-PD-1/PD-L1 immunotherapy. Although anti-PD-1/PD-L1 mAbs have obtained large market share and a clinical impact on one or more tumors, difficult and expensive production and deficiency of key parameters suggest that there is still room for improvement.</div><div class="NLM_p">In comparison to mAbs, non-mAbs small-molecule inhibitors have considerable therapeutic advantages. For this reason, various small-molecule non-mAbs inhibitors have been developed in academia and in the pharmaceutical industry in the past 5 years. <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> lists small-molecule inhibitors currently in promising clinical trails targeting the PD-1/PD-L1 pathway. However, the development of marketable inhibitors targeting the PD-1/PD-L1 pathway for clinical applications is a challenging process. To date, no small-molecule inhibitor has been approved for cancer treatment.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Small-Molecule Inhibitors Currently in Promising Clinical Trials Targeting the PD-1/PD-L1 Pathway</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">code name</th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">organization</th><th class="colsep0 rowsep0" align="center">compound category</th><th class="colsep0 rowsep0" align="center">highest phase</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CA-170</td><td class="colsep0 rowsep0" align="left">PD-L1, VISTA</td><td class="colsep0 rowsep0" align="left">Aurigene/Curis</td><td class="colsep0 rowsep0" align="left">Dual small-molecule, orally bioavailable inhibitor</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS-986189</td><td class="colsep0 rowsep0" align="left">PD-L1</td><td class="colsep0 rowsep0" align="left">Bristol-Myers Squibb</td><td class="colsep0 rowsep0" align="left">Macrocyclic peptide</td><td class="colsep0 rowsep0" align="left">Phase I</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CA-327</td><td class="colsep0 rowsep0" align="left">PD-L1, TIM3</td><td class="colsep0 rowsep0" align="left">Aurigene/Curis</td><td class="colsep0 rowsep0" align="left">Dual small-molecule, orally bioavailable inhibitor</td><td class="colsep0 rowsep0" align="left">IND filed</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUNP-12</td><td class="colsep0 rowsep0" align="left">PD-1</td><td class="colsep0 rowsep0" align="left">Aurigene/Curis</td><td class="colsep0 rowsep0" align="left">Peptide-based inhibitor</td><td class="colsep0 rowsep0" align="left">Preclinical</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAX-10129</td><td class="colsep0 rowsep0" align="left">PD-1/PD-L1</td><td class="colsep0 rowsep0" align="left">Guangzhou Maxinovel Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">Small-molecule, orally bioavailable inhibitor</td><td class="colsep0 rowsep0" align="left">Preclinical</td></tr></tbody></table></div></div><div class="NLM_p">According to the structural analysis of reported small-molecule anti-PD-1/PD-L1 antagonists, oxadiazole and two aromatic ring systems are considered as core pharmacophores for PD-L1 binding. Comprised of a core oxadiazole, CA-170 displayed inhibition of dual immune checkpoint, which initiated a phase I trail with improved oral bioavailability. Presented by Holak et al., X-ray characterizations of compounds comprising a two aromatic ring system complexed with PD-L1 revealed the features of their ligand-binding model. Further optimization of these active molecules will help to develop a series of compounds for further clinical trials. Moreover, studies of the interactions between small-molecule inhibitors and PD-1 or PD-L1 will provide the structural basis for anti-PD-1/PD-L1 inhibitors and direct further optimization. For example, compounds <b>13</b> and <b>14</b> mimic only about 37% of the PD-L1/mAbs interactions, and thus it can be seen that the binding interfaces of avelumab may provide additional information enabling further peptide modifications to enhance their potency. Learning from the anti-PD-1/PD-L1 mAbs, small-molecule inhibitors targeting dual immune checkpoints are very promising. The coincidence of VISTA and PD-L1 expression indicates a dual immune evasion mechanism in some specific tumor cells, and the development of CA-170 demonstrates the potential of dual immune checkpoint inhibitors.</div><div class="NLM_p last">Since the first anti-PD-1/PD-L1 mAbs drug was approved by FDA in 2014, the development of small-molecule inhibitors targeting the PD-1/PD-L1 pathway is still in its early stages. It will be promising and challenging to develop small-molecule drugs targeting the PD-1/PD-L1 pathway. We hope that this perspective will be helpful for medicinal chemists to design future anti-PD-1/PD-L1 inhibitors.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00990" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76650" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76650" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheng Jiang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry,
School of Pharmacy, China Pharmaceutical
University, Nanjing 210009, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4550-5024" title="Orcid link">http://orcid.org/0000-0002-4550-5024</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d8b2b1b9b6bfabb0e198bfb5b9b1b4f6bbb7b5"><span class="__cf_email__" data-cfemail="3a50535b545d4952037a5d575b535614595557">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tianyu Wang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry,
School of Pharmacy, China Pharmaceutical
University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoxing Wu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry,
School of Pharmacy, China Pharmaceutical
University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Changying Guo</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry,
School of Pharmacy, China Pharmaceutical
University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kuojun Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry,
School of Pharmacy, China Pharmaceutical
University, Nanjing 210009, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinyi Xu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines and Department of Medicinal Chemistry,
School of Pharmacy, China Pharmaceutical
University, Nanjing 210009, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1961-0402" title="Orcid link">http://orcid.org/0000-0002-1961-0402</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zheng Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Nanomedicine, Center for Bioenergetics, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47243" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47243" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Tianyu Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=BIO-d7e1991-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Tianyu Wang</b> obtained his B.Eng. (Hons.) in Pharmaceutical Engineering in 2015 from China Pharmaceutical University, China. He is currently doing his doctoral research under supervision of Professor Sheng Jiang at China Pharmaceutical University in Medicinal Chemistry. His research topic focuses on the structure-based design of anticancer agents, with primary focus on the design of PD-1/PD-L1 inhibitors.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Xiaoxing Wu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=BIO-d7e1996-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xiaoxing Wu</b> received his Ph.D. from Brandeis University in 2009 and continued his postdoctoral research at the Massachusetts Institute of Technology. After 2 years working in academia and 4 years in top pharmaceutical companies, he joined in faculty at China Pharmaceutical University as a Principal Investigator in 2017. His current research interests are in the discovery of small-molecule drugs for treatment of metabolic diseases or immuno-oncology.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Changying Guo</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=BIO-d7e2001-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Changying Guo</b> obtained his Ph.D. degree at the Institute of Microbiology, Chinese Academy of Sciences in 2006. He had his postdoctoral training at National Institute on Aging, National Institutes of Health, and Boston Children’s Hospital, Harvard Medical School. In 2016, he set up his own lab in China Pharmaceutical University. His lab studies the functional roles and epigenetic mechanisms of biomacromolecules in tumorigenesis and metastasis, including oncoprotein and noncoding RNA.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Kuojun Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=BIO-d7e2006-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Kuojun Zhang</b> received her Master’s degree at China Pharmaceutical University. Currently, she is pursuing her Ph.D. under the supervision of Professor Sheng Jiang. Her research topics are focused on the discovery of effective inhibitors of NQO1.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Jinyi Xu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=BIO-d7e2011-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jinyi Xu</b> received her Ph.D. degree from China Pharmaceutical University in 2001. After 2 years of postdoctoral training in Kindai University (Japan), Dr. Xu started her independent career in China Pharmaceutical University and became a Full Professor since 2006. Xu’s research focuses on the design and synthesis of novel small drug-like molecules and conducts structural modification, biological evaluation, and optimization of natural products.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Zheng Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=BIO-d7e2016-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Zheng Li</b> received her Ph.D. degree from Fudan University in 2003. She continued her postdoctoral research at the National Institutes of Health. She started her independent career in 2007 at the Houston Methodist Research Institute. Dr. Li’s research involves the development and validation of novel molecular imaging probes for better understanding and early diagnosis of cancer and cardiovascular disease.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Sheng Jiang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=BIO-d7e2021-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sheng Jiang</b> completed his Ph.D. degree from Shanghai Institute of Organic Chemistry (China) in 2003. He started his independent career in 2008 at Guangzhou Biomedicine and Health, CAS. In 2017, Professor Jiang moved his research group to the China Pharmaceutical University. His scientific interest is mainly focused on development of novel small drug-like molecules and peptidomimetic derivatives acting on targets of epigenetics and immuno-oncology.</p></figure></div><div class="ack" id="ACK-d7e2026-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05201" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05201" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation (Grants 21472191, 81773559), the National Major Scientific and Technological Program for Drug Discovery Grant (Grant 2018ZX09301045002), the International Cooperation Special Grant (Grant 2016A050502036) from the Science and Technology Development Project of Guangdong Province, the International Cooperation Grant (Grant 201704030099) of Guangzhou, and the Science and Technology Planning Project of Guangdong Province (Grant 2013A022100019), and Chinese Pharmaceutical Association-Yiling Biopharmaceutical Innovation Foundation.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">IL-2</td><td class="NLM_def"><p class="first last">interleukin 2</p></td></tr><tr><td class="NLM_term">mAbs</td><td class="NLM_def"><p class="first last">monoclonal antibodies</p></td></tr><tr><td class="NLM_term">CTLA-4</td><td class="NLM_def"><p class="first last">cytotoxic T lymphocyte antigen-4</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">PD-1</td><td class="NLM_def"><p class="first last">programmed cell death-1</p></td></tr><tr><td class="NLM_term">TIM3</td><td class="NLM_def"><p class="first last">T cell membrane protein 3</p></td></tr><tr><td class="NLM_term">LAG3</td><td class="NLM_def"><p class="first last">lymphocyte activation gene 3</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">protein–protein interaction</p></td></tr><tr><td class="NLM_term">IDO</td><td class="NLM_def"><p class="first last">indoleamine-(2,3)-dioxygenase</p></td></tr><tr><td class="NLM_term">COX-2</td><td class="NLM_def"><p class="first last">cyclooxygenase-2</p></td></tr><tr><td class="NLM_term">Ig</td><td class="NLM_def"><p class="first last">immunoglobulin</p></td></tr><tr><td class="NLM_term">NK</td><td class="NLM_def"><p class="first last">natural killer</p></td></tr><tr><td class="NLM_term">DC</td><td class="NLM_def"><p class="first last">dendritic cell</p></td></tr><tr><td class="NLM_term">PD-L1</td><td class="NLM_def"><p class="first last">programmed cell death-ligand 1</p></td></tr><tr><td class="NLM_term">PD-L2</td><td class="NLM_def"><p class="first last">programmed cell death-ligand 2</p></td></tr><tr><td class="NLM_term">APC</td><td class="NLM_def"><p class="first last">antigen-presenting cell</p></td></tr><tr><td class="NLM_term">TCR</td><td class="NLM_def"><p class="first last">T cell receptor</p></td></tr><tr><td class="NLM_term">PI3K/AKT</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase/protein kinase B</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma kinase</p></td></tr><tr><td class="NLM_term">IFN</td><td class="NLM_def"><p class="first last">interferon</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">UC</td><td class="NLM_def"><p class="first last">urothelial carcinoma</p></td></tr><tr><td class="NLM_term">RCC</td><td class="NLM_def"><p class="first last">renal cell carcinoma</p></td></tr><tr><td class="NLM_term">HCC</td><td class="NLM_def"><p class="first last">hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">CRC</td><td class="NLM_def"><p class="first last">colorectal cancer</p></td></tr><tr><td class="NLM_term">GEJ</td><td class="NLM_def"><p class="first last">gastroesophageal junction</p></td></tr><tr><td class="NLM_term">CSCC</td><td class="NLM_def"><p class="first last">cutaneous squamous cell carcinoma</p></td></tr><tr><td class="NLM_term">irAE</td><td class="NLM_def"><p class="first last">immune-related adverse event</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immune sorbent assay</p></td></tr><tr><td class="NLM_term">CFSE</td><td class="NLM_def"><p class="first last">carboxyfluorescein succinimidyl amino ester</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">VISTA</td><td class="NLM_def"><p class="first last">v-type immunoglobulin domain-containing suppressor of T-cell activation</p></td></tr><tr><td class="NLM_term">CADD</td><td class="NLM_def"><p class="first last">computer-aided drug design</p></td></tr><tr><td class="NLM_term">IND</td><td class="NLM_def"><p class="first last">investigational new drug</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">HMQC</td><td class="NLM_def"><p class="first last">heteronuclear multiple quantum coherence</p></td></tr><tr><td class="NLM_term">Met</td><td class="NLM_def"><p class="first last">methionine</p></td></tr><tr><td class="NLM_term">Ala</td><td class="NLM_def"><p class="first last">alanine</p></td></tr><tr><td class="NLM_term">Thr</td><td class="NLM_def"><p class="first last">threonine</p></td></tr><tr><td class="NLM_term">Gln</td><td class="NLM_def"><p class="first last">glutamine</p></td></tr><tr><td class="NLM_term">Tyr</td><td class="NLM_def"><p class="first last">tyrosine</p></td></tr><tr><td class="NLM_term">Val</td><td class="NLM_def"><p class="first last">valine</p></td></tr><tr><td class="NLM_term">Ile</td><td class="NLM_def"><p class="first last">isoleucine</p></td></tr><tr><td class="NLM_term">Leu</td><td class="NLM_def"><p class="first last">leucine</p></td></tr><tr><td class="NLM_term">Glu</td><td class="NLM_def"><p class="first last">glutamic acid</p></td></tr><tr><td class="NLM_term">Arg</td><td class="NLM_def"><p class="first last">arginine</p></td></tr><tr><td class="NLM_term">Asp</td><td class="NLM_def"><p class="first last">aspartic acid</p></td></tr><tr><td class="NLM_term">NPM</td><td class="NLM_def"><p class="first last">nucleophosmin</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86552" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86552" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 127 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehrlich, P.</span></span> <span> </span><span class="NLM_article-title">Ueber den jetzigen Stand der Karzinomforschung</span>. <i>Ned Tijdschr Geneeskd</i> <span class="NLM_year" style="font-weight: bold;">1909</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">290</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1909&pages=273-290&author=P.+Ehrlich&title=Ueber+den+jetzigen+Stand+der+Karzinomforschung"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEhrlich%26aufirst%3DP.%26atitle%3DUeber%2520den%2520jetzigen%2520Stand%2520der%2520Karzinomforschung%26jtitle%3DNed%2520Tijdschr%2520Geneeskd%26date%3D1909%26volume%3D5%26spage%3D273%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burnet, F. M.</span></span> <span> </span><span class="NLM_article-title">Immunological aspects of maligant disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">1171</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(67)92837-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2FS0140-6736%2867%2992837-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=1967&pages=1171-1174&author=F.+M.+Burnet&title=Immunological+aspects+of+maligant+disease&doi=10.1016%2FS0140-6736%2867%2992837-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2867%2992837-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252867%252992837-1%26sid%3Dliteratum%253Aachs%26aulast%3DBurnet%26aufirst%3DF.%2BM.%26atitle%3DImmunological%2520aspects%2520of%2520maligant%2520disease%26jtitle%3DLancet%26date%3D1967%26volume%3D289%26spage%3D1171%26epage%3D1174%26doi%3D10.1016%2FS0140-6736%2867%2992837-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Old, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R. D.</span></span> <span> </span><span class="NLM_article-title">Cancer immunoediting: from immunosurveillance to tumor escape</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">998</span>, <span class="refDoi"> DOI: 10.1038/ni1102-991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fni1102-991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=12407406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot1Chs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=991-998&author=G.+P.+Dunnauthor=A.+T.+Bruceauthor=H.+Ikedaauthor=L.+J.+Oldauthor=R.+D.+Schreiber&title=Cancer+immunoediting%3A+from+immunosurveillance+to+tumor+escape&doi=10.1038%2Fni1102-991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunoediting: from immunosurveillance to tumor escape</span></div><div class="casAuthors">Dunn, Gavin P.; Bruce, Allen T.; Ikeda, Hiroaki; Old, Lloyd J.; Schreiber, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">991-998</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The concept that the immune system can recognize and destroy nascent transformed cells was originally embodied in the cancer immunosurveillance hypothesis of Burnet and Thomas.  This hypothesis was abandoned shortly afterwards because of the absence of strong exptl. evidence supporting the concept.  New data, however, clearly show the existence of cancer immunosurveillance and also indicate that it may function as a component of a more general process of cancer immunoediting.  This process is responsible for both eliminating tumors and sculpting the immunogenic phenotypes of tumors that eventually form in immunocompetent hosts.  In this review, we will summarize the historical and exptl. basis of cancer immunoediting and discuss its dual roles in promoting host protection against cancer and facilitating tumor escape from immune destruction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO7C-v7QxET7Vg90H21EOLACvtfcHk0lg8EXg-K1NU2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot1Chs70%253D&md5=d9d00d443fbac9bcf5b7cbf089ff15ab</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fni1102-991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1102-991%26sid%3Dliteratum%253Aachs%26aulast%3DDunn%26aufirst%3DG.%2BP.%26aulast%3DBruce%26aufirst%3DA.%2BT.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DOld%26aufirst%3DL.%2BJ.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DCancer%2520immunoediting%253A%2520from%2520immunosurveillance%2520to%2520tumor%2520escape%26jtitle%3DNat.%2520Immunol.%26date%3D2002%26volume%3D3%26spage%3D991%26epage%3D998%26doi%3D10.1038%2Fni1102-991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotze, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muul, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettinghausen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matory, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skibber, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiloni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetto, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seipp, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, C. M.</span></span> <span> </span><span class="NLM_article-title">Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>313</i></span>,  <span class="NLM_fpage">1485</span>– <span class="NLM_lpage">1492</span>, <span class="refDoi"> DOI: 10.1056/NEJM198512053132327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJM198512053132327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=3903508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADyaL28%252FktVehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=1985&pages=1485-1492&author=S.+A.+Rosenbergauthor=M.+T.+Lotzeauthor=L.+M.+Muulauthor=S.+Leitmanauthor=A.+E.+Changauthor=S.+E.+Ettinghausenauthor=Y.+L.+Matoryauthor=J.+M.+Skibberauthor=E.+Shiloniauthor=J.+T.+Vettoauthor=C.+A.+Seippauthor=C.+Simpsonauthor=C.+M.+Reichert&title=Observations+on+the+systemic+administration+of+autologous+lymphokine-activated+killer+cells+and+recombinant+interleukin-2+to+patients+with+metastatic+cancer&doi=10.1056%2FNEJM198512053132327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer</span></div><div class="casAuthors">Rosenberg S A; Lotze M T; Muul L M; Leitman S; Chang A E; Ettinghausen S E; Matory Y L; Skibber J M; Shiloni E; Vetto J T</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1485-92</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">We describe here the preliminary results of the systemic administration of autologous lymphokine-activated killer (LAK) cells and the recombinant-derived lymphokine interleukin-2 to patients with advanced cancer.  This regimen was based on animal models in which the systemic administration of LAK cells plus interleukin-2 mediated the regression of established pulmonary and hepatic metastases from a variety of murine tumors in several strains of mice.  We treated 25 patients with metastatic cancer in whom standard therapy had failed.  Patients received both 1.8 to 18.4 X 10(10) autologous LAK cells, generated from lymphocytes obtained through multiple leukaphereses, and up to 90 doses of interleukin-2.  Objective regression of cancer (more than 50 per cent of volume) was observed in 11 of the 25 patients: complete tumor regression occurred in one patient with metastatic melanoma and has been sustained for up to 10 months after therapy, and partial responses occurred in nine patients with pulmonary or hepatic metastases from melanoma, colon cancer, or renal-cell cancer and in one patient with a primary unresectable lung adenocarcinoma.  Severe fluid retention was the major side effect of therapy, although all side effects resolved after interleukin-2 administration was stopped.  Further development of this approach and additional patient follow-up are required before conclusions about its therapeutic value can be drawn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGpv_rFVnf-d0Q2ypr7jHkfW6udTcc2eYkK71IVpwP2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL28%252FktVehug%253D%253D&md5=e2c1c071833a72770c08e72b49ad5226</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJM198512053132327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM198512053132327%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26aulast%3DLotze%26aufirst%3DM.%2BT.%26aulast%3DMuul%26aufirst%3DL.%2BM.%26aulast%3DLeitman%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DA.%2BE.%26aulast%3DEttinghausen%26aufirst%3DS.%2BE.%26aulast%3DMatory%26aufirst%3DY.%2BL.%26aulast%3DSkibber%26aufirst%3DJ.%2BM.%26aulast%3DShiloni%26aufirst%3DE.%26aulast%3DVetto%26aufirst%3DJ.%2BT.%26aulast%3DSeipp%26aufirst%3DC.%2BA.%26aulast%3DSimpson%26aufirst%3DC.%26aulast%3DReichert%26aufirst%3DC.%2BM.%26atitle%3DObservations%2520on%2520the%2520systemic%2520administration%2520of%2520autologous%2520lymphokine-activated%2520killer%2520cells%2520and%2520recombinant%2520interleukin-2%2520to%2520patients%2520with%2520metastatic%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1985%26volume%3D313%26spage%3D1485%26epage%3D1492%26doi%3D10.1056%2FNEJM198512053132327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S. M.</span></span> <span> </span><span class="NLM_article-title">Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2</span>. <i>Ann. Surg.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1097/00000658-199809000-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1097%2F00000658-199809000-00004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=1998&pages=307-319&author=S.+A.+Rosenbergauthor=J.+C.+Yangauthor=D.+E.+Whiteauthor=S.+M.+Steinberg&title=Durability+of+complete+responses+in+patients+with+metastatic+cancer+treated+with+high-dose+interleukin-2&doi=10.1097%2F00000658-199809000-00004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2F00000658-199809000-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000658-199809000-00004%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DWhite%26aufirst%3DD.%2BE.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26atitle%3DDurability%2520of%2520complete%2520responses%2520in%2520patients%2520with%2520metastatic%2520cancer%2520treated%2520with%2520high-dose%2520interleukin-2%26jtitle%3DAnn.%2520Surg.%26date%3D1998%26volume%3D228%26spage%3D307%26epage%3D319%26doi%3D10.1097%2F00000658-199809000-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy using checkpoint blockade</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1355</span>, <span class="refDoi"> DOI: 10.1126/science.aar4060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1126%2Fscience.aar4060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=29567705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFehtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2018&pages=1350-1355&author=A.+Ribasauthor=J.+D.+Wolchok&title=Cancer+immunotherapy+using+checkpoint+blockade&doi=10.1126%2Fscience.aar4060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy using checkpoint blockade</span></div><div class="casAuthors">Ribas, Antoni; Wolchok, Jedd D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">6382</span>),
    <span class="NLM_cas:pages">1350-1355</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The release of neg. regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers.  This can be achieved by antibodies blocking the cytotoxic T lymphocyte-assocd. protein 4 (CTLA-4) or the programmed cell death 1 (PD-1) pathway, either alone or in combination.  The main premise for inducing an immune response is the preexistence of antitumor T cells that were limited by specific immune checkpoints.  Most patients who have tumor responses maintain long-lasting disease control, yet one-third of patients relapse.  Mechanisms of acquired resistance are currently poorly understood, but evidence points to alterations that converge on the antigen presentation and interferon-γ signaling pathways.  New-generation combinatorial therapies may overcome resistance mechanisms to immune checkpoint therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHaFGKqeFnWLVg90H21EOLACvtfcHk0liU5OMyMUs0tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFehtb8%253D&md5=65120662af8a2c63425212b07e423939</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.aar4060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aar4060%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DCancer%2520immunotherapy%2520using%2520checkpoint%2520blockade%26jtitle%3DScience%26date%3D2018%26volume%3D359%26spage%3D1350%26epage%3D1355%26doi%3D10.1126%2Fscience.aar4060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coukos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy comes of age</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>480</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1038/nature10673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnature10673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=22193102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1GksLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2011&pages=480-489&author=I.+Mellmanauthor=G.+Coukosauthor=G.+Dranoff&title=Cancer+immunotherapy+comes+of+age&doi=10.1038%2Fnature10673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy comes of age</span></div><div class="casAuthors">Mellman, Ira; Coukos, George; Dranoff, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">480</span>
        (<span class="NLM_cas:issue">7378</span>),
    <span class="NLM_cas:pages">480-489</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  An overview of the latest advances in cancer immunotherapy.  Activating the immune system for therapeutic benefit in cancer has long been a goal in immunol. and oncol.  After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clin. trials.  Most notable was the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed.  In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumor immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMJTF8Ma_xMrVg90H21EOLACvtfcHk0liU5OMyMUs0tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1GksLjO&md5=c789086953e75829be713a1971901fd4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature10673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10673%26sid%3Dliteratum%253Aachs%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DCoukos%26aufirst%3DG.%26aulast%3DDranoff%26aufirst%3DG.%26atitle%3DCancer%2520immunotherapy%2520comes%2520of%2520age%26jtitle%3DNature%26date%3D2011%26volume%3D480%26spage%3D480%26epage%3D489%26doi%3D10.1038%2Fnature10673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuehn, B. M.</span></span> <span> </span><span class="NLM_article-title">The promise and challenges of CAR-T gene therapy</span>. <i>J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>318</i></span>,  <span class="NLM_fpage">2167</span>– <span class="NLM_lpage">2169</span>, <span class="refDoi"> DOI: 10.1001/jama.2017.15605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1001%2Fjama.2017.15605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BC1M3kt1WqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2017&pages=2167-2169&author=B.+M.+Kuehn&title=The+promise+and+challenges+of+CAR-T+gene+therapy&doi=10.1001%2Fjama.2017.15605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Promise and Challenges of CAR-T Gene Therapy</span></div><div class="casAuthors">Kuehn Bridget M</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2167-2169</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0f9Uo2QdIhUNHe_gFldTbfW6udTcc2ea4J-lJriYs17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3kt1WqtQ%253D%253D&md5=8bcd7b8acf175b94f3e208368c2c5487</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1001%2Fjama.2017.15605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2017.15605%26sid%3Dliteratum%253Aachs%26aulast%3DKuehn%26aufirst%3DB.%2BM.%26atitle%3DThe%2520promise%2520and%2520challenges%2520of%2520CAR-T%2520gene%2520therapy%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2017%26volume%3D318%26spage%3D2167%26epage%3D2169%26doi%3D10.1001%2Fjama.2017.15605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restifo, N. P.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy: moving beyond current vaccines</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1038/nm1100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnm1100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=15340416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFSktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=909-915&author=S.+A.+Rosenbergauthor=J.+C.+Yangauthor=N.+P.+Restifo&title=Cancer+immunotherapy%3A+moving+beyond+current+vaccines&doi=10.1038%2Fnm1100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy: moving beyond current vaccines</span></div><div class="casAuthors">Rosenberg, Steven A.; Yang, James C.; Restifo, Nicholas P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">909-915</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Great progress has been made in the field of tumor immunol. in the past decade, but optimism about the clin. application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clin. tumor regression.  In the authors' cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others.  The authors consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclin. and clin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowXfcqR46cB7Vg90H21EOLACvtfcHk0lik1EIQ-UlxZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFSktL0%253D&md5=07887dc692bb6268553e25c3fab1a32a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnm1100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1100%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DRestifo%26aufirst%3DN.%2BP.%26atitle%3DCancer%2520immunotherapy%253A%2520moving%2520beyond%2520current%2520vaccines%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D909%26epage%3D915%26doi%3D10.1038%2Fnm1100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">The blockade of immune checkpoints in cancer immunotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/nrc3239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnrc3239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=22437870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVegtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=252-264&author=D.+M.+Pardoll&title=The+blockade+of+immune+checkpoints+in+cancer+immunotherapy&doi=10.1038%2Fnrc3239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The blockade of immune checkpoints in cancer immunotherapy</span></div><div class="casAuthors">Pardoll, Drew M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">252-264</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Among the most promising approaches to activating therapeutic antitumor immunity is the blockade of immune checkpoints.  Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiol. immune responses in peripheral tissues in order to minimize collateral tissue damage.  It is now clear that tumors co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumor antigens.  Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors.  Cytotoxic T-lymphocyte-assocd. antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval.  Preliminary clin. findings with blockers of addnl. immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumor immunity with the potential to produce durable clin. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosDPsOq8t6CrVg90H21EOLACvtfcHk0lik1EIQ-UlxZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVegtrw%253D&md5=d278a058ffb1ccd3f678c1ae3ac0e55e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc3239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3239%26sid%3Dliteratum%253Aachs%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26atitle%3DThe%2520blockade%2520of%2520immune%2520checkpoints%2520in%2520cancer%2520immunotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D252%26epage%3D264%26doi%3D10.1038%2Fnrc3239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span> <span> </span><span class="NLM_article-title">The future of immune checkpoint therapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1126/science.aaa8172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1126%2Fscience.aaa8172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25838373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1Wmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=56-61&author=P.+Sharmaauthor=J.+P.+Allison&title=The+future+of+immune+checkpoint+therapy&doi=10.1126%2Fscience.aaa8172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The future of immune checkpoint therapy</span></div><div class="casAuthors">Sharma, Padmanee; Allison, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6230</span>),
    <span class="NLM_cas:pages">56-61</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clin. advances and provided a new weapon against cancer.  This therapy has elicited durable clin. responses and, in a fraction of patients, long-term remissions where patients exhibit no clin. signs of cancer for many years.  The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment.  This will provide valuable information regarding the dynamic nature of the immune response and regulation of addnl. pathways that will need to be targeted through combination therapies to provide survival benefit for greater nos. of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYdwRFIm59-7Vg90H21EOLACvtfcHk0lik1EIQ-UlxZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1Wmurg%253D&md5=d63ae85b9c651ec64a3b5b002c609e35</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaa8172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaa8172%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520future%2520of%2520immune%2520checkpoint%2520therapy%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D56%26epage%3D61%26doi%3D10.1126%2Fscience.aaa8172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">Immune checkpoint blockade: a common denominator approach to cancer therapy</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.ccell.2015.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25858804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVaku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=450-461&author=S.+L.+Topalianauthor=C.+G.+Drakeauthor=D.+M.+Pardoll&title=Immune+checkpoint+blockade%3A+a+common+denominator+approach+to+cancer+therapy&doi=10.1016%2Fj.ccell.2015.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy</span></div><div class="casAuthors">Topalian, Suzanne L.; Drake, Charles G.; Pardoll, Drew M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">450-461</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands.  These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction.  Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions.  The complex biol. of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb0YUggJYBrLVg90H21EOLACvtfcHk0ljz9z9UP9g6Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVaku7k%253D&md5=e42c02d50881184b78630e5dd23f7f2e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26atitle%3DImmune%2520checkpoint%2520blockade%253A%2520a%2520common%2520denominator%2520approach%2520to%2520cancer%2520therapy%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D450%26epage%3D461%26doi%3D10.1016%2Fj.ccell.2015.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Immune checkpoint blockade in cancer therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1974</span>– <span class="NLM_lpage">1982</span>, <span class="refDoi"> DOI: 10.1200/JCO.2014.59.4358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1200%2FJCO.2014.59.4358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25605845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKmt7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1974-1982&author=M.+A.+Postowauthor=M.+K.+Callahanauthor=J.+D.+Wolchok&title=Immune+checkpoint+blockade+in+cancer+therapy&doi=10.1200%2FJCO.2014.59.4358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Immune checkpoint blockade in cancer therapy</span></div><div class="casAuthors">Postow, Michael A.; Callahan, Margaret K.; Wolchok, Jedd D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1974-1982</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Immunol. checkpoint blockade with antibodies that target cytotoxic T lymphocyte-assocd. antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies.  Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and addnl. regulatory approvals are expected across the oncol. spectrum for a variety of other agents that target these pathways.  Treatment with both CTLA-4 and PD-1/PD-L1 blockade is assocd. with a unique pattern of adverse events called immune-related adverse events, and occasionally, unusual kinetics of tumor response are seen.  Combination approaches involving CTLA-4 and PD-1/PD-L1 blockade are being investigated to det. whether they enhance the efficacy of either approach alone.  Principles learned during the development of CTLA-4 and PD-1/PD-L1 approaches will likely be used as new immunol. checkpoint blocking antibodies begin clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIUWb7xh6PgbVg90H21EOLACvtfcHk0ljz9z9UP9g6Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKmt7%252FN&md5=8d79becb621a7945974641c7e3a69de7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.59.4358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.59.4358%26sid%3Dliteratum%253Aachs%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DImmune%2520checkpoint%2520blockade%2520in%2520cancer%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1974%26epage%3D1982%26doi%3D10.1200%2FJCO.2014.59.4358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Couzin-Frankel, J.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">1432</span>– <span class="NLM_lpage">1433</span>, <span class="refDoi"> DOI: 10.1126/science.342.6165.1432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1126%2Fscience.342.6165.1432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=24357284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotF2qsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2013&pages=1432-1433&author=J.+Couzin-Frankel&title=Cancer+immunotherapy&doi=10.1126%2Fscience.342.6165.1432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy</span></div><div class="casAuthors">Couzin-Frankel, Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">6165</span>),
    <span class="NLM_cas:pages">1432-1433</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxASV1j-6kL7Vg90H21EOLACvtfcHk0ljz9z9UP9g6Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotF2qsg%253D%253D&md5=2e0995fd567c5b59f40c46981da0bef4</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.342.6165.1432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.342.6165.1432%26sid%3Dliteratum%253Aachs%26aulast%3DCouzin-Frankel%26aufirst%3DJ.%26atitle%3DCancer%2520immunotherapy%26jtitle%3DScience%26date%3D2013%26volume%3D342%26spage%3D1432%26epage%3D1433%26doi%3D10.1126%2Fscience.342.6165.1432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Inhibitory B7-family molecules in the tumour microenvironment</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.1038/nri2326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnri2326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=18500231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Ojt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=467-477&author=W.+Zouauthor=L.+Chen&title=Inhibitory+B7-family+molecules+in+the+tumour+microenvironment&doi=10.1038%2Fnri2326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory B7-family molecules in the tumor microenvironment</span></div><div class="casAuthors">Zou, Weiping; Chen, Lieping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">467-477</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review describes how the expression of inhibitory members of the B7 family, particularly B7-H1 and B7-H4, by cancer cells, stromal cells, and haematopoietic cells in the tumor microenvironment is regulated and acts to inhibit T-cell immunity, as well as the therapeutic implications.  The B7 family consists of activating and inhibitory co-stimulatory mols. that pos. and neg. regulate immune responses.  Recent studies have shown that human and rodent cancer cells, and stromal cells and immune cells in the cancer microenvironment upregulate expression of inhibitory B7 mols. and that these contribute to tumor immune evasion.  Here, the authors focus on the roles of these B7 mols. in the dynamic interactions between tumors and the host immune system, including their expression, regulation, and function in the tumor microenvironment.  The authors also discuss novel therapeutic strategies that target these inhibitory B7 mols. and their signaling pathways to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeeD0mme0N57Vg90H21EOLACvtfcHk0ljz9z9UP9g6Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Ojt74%253D&md5=ba19bdd9603fbb1425fea3509697477a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnri2326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2326%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DInhibitory%2520B7-family%2520molecules%2520in%2520the%2520tumour%2520microenvironment%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D467%26epage%3D477%26doi%3D10.1038%2Fnri2326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">The B7 family revisited</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.23.021704.115611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1146%2Fannurev.immunol.23.021704.115611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=15771580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BD2M3otFKhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=515-548&author=R.+J.+Greenwaldauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=The+B7+family+revisited&doi=10.1146%2Fannurev.immunol.23.021704.115611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The B7 family revisited</span></div><div class="casAuthors">Greenwald Rebecca J; Freeman Gordon J; Sharpe Arlene H</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">515-48</span>
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    </div><div class="casAbstract">The discovery of new functions for the original B7 family members, together with the identification of additional B7 and CD28 family members, have revealed new ways in which the B7:CD28 family regulates T cell activation and tolerance.  B7-1/B7-2:CD28 interactions not only promote initial T cell activation but also regulate self-tolerance by supporting CD4+CD25+ T regulatory cell homeostasis.  CTLA-4 can exert its inhibitory effects in both B7-1/B7-2 dependent and independent fashions.  B7-1 and B7-2 can signal bidirectionally by engaging CD28 and CTLA-4 on T cells and by delivering signals into B7-expressing cells.  The five new B7 family members, ICOS ligand, PD-L1 (B7-H1), PD-L2 (B7-DC), B7-H3, and B7-H4 (B7x/B7-S1) are expressed on professional antigen-presenting cells as well as on cells within nonlymphoid organs, providing new means for regulating T cell activation and tolerance in peripheral tissues.  The new CD28 families members, ICOS, PD-1, and BTLA, are inducibly expressed on T cells, and they have important roles in regulating previously activated T cells.  PD-1 and BTLA also are expressed on B cells and may have broader immunoregulatory functions.  The ICOS:ICOSL pathway appears to be particularly important for stimulating effector T cell responses and T cell-dependent B cell responses, but it also has an important role in regulating T cell tolerance.  In addition, the PD-1:PD-L1/PD-L2 pathway plays a critical role in regulating T cell activation and tolerance.  In this review, we revisit the roles of the B7:CD28 family members in regulating immune responses, and we discuss their therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSomh-zCjwWu6qcneEtCi92fW6udTcc2eagOeXDIHIYg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3otFKhug%253D%253D&md5=5c0d37e8233c089d731fe5bb6bac44ea</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.23.021704.115611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.23.021704.115611%26sid%3Dliteratum%253Aachs%26aulast%3DGreenwald%26aufirst%3DR.%2BJ.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DThe%2520B7%2520family%2520revisited%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2005%26volume%3D23%26spage%3D515%26epage%3D548%26doi%3D10.1146%2Fannurev.immunol.23.021704.115611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sondak, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Ipilimumab</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1038/nrd3463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnrd3463" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=411-412&author=V.+K.+Sondakauthor=K.+S.+M.+Smalleyauthor=R.+Kudchadkarauthor=S.+Gripponauthor=P.+Kirkpatrick&title=Ipilimumab&doi=10.1038%2Fnrd3463"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrd3463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3463%26sid%3Dliteratum%253Aachs%26aulast%3DSondak%26aufirst%3DV.%2BK.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DKudchadkar%26aufirst%3DR.%26aulast%3DGrippon%26aufirst%3DS.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DIpilimumab%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D411%26epage%3D412%26doi%3D10.1038%2Fnrd3463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M.</span></span> <span> </span><span class="NLM_article-title">Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2968</span>– <span class="NLM_lpage">2971</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2013.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.ejca.2013.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=23907003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2itLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=2968-2971&author=C.+Robertauthor=J.+C.+Soriaauthor=A.+M.+Eggermont&title=Drug+of+the+year%3A+programmed+death-1+receptor%2Fprogrammed+death-1+ligand-1+receptor+monoclonal+antibodies&doi=10.1016%2Fj.ejca.2013.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies</span></div><div class="casAuthors">Robert, Caroline; Soria, Jean-Charles; Eggermont, Alexander M. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2968-2971</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Programmed death-1 receptor (PD-1)/its ligand (PD-L1) antibodies have changed the landscape in oncol. in 2013.  The most mature results have been obtained in advanced melanoma patients.  They indicate important response rates and high quality responses or prolonged duration.  Also in renal cancer and in lung cancer remarkable activity has been demonstrated.  Thus it is clear that these antibodies have a very broad potential and trials in many tumor types are being initiated.  Breaking tolerance at the tumor site is a potent phenomenon and the potential for synergy with other checkpoint inhibitors such as ipilimumab have also been demonstrated in 2013.  Long term tumor control now seems achievable and thus the concept of a clin. cure is emerging by modulation of the immune system.  These antibodies bring immunotherapy to the forefront and indicate that immune-modulation will be a key component of therapeutic strategies from now on.  Because of all these reasons PD-1/PD-L1 antibodies are considered 'drug of the year'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm0I44ghnzX7Vg90H21EOLACvtfcHk0lgaiCachOqtPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2itLbN&md5=0868af3f73d5ef02432b1a633bac72a2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2013.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2013.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26atitle%3DDrug%2520of%2520the%2520year%253A%2520programmed%2520death-1%2520receptor%252Fprogrammed%2520death-1%2520ligand-1%2520receptor%2520monoclonal%2520antibodies%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26spage%3D2968%26epage%3D2971%26doi%3D10.1016%2Fj.ejca.2013.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leming, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharfman, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMiller, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollia, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigginton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span> <span> </span><span class="NLM_article-title">Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">2443</span>– <span class="NLM_lpage">3454</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1200690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJMoa1200690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=22658127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2rs7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=2443-3454&author=S.+L.+Topalianauthor=F.+S.+Hodiauthor=J.+R.+Brahmerauthor=S.+N.+Gettingerauthor=D.+C.+Smithauthor=D.+F.+McDermottauthor=J.+D.+Powderlyauthor=R.+D.+Carvajalauthor=J.+A.+Sosmanauthor=M.+B.+Atkinsauthor=P.+D.+Lemingauthor=D.+R.+Spigelauthor=S.+J.+Antoniaauthor=L.+Hornauthor=C.+G.+Drakeauthor=D.+M.+Pardollauthor=L.+Chenauthor=W.+H.+Sharfmanauthor=R.+A.+Andersauthor=J.+M.+Taubeauthor=T.+L.+McMillerauthor=H.+Xuauthor=A.+J.+Kormanauthor=M.+Jure-Kunkelauthor=S.+Agrawalauthor=D.+McDonaldauthor=G.+D.+Kolliaauthor=A.+Guptaauthor=J.+M.+Wiggintonauthor=M.+Sznol&title=Safety%2C+activity%2C+and+immune+correlates+of+anti-PD-1+antibody+in+cancer&doi=10.1056%2FNEJMoa1200690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</span></div><div class="casAuthors">Topalian, Suzanne L.; Hodi, F. Stephen; Brahmer, Julie R.; Gettinger, Scott N.; Smith, David C.; McDermott, David F.; Powderly, John D.; Carvajal, Richard D.; Sosman, Jeffrey A.; Atkins, Michael B.; Leming, Philip D.; Spigel, David R.; Antonia, Scott J.; Horn, Leora; Drake, Charles G.; Pardoll, Drew M.; Chen, Lieping; Sharfman, William H.; Anders, Robert A.; Taube, Janis M.; McMiller, Tracee L.; Xu, Haiying; Korman, Alan J.; Jure-Kunkel, Maria; Agrawal, Shruti; McDonald, Daniel; Kollia, Georgia D.; Gupta, Ashok; Wigginton, Jon M.; Sznol, Mario</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2443-2454</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance.  We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1.  Methods: We enrolled patients with advanced melanoma, non-small-cell lung cancer, castration-resistant prostate cancer, or renal-cell or colorectal cancer to receive anti-PD-1 antibody at a dose of 0.1 to 10.0 mg per kg of body wt. every 2 wk.  Response was assessed after each 8-wk treatment cycle.  Patients received up to 12 cycles until disease progression or a complete response occurred.  Results: A total of 296 patients received treatment through Feb. 24, 2012.  Grade 3 or 4 drug-related adverse events occurred in 14% of patients; there were three deaths from pulmonary toxicity.  No max. tolerated dose was defined.  Adverse events consistent with immune-related causes were obsd.  Among 236 patients in whom response could be evaluated, objective responses (complete or partial responses) were obsd. in those with non-small-cell lung cancer, melanoma, or renal-cell cancer.  Cumulative response rates (all doses) were 18% among patients with non-small-cell lung cancer (14 of 76 patients), 28% among patients with melanoma (26 of 94 patients), and 27% among patients with renal-cell cancer (9 of 33 patients).  Responses were durable; 20 of 31 responses lasted 1 yr or more in patients with 1 yr or more of follow-up.  To assess the role of intratumoral PD-1 ligand (PD-L1) expression in the modulation of the PD-1-PD-L1 pathway, immunohistochem. anal. was performed on pretreatment tumor specimens obtained from 42 patients.  Of 17 patients with PD-L1-neg. tumors, none had an objective response; 9 of 25 patients (36%) with PD-L1-pos. tumors had an objective response (P = 0.006).  Conclusions: Anti-PD-1 antibody produced objective responses in approx. one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.  Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLOPvHybmlvbVg90H21EOLACvtfcHk0liXNBvrfHqWrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2rs7fN&md5=7c13f228ef92b6089982fc878d3a394b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1200690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1200690%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DLeming%26aufirst%3DP.%2BD.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSharfman%26aufirst%3DW.%2BH.%26aulast%3DAnders%26aufirst%3DR.%2BA.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26aulast%3DMcMiller%26aufirst%3DT.%2BL.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DKorman%26aufirst%3DA.%2BJ.%26aulast%3DJure-Kunkel%26aufirst%3DM.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DD.%26aulast%3DKollia%26aufirst%3DG.%2BD.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DWigginton%26aufirst%3DJ.%2BM.%26aulast%3DSznol%26aufirst%3DM.%26atitle%3DSafety%252C%2520activity%252C%2520and%2520immune%2520correlates%2520of%2520anti-PD-1%2520antibody%2520in%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D2443%26epage%3D3454%26doi%3D10.1056%2FNEJMoa1200690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangadhar, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarour, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshua, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gergich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elassaiss-Schaap, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boasberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumeh, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebbinghaus, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Safety and tumor responses with lambrolizumab(anti-PD-1) in melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1305133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJMoa1305133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=23724846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1emsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=134-144&author=O.+Hamidauthor=C.+Robertauthor=A.+Daudauthor=F.+S.+Hodiauthor=W.+J.+Hwuauthor=R.+Keffordauthor=J.+D.+Wolchokauthor=P.+Herseyauthor=R.+W.+Josephauthor=J.+S.+Weberauthor=R.+Droncaauthor=T.+C.+Gangadharauthor=A.+Patnaikauthor=H.+Zarourauthor=A.+M.+Joshuaauthor=K.+Gergichauthor=J.+Elassaiss-Schaapauthor=A.+Algaziauthor=C.+Mateusauthor=P.+Boasbergauthor=P.+C.+Tumehauthor=B.+Chmielowskiauthor=S.+W.+Ebbinghausauthor=X.+N.+Liauthor=S.+P.+Kangauthor=A.+Ribas&title=Safety+and+tumor+responses+with+lambrolizumab%28anti-PD-1%29+in+melanoma&doi=10.1056%2FNEJMoa1305133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma</span></div><div class="casAuthors">Hamid, Omid; Robert, Caroline; Daud, Adil; Hodi, F. Stephen; Hwu, Wen-Jen; Kefford, Richard; Wolchok, Jedd D.; Mersey, Peter; Joseph, Richard W.; Weber, Jeffrey S.; Dronca, Roxana; Gangadhar, Tara C.; Patnaik, Amita; Zarour, Hassane; Joshua, Anthony M.; Gergich, Kevin; Elassaiss-Schaap, Jeroen; Algazi, Alain; Mateus, Christine; Boasberg, Peter; Tumeh, Paul C.; Chmielowski, Bartosz; Ebbinghaus, Scot W.; Li, Xiaoyun Nicole; Kang, S. Peter; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-144</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The programmed death 1 (PD-1) receptor is a neg. regulator of T-cell effector mechanisms that limits immune responses against cancer.  The authors tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma.  The authors administered lambrolizumab i.v. at a dose of 10 mg per kg of body wt. every 2 or 3 wk or 2 mg per kg every 3 wk in patients with advanced melanoma, both those who had received prior treatment with the immune checkpoint inhibitor ipilimumab and those who had not.  Tumor responses were assessed every 12 wk.  A total of 135 patients with advanced melanoma were treated.  Common adverse events attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of the adverse events were low grade.  The confirmed response rate across all dose cohorts, evaluated by central radiol. review according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was 38% (95% confidence interval [CI], 25 to 44), with the highest confirmed response rate obsd. in the cohort that received 10 mg per kg every 2 wk (52%; 95% CI, 38 to 66).  The response rate did not differ significantly between patients who had received prior ipilimumab treatment and those who had not (confirmed response rate, 38% [95% CI, 23 to 55] and 37% [95% CI, 26 to 49], resp.).  Responses were durable in the majority of patients (median follow-up, 11 mo among patients who had a response); 81% of the patients who had a response (42 of 52) were still receiving treatment at the time of anal. in March 2013.  The overall median progression-free survival among the 135 patients was longer than 7 mo.  In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX32-HobXKEbVg90H21EOLACvtfcHk0liXNBvrfHqWrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1emsbjP&md5=e325ca09569a6e2786f0523f197fd8c2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1305133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1305133%26sid%3Dliteratum%253Aachs%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DHwu%26aufirst%3DW.%2BJ.%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DJoseph%26aufirst%3DR.%2BW.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DDronca%26aufirst%3DR.%26aulast%3DGangadhar%26aufirst%3DT.%2BC.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DZarour%26aufirst%3DH.%26aulast%3DJoshua%26aufirst%3DA.%2BM.%26aulast%3DGergich%26aufirst%3DK.%26aulast%3DElassaiss-Schaap%26aufirst%3DJ.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DMateus%26aufirst%3DC.%26aulast%3DBoasberg%26aufirst%3DP.%26aulast%3DTumeh%26aufirst%3DP.%2BC.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DEbbinghaus%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DX.%2BN.%26aulast%3DKang%26aufirst%3DS.%2BP.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DSafety%2520and%2520tumor%2520responses%2520with%2520lambrolizumab%2528anti-PD-1%2529%2520in%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D134%26epage%3D144%26doi%3D10.1056%2FNEJMoa1305133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmanoukian, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gubens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcereny, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolled-Filhart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutledge, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunceford, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangwala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubiniecki, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emancipator, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab for the treatment of non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">2018</span>– <span class="NLM_lpage">2028</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1501824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJMoa1501824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25891174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BC2MjmtVWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=2018-2028&author=E.+B.+Garonauthor=N.+A.+Rizviauthor=R.+Huiauthor=N.+Leighlauthor=A.+S.+Balmanoukianauthor=J.+P.+Ederauthor=A.+Patnaikauthor=C.+Aggarwalauthor=M.+Gubensauthor=L.+Hornauthor=E.+Carcerenyauthor=M.+J.+Ahnauthor=E.+Felipauthor=J.+S.+Leeauthor=M.+D.+Hellmannauthor=O.+Hamidauthor=J.+W.+Goldmanauthor=J.+C.+Soriaauthor=M.+Dolled-Filhartauthor=R.+Z.+Rutledgeauthor=J.+Zhangauthor=J.+K.+Luncefordauthor=R.+Rangwalaauthor=G.+M.+Lubinieckiauthor=C.+Roachauthor=K.+Emancipatorauthor=L.+Gandhi&title=Pembrolizumab+for+the+treatment+of+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1501824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab for the treatment of non-small-cell lung cancer</span></div><div class="casAuthors">Garon Edward B; Rizvi Naiyer A; Hui Rina; Leighl Natasha; Balmanoukian Ani S; Eder Joseph Paul; Patnaik Amita; Aggarwal Charu; Gubens Matthew; Horn Leora; Carcereny Enric; Ahn Myung-Ju; Felip Enriqueta; Lee Jong-Seok; Hellmann Matthew D; Hamid Omid; Goldman Jonathan W; Soria Jean-Charles; Dolled-Filhart Marisa; Rutledge Ruth Z; Zhang Jin; Lunceford Jared K; Rangwala Reshma; Lubiniecki Gregory M; Roach Charlotte; Emancipator Kenneth; Gandhi Leena</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2018-28</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study.  We also sought to define and validate an expression level of the PD-1 ligand 1 (PD-L1) that is associated with the likelihood of clinical benefit.  METHODS:  We assigned 495 patients receiving pembrolizumab (at a dose of either 2 mg or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182 patients) or a validation group (313 patients).  We assessed PD-L1 expression in tumor samples using immunohistochemical analysis, with results reported as the percentage of neoplastic cells with staining for membranous PD-L1 (proportion score).  Response was assessed every 9 weeks by central review.  RESULTS:  Common side effects that were attributed to pembrolizumab were fatigue, pruritus, and decreased appetite, with no clear difference according to dose or schedule.  Among all the patients, the objective response rate was 19.4%, and the median duration of response was 12.5 months.  The median duration of progression-free survival was 3.7 months, and the median duration of overall survival was 12.0 months.  PD-L1 expression in at least 50% of tumor cells was selected as the cutoff from the training group.  Among patients with a proportion score of at least 50% in the validation group, the response rate was 45.2%.  Among all the patients with a proportion score of at least 50%, median progression-free survival was 6.3 months; median overall survival was not reached.  CONCLUSIONS:  Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer.  PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. (Funded by Merck; KEYNOTE-001 ClinicalTrials.gov number, NCT01295827.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsaUZ3ot54zxwLZxei1HN8fW6udTcc2eYYszEaRFExHbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjmtVWmtw%253D%253D&md5=df2eb1c37d57efb58d1863b5988b7a82</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1501824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1501824%26sid%3Dliteratum%253Aachs%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DRizvi%26aufirst%3DN.%2BA.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DLeighl%26aufirst%3DN.%26aulast%3DBalmanoukian%26aufirst%3DA.%2BS.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DAggarwal%26aufirst%3DC.%26aulast%3DGubens%26aufirst%3DM.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DHellmann%26aufirst%3DM.%2BD.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DDolled-Filhart%26aufirst%3DM.%26aulast%3DRutledge%26aufirst%3DR.%2BZ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLunceford%26aufirst%3DJ.%2BK.%26aulast%3DRangwala%26aufirst%3DR.%26aulast%3DLubiniecki%26aufirst%3DG.%2BM.%26aulast%3DRoach%26aufirst%3DC.%26aulast%3DEmancipator%26aufirst%3DK.%26aulast%3DGandhi%26aufirst%3DL.%26atitle%3DPembrolizumab%2520for%2520the%2520treatment%2520of%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D2018%26epage%3D2028%26doi%3D10.1056%2FNEJMoa1501824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira-Frommer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebbinghaus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab versus ipilimumab in advanced melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">2521</span>– <span class="NLM_lpage">2532</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1503093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJMoa1503093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25891173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyrsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=2521-2532&author=C.+Robertauthor=J.+Schachterauthor=G.+V.+Longauthor=A.+Aranceauthor=J.+J.+Grobauthor=L.+Mortierauthor=A.+Daudauthor=M.+S.+Carlinoauthor=C.+McNeilauthor=M.+Lotemauthor=J.+Larkinauthor=P.+Loriganauthor=B.+Neynsauthor=C.+U.+Blankauthor=O.+Hamidauthor=C.+Mateusauthor=R.+Shapira-Frommerauthor=M.+Koshauthor=H.+Zhouauthor=N.+Ibrahimauthor=S.+Ebbinghausauthor=A.+Ribas&title=Pembrolizumab+versus+ipilimumab+in+advanced+melanoma&doi=10.1056%2FNEJMoa1503093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab versus ipilimumab in advanced melanoma</span></div><div class="casAuthors">Robert, Caroline; Schachter, Jacob; Long, Georgina V.; Arance, Ana; Grob, Jean Jacques; Mortier, Laurent; Daud, Adil; Carlino, Matteo S.; McNeil, Catriona; Lotem, Michal; Larkin, James; Lorigan, Paul; Neyns, Bart; Blank, Christian U.; Hamid, Omid; Mateus, Christine; Shapira-Frommer, Ronnie; Kosh, Michele; Zhou, Honghong; Ibrahim, Nageatte; Ebbinghaus, Scot; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2521-2532</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The immune checkpoint inhibitor ipilimumab is the std.-of-care treatment for patients with advanced melanoma.  Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma.  Methods In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kg of body wt.) every 2 wk or every 3 wk or four doses of ipilimumab (at 3 mg per kg) every 3 wk.  Primary end points were progression-free and overall survival. results The estd. 6-mo progression-free-survival rates were 47.3% for pembrolizumab every 2 wk, 46.4% for pembrolizumab every 3 wk, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens vs. ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, resp.).  Estd. 12-mo survival rates were 74.1%, 68.4%, and 58.2%, resp. (hazard ratio for death for pembrolizumab every 2 wk, 0.63; 95% CI, 0.47 to 0.83; P = 0.0005; hazard ratio for pembrolizumab every 3 wk, 0.69; 95% CI, 0.52 to 0.90; P = 0.0036).  The response rate was improved with pembrolizumab administered every 2 wk (33.7%) and every 3 wk (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons).  Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, resp., after a median follow-up of 7.9 mo.  Efficacy was similar in the two pembrolizumab groups.  Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%).  Conclusions The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtKg2FC7SX5rVg90H21EOLACvtfcHk0ljqUfb9buSQDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyrsbrF&md5=b37f62f7aefe7d8948ff06babb9b711e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1503093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1503093%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DSchachter%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DMortier%26aufirst%3DL.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DMcNeil%26aufirst%3DC.%26aulast%3DLotem%26aufirst%3DM.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DNeyns%26aufirst%3DB.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DMateus%26aufirst%3DC.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DKosh%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DEbbinghaus%26aufirst%3DS.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DPembrolizumab%2520versus%2520ipilimumab%2520in%2520advanced%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D2521%26epage%3D2532%26doi%3D10.1056%2FNEJMoa1503093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowy, I.</span></span> <span> </span><span class="NLM_article-title">Safety and activity of MDX-1106(ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3006</span>– <span class="NLM_lpage">3006</span>, <span class="refDoi"> DOI: 10.1200/jco.2008.26.15_suppl.3006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1200%2Fjco.2008.26.15_suppl.3006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=18458044" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3006-3006&author=J.+R.+Brahmerauthor=S.+Topalianauthor=I.+Wollnerauthor=J.+D.+Powderlyauthor=J.+Picusauthor=C.+Drakeauthor=J.+Covinoauthor=A.+Kormanauthor=D.+Pardollauthor=I.+Lowy&title=Safety+and+activity+of+MDX-1106%28ONO-4538%29%2C+an+anti-PD-1+monoclonal+antibody%2C+in+patients+with+selected+refractory+or+relapsed+malignancies&doi=10.1200%2Fjco.2008.26.15_suppl.3006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1200%2Fjco.2008.26.15_suppl.3006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2008.26.15_suppl.3006%26sid%3Dliteratum%253Aachs%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DTopalian%26aufirst%3DS.%26aulast%3DWollner%26aufirst%3DI.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3DPicus%26aufirst%3DJ.%26aulast%3DDrake%26aufirst%3DC.%26aulast%3DCovino%26aufirst%3DJ.%26aulast%3DKorman%26aufirst%3DA.%26aulast%3DPardoll%26aufirst%3DD.%26aulast%3DLowy%26aufirst%3DI.%26atitle%3DSafety%2520and%2520activity%2520of%2520MDX-1106%2528ONO-4538%2529%252C%2520an%2520anti-PD-1%2520monoclonal%2520antibody%252C%2520in%2520patients%2520with%2520selected%2520refractory%2520or%2520relapsed%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D3006%26epage%3D3006%26doi%3D10.1200%2Fjco.2008.26.15_suppl.3006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowanetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrt, H. E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rost, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leabman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokatrin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span> <span> </span><span class="NLM_article-title">Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>515</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1038/nature14011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnature14011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25428504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFanurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=515&publication_year=2014&pages=563-567&author=R.+S.+Herbstauthor=J.+C.+Soriaauthor=M.+Kowanetzauthor=G.+D.+Fineauthor=O.+Hamidauthor=M.+S.+Gordonauthor=J.+A.+Sosmanauthor=D.+F.+McDermottauthor=J.+D.+Powderlyauthor=S.+N.+Gettingerauthor=H.+E.+K.+Kohrtauthor=L.+Hornauthor=D.+P.+Lawrenceauthor=S.+Rostauthor=M.+Leabmanauthor=Y.+Xiaoauthor=A.+Mokatrinauthor=H.+Koeppenauthor=P.+S.+Hegdeauthor=I.+Mellmanauthor=D.+S.+Chenauthor=F.+S.+Hodi&title=Predictive+correlates+of+response+to+the+anti-PD-L1+antibody+MPDL3280A+in+cancer+patients&doi=10.1038%2Fnature14011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients</span></div><div class="casAuthors">Herbst, Roy S.; Soria, Jean-Charles; Kowanetz, Marcin; Fine, Gregg D.; Hamid, Omid; Gordon, Michael S.; Sosman, Jeffery A.; McDermott, David F.; Powderly, John D.; Gettinger, Scott N.; Kohrt, Holbrook E. K.; Horn, Leora; Lawrence, Donald P.; Rost, Sandra; Leabman, Maya; Xiao, Yuanyuan; Mokatrin, Ahmad; Koeppen, Hartmut; Hegde, Priti S.; Mellman, Ira; Chen, Daniel S.; Hodi, F. Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">515</span>
        (<span class="NLM_cas:issue">7528</span>),
    <span class="NLM_cas:pages">563-567</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumor progression.  These changes distinguish cancer cells from their normal counterparts, allowing tumors to be recognized as foreign by the immune system.  However, tumors are rarely rejected spontaneously, reflecting their ability to maintain an immunosuppressive microenvironment.  Programmed death-ligand 1 (PD-L1; also called B7-H1 or CD274), which is expressed on many cancer and immune cells, plays an important part in blocking the 'cancer immunity cycle' by binding programmed death-1 (PD-1) and B7.1 (CD80), both of which are neg. regulators of T-lymphocyte activation.  Binding of PD-L1 to its receptors suppresses T-cell migration, proliferation and secretion of cytotoxic mediators, and restricts tumor cell killing.  The PD-L1-PD-1 axis protects the host from overactive T-effector cells not only in cancer but also during microbial infections.  Blocking PD-L1 should therefore enhance anticancer immunity, but little is known about predictive factors of efficacy.  This study was designed to evaluate the safety, activity and biomarkers of PD-L1 inhibition using the engineered humanized antibody MPDL3280A.  Here we show that across multiple cancer types, responses (as evaluated by Response Evaluation Criteria in Solid Tumors, version 1.1) were obsd. in patients with tumors expressing high levels of PD-L1, esp. when PD-L1 was expressed by tumor-infiltrating immune cells.  Furthermore, responses were assocd. with T-helper type 1 (TH1) gene expression, CTLA4 expression and the absence of fractalkine (CX3CL1) in baseline tumor specimens.  Together, these data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWwkJV0J8Y_bVg90H21EOLACvtfcHk0ljqUfb9buSQDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFanurbM&md5=1a5efa7b5929ca48ed17cb530e4f7916</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature14011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14011%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DKowanetz%26aufirst%3DM.%26aulast%3DFine%26aufirst%3DG.%2BD.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DKohrt%26aufirst%3DH.%2BE.%2BK.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DLawrence%26aufirst%3DD.%2BP.%26aulast%3DRost%26aufirst%3DS.%26aulast%3DLeabman%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DMokatrin%26aufirst%3DA.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DHegde%26aufirst%3DP.%2BS.%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DD.%2BS.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26atitle%3DPredictive%2520correlates%2520of%2520response%2520to%2520the%2520anti-PD-L1%2520antibody%2520MPDL3280A%2520in%2520cancer%2520patients%26jtitle%3DNature%26date%3D2014%26volume%3D515%26spage%3D563%26epage%3D567%26doi%3D10.1038%2Fnature14011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafii, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colon-Otero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanborn, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drakaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurland, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebelatto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake-Haskins, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, N. H.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of durvalumab(MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3119</span>– <span class="NLM_lpage">3125</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.67.9761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1200%2FJCO.2016.67.9761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=27269937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFertrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=3119-3125&author=C.+Massardauthor=M.+S.+Gordonauthor=S.+Sharmaauthor=S.+Rafiiauthor=Z.+A.+Wainbergauthor=J.+Lukeauthor=T.+J.+Curielauthor=G.+Colon-Oteroauthor=O.+Hamidauthor=R.+E.+Sanbornauthor=P.+H.+O%E2%80%99Donnellauthor=A.+Drakakiauthor=W.+Tanauthor=J.+F.+Kurlandauthor=M.+C.+Rebelattoauthor=X.+Jinauthor=J.+A.+Blake-Haskinsauthor=A.+Guptaauthor=N.+H.+Segal&title=Safety+and+efficacy+of+durvalumab%28MEDI4736%29%2C+an+anti-programmed+cell+death+ligand-1+immune+checkpoint+inhibitor%2C+in+patients+with+advanced+urothelial+bladder+cancer&doi=10.1200%2FJCO.2016.67.9761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer</span></div><div class="casAuthors">Massard, Christophe; Gordon, Michael S.; Sharma, Sunil; Rafii, Saeed; Wainberg, Zev A.; Luke, Jason; Curiel, Tyler J.; Colon-Otero, Gerardo; Hamid, Omid; Sanborn, Rachel E.; O'Donnell, Peter H.; Drakaki, Alexandra; Tan, Winston; Kurland, John F.; Rebelatto, Marlon C.; Jin, Xiaoping; Blake-Haskins, John A.; Gupta, Ashok; Segal, Neil H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3119-3125</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose To investigate the safety and efficacy of durvalumab, a human monoclonal antibody that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1 expression on clin. response in patients with advanced urothelial bladder cancer (UBC).  Methods A phase 1/2 multicenter, open-label study is being conducted in patients with inoperable or metastatic solid tumors.  We report here the results from the UBC expansion cohort.  Durvalumab (MEDI4736, 10 mg/kg every 2 wk) was administered i.v. for up to 12 mo.  The primary end point was safety, and objective response rate (ORR, confirmed) was a key secondary end point.  An exploratory anal. of pretreatment tumor biopsies led to defining PD-L1-pos. as $ 25% of tumor cells or tumor-infiltrating immune cells expressing membrane PD-L1.  Results A total of 61 patients (40 PD-L1-pos., 21 PD-L1-neg.), 93.4% of whom received one or more prior therapies for advanced disease, were treated (median duration of follow-up, 4.3 mo).  The most common treatment-related adverse events (AEs) of any grade were fatigue (13.1%), diarrhea (9.8%), and decreased appetite (8.2%).  Grade 3 treatment-related AEs occurred in three patients (4.9%); there were no treatment-related grade 4 or 5 AEs.  One treatment-related AE (acute kidney injury) resulted in treatment discontinuation.  The ORR was 31.0% (95% CI, 17.6 to 47.1) in 42 response-evaluable patients, 46.4% (95% CI, 27.5 to 66.1) in the PD-L1-pos. subgroup, and 0% (95% CI, 0.0 to 23.2) in the PD-L1-neg. subgroup.  Responses are ongoing in 12 of 13 responding patients, withmedian duration of response not yet reached (range, 4.1+ to 49.3+ weeks).  Conclusion Durvalumab demonstrated a manageable safety profile and evidence of meaningful clin. activity in PD-L1-pos. patients with UBC, many of whom were heavily pretreated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRRzGthbTE1rVg90H21EOLACvtfcHk0lhaoatbBkmHfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFertrzP&md5=0704b7e421e36d91f953139b40890d17</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.67.9761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.67.9761%26sid%3Dliteratum%253Aachs%26aulast%3DMassard%26aufirst%3DC.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DRafii%26aufirst%3DS.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DLuke%26aufirst%3DJ.%26aulast%3DCuriel%26aufirst%3DT.%2BJ.%26aulast%3DColon-Otero%26aufirst%3DG.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSanborn%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DP.%2BH.%26aulast%3DDrakaki%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DKurland%26aufirst%3DJ.%2BF.%26aulast%3DRebelatto%26aufirst%3DM.%2BC.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DBlake-Haskins%26aufirst%3DJ.%2BA.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DSegal%26aufirst%3DN.%2BH.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520durvalumab%2528MEDI4736%2529%252C%2520an%2520anti-programmed%2520cell%2520death%2520ligand-1%2520immune%2520checkpoint%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520urothelial%2520bladder%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D3119%26epage%3D3125%26doi%3D10.1200%2FJCO.2016.67.9761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowey, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrucci, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smylie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechter, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez-Rodas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidoboni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span> <span> </span><span class="NLM_article-title">Overall survival with combined nivolumab and ipilimumab in advanced melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1709684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJMoa1709684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=28889792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Git73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1345-1356&author=J.+D.+Wolchokauthor=V.+Chiarion-Sileniauthor=R.+Gonzalezauthor=P.+Rutkowskiauthor=J.+J.+Grobauthor=C.+L.+Coweyauthor=C.+D.+Laoauthor=J.+Wagstaffauthor=D.+Schadendorfauthor=P.+F.+Ferrucciauthor=M.+Smylieauthor=R.+Dummerauthor=A.+Hillauthor=D.+Hoggauthor=J.+Haanenauthor=M.+S.+Carlinoauthor=O.+Bechterauthor=M.+Maioauthor=I.+Marquez-Rodasauthor=M.+Guidoboniauthor=G.+McArthurauthor=C.+Lebbeauthor=P.+A.+Asciertoauthor=G.+V.+Longauthor=J.+Cebonauthor=J.+Sosmanauthor=M.+A.+Postowauthor=M.+K.+Callahanauthor=D.+Walkerauthor=L.+Rollinauthor=R.+Bhoreauthor=F.+S.+Hodiauthor=J.+Larkin&title=Overall+survival+with+combined+nivolumab+and+ipilimumab+in+advanced+melanoma&doi=10.1056%2FNEJMoa1709684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Overall survival with combined nivolumab and ipilimumab in advanced melanoma</span></div><div class="casAuthors">Wolchok, J. D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J.-J.; Cowey, C. L.; Lao, C. D.; Wagstaff, J.; Schadendorf, D.; Ferrucci, P. F.; Smylie, M.; Dummer, R.; Hill, A.; Hogg, D.; Haanen, J.; Carlino, M. S.; Bechter, O.; Maio, M.; Marquez-Rodas, I.; Guidoboni, M.; McArthur, G.; Lebbe, C.; Ascierto, P. A.; Long, G. V.; Cebon, J.; Sosman, J.; Postow, M. A.; Callahan, M. K.; Walker, D.; Rollin, L.; Bhore, R.; Hodi, F. S.; Larkin, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1345-1356</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma.  We now report 3-yr overall survival outcomes in this trial. methods We randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kg of body wt. plus ipilimumab at a dose of 3 mg per kg every 3 wk for four doses, followed by nivolumab at a dose of 3 mg per kg every 2 wk; nivolumab at a dose of 3 mg per kg every 2 wk plus placebo; or ipilimumab at a dose of 3 mg per kg every 3 wk for four doses plus placebo, until progression, the occurrence of unacceptable toxic effects, or withdrawal of consent.  Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage.  The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group vs. the ipilimumab group. results At a min. follow-up of 36 mo, the median overall survival had not been reached in the nivolumab-plus-ipilimumab group and was 37.6 mo in the nivolumab group, as compared with 19.9 mo in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.55 [P<0.001]; hazard ratio for death with nivolumab vs. ipilimumab, 0.65 [P<0.001]).  The overall survival rate at 3 years was 58% in the nivolumab-plus-ipilimumab group and 52% in the nivolumab group, as compared with 34% in the ipilimumab group.  The safety profile was unchanged from the initial report.  Treatment-related adverse events of grade 3 or 4 occurred in 59% of the patients in the nivolumab-plus-ipilimumab group, in 21% of those in the nivolumab group, and in 28% of those in the ipilimumab group. conclusions Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with ipilimumab alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY91ga-k7LxbVg90H21EOLACvtfcHk0lhaoatbBkmHfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Git73I&md5=bf5e5c47178631cd4485cf79dca12dd8</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1709684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1709684%26sid%3Dliteratum%253Aachs%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DCowey%26aufirst%3DC.%2BL.%26aulast%3DLao%26aufirst%3DC.%2BD.%26aulast%3DWagstaff%26aufirst%3DJ.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DFerrucci%26aufirst%3DP.%2BF.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DHill%26aufirst%3DA.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DHaanen%26aufirst%3DJ.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DBechter%26aufirst%3DO.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DMarquez-Rodas%26aufirst%3DI.%26aulast%3DGuidoboni%26aufirst%3DM.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DRollin%26aufirst%3DL.%26aulast%3DBhore%26aufirst%3DR.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DLarkin%26aufirst%3DJ.%26atitle%3DOverall%2520survival%2520with%2520combined%2520nivolumab%2520and%2520ipilimumab%2520in%2520advanced%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1345%26epage%3D1356%26doi%3D10.1056%2FNEJMoa1709684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ngiow, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Scheidt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3540</span>– <span class="NLM_lpage">3551</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-0096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1158%2F0008-5472.CAN-11-0096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3540-3551&author=S.+F.+Ngiowauthor=B.+von+Scheidtauthor=H.+Akibaauthor=H.+Yagitaauthor=M.+W.+Tengauthor=M.+J.+Smyth&title=Anti-TIM3+antibody+promotes+T+cell+IFN-gamma-mediated+antitumor+immunity+and+suppresses+established+tumors&doi=10.1158%2F0008-5472.CAN-11-0096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-0096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-0096%26sid%3Dliteratum%253Aachs%26aulast%3DNgiow%26aufirst%3DS.%2BF.%26aulast%3Dvon%2BScheidt%26aufirst%3DB.%26aulast%3DAkiba%26aufirst%3DH.%26aulast%3DYagita%26aufirst%3DH.%26aulast%3DTeng%26aufirst%3DM.%2BW.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DAnti-TIM3%2520antibody%2520promotes%2520T%2520cell%2520IFN-gamma-mediated%2520antitumor%2520immunity%2520and%2520suppresses%2520established%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3540%26epage%3D3551%26doi%3D10.1158%2F0008-5472.CAN-11-0096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnis, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankoti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selby, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirschl, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gravano, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangsombatvisit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosso, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeltzer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignali, D. A.</span></span> <span> </span><span class="NLM_article-title">Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1158%2F0008-5472.CAN-11-1620" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=917-927&author=S.+R.+Wooauthor=M.+E.+Turnisauthor=M.+V.+Goldbergauthor=J.+Bankotiauthor=M.+Selbyauthor=C.+J.+Nirschlauthor=M.+L.+Bettiniauthor=D.+M.+Gravanoauthor=P.+Vogelauthor=C.+L.+Liuauthor=S.+Tangsombatvisitauthor=J.+F.+Grossoauthor=G.+Nettoauthor=M.+P.+Smeltzerauthor=A.+Chauxauthor=P.+J.+Utzauthor=C.+J.+Workmanauthor=D.+M.+Pardollauthor=A.+J.+Kormanauthor=C.+G.+Drakeauthor=D.+A.+Vignali&title=Immune+inhibitory+molecules+LAG-3+and+PD-1+synergistically+regulate+T-cell+function+to+promote+tumoral+immune+escape&doi=10.1158%2F0008-5472.CAN-11-1620"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1620%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DS.%2BR.%26aulast%3DTurnis%26aufirst%3DM.%2BE.%26aulast%3DGoldberg%26aufirst%3DM.%2BV.%26aulast%3DBankoti%26aufirst%3DJ.%26aulast%3DSelby%26aufirst%3DM.%26aulast%3DNirschl%26aufirst%3DC.%2BJ.%26aulast%3DBettini%26aufirst%3DM.%2BL.%26aulast%3DGravano%26aufirst%3DD.%2BM.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DC.%2BL.%26aulast%3DTangsombatvisit%26aufirst%3DS.%26aulast%3DGrosso%26aufirst%3DJ.%2BF.%26aulast%3DNetto%26aufirst%3DG.%26aulast%3DSmeltzer%26aufirst%3DM.%2BP.%26aulast%3DChaux%26aufirst%3DA.%26aulast%3DUtz%26aufirst%3DP.%2BJ.%26aulast%3DWorkman%26aufirst%3DC.%2BJ.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DKorman%26aufirst%3DA.%2BJ.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DVignali%26aufirst%3DD.%2BA.%26atitle%3DImmune%2520inhibitory%2520molecules%2520LAG-3%2520and%2520PD-1%2520synergistically%2520regulate%2520T-cell%2520function%2520to%2520promote%2520tumoral%2520immune%2520escape%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D917%26epage%3D927%26doi%3D10.1158%2F0008-5472.CAN-11-1620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarganes-Tzitzikas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinidou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzemien, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of programmed cell death 1(PD-1): a patent review (2010–2015)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">977</span>, <span class="refDoi"> DOI: 10.1080/13543776.2016.1206527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1080%2F13543776.2016.1206527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=27367741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFaht7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=973-977&author=T.+Zarganes-Tzitzikasauthor=M.+Konstantinidouauthor=Y.+Gaoauthor=D.+Krzemienauthor=K.+Zakauthor=G.+Dubinauthor=T.+A.+Holakauthor=A.+Domling&title=Inhibitors+of+programmed+cell+death+1%28PD-1%29%3A+a+patent+review+%282010%E2%80%932015%29&doi=10.1080%2F13543776.2016.1206527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)</span></div><div class="casAuthors">Zarganes-Tzitzikas, Tryfon; Konstantinidou, Markella; Gao, Yongzhi; Krzemien, Dobroslawa; Zak, Krzysztof; Dubin, Grzegorz; Holak, Tad A.; Doemling, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">973-977</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Inhibitors of programmed cell death 1 (PD-1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr524OBaXrAsbVg90H21EOLACvtfcHk0ljiZTy_unJm-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFaht7%252FK&md5=98f7c61ae47a48075d254454117fdfe3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1080%2F13543776.2016.1206527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2016.1206527%26sid%3Dliteratum%253Aachs%26aulast%3DZarganes-Tzitzikas%26aufirst%3DT.%26aulast%3DKonstantinidou%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DKrzemien%26aufirst%3DD.%26aulast%3DZak%26aufirst%3DK.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DDomling%26aufirst%3DA.%26atitle%3DInhibitors%2520of%2520programmed%2520cell%2520death%25201%2528PD-1%2529%253A%2520a%2520patent%2520review%2520%25282010%25E2%2580%25932015%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D973%26epage%3D977%26doi%3D10.1080%2F13543776.2016.1206527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span> <span> </span><span class="NLM_article-title">From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.drudis.2016.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=27094104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Krt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1027-1036&author=M.+M.+Zhanauthor=X.+Q.+Huauthor=X.+X.+Liuauthor=B.+F.+Ruanauthor=J.+Xuauthor=C.+Liao&title=From+monoclonal+antibodies+to+small+molecules%3A+the+development+of+inhibitors+targeting+the+PD-1%2FPD-L1+pathway&doi=10.1016%2Fj.drudis.2016.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway</span></div><div class="casAuthors">Zhan, Mei-Miao; Hu, Xue-Qin; Liu, Xiu-Xiu; Ruan, Ban-Feng; Xu, Jun; Liao, Chenzhong</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1027-1036</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cancer immunotherapy has made an extraordinary journey from bench to bedside.  Blocking the interactions between programmed cell death protein 1 (PD-1) and its ligand, PD-L1, has emerged as a promising immunotherapy for treating cancer.  Here, we review the development of drugs targeting the PD-1/PD-L1 pathway.  We discuss the monoclonal antibodies (mAbs) approved or in clin. trials, peptides and patented small mols. developed against this pathway.  Such compds. have the potential to treat cancer as well as chronic virol. diseases.  We also detail PD-1/PD-L1 interactions, an understanding of which will be useful for the rational design of small-mol. therapeutics that disrupt the PD-1/PD-L1 pathway.  It is likely that more mAbs targeting the PD-1/PD-L1 pathway will be approved for the treatment of a range of cancers.  By contrast, it is likely to be more difficult to successfully develop small mols. or peptides and for them to reach the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYsq7LUmul7bVg90H21EOLACvtfcHk0liX3R8B8pBJLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Krt74%253D&md5=e7bfff84cb527571846c9d82a1d8accf</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DM.%2BM.%26aulast%3DHu%26aufirst%3DX.%2BQ.%26aulast%3DLiu%26aufirst%3DX.%2BX.%26aulast%3DRuan%26aufirst%3DB.%2BF.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DC.%26atitle%3DFrom%2520monoclonal%2520antibodies%2520to%2520small%2520molecules%253A%2520the%2520development%2520of%2520inhibitors%2520targeting%2520the%2520PD-1%252FPD-L1%2520pathway%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1027%26epage%3D1036%26doi%3D10.1016%2Fj.drudis.2016.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chehrazi-Raffle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span> <span> </span><span class="NLM_article-title">Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations</span>. <i>J. Immunother Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.1186/s40425-018-0316-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1186%2Fs40425-018-0316-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=29357948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BC1MvjtFWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=8&author=J.+Gongauthor=A.+Chehrazi-Raffleauthor=S.+Reddiauthor=R.+Salgia&title=Development+of+PD-1+and+PD-L1+inhibitors+as+a+form+of+cancer+immunotherapy%3A+a+comprehensive+review+of+registration+trials+and+future+considerations&doi=10.1186%2Fs40425-018-0316-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations</span></div><div class="casAuthors">Gong Jun; Chehrazi-Raffle Alexander; Reddi Srikanth; Salgia Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy given that activation of the PD-1/PD-L1 axis putatively served as a mechanism for tumor evasion of host tumor antigen-specific T-cell immunity.  Early-phase studies investigating several humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in advanced solid tumors paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.  The number of FDA-approved agents of this class is rapidly enlarging with indications for treatment spanning across a spectrum of malignancies.  The purpose of this review is to highlight the clinical development of PD-1 and PD-L1 inhibitors in cancer therapy to date.  In particular, we focus on detailing the registration trials that have led to FDA-approved indications of anti-PD-1 and anti-PD-L1 therapies in cancer.  As the number of PD-1/PD-L1 inhibitors continues to grow, predictive biomarkers, mechanisms of resistance, hyperprogressors, treatment duration and treatment beyond progression, immune-related toxicities, and clinical trial design are key concepts in need of further consideration to optimize the anticancer potential of this class of immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9ioF2w_a5-bGbPKh4T9eAfW6udTcc2ebLA1KpHAQ3QLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvjtFWnsg%253D%253D&md5=4b6b86e0539b18080af0bd30c562620e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2Fs40425-018-0316-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-018-0316-z%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DChehrazi-Raffle%26aufirst%3DA.%26aulast%3DReddi%26aufirst%3DS.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DDevelopment%2520of%2520PD-1%2520and%2520PD-L1%2520inhibitors%2520as%2520a%2520form%2520of%2520cancer%2520immunotherapy%253A%2520a%2520comprehensive%2520review%2520of%2520registration%2520trials%2520and%2520future%2520considerations%26jtitle%3DJ.%2520Immunother%2520Cancer.%26date%3D2018%26volume%3D6%26spage%3D8%26doi%3D10.1186%2Fs40425-018-0316-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huck, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kötzner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbahns, K.</span></span> <span> </span><span class="NLM_article-title">Small molecules drive big improvements in immuno-oncology therapies</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4412</span>– <span class="NLM_lpage">4428</span>, <span class="refDoi"> DOI: 10.1002/anie.201707816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1002%2Fanie.201707816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlWqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=4412-4428&author=B.+R.+Huckauthor=L.+K%C3%B6tznerauthor=K.+Urbahns&title=Small+molecules+drive+big+improvements+in+immuno-oncology+therapies&doi=10.1002%2Fanie.201707816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecules Drive Big Improvements in Immuno-Oncology Therapies</span></div><div class="casAuthors">Huck, Bayard R.; Koetzner, Lisa; Urbahns, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4412-4428</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Immunooncol. therapies have the potential to revolutionize the armamentarium of available cancer treatments.  To further improve clin. response rates, researchers are looking for novel combination regimens, with checkpoint blockade being used as a backbone of the treatment.  This Review highlights the significance of small mols. in this approach, which holds promise to provide increased benefit to cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobJKXxvd05sLVg90H21EOLACvtfcHk0liX3R8B8pBJLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlWqsbo%253D&md5=bef3a381977686b5bdb432a76364b066</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fanie.201707816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201707816%26sid%3Dliteratum%253Aachs%26aulast%3DHuck%26aufirst%3DB.%2BR.%26aulast%3DK%25C3%25B6tzner%26aufirst%3DL.%26aulast%3DUrbahns%26aufirst%3DK.%26atitle%3DSmall%2520molecules%2520drive%2520big%2520improvements%2520in%2520immuno-oncology%2520therapies%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D4412%26epage%3D4428%26doi%3D10.1002%2Fanie.201707816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinidou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarganes-Tzitzikas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span> <span> </span><span class="NLM_article-title">Immune checkpoint PD-1/PD-L1: is there life beyond antibodies?</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4840</span>– <span class="NLM_lpage">4848</span>, <span class="refDoi"> DOI: 10.1002/anie.201710407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1002%2Fanie.201710407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlajtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=4840-4848&author=M.+Konstantinidouauthor=T.+Zarganes-Tzitzikasauthor=K.+Magiera-Mularzauthor=T.+A.+Holakauthor=A.+Domling&title=Immune+checkpoint+PD-1%2FPD-L1%3A+is+there+life+beyond+antibodies%3F&doi=10.1002%2Fanie.201710407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?</span></div><div class="casAuthors">Konstantinidou, Markella; Zarganes-Tzitzikas, Tryfon; Magiera-Mularz, Katarzyna; Holak, Tad A.; Doemling, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4840-4848</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The PD-1/PD-L1 interaction has emerged as a significant target in cancer immunotherapy.  Current medications include monoclonal antibodies, which have shown impressive clin. results in the treatment of several types of tumors.  The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small mols., and macrocycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptGmK21i2_fLVg90H21EOLACvtfcHk0liX3R8B8pBJLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlajtrk%253D&md5=b95fda31d16a4847bb6eb4eabdd1d84e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fanie.201710407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201710407%26sid%3Dliteratum%253Aachs%26aulast%3DKonstantinidou%26aufirst%3DM.%26aulast%3DZarganes-Tzitzikas%26aufirst%3DT.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DDomling%26aufirst%3DA.%26atitle%3DImmune%2520checkpoint%2520PD-1%252FPD-L1%253A%2520is%2520there%2520life%2520beyond%2520antibodies%253F%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D4840%26epage%3D4848%26doi%3D10.1002%2Fanie.201710407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bojadzic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, P.</span></span> <span> </span><span class="NLM_article-title">Toward small-molecule inhibition of protein-protein interactions: general aspects and recent progress in targeting costimulatory and coinhibitory(immune checkpoint) interactions</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.2174/1568026618666180531092503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.2174%2F1568026618666180531092503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=29848279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVekurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=674-699&author=D.+Bojadzicauthor=P.+Buchwald&title=Toward+small-molecule+inhibition+of+protein-protein+interactions%3A+general+aspects+and+recent+progress+in+targeting+costimulatory+and+coinhibitory%28immune+checkpoint%29+interactions&doi=10.2174%2F1568026618666180531092503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions</span></div><div class="casAuthors">Bojadzic, Damir; Buchwald, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">674-699</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein-Protein Interactions (PPIs) that are part of the costimulatory and coinhibitory (immune checkpoint) signaling are crit. for adequate T cell response and are important therapeutic targets for immunomodulation.  Biologics targeting them have already achieved considerable clin. success in the treatment of autoimmune diseases or transplant recipients (e.g., abatacept, belatacept, and belimumab) as well as cancer (e.g., ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab).  In view of such progress, there have been only relatively limited efforts toward developing small-mol. PPI inhibitors (SMPPIIs) targeting these cosignaling interactions, possibly because they, as all other PPIs, are difficult to target by small mols. and were not considered druggable.  Nevertheless, substantial progress has been achieved during the last decade.  SMPPIIs proving the feasibility of such approaches have been identified through various strategies for a no. of cosignaling interactions including CD40-CD40L, OX40-OX40L, BAFFR-BAFF, CD80-CD28, and PD-1-PD-L1s.  Here, after an overview of the general aspects and challenges of SMPPII-focused drug discovery, we review them briefly together with relevant structural, immune-signaling, physicochem., and medicinal chem. aspects.  While so far only a few of these SMPPIIs have shown activity in animal models (DRI-C21045 for CD40-D40L, KR33426 for BAFFR-BAFF) or reached clin. development (RhuDex for CD80-CD28, CA-170 for PD-1-PD-L1), there is proof-of-principle evidence for the feasibility of such approaches in immunomodulation.  They can result in products that are easier to develop/ manuf. and are less likely to be immunogenic or encounter postmarket safety events than corresponding biologics, and, contrary to them, can even become orally bioavailable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxFgcfDDFwirVg90H21EOLACvtfcHk0lhrjBT9Bd12BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVekurbM&md5=0c3c3adbf37198bf3db786209abb5892</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F1568026618666180531092503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026618666180531092503%26sid%3Dliteratum%253Aachs%26aulast%3DBojadzic%26aufirst%3DD.%26aulast%3DBuchwald%26aufirst%3DP.%26atitle%3DToward%2520small-molecule%2520inhibition%2520of%2520protein-protein%2520interactions%253A%2520general%2520aspects%2520and%2520recent%2520progress%2520in%2520targeting%2520costimulatory%2520and%2520coinhibitory%2528immune%2520checkpoint%2529%2520interactions%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2018%26volume%3D18%26spage%3D674%26epage%3D699%26doi%3D10.2174%2F1568026618666180531092503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geng, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span> <span> </span><span class="NLM_article-title">PD-1/PD-L1 inhibitors for immuno-oncology: from antibodies to small molecules</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6033</span>– <span class="NLM_lpage">6041</span>, <span class="refDoi"> DOI: 10.2174/1381612823666171004120152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.2174%2F1381612823666171004120152" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=6033-6041&author=Q.+H.+Gengauthor=P.+F.+Jiaoauthor=P.+Jinauthor=G.+X.+Suauthor=J.+L.+Dongauthor=B.+Yan&title=PD-1%2FPD-L1+inhibitors+for+immuno-oncology%3A+from+antibodies+to+small+molecules&doi=10.2174%2F1381612823666171004120152"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2174%2F1381612823666171004120152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612823666171004120152%26sid%3Dliteratum%253Aachs%26aulast%3DGeng%26aufirst%3DQ.%2BH.%26aulast%3DJiao%26aufirst%3DP.%2BF.%26aulast%3DJin%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DG.%2BX.%26aulast%3DDong%26aufirst%3DJ.%2BL.%26aulast%3DYan%26aufirst%3DB.%26atitle%3DPD-1%252FPD-L1%2520inhibitors%2520for%2520immuno-oncology%253A%2520from%2520antibodies%2520to%2520small%2520molecules%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2017%26volume%3D23%26spage%3D6033%26epage%3D6041%26doi%3D10.2174%2F1381612823666171004120152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3887</span>– <span class="NLM_lpage">3895</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1992.tb05481.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1002%2Fj.1460-2075.1992.tb05481.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1396582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADyaK3sXkslShtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1992&pages=3887-3895&author=Y.+Ishidaauthor=Y.+Agataauthor=K.+Shibaharaauthor=T.+Honjo&title=Induced+expression+of+PD-1%2C+a+novel+member+of+the+immunoglobulin+gene+superfamily%2C+upon+programmed+cell+death&doi=10.1002%2Fj.1460-2075.1992.tb05481.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death</span></div><div class="casAuthors">Ishida, Yasumasa; Agata, Yasutoshi; Shibahara, Keiichi; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3887-95</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    </div><div class="casAbstract">The classical type of programmed cell death is characterized by its dependence on de novo RNA and protein synthesis and morphol. features of apoptosis.  It was confirmed that stimulated 2B4.11 (a murine T-cell hybridoma) and interleukin-3 (IL-3)-deprived LyD9 (a murine hematopoietic progenitor cell line) died by the classical type of programmed cell death.  Assuming that common biochem. pathways might be involved in the deaths of 2B4.11 and LyD9, the authors isolated the PD-1 gene, a novel member of the Ig gene superfamily, by using subtractive hybridization technique.  The predicted PD-1 protein has a variant form of the consensus sequence found in cytoplasmic tails of signal transducing polypeptides assocd. with immune recognition receptors.  The PD-1 gene was activated in both stimulated 2B4.11 and IL-3-deprived LyD9 cells, but not in other death-induced cell lines that did not show the characteristic features of the classical programmed cell death.  Expression of the PD-1 mRNA in mouse was restricted to the thymus and increased when thymocyte death was augmented by in vivo injection of anti-CD3 antibody.  These results suggest that activation of the PD-1 gene may be involved in the classical type of programmed cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbDcD6IecsO7Vg90H21EOLACvtfcHk0lhrjBT9Bd12BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXkslShtbs%253D&md5=7e677e5da5923a9f27cd5166de394243</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1992.tb05481.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1992.tb05481.x%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DY.%26aulast%3DAgata%26aufirst%3DY.%26aulast%3DShibahara%26aufirst%3DK.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DInduced%2520expression%2520of%2520PD-1%252C%2520a%2520novel%2520member%2520of%2520the%2520immunoglobulin%2520gene%2520superfamily%252C%2520upon%2520programmed%2520cell%2520death%26jtitle%3DEMBO%2520J.%26date%3D1992%26volume%3D11%26spage%3D3887%26epage%3D3895%26doi%3D10.1002%2Fj.1460-2075.1992.tb05481.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniwaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaichi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Structure and chromosomal localization of the human PD-1 gene(PDCD1)</span>. <i>Genomics</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">704</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1006/geno.1994.1562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1006%2Fgeno.1994.1562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=7851902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADyaK2MXhvFWmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1994&pages=704-706&author=T.+Shinoharaauthor=M.+Taniwakiauthor=Y.+Ishidaauthor=M.+Kawaichiauthor=T.+Honjo&title=Structure+and+chromosomal+localization+of+the+human+PD-1+gene%28PDCD1%29&doi=10.1006%2Fgeno.1994.1562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and chromosomal localization of the human PD-1 gene (PDCD1)</span></div><div class="casAuthors">Shinohara, Takashi; Taniwaki, Masafumi; Ishida, Yasumasa; Kawaichi, Masashi; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Genomics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">704-6</span>CODEN:
                <span class="NLM_cas:coden">GNMCEP</span>;
        ISSN:<span class="NLM_cas:issn">0888-7543</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A cDNA encoding mouse PD-1, a member of the Ig superfamily was previously isolated from apoptosis-induced cells by subtractive hybridization.  To det. the structure and chromosomal location of the human PD-1 gene, the authors screened a human T cell cDNA library by mouse PD-1 probe and isolated a cDNA coding for the human PD-1 protein.  The deduced amino acid sequence of human PD-1 was 60% identical to the mouse counterpart, and a putative tyrosine kinase-assocn. motif was well conserved.  The human PD-1 gene was mapped to 2q37.3 by chromosomal in situ hybridization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSAAD8AW1bfbVg90H21EOLACvtfcHk0lhrjBT9Bd12BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhvFWmt7o%253D&md5=82fa9ea9123891c54f089e7ee50ee0a9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1006%2Fgeno.1994.1562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fgeno.1994.1562%26sid%3Dliteratum%253Aachs%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DTaniwaki%26aufirst%3DM.%26aulast%3DIshida%26aufirst%3DY.%26aulast%3DKawaichi%26aufirst%3DM.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DStructure%2520and%2520chromosomal%2520localization%2520of%2520the%2520human%2520PD-1%2520gene%2528PDCD1%2529%26jtitle%3DGenomics%26date%3D1994%26volume%3D23%26spage%3D704%26epage%3D706%26doi%3D10.1006%2Fgeno.1994.1562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edidin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathenson, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almo, S. C.</span></span> <span> </span><span class="NLM_article-title">Structural and functional analysis of the costimulatory receptor programmed death-1</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1016/S1074-7613(04)00051-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2FS1074-7613%2804%2900051-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=15030777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Kht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2004&pages=337-347&author=X.+Zhangauthor=J.+C.+D.+Schwartzauthor=X.+Guoauthor=S.+Bhatiaauthor=E.+Caoauthor=L.+Chenauthor=Z.+Y.+Zhangauthor=M.+A.+Edidinauthor=S.+G.+Nathensonauthor=S.+C.+Almo&title=Structural+and+functional+analysis+of+the+costimulatory+receptor+programmed+death-1&doi=10.1016%2FS1074-7613%2804%2900051-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional analysis of the costimulatory receptor programmed death-1</span></div><div class="casAuthors">Zhang, Xuewu; Schwartz, Jean-Claude D.; Guo, Xiaoling; Bhatia, Sumeena; Cao, Erhu; Chen, Lieping; Zhang, Zhong-Yin; Edidin, Michael A.; Nathenson, Stanley G.; Almo, Steven C.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">337-347</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PD-1, a member of the CD28/CTLA-4/ICOS costimulatory receptor family, delivers neg. signals that have profound effects on T and B cell immunity.  The 2.0 Å crystal structure of the extracellular domain of murine PD-1 reveals an Ig V-type topol. with overall similarity to the CTLA-4 monomer; however, there are notable differences in regions relevant to function.  Structural and biophys. data show that PD-1 is monomeric both in soln. as well as on cell surface, in contrast to CTLA-4 and other family members that are all disulfide-linked homodimers.  Furthermore, the authors' structure-based mutagenesis studies identify the ligand binding surface of PD-1, which displays significant differences compared to those present in the other members of the family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo63-pm8vX3trVg90H21EOLACvtfcHk0lg1i-7F8Xlt3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Kht70%253D&md5=6690369dc08ae119677a9c602c110508</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2804%2900051-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252804%252900051-2%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%2BD.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DBhatia%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26aulast%3DEdidin%26aufirst%3DM.%2BA.%26aulast%3DNathenson%26aufirst%3DS.%2BG.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26atitle%3DStructural%2520and%2520functional%2520analysis%2520of%2520the%2520costimulatory%2520receptor%2520programmed%2520death-1%26jtitle%3DImmunity%26date%3D2004%26volume%3D20%26spage%3D337%26epage%3D347%26doi%3D10.1016%2FS1074-7613%2804%2900051-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1093/intimm/8.5.765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1093%2Fintimm%2F8.5.765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=8671665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADyaK28Xjt1Kmurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1996&pages=765-772&author=Y.+Agataauthor=A.+Kawasakiauthor=H.+Nishimuraauthor=Y.+Ishidaauthor=T.+Tsubatauthor=H.+Yagitaauthor=T.+Honjo&title=Expression+of+the+PD-1+antigen+on+the+surface+of+stimulated+mouse+T+and+B+lymphocytes&doi=10.1093%2Fintimm%2F8.5.765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes</span></div><div class="casAuthors">Agata, Yasutoshi; Kawasaki, Akemi; Nishimura, Hiroyuki; Ishida, Yasumasa; Tsubata, Takeshi; Yagita, Hideo; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">765-772</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A mAb J43 has been produced against the product of the mouse PD-1 gene, a member of the Ig gene superfamily, which was previously isolated from an apoptosis-induced T cell hybridoma (2B4.11) by using subtractive hybridization.  Analyses by flow cytometry and immunopptn. using the J43 mAb revealed that the PD-1 gene product is a 50-55 kDa membrane protein expressed on the cell surface of several PD-1 cDNA transfectants and 2B4.11 cells.  Since the mol. wt. calcd. from the amino acid sequence is 29,310, the PD-1 protein appears to be heavily glycosylated.  Normal murine lymphoid tissues such as thymus, spleen, lymph node and bone marrow contained very small nos. of PD-1+ cells.  However, a significant PD-1+ population appeared in the thymocytes as well as T cells in spleen and lymph nodes by the in vivo anti-CD3 mAb treatment.  Furthermore, the PD-1 antigen expression was strongly induced in distinct subsets of thymocytes and spleen T cells by in vitro stimulation with either anti-CD3 mAb or Con A (Con A) which could lead T cells to both activation and cell death.  Similarly, PD-1 expression was induced on spleen B cells by in vitro stimulation with anti-IgM antibody.  By contrast, PD-1 was not significantly expressed on lymphocytes by treatment with growth factor deprivation, dexamethasone or lipopolysaccharide.  These results suggest that the expression of the PD-1 antigen is tightly regulated and induced by signal transduction through the antigen receptor and do not exclude the possibility that the PD-1 antigen may play a role in clonal selection of lymphocytes although PD-1 expression is not required for the common pathway of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUdMmfGmC3rVg90H21EOLACvtfcHk0lg1i-7F8Xlt3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjt1Kmurw%253D&md5=af84123a1dd38ee82c3c72877db76761</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2F8.5.765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252F8.5.765%26sid%3Dliteratum%253Aachs%26aulast%3DAgata%26aufirst%3DY.%26aulast%3DKawasaki%26aufirst%3DA.%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DY.%26aulast%3DTsubat%26aufirst%3DT.%26aulast%3DYagita%26aufirst%3DH.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DExpression%2520of%2520the%2520PD-1%2520antigen%2520on%2520the%2520surface%2520of%2520stimulated%2520mouse%2520T%2520and%2520B%2520lymphocytes%26jtitle%3DInt.%2520Immunol.%26date%3D1996%26volume%3D8%26spage%3D765%26epage%3D772%26doi%3D10.1093%2Fintimm%2F8.5.765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Developmentally regulated expression of the PD-1 protein on the surface of double-negative(CD4(-)CD8(-)) thymocytes</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1093/intimm/8.5.773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1093%2Fintimm%2F8.5.773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=8671666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADyaK28Xjt1Kmuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1996&pages=773-780&author=H.+Nishimuraauthor=Y.+Agataauthor=A.+Kawasakiauthor=M.+Satoauthor=S.+Imamuraauthor=N.+Minatoauthor=H.+Yagitaauthor=T.+Nakanoauthor=T.+Honjo&title=Developmentally+regulated+expression+of+the+PD-1+protein+on+the+surface+of+double-negative%28CD4%28-%29CD8%28-%29%29+thymocytes&doi=10.1093%2Fintimm%2F8.5.773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes</span></div><div class="casAuthors">Nishimura, Hiroyuki; Agata, Yasutoshi; Kawasaki, Akemi; Sato, Masaki; Imamura, Sadao; Minato, Nagahiro; Yagita, Hideo; Nakano, Toru; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">773-780</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">PD-1, a member of the Ig superfamily, was previously isolated from an apoptosis-induced T cell hybridoma 2B4.11 by subtractive hybridization.  Expression of the PD-1 mRNA is restricted to thymus in adult mice.  Using an anti-PD-1 mAb (J43), we examd. expression of the PD-1 protein during differentiation of thymocytes in normal adult, fetal and RAG-2-l-mice with or without anti-CD3 mAb stimulation.  While PD-1 was expressed only on 3-5% of total normal thymocytes, ∼34% of the CD4-CD8- double-neg. (DN) fraction are PD-1+ cells with two distinct expression levels (low and high).  PD-1high thymocytes belonged to TCR γδ lineage cells.  In the DN compartment of the TCR αβ lineage, PD-1 expression started at the low level from the CD44+CD25+ stage and the majority of thymocytes expressed PD-1 at the CD44-CD25- stage in which thymocytes express TCR β chains.  The anti-CD3ε antibody administration augmented the PD-1 expression as well as the differentiation of the CD44-CD25+ DN cells into the CD44-CD25- DN stage, not only in normal mice but also in RAG-2-deficient mice.  The fraction of the PD-1low cells in the CD4+CD8+ double-pos. (DP) compartment was very small (<5%) but increased by stimulation with the anti-CD3 antibody, although the total no. of DP cells was drastically reduced.  The results show that PD-1 expression is specifically induced at the stages preceding clonal selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPO38YNwp-nbVg90H21EOLACvtfcHk0lg1i-7F8Xlt3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjt1Kmuro%253D&md5=be831e803a7805df30fc72c84eea77be</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2F8.5.773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252F8.5.773%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DAgata%26aufirst%3DY.%26aulast%3DKawasaki%26aufirst%3DA.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DImamura%26aufirst%3DS.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DYagita%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DDevelopmentally%2520regulated%2520expression%2520of%2520the%2520PD-1%2520protein%2520on%2520the%2520surface%2520of%2520double-negative%2528CD4%2528-%2529CD8%2528-%2529%2529%2520thymocytes%26jtitle%3DInt.%2520Immunol.%26date%3D1996%26volume%3D8%26spage%3D773%26epage%3D780%26doi%3D10.1093%2Fintimm%2F8.5.773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1126/science.291.5502.319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1126%2Fscience.291.5502.319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=11209085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlKlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2001&pages=319-322&author=H.+Nishimuraauthor=T.+Okazakiauthor=Y.+Tanakaauthor=K.+Nakataniauthor=M.+Haraauthor=A.+Matsumoriauthor=S.+Sasayamaauthor=A.+Mizoguchiauthor=H.+Hiaiauthor=N.+Minatoauthor=T.+Honjo&title=Autoimmune+dilated+cardiomyopathy+in+PD-1+receptor-deficient+mice&doi=10.1126%2Fscience.291.5502.319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice</span></div><div class="casAuthors">Nishimura, Hiroyuki; Okazaki, Taku; Tanaka, Yoshimasa; Nakatani, Kazuki; Hara, Masatake; Matsumori, Akira; Sasayama, Shigetake; Mizoguchi, Akira; Hiai, Hiroshi; Minato, Nagahiro; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">5502</span>),
    <span class="NLM_cas:pages">319-322</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dilated cardiomyopathy is a severe pathol. of the heart with poorly understood etiol.  Disruption of the gene encoding the neg. immunoregulatory receptor PD-1 in BALB/c mice, but not in BALB/c RAG-2-/- mice, cause dilated cardiomyopathy with severely impaired contraction and sudden death by congestive heart failure.  Affected hearts showed diffuse deposition of IgG on the surface of cardiomyocytes.  All of the affected PD-1-/- mice exhibited high-titer circulating IgG autoantibodies reactive to a 33-kDa protein expressed specifically on the surface of cardiomyocytes.  These results indicate that PD-1 may be an important factor contributing to the prevention of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAkP6AbmRol7Vg90H21EOLACvtfcHk0lgzL6eiijVYrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlKlsw%253D%253D&md5=eaf356d0fdef363b003be973ade36d84</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1126%2Fscience.291.5502.319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.291.5502.319%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DNakatani%26aufirst%3DK.%26aulast%3DHara%26aufirst%3DM.%26aulast%3DMatsumori%26aufirst%3DA.%26aulast%3DSasayama%26aufirst%3DS.%26aulast%3DMizoguchi%26aufirst%3DA.%26aulast%3DHiai%26aufirst%3DH.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DAutoimmune%2520dilated%2520cardiomyopathy%2520in%2520PD-1%2520receptor-deficient%2520mice%26jtitle%3DScience%26date%3D2001%26volume%3D291%26spage%3D319%26epage%3D322%26doi%3D10.1126%2Fscience.291.5502.319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1016/S1074-7613(00)80089-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2FS1074-7613%2800%2980089-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10485649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADyaK1MXlvVShsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1999&pages=141-151&author=H.+Nishimuraauthor=M.+Noseauthor=H.+Hiaiauthor=N.+Minatoauthor=T.+Honjo&title=Development+of+lupus-like+autoimmune+diseases+by+disruption+of+the+PD-1+gene+encoding+an+ITIM+motif-carrying+immunoreceptor&doi=10.1016%2FS1074-7613%2800%2980089-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor</span></div><div class="casAuthors">Nishimura, Hiroyuki; Nose, Masato; Hiai, Hiroshi; Minato, Nagahiro; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-151</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PD-1, a 55 kDa transmembrane protein contg. an immunoreceptor tyrosine-based inhibitory motif, is induced in lymphocytes and monocytes following activation.  Aged C57BL/6(B6)-PD-1-/- congenic mice spontaneously developed characteristic lupus-like proliferative arthritis and glomerulonephritis with predominant IgG3 deposition, which were markedly accelerated by introduction of a Fas mutation (lpr).  Introduction of a PD-1 null mutation into the 2C-TCR (anti-H-2Ld) transgenic mice of the H-2b/d background resulted in the chronic and systemic graft-vs.- host-like disease.  Furthermore, CD8+2C-TCR+PD-1-/- T cells exhibited markedly augmented proliferation in vitro in response to H-2d allogeneic cells.  Collectively, it is suggested that PD-1 is involved in the maintenance of peripheral self-tolerance by serving as a neg. regulator of immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHFuMDDfhG3bVg90H21EOLACvtfcHk0lgzL6eiijVYrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvVShsb8%253D&md5=f627767082377fb523671a1635cb0a8f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2800%2980089-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252800%252980089-8%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DNose%26aufirst%3DM.%26aulast%3DHiai%26aufirst%3DH.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520lupus-like%2520autoimmune%2520diseases%2520by%2520disruption%2520of%2520the%2520PD-1%2520gene%2520encoding%2520an%2520ITIM%2520motif-carrying%2520immunoreceptor%26jtitle%3DImmunity%26date%3D1999%26volume%3D11%26spage%3D141%26epage%3D151%26doi%3D10.1016%2FS1074-7613%2800%2980089-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labarriere, N.</span></span> <span> </span><span class="NLM_article-title">PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e1364828</span>, <span class="refDoi"> DOI: 10.1080/2162402X.2017.1364828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1080%2F2162402X.2017.1364828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFajtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=e1364828&author=S.+Simonauthor=N.+Labarriere&title=PD-1+expression+on+tumor-specific+T+cells%3A+Friend+or+foe+for+immunotherapy%3F&doi=10.1080%2F2162402X.2017.1364828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?</span></div><div class="casAuthors">Simon, Sylvain; Labarriere, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1364828/1-e1364828/7</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Inhibitory properties of PD-1 receptor engagement on activated T cells are well established in physiol. and pathol. contexts.  In cancer, the use of checkpoint blockade, such as anti-PD-1 antibodies, becomes progressively a ref. treatment of a growing no. of tumors.  Nonetheless, it is also established that PD-1 expression on antigen-specific T cells reflects the functional avidity and anti-tumor reactivity of these T cells.  We will discuss this dual significance of PD-1 expression on tumor-specific T cells, due to a complex regulation and the opportunity to exploit this expression to define, monitor and exploit tumor-reactive T cells for immunotherapy purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzOU6-AtgPlbVg90H21EOLACvtfcHk0lgzL6eiijVYrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFajtrnF&md5=f2b520772c0462f652888e45fe2cd4f6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2017.1364828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2017.1364828%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DS.%26aulast%3DLabarriere%26aufirst%3DN.%26atitle%3DPD-1%2520expression%2520on%2520tumor-specific%2520T%2520cells%253A%2520Friend%2520or%2520foe%2520for%2520immunotherapy%253F%26jtitle%3DOncoimmunology%26date%3D2018%26volume%3D7%26spage%3De1364828%26doi%3D10.1080%2F2162402X.2017.1364828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span> <span> </span><span class="NLM_article-title">Expression of programmed death 1 ligands by murine T cells and APC</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">5538</span>– <span class="NLM_lpage">5545</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.169.10.5538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.4049%2Fjimmunol.169.10.5538" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2002&pages=5538-5545&author=T.+Yamazakiauthor=H.+Akibaauthor=H.+Iwaiauthor=H.+Matsudaauthor=M.+Aokiauthor=Y.+Tannoauthor=T.+Shinauthor=H.+Tsuchiyaauthor=D.+M.+Pardollauthor=K.+Okumuraauthor=M.+Azumaauthor=H.+Yagita&title=Expression+of+programmed+death+1+ligands+by+murine+T+cells+and+APC&doi=10.4049%2Fjimmunol.169.10.5538"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.169.10.5538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.169.10.5538%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DAkiba%26aufirst%3DH.%26aulast%3DIwai%26aufirst%3DH.%26aulast%3DMatsuda%26aufirst%3DH.%26aulast%3DAoki%26aufirst%3DM.%26aulast%3DTanno%26aufirst%3DY.%26aulast%3DShin%26aufirst%3DT.%26aulast%3DTsuchiya%26aufirst%3DH.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DOkumura%26aufirst%3DK.%26aulast%3DAzuma%26aufirst%3DM.%26aulast%3DYagita%26aufirst%3DH.%26atitle%3DExpression%2520of%2520programmed%2520death%25201%2520ligands%2520by%2520murine%2520T%2520cells%2520and%2520APC%26jtitle%3DJ.%2520Immunol.%26date%3D2002%26volume%3D169%26spage%3D5538%26epage%3D5545%26doi%3D10.4049%2Fjimmunol.169.10.5538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keir, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">PD-1 and its ligands in tolerance and immunity</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.26.021607.090331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1146%2Fannurev.immunol.26.021607.090331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=18173375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=677-704&author=M.+E.+Keirauthor=M.+J.+Butteauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=PD-1+and+its+ligands+in+tolerance+and+immunity&doi=10.1146%2Fannurev.immunol.26.021607.090331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 and its ligands in tolerance and immunity</span></div><div class="casAuthors">Keir, Mary E.; Butte, Manish J.; Freeman, Gordon J.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">677-704</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathol.  Immune responses to foreign and self-antigens require specific and balanced responses to clear pathogens and tumors and yet maintain tolerance.  Induction and maintenance of T cell tolerance requires PD-1, and its ligand PD-L1 on nonhematopoietic cells can limit effector T cell responses and protect tissues from immune-mediated tissue damage.  The PD-1:PD-L pathway also has been usurped by microorganisms and tumors to attenuate antimicrobial or tumor immunity and facilitate chronic infection and tumor survival.  The identification of B7-1 as an addnl. binding partner for PD-L1, together with the discovery of an inhibitory bidirectional interaction between PD-L1 and B7-1, reveals new ways the B7:CD28 family regulates T cell activation and tolerance.  In this review, we discuss current understanding of the immunoregulatory functions of PD-1 and its ligands and their therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTbTIs2Ruos7Vg90H21EOLACvtfcHk0lg1crB8D8HAPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWktrY%253D&md5=4b9b36a8716b8b1b47b7953f134448cf</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.26.021607.090331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.26.021607.090331%26sid%3Dliteratum%253Aachs%26aulast%3DKeir%26aufirst%3DM.%2BE.%26aulast%3DButte%26aufirst%3DM.%2BJ.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DPD-1%2520and%2520its%2520ligands%2520in%2520tolerance%2520and%2520immunity%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D26%26spage%3D677%26epage%3D704%26doi%3D10.1146%2Fannurev.immunol.26.021607.090331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourque, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitz, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenkovich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1084/jem.192.7.1027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1084%2Fjem.192.7.1027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=11015443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFSlt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2000&pages=1027-1034&author=G.+J.+Freemanauthor=A.+J.+Longauthor=Y.+Iwaiauthor=K.+Bourqueauthor=T.+Chernovaauthor=H.+Nishimuraauthor=L.+J.+Fitzauthor=N.+Malenkovichauthor=T.+Okazakiauthor=M.+C.+Byrneauthor=H.+F.+Hortonauthor=L.+Fouserauthor=L.+Carterauthor=V.+Lingauthor=M.+R.+Bowmanauthor=B.+M.+Carrenoauthor=M.+Collinsauthor=C.+R.+Woodauthor=T.+Honjo&title=Engagement+of+the+PD-1+immunoinhibitory+receptor+by+a+novel+B7+family+member+leads+to+negative+regulation+of+lymphocyte+activation&doi=10.1084%2Fjem.192.7.1027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</span></div><div class="casAuthors">Freeman, Gordon J.; Long, Andrew J.; Iwai, Yoshiko; Bourque, Karen; Chernova, Tatyana; Nishimura, Hiroyuki; Fitz, Lori J.; Malenkovich, Nelly; Okazaki, Taku; Byrne, Michael C.; Horton, Heidi F.; Fouser, Lynette; Carter, Laura; Ling, Vincent; Bowman, Michael R.; Carreno, Beatriz M.; Collins, Mary; Wood, Clive R.; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1027-1034</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">PD-1 is an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells.  Mice deficient in PD-1 exhibit a breakdown of peripheral tolerance and demonstrate multiple autoimmune features.  The authors report here that the ligand of PD-1 (PD-L1) is a member of the B7 gene family.  Engagement of PD-1 by PD-L1 leads to the inhibition of T cell receptor-mediated lymphocyte proliferation and cytokine secretion.  In addn., PD-1 signaling can inhibit at least suboptimal levels of CD28-mediated costimulation.  PD-L1 is expressed by antigen-presenting cells, including human peripheral blood monocytes stimulated with interferon γ, and activated human and murine dendritic cells.  In addn., PD-L1 is expressed in nonlymphoid tissues such as heart and lung.  The relative levels of inhibitory PD-L1 and costimulatory B7-1/B7-2 signals on antigen-presenting cells may det. the extent of T cell activation and consequently the threshold between tolerance and autoimmunity.  PD-L1 expression on nonlymphoid tissues and its potential interaction with PD-1 may subsequently det. the extent of immune responses at sites of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZIeEjiecqBbVg90H21EOLACvtfcHk0lg1crB8D8HAPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFSlt7o%253D&md5=bc1499033282cd9dbfa396a4e2697f6e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1084%2Fjem.192.7.1027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.192.7.1027%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DBourque%26aufirst%3DK.%26aulast%3DChernova%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DFitz%26aufirst%3DL.%2BJ.%26aulast%3DMalenkovich%26aufirst%3DN.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DByrne%26aufirst%3DM.%2BC.%26aulast%3DHorton%26aufirst%3DH.%2BF.%26aulast%3DFouser%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DV.%26aulast%3DBowman%26aufirst%3DM.%2BR.%26aulast%3DCarreno%26aufirst%3DB.%2BM.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DC.%2BR.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DEngagement%2520of%2520the%2520PD-1%2520immunoinhibitory%2520receptor%2520by%2520a%2520novel%2520B7%2520family%2520member%2520leads%2520to%2520negative%2520regulation%2520of%2520lymphocyte%2520activation%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D192%26spage%3D1027%26epage%3D1034%26doi%3D10.1084%2Fjem.192.7.1027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">PD-1 and PD-1 ligands: from discovery to clinical application</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">824</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxm057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1093%2Fintimm%2Fdxm057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=17606980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtValtbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=813-824&author=T.+Okazakiauthor=T.+Honjo&title=PD-1+and+PD-1+ligands%3A+from+discovery+to+clinical+application&doi=10.1093%2Fintimm%2Fdxm057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 and PD-1 ligands: from discovery to clinical application</span></div><div class="casAuthors">Okazaki, Taku; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">813-824</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family neg. regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2.  Because of the wide range of ligand distribution in the body, its biol. significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunol. privilege.  In this review, the authors would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clin. application of PD-1 agonists and antagonists to various human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1eGKswQHDqbVg90H21EOLACvtfcHk0lg1crB8D8HAPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtValtbbO&md5=aca4a61a3d4bf65e0abb620510eb7f38</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxm057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxm057%26sid%3Dliteratum%253Aachs%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DPD-1%2520and%2520PD-1%2520ligands%253A%2520from%2520discovery%2520to%2520clinical%2520application%26jtitle%3DInt.%2520Immunol.%26date%3D2007%26volume%3D19%26spage%3D813%26epage%3D824%26doi%3D10.1093%2Fintimm%2Fdxm057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Latchman, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourque, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boussiotis, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenkovich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span> <span> </span><span class="NLM_article-title">PD-L2 is a second ligand for PD-1 and inhibits T cell activation</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1038/85330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2F85330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=11224527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhvVaksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=261-268&author=Y.+Latchmanauthor=C.+R.+Woodauthor=T.+Chernovaauthor=D.+Chaudharyauthor=M.+Bordeauthor=I.+Chernovaauthor=Y.+Iwaiauthor=A.+J.+Longauthor=J.+A.+Brownauthor=R.+Nunesauthor=E.+A.+Greenfieldauthor=K.+Bourqueauthor=V.+A.+Boussiotisauthor=L.+L.+Carterauthor=B.+M.+Carrenoauthor=N.+Malenkovichauthor=H.+Nishimuraauthor=T.+Okazakiauthor=T.+Honjoauthor=A.+H.+Sharpeauthor=G.+J.+Freeman&title=PD-L2+is+a+second+ligand+for+PD-1+and+inhibits+T+cell+activation&doi=10.1038%2F85330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L2 is a second ligand for PD-1 and inhibits T cell activation</span></div><div class="casAuthors">Latchman, Yvette; Wood, Clive R.; Chernova, Tatyana; Chaudhary, Divya; Borde, Madhuri; Chernova, Irene; Iwai, Yoshiko; Long, Andrew J.; Brown, Julia A.; Nunes, Raquel; Greenfield, Edward A.; Borque, Karen; Boussiotis, Vassiliki A.; Carter, Laura L.; Carreno, Beatriz M.; Malenkovich, Nelly; Nishimura, Hiroyuki; Okazaki, Taku; Honjo, Tasuku; Sharpe, Arlene H.; Freeman, Gordon J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-268</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Programmed death 1 (PD-1)-deficient mice develop a variety of autoimmune-like diseases, which suggests that this immunoinhibitory receptor plays an important role in tolerance.  The authors identify here PD-1 ligand 2 (PD-L2) as a second ligand for PD-1 and compare the function and expression of PD-L I and PD-L2.  Engagement of PD-I by PD-L2 dramatically inhibits T cell receptor (TCR)-mediated proliferation and cytokine prodn. by CD4+ T cells.  At low antigen concns., PD-L2-PD-1 interactions inhibit strong B7-CD28 signals.  In contrast, at high antigen concns., PD-L2-PD-I interactions reduce cytokine prodn. but do not inhibit T cell proliferation.  PD-L-PD-1 interactions lead to cell cycle arrest in G0/G1 but do not increase cell death.  In addn., ligation of PD-1 + TCR leads to rapid phosphorylation of SHP-2, as compared to TCR ligation alone.  PD-L expression was up-regulated on antigen-presenting cells by interferon γ treatment and was also present on some normal tissues and tumor cell lines.  Taken together, these studies show overlapping functions of PD-L1 and PD-L2 and indicate a key role for the PD-L-PD-1 pathway in regulating T cell responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqUwK7ud9M77Vg90H21EOLACvtfcHk0ljdyYTDNmqqBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhvVaksrc%253D&md5=5f22eb9ddfa496a760c07e235e9e2c8e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2F85330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F85330%26sid%3Dliteratum%253Aachs%26aulast%3DLatchman%26aufirst%3DY.%26aulast%3DWood%26aufirst%3DC.%2BR.%26aulast%3DChernova%26aufirst%3DT.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DBorde%26aufirst%3DM.%26aulast%3DChernova%26aufirst%3DI.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26aulast%3DBrown%26aufirst%3DJ.%2BA.%26aulast%3DNunes%26aufirst%3DR.%26aulast%3DGreenfield%26aufirst%3DE.%2BA.%26aulast%3DBourque%26aufirst%3DK.%26aulast%3DBoussiotis%26aufirst%3DV.%2BA.%26aulast%3DCarter%26aufirst%3DL.%2BL.%26aulast%3DCarreno%26aufirst%3DB.%2BM.%26aulast%3DMalenkovich%26aufirst%3DN.%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DHonjo%26aufirst%3DT.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26atitle%3DPD-L2%2520is%2520a%2520second%2520ligand%2520for%2520PD-1%2520and%2520inhibits%2520T%2520cell%2520activation%26jtitle%3DNat.%2520Immunol.%26date%3D2001%26volume%3D2%26spage%3D261%26epage%3D268%26doi%3D10.1038%2F85330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouser, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, B. M.</span></span> <span> </span><span class="NLM_article-title">PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">634</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1002%2F1521-4141%28200203%2932%3A3%3C634%3A%3AAID-IMMU634%3E3.0.CO%3B2-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=634-643&author=L.+L.+Carterauthor=L.+A.+Fouserauthor=J.+Jussifauthor=L.+Fitzauthor=B.+Dengauthor=C.+R.+Woodauthor=M.+Collinsauthor=T.+Honjoauthor=G.+J.+Freemanauthor=B.+M.+Carreno&title=PD-1%3APD-L+inhibitory+pathway+affects+both+CD4%2B+and+CD8%2B+T+cells+and+is+overcome+by+IL-2&doi=10.1002%2F1521-4141%28200203%2932%3A3%3C634%3A%3AAID-IMMU634%3E3.0.CO%3B2-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2F1521-4141%28200203%2932%3A3%3C634%3A%3AAID-IMMU634%3E3.0.CO%3B2-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-4141%2528200203%252932%253A3%253C634%253A%253AAID-IMMU634%253E3.0.CO%253B2-9%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DL.%2BL.%26aulast%3DFouser%26aufirst%3DL.%2BA.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DFitz%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DC.%2BR.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DHonjo%26aufirst%3DT.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DCarreno%26aufirst%3DB.%2BM.%26atitle%3DPD-1%253APD-L%2520inhibitory%2520pathway%2520affects%2520both%2520CD4%252B%2520and%2520CD8%252B%2520T%2520cells%2520and%2520is%2520overcome%2520by%2520IL-2%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2002%26volume%3D32%26spage%3D634%26epage%3D643%26doi%3D10.1002%2F1521-4141%28200203%2932%3A3%3C634%3A%3AAID-IMMU634%3E3.0.CO%3B2-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youngnak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, M.</span></span> <span> </span><span class="NLM_article-title">Differential binding properties of B7-H1 and B7-DC to programmed death-1</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">672</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/S0006-291X(03)01257-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2FS0006-291X%2803%2901257-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2003&pages=672-677&author=P.+Youngnakauthor=Y.+Kozonoauthor=H.+Kozonoauthor=H.+Iwaiauthor=N.+Otsukiauthor=H.+Jinauthor=K.+Omuraauthor=H.+Yagitaauthor=D.+M.+Pardollauthor=L.+Chenauthor=M.+Azuma&title=Differential+binding+properties+of+B7-H1+and+B7-DC+to+programmed+death-1&doi=10.1016%2FS0006-291X%2803%2901257-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2803%2901257-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252803%252901257-9%26sid%3Dliteratum%253Aachs%26aulast%3DYoungnak%26aufirst%3DP.%26aulast%3DKozono%26aufirst%3DY.%26aulast%3DKozono%26aufirst%3DH.%26aulast%3DIwai%26aufirst%3DH.%26aulast%3DOtsuki%26aufirst%3DN.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DOmura%26aufirst%3DK.%26aulast%3DYagita%26aufirst%3DH.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAzuma%26aufirst%3DM.%26atitle%3DDifferential%2520binding%2520properties%2520of%2520B7-H1%2520and%2520B7-DC%2520to%2520programmed%2520death-1%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D307%26spage%3D672%26epage%3D677%26doi%3D10.1016%2FS0006-291X%2803%2901257-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghiotto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serriari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truneh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, D.</span></span> <span> </span><span class="NLM_article-title">PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxq049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1093%2Fintimm%2Fdxq049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=20587542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Oit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=651-660&author=M.+Ghiottoauthor=L.+Gauthierauthor=N.+Serriariauthor=S.+Pastorauthor=A.+Trunehauthor=J.+A.+Nunesauthor=D.+Olive&title=PD-L1+and+PD-L2+differ+in+their+molecular+mechanisms+of+interaction+with+PD-1&doi=10.1093%2Fintimm%2Fdxq049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1</span></div><div class="casAuthors">Ghiotto, Marguerite; Gauthier, Laurent; Serriari, Nacer; Pastor, Sonia; Truneh, Alemseged; Nunes, Jacques A.; Olive, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">651-660</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The programmed death-1 (PD-1) mol. is involved in peripheral tolerance and in the immune escape mechanisms during chronic viral infections and cancer.  PD-1 interacts with two ligands, PD-L1 and PD-L2.  We have investigated the mol. mechanisms of PD-1 interactions with its ligands by surface plasmon resonance and cell surface binding as well as the ability of the two ligands to compete for PD-1 binding.  PD-L1 and PD-L2 bound PD-1 with comparable affinities, but striking differences were obsd. at the level of the assocn. and dissocn. characteristics.  PD-L1, but not PD-L2, had a delayed interaction reminiscent of a phenomenon of conformational transition.  These mechanisms were confirmed by using PD-L1 mAbs that delayed the dissocn. of PD-L1 from PD-1.  This mechanism was not restricted to PD-1 binding since PD-L1 behaved in a similar manner with its second ligand, CD80.  Finally, we could demonstrate that PD-L1 and PD-L2 competed for PD-1 binding and conversely, an antagonist PD-1 mAb blocked both PD-L1 and PD-L2 binding to PD-1 and strongly enhanced T-cell proliferation.  These data further emphasize the differential mol. mechanisms of interaction of PD-L1 and PD-L2 with PD-1, and suggest possible new approach for the therapy of chronic infection, cancer and transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0NI_hTjJfRrVg90H21EOLACvtfcHk0ljdyYTDNmqqBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Oit74%253D&md5=ea53e559075444f0827d98fd1ccc1768</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxq049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxq049%26sid%3Dliteratum%253Aachs%26aulast%3DGhiotto%26aufirst%3DM.%26aulast%3DGauthier%26aufirst%3DL.%26aulast%3DSerriari%26aufirst%3DN.%26aulast%3DPastor%26aufirst%3DS.%26aulast%3DTruneh%26aufirst%3DA.%26aulast%3DNunes%26aufirst%3DJ.%2BA.%26aulast%3DOlive%26aufirst%3DD.%26atitle%3DPD-L1%2520and%2520PD-L2%2520differ%2520in%2520their%2520molecular%2520mechanisms%2520of%2520interaction%2520with%2520PD-1%26jtitle%3DInt.%2520Immunol.%26date%3D2010%26volume%3D22%26spage%3D651%26epage%3D660%26doi%3D10.1093%2Fintimm%2Fdxq049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamanishi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, S.</span></span> <span> </span><span class="NLM_article-title">Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">3360</span>– <span class="NLM_lpage">3365</span>, <span class="refDoi"> DOI: 10.1073/pnas.0611533104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1073%2Fpnas.0611533104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=17360651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtVWlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=3360-3365&author=J.+Hamanishiauthor=M.+Mandaiauthor=M.+Iwasakiauthor=T.+Okazakiauthor=Y.+Tanakaauthor=K.+Yamaguchiauthor=T.+Higuchiauthor=H.+Yagiauthor=K.+Takakuraauthor=N.+Minatoauthor=T.+Honjoauthor=S.+Fujii&title=Programmed+cell+death+1+ligand+1+and+tumor-infiltrating+CD8%2B+T+lymphocytes+are+prognostic+factors+of+human+ovarian+cancer&doi=10.1073%2Fpnas.0611533104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer</span></div><div class="casAuthors">Hamanishi, Junzo; Mandai, Masaki; Iwasaki, Masashi; Okazaki, Taku; Tanaka, Yoshimasa; Yamaguchi, Ken; Higuchi, Toshihiro; Yagi, Haruhiko; Takakura, Kenji; Minato, Nagahiro; Honjo, Tasuku; Fujii, Shingo</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3360-3365</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The ligands for programmed cell death 1 (PD-1), an immunoinhibitory receptor belonging to CD28/cytotoxic T lymphocyte antigen 4 family, are PD-1 ligand 1 and 2 (PD-Ls).  Recent reports suggest that the aberrant expression of PD-Ls on tumor cells impairs antitumor immunity, resulting in the immune evasion of the tumor cells.  Although an inverse correlation between the expression level of PD-Ls and patients' prognosis has been reported for several malignant tumors, the follow-up period was limited because of the lack of the antibody (Ab) applicable to paraffin-embedded specimens.  Here the authors generated a new Ab against PD-1 ligand 1 (PD-L1) and analyzed the expression level of PD-Ls in human ovarian cancer using paraffin-embedded specimens.  Patients with higher expression of PD-L1 had a significantly poorer prognosis than patients with lower expression.  Although patients with higher expression of PD-1 ligand 2 also had a poorer prognosis, the difference was not statistically significant.  A significant inverse correlation was obsd. between PD-L1 expression and the intraepithelial CD8+ T lymphocyte count, suggesting that PD-L1 on tumor cells directly suppresses antitumor CD8+ T cells.  Multivariate anal. showed the expression of PD-L1 on tumor cells and intraepithelial CD8+ T lymphocyte count are independent prognostic factors.  The PD-1/PD-L pathway can be a good target for restoring antitumor immunity in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8qybSgtrVmLVg90H21EOLACvtfcHk0lj-XInJcnSYtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtVWlt7s%253D&md5=0be1fefec8110b344e8279b2d16da88a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0611533104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0611533104%26sid%3Dliteratum%253Aachs%26aulast%3DHamanishi%26aufirst%3DJ.%26aulast%3DMandai%26aufirst%3DM.%26aulast%3DIwasaki%26aufirst%3DM.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DHiguchi%26aufirst%3DT.%26aulast%3DYagi%26aufirst%3DH.%26aulast%3DTakakura%26aufirst%3DK.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DHonjo%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DS.%26atitle%3DProgrammed%2520cell%2520death%25201%2520ligand%25201%2520and%2520tumor-infiltrating%2520CD8%252B%2520T%2520lymphocytes%2520are%2520prognostic%2520factors%2520of%2520human%2520ovarian%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D3360%26epage%3D3365%26doi%3D10.1073%2Fpnas.0611533104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parsa, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parney, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cachola, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tihan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischel, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieper, R. O.</span></span> <span> </span><span class="NLM_article-title">Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1038/nm1517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnm1517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=17159987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FhtFOkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=84-88&author=A.+T.+Parsaauthor=J.+S.+Waldronauthor=A.+Pannerauthor=C.+A.+Craneauthor=I.+F.+Parneyauthor=J.+J.+Barryauthor=K.+E.+Cacholaauthor=J.+C.+Murrayauthor=T.+Tihanauthor=M.+C.+Jensenauthor=P.+S.+Mischelauthor=D.+Stokoeauthor=R.+O.+Pieper&title=Loss+of+tumor+suppressor+PTEN+function+increases+B7-H1+expression+and+immunoresistance+in+glioma&doi=10.1038%2Fnm1517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma</span></div><div class="casAuthors">Parsa Andrew T; Waldron James S; Panner Amith; Crane Courtney A; Parney Ian F; Barry Jeffrey J; Cachola Kristine E; Murray Joseph C; Tihan Tarik; Jensen Michael C; Mischel Paul S; Stokoe David; Pieper Russell O</div><div class="citationInfo"><span class="NLM_cas:title">Nature medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-8</span>
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    </div><div class="casAbstract">Cancer immunoresistance and immune escape may play important roles in tumor progression and pose obstacles for immunotherapy.  Expression of the immunosuppressive protein B7 homolog 1 (B7-H1), also known as programmed death ligand-1 (PD-L1), is increased in many pathological conditions, including cancer.  Here we show that expression of the gene encoding B7-H1 increases post transcriptionally in human glioma after loss of phosphatase and tensin homolog (PTEN) and activation of the phosphatidylinositol-3-OH kinase (PI(3)K) pathway.  Tumor specimens from individuals with glioblastoma multiforme (GBM) had levels of B7-H1 protein that correlated with PTEN loss, and tumor-specific T cells lysed human glioma targets expressing wild-type PTEN more effectively than those expressing mutant PTEN.  These data identify a previously unrecognized mechanism linking loss of the tumor suppressor PTEN with immunoresistance, mediated in part by B7-H1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbpgtPeBjOUT69zv1FsJFMfW6udTcc2eY6y47ACgSdP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FhtFOkuw%253D%253D&md5=5e270877e35126e5433af850053ce480</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnm1517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1517%26sid%3Dliteratum%253Aachs%26aulast%3DParsa%26aufirst%3DA.%2BT.%26aulast%3DWaldron%26aufirst%3DJ.%2BS.%26aulast%3DPanner%26aufirst%3DA.%26aulast%3DCrane%26aufirst%3DC.%2BA.%26aulast%3DParney%26aufirst%3DI.%2BF.%26aulast%3DBarry%26aufirst%3DJ.%2BJ.%26aulast%3DCachola%26aufirst%3DK.%2BE.%26aulast%3DMurray%26aufirst%3DJ.%2BC.%26aulast%3DTihan%26aufirst%3DT.%26aulast%3DJensen%26aufirst%3DM.%2BC.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DPieper%26aufirst%3DR.%2BO.%26atitle%3DLoss%2520of%2520tumor%2520suppressor%2520PTEN%2520function%2520increases%2520B7-H1%2520expression%2520and%2520immunoresistance%2520in%2520glioma%26jtitle%3DNat.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D84%26epage%3D88%26doi%3D10.1038%2Fnm1517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marzec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goradia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghunath, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paessler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wysocka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasik, M. A.</span></span> <span> </span><span class="NLM_article-title">Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274(PD-L1, B7-H1)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">20852</span>– <span class="NLM_lpage">20857</span>, <span class="refDoi"> DOI: 10.1073/pnas.0810958105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1073%2Fpnas.0810958105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=20852-20857&author=M.+Marzecauthor=Q.+Zhangauthor=A.+Goradiaauthor=P.+N.+Raghunathauthor=X.+B.+Liuauthor=M.+Paesslerauthor=H.+Y.+Wangauthor=M.+Wysockaauthor=M.+G.+Chengauthor=B.+A.+Ruggeriauthor=M.+A.+Wasik&title=Oncogenic+kinase+NPM%2FALK+induces+through+STAT3+expression+of+immunosuppressive+protein+CD274%28PD-L1%2C+B7-H1%29&doi=10.1073%2Fpnas.0810958105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0810958105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0810958105%26sid%3Dliteratum%253Aachs%26aulast%3DMarzec%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGoradia%26aufirst%3DA.%26aulast%3DRaghunath%26aufirst%3DP.%2BN.%26aulast%3DLiu%26aufirst%3DX.%2BB.%26aulast%3DPaessler%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DWysocka%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DM.%2BG.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DWasik%26aufirst%3DM.%2BA.%26atitle%3DOncogenic%2520kinase%2520NPM%252FALK%2520induces%2520through%2520STAT3%2520expression%2520of%2520immunosuppressive%2520protein%2520CD274%2528PD-L1%252C%2520B7-H1%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D20852%26epage%3D20857%26doi%3D10.1073%2Fpnas.0810958105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeng, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. S.</span></span> <span> </span><span class="NLM_article-title">IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells</span>. <i>J. Dermatol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/j.jdermsci.2005.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.jdermsci.2005.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=16085391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFSmtrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2005&pages=95-103&author=S.+K.+Leeauthor=S.+H.+Seoauthor=B.+S.+Kimauthor=C.+D.+Kimauthor=J.+H.+Leeauthor=J.+S.+Kangauthor=P.+J.+Maengauthor=J.+S.+Lim&title=IFN-gamma+regulates+the+expression+of+B7-H1+in+dermal+fibroblast+cells&doi=10.1016%2Fj.jdermsci.2005.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells</span></div><div class="casAuthors">Lee, Sang-Keun; Seo, Sam-Hwa; Kim, Byoung-Soo; Kim, Chang-Deok; Lee, Jeung-Hoon; Kang, Jung-Soo; Maeng, Pil Jae; Lim, Jong-Soon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatological Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-103</span>CODEN:
                <span class="NLM_cas:coden">JDSCEI</span>;
        ISSN:<span class="NLM_cas:issn">0923-1811</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Programmed cell death ligand 1 (B7-H1) was recently cloned in antigen presenting cells (APCs) and represents a third member of the B7 family.  Thus, B7-H1 may be a novel target for clin. intervention in human inflammatory disease.  The aim of this study is to investigate the signal transduction mechanism and transcriptional regulation of B7-H1 expression in human dermal fibroblasts.  We performed reverse transcription PCR (RT-PCR) for the detection of mRNA expression, luciferase reporter assays with B7-H1 promoter constructs, and Western blot anal.  From RT-PCR anal., IFN-γ can induce the expression of B7-H1 mRNA in dermal fibroblast.  This expression is similar to the results of luciferase reporter assay with B7-H1 promoter.  Western blot anal. and EMSA revealed that NF-κB transcription factors mediate the induction of B7-H1 expression via the transient phosphorylation of ERK1/2 and PI3K when cells are stimulated by IFN-γ.  Also, Specific destruction of the NF-κB binding site abolished the induction of the promoter activity by IFN-γ.  Our data not only provides the first evidence to demonstrate that dermal fibroblast express the B7-H1 mRNA in the process of skin inflammation, but also suggests the involvement of NF-κB and MAPK and PI3K, that may play some important roles in inflammation process in human skin diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvsU0FiZBZ2bVg90H21EOLACvtfcHk0li6VqhSv7eQRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFSmtrzE&md5=7a614c95c8aa3f2d9e7dc37f57c96608</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.jdermsci.2005.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jdermsci.2005.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DSeo%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DB.%2BS.%26aulast%3DKim%26aufirst%3DC.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DMaeng%26aufirst%3DP.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%2BS.%26atitle%3DIFN-gamma%2520regulates%2520the%2520expression%2520of%2520B7-H1%2520in%2520dermal%2520fibroblast%2520cells%26jtitle%3DJ.%2520Dermatol.%2520Sci.%26date%3D2005%26volume%3D40%26spage%3D95%26epage%3D103%26doi%3D10.1016%2Fj.jdermsci.2005.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phamduy, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span> <span> </span><span class="NLM_article-title">Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2007.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.immuni.2007.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=17629517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=111-122&author=M.+J.+Butteauthor=M.+E.+Keirauthor=T.+B.+Phamduyauthor=A.+H.+Sharpeauthor=G.+J.+Freeman&title=Programmed+death-1+ligand+1+interacts+specifically+with+the+B7-1+costimulatory+molecule+to+inhibit+T+cell+responses&doi=10.1016%2Fj.immuni.2007.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed Death-1 Ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</span></div><div class="casAuthors">Butte, Manish J.; Keir, Mary E.; Phamduy, Theresa B.; Sharpe, Arlene H.; Freeman, Gordon J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-122</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Pathways in the B7:CD28 family of costimulatory mols. regulate T cell activation and tolerance.  B7-dependent responses in Cd28-/- Ctla4-/- T cells together with reports of stimulatory and inhibitory functions for Programmed Death-1 Ligand 1 or 2 mols. (PD-L1 or PD-L2) have suggested addnl. receptors for these B7 family members.  The authors show that B7-1 and PD-L1 interacted with affinity intermediate to that of B7-1:CD28 and B7-1:CTLA-4.  The PD-L1:B7-1 interface overlapped with the B7-1:CTLA-4 and PD-L1:PD-1 (Programmed Death-1) interfaces.  T cell activation and cytokine prodn. were inhibited by the interaction of B7-1 with PD-L1.  The responses of PD-1-deficient vs. PD-1,B7-1 double-deficient T cells to PD-L1 and of CD28,CTLA-4 double-deficient vs. CD28,CTLA-4,PD-L1 triple-deficient T cells to B7-1 demonstrated that PD-L1 and B7-1 interact specifically to inhibit T cell activation.  The authors' findings point to a substantial bidirectional inhibitory interaction between B7-1 and PD-L1 and add an addnl. dimension to immunoregulatory functions of the B7:CD28 family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMR5dpv_Vr5LVg90H21EOLACvtfcHk0li6VqhSv7eQRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFeqtrk%253D&md5=8fabef0e1244a1d356378867d92a248e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2007.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2007.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DButte%26aufirst%3DM.%2BJ.%26aulast%3DKeir%26aufirst%3DM.%2BE.%26aulast%3DPhamduy%26aufirst%3DT.%2BB.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26atitle%3DProgrammed%2520death-1%2520ligand%25201%2520interacts%2520specifically%2520with%2520the%2520B7-1%2520costimulatory%2520molecule%2520to%2520inhibit%2520T%2520cell%2520responses%26jtitle%3DImmunity%26date%3D2007%26volume%3D27%26spage%3D111%26epage%3D122%26doi%3D10.1016%2Fj.immuni.2007.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tumeh, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harview, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yearley, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shintaku, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spasic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciobanu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivork, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seja, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaspy, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elashoff, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">PD-1 blockade induces responses by inhibiting adaptive immune resistance</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>515</i></span>,  <span class="NLM_fpage">568</span>– <span class="NLM_lpage">571</span>, <span class="refDoi"> DOI: 10.1038/nature13954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnature13954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25428505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFanu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=515&publication_year=2014&pages=568-571&author=P.+C.+Tumehauthor=C.+L.+Harviewauthor=J.+H.+Yearleyauthor=I.+P.+Shintakuauthor=E.+J.+Taylorauthor=L.+Robertauthor=B.+Chmielowskiauthor=M.+Spasicauthor=G.+Henryauthor=V.+Ciobanuauthor=A.+N.+Westauthor=M.+Carmonaauthor=C.+Kivorkauthor=E.+Sejaauthor=G.+Cherryauthor=A.+J.+Gutierrezauthor=T.+R.+Groganauthor=C.+Mateusauthor=G.+Tomasicauthor=J.+A.+Glaspyauthor=R.+O.+Emersonauthor=H.+Robinsauthor=R.+H.+Pierceauthor=D.+A.+Elashoffauthor=C.+Robertauthor=A.+Ribas&title=PD-1+blockade+induces+responses+by+inhibiting+adaptive+immune+resistance&doi=10.1038%2Fnature13954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 blockade induces responses by inhibiting adaptive immune resistance</span></div><div class="casAuthors">Tumeh, Paul C.; Harview, Christina L.; Yearley, Jennifer H.; Shintaku, I. Peter; Taylor, Emma J. M.; Robert, Lidia; Chmielowski, Bartosz; Spasic, Marko; Henry, Gina; Ciobanu, Voicu; West, Alisha N.; Carmona, Manuel; Kivork, Christine; Seja, Elizabeth; Cherry, Grace; Gutierrez, Antonio J.; Grogan, Tristan R.; Mateus, Christine; Tomasic, Gorana; Glaspy, John A.; Emerson, Ryan O.; Robins, Harlan; Pierce, Robert H.; Elashoff, David A.; Robert, Caroline; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">515</span>
        (<span class="NLM_cas:issue">7528</span>),
    <span class="NLM_cas:pages">568-571</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durable clin. responses in patients with various cancer types.  One mechanism by which cancer tissues limit the host immune response is via upregulation of PD-1 ligand (PD-L1) and its ligation to PD-1 on antigen-specific CD8+ T cells (termed adaptive immune resistance).  Here we show that pre-existing CD8+ T cells distinctly located at the invasive tumor margin are assocd. with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy.  We analyzed samples from 46 patients with metastatic melanoma obtained before and during anti-PD-1 therapy (pembrolizumab) using quant. immunohistochem., quant. multiplex immunofluorescence, and next-generation sequencing for T-cell antigen receptors (TCRs).  In serially sampled tumors, patients responding to treatment showed proliferation of intratumoral CD8+ T cells that directly correlated with radiog. redn. in tumor size.  Pre-treatment samples obtained from responding patients showed higher nos. of CD8-, PD-1- and PD-L1-expressing cells at the invasive tumor margin and inside tumors, with close proximity between PD-1 and PD-L1, and a more clonal TCR repertoire.  Using multivariate anal., we established a predictive model based on CD8 expression at the invasive margin and validated the model in an independent cohort of 15 patients.  Our findings indicate that tumor regression after therapeutic PD-1 blockade requires pre-existing CD8+ T cells that are neg. regulated by PD-1/PD-L1-mediated adaptive immune resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHvr5NAB5kD7Vg90H21EOLACvtfcHk0li6VqhSv7eQRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFanu7jL&md5=df43fa2237e9e66d99ad230159e0fe9e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnature13954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13954%26sid%3Dliteratum%253Aachs%26aulast%3DTumeh%26aufirst%3DP.%2BC.%26aulast%3DHarview%26aufirst%3DC.%2BL.%26aulast%3DYearley%26aufirst%3DJ.%2BH.%26aulast%3DShintaku%26aufirst%3DI.%2BP.%26aulast%3DTaylor%26aufirst%3DE.%2BJ.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DSpasic%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DG.%26aulast%3DCiobanu%26aufirst%3DV.%26aulast%3DWest%26aufirst%3DA.%2BN.%26aulast%3DCarmona%26aufirst%3DM.%26aulast%3DKivork%26aufirst%3DC.%26aulast%3DSeja%26aufirst%3DE.%26aulast%3DCherry%26aufirst%3DG.%26aulast%3DGutierrez%26aufirst%3DA.%2BJ.%26aulast%3DGrogan%26aufirst%3DT.%2BR.%26aulast%3DMateus%26aufirst%3DC.%26aulast%3DTomasic%26aufirst%3DG.%26aulast%3DGlaspy%26aufirst%3DJ.%2BA.%26aulast%3DEmerson%26aufirst%3DR.%2BO.%26aulast%3DRobins%26aufirst%3DH.%26aulast%3DPierce%26aufirst%3DR.%2BH.%26aulast%3DElashoff%26aufirst%3DD.%2BA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DPD-1%2520blockade%2520induces%2520responses%2520by%2520inhibiting%2520adaptive%2520immune%2520resistance%26jtitle%3DNature%26date%3D2014%26volume%3D515%26spage%3D568%26epage%3D571%26doi%3D10.1038%2Fnature13954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span> <span> </span><span class="NLM_article-title">Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">12293</span>– <span class="NLM_lpage">12297</span>, <span class="refDoi"> DOI: 10.1073/pnas.192461099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1073%2Fpnas.192461099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=12218188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD38XntlCksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=12293-12297&author=Y.+Iwaiauthor=M.+Ishidaauthor=Y.+Tanakaauthor=T.+Okazakiauthor=T.+Honjoauthor=N.+Minato&title=Involvement+of+PD-L1+on+tumor+cells+in+the+escape+from+host+immune+system+and+tumor+immunotherapy+by+PD-L1+blockade&doi=10.1073%2Fpnas.192461099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade</span></div><div class="casAuthors">Iwai, Yoshiko; Ishida, Masayoshi; Tanaka, Yoshimasa; Okazaki, Taku; Honjo, Tasuku; Minato, Nagahiro</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">12293-12297</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">PD-1 is a receptor of the Ig superfamily that neg. regulates T cell antigen receptor signaling by interacting with the specific ligands (PD-L) and is suggested to play a role in the maintenance of self-tolerance.  In the present study, we examd. possible roles of the PD-1/PD-L system in tumor immunity.  Transgenic expression of PD-L1, one of the PD-L, in P815 tumor cells rendered them less susceptible to the specific T cell antigen receptor-mediated lysis by cytotoxic T cells in vitro, and markedly enhanced their tumorigenesis and invasiveness in vivo in the syngeneic hosts as compared with the parental tumor cells that lacked endogenous PD-L.  Both effects could be reversed by anti-PD-L1 Ab.  Survey of murine tumor lines revealed that all of the myeloma cell lines examd. naturally expressed PD-L1.  Growth of the myeloma cells in normal syngeneic mice was inhibited significantly albeit transiently by the administration of anti-PD-L1 Ab in vivo and was suppressed completely in the syngeneic PD-1-deficient mice.  These results suggest that the expression of PD-L1 can serve as a potent mechanism for potentially immunogenic tumors to escape from host immune responses and that blockade of interaction between PD-1 and PD-L may provide a promising strategy for specific tumor immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMFtH51vQ-YbVg90H21EOLACvtfcHk0lg_79ZnvXbDCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntlCksL8%253D&md5=d6fda8be518526bf50e89fd9a44a8060</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1073%2Fpnas.192461099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.192461099%26sid%3Dliteratum%253Aachs%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DIshida%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DHonjo%26aufirst%3DT.%26aulast%3DMinato%26aufirst%3DN.%26atitle%3DInvolvement%2520of%2520PD-L1%2520on%2520tumor%2520cells%2520in%2520the%2520escape%2520from%2520host%2520immune%2520system%2520and%2520tumor%2520immunotherapy%2520by%2520PD-L1%2520blockade%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D12293%26epage%3D12297%26doi%3D10.1073%2Fpnas.192461099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strome, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomao, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flies, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennon, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1038/nm730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnm730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=12091876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls12msLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=793-800&author=H.+Dongauthor=S.+E.+Stromeauthor=D.+R.+Salomaoauthor=H.+Tamuraauthor=F.+Hiranoauthor=D.+B.+Fliesauthor=P.+C.+Rocheauthor=J.+Luauthor=G.+Zhuauthor=K.+Tamadaauthor=V.+A.+Lennonauthor=E.+Celisauthor=L.+Chen&title=Tumor-associated+B7-H1+promotes+T-cell+apoptosis%3A+A+potential+mechanism+of+immune+evasion&doi=10.1038%2Fnm730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion</span></div><div class="casAuthors">Dong, Haidong; Strome, Scott E.; Salomao, Diva R.; Tamura, Hideto; Hirano, Fumiya; Flies, Dallas B.; Roche, Patrick C.; Lu, Jun; Zhu, Gefeng; Tamada, Koji; Lennon, Vanda A.; Celis, Esteban; Chen, Lieping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">793-800</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B7-H1, a recently described member of the B7 family of costimulatory mols., is thought to be involved in the regulation of cellular and humoral immune responses through the PD-1 receptor on activated T and B cells.  We report here that, except for cells of the macrophage lineage, normal human tissues do not express B7-H1.  In contrast, B7-H1 is abundant in human carcinomas of lung, ovary and colon and in melanomas.  The pro-inflammatory cytokine interferon-γ upregulates B7-H1 on the surface of tumor cell lines.  Cancer cell-assocd. B7-H1 increases apoptosis of antigen-specific human T-cell clones in vitro, and the apoptotic effect of B7-H1 is mediated largely by one or more receptors other than PD-1.  In addn., expression of B7-H1 on mouse P815 tumor increases apoptosis of activated tumor-reactive T cells and promotes the growth of highly immunogenic B7-1+ tumors in vivo.  These findings have implications for the design of T cell-based cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo8Nj_X-lk-7Vg90H21EOLACvtfcHk0lg_79ZnvXbDCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls12msLo%253D&md5=a5a1fae0101d6b100eb456c4e4b4d5dc</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fnm730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm730%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DH.%26aulast%3DStrome%26aufirst%3DS.%2BE.%26aulast%3DSalomao%26aufirst%3DD.%2BR.%26aulast%3DTamura%26aufirst%3DH.%26aulast%3DHirano%26aufirst%3DF.%26aulast%3DFlies%26aufirst%3DD.%2BB.%26aulast%3DRoche%26aufirst%3DP.%2BC.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DG.%26aulast%3DTamada%26aufirst%3DK.%26aulast%3DLennon%26aufirst%3DV.%2BA.%26aulast%3DCelis%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DTumor-associated%2520B7-H1%2520promotes%2520T-cell%2520apoptosis%253A%2520A%2520potential%2520mechanism%2520of%2520immune%2520evasion%26jtitle%3DNat.%2520Med.%26date%3D2002%26volume%3D8%26spage%3D793%26epage%3D800%26doi%3D10.1038%2Fnm730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yearley, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunceford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. Q. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiwert, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomassini, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClanahan, T.</span></span> <span> </span><span class="NLM_article-title">PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3158</span>– <span class="NLM_lpage">3167</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-1761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1158%2F1078-0432.CCR-16-1761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=28619999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVSqurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3158-3167&author=J.+H.+Yearleyauthor=C.+Gibsonauthor=N.+Yuauthor=C.+Moonauthor=E.+Murphyauthor=J.+Jucoauthor=J.+Luncefordauthor=J.+Chengauthor=L.+Q.+M.+Chowauthor=T.+Y.+Seiwertauthor=M.+Handaauthor=J.+E.+Tomassiniauthor=T.+McClanahan&title=PD-L2+expression+in+human+tumors%3A+relevance+to+anti-PD-1+therapy+in+cancer&doi=10.1158%2F1078-0432.CCR-16-1761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer</span></div><div class="casAuthors">Yearley, Jennifer H.; Gibson, Christopher; Yu, Ni; Moon, Christina; Murphy, Erin; Juco, Jonathan; Lunceford, Jared; Cheng, Jonathan; Chow, Laura Q. M.; Seiwert, Tanguy Y.; Handa, Masahisa; Tomassini, Joanne E.; McClanahan, Terrill</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3158-3167</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Tumor-assocd. PD-L1 expression is predictive of clin. response to PD-1-directed immunotherapy.  However, PD-L1-neg. patients may also respond to PD-1 checkpoint blockade, suggesting that other PD-1 ligands may be relevant to the clin. activity of these therapies.  The prevalence of PD-L2, the other known ligand of PD-1, and its relationship to response to anti-PD-1 therapy were evaluated.  Exptl. Design: PD-L2 expression was assessed in archival tumor tissue from seven indications using a novel immunohistochem. assay.  In addn., relationships between clin. response and PD-L2 status were evaluated in tumor tissues from patients with head and neck squamous cell carcinoma (HNSCC) with recurrent or metastatic disease, treated with pembrolizumab.  Results: PD-L2 expression was obsd. in all tumor types and present in stromal, tumor, and endothelial cells.  The prevalence and distribution of PD-L2 correlated significantly with PD-L1 (P = 0.0012-<0.0001); however, PD-L2 was detected in the absence of PD-L1 in some tumor types.  Both PD-L1 and PD-L2 positivity significantly predicted clin. response to pembrolizumab on combined tumor, stromal and immune cells, with PD-L2 predictive independent of PD-L1.  Response was greater in patients pos. for both PD-L1 and PD-L2 (27.5%) than those pos. only for PD-L1 (11.4%).  PD-L2 status was also a significant predictor of progression-free survival (PFS) with pembrolizumab independent of PD-L1 status.  Longer median times for PFS and overall survival were obsd. for PD-L2-pos. than PD-L2-neg. patients.  Conclusions: Clin. response to pembrolizumab in patients with HNSCC may be related partly to blockade of PD-1/PD-L2 interactions.  Therapy targeting both PD-1 ligands may provide clin. benefit in these patients.  Clin Cancer Res; 23(12); 3158-67. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvguMmZLnrNbVg90H21EOLACvtfcHk0lg_79ZnvXbDCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVSqurbL&md5=3d66a39c89e87561ff0fec1a752bfd55</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-1761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-1761%26sid%3Dliteratum%253Aachs%26aulast%3DYearley%26aufirst%3DJ.%2BH.%26aulast%3DGibson%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DMoon%26aufirst%3DC.%26aulast%3DMurphy%26aufirst%3DE.%26aulast%3DJuco%26aufirst%3DJ.%26aulast%3DLunceford%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DChow%26aufirst%3DL.%2BQ.%2BM.%26aulast%3DSeiwert%26aufirst%3DT.%2BY.%26aulast%3DHanda%26aufirst%3DM.%26aulast%3DTomassini%26aufirst%3DJ.%2BE.%26aulast%3DMcClanahan%26aufirst%3DT.%26atitle%3DPD-L2%2520expression%2520in%2520human%2520tumors%253A%2520relevance%2520to%2520anti-PD-1%2520therapy%2520in%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D3158%26epage%3D3167%26doi%3D10.1158%2F1078-0432.CCR-16-1761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazar-Molnar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramagopal, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathenson, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almo, S. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the complex between programmed death-1(PD-1) and its ligand PD-L2</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">10483</span>– <span class="NLM_lpage">10488</span>, <span class="refDoi"> DOI: 10.1073/pnas.0804453105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1073%2Fpnas.0804453105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=10483-10488&author=E.+Lazar-Molnarauthor=Q.+Yanauthor=E.+Caoauthor=U.+Ramagopalauthor=S.+G.+Nathensonauthor=S.+C.+Almo&title=Crystal+structure+of+the+complex+between+programmed+death-1%28PD-1%29+and+its+ligand+PD-L2&doi=10.1073%2Fpnas.0804453105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0804453105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0804453105%26sid%3Dliteratum%253Aachs%26aulast%3DLazar-Molnar%26aufirst%3DE.%26aulast%3DYan%26aufirst%3DQ.%26aulast%3DCao%26aufirst%3DE.%26aulast%3DRamagopal%26aufirst%3DU.%26aulast%3DNathenson%26aufirst%3DS.%2BG.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520complex%2520between%2520programmed%2520death-1%2528PD-1%2529%2520and%2520its%2520ligand%2520PD-L2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D10483%26epage%3D10488%26doi%3D10.1073%2Fpnas.0804453105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veverka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radhakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muskett, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubberfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladbury, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikemizu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. J.</span></span> <span> </span><span class="NLM_article-title">Structure and interactions of the human programmed cell death 1 receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">11771</span>– <span class="NLM_lpage">11785</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.448126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1074%2Fjbc.M112.448126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=23417675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1OjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=11771-11785&author=X.+Chengauthor=V.+Veverkaauthor=A.+Radhakrishnanauthor=L.+C.+Watersauthor=F.+W.+Muskettauthor=S.+H.+Morganauthor=J.+Huoauthor=C.+Yuauthor=E.+J.+Evansauthor=A.+J.+Leslieauthor=M.+Griffithsauthor=C.+Stubberfieldauthor=R.+Griffinauthor=A.+J.+Henryauthor=A.+Janssonauthor=J.+E.+Ladburyauthor=S.+Ikemizuauthor=M.+D.+Carrauthor=S.+J.+Davis&title=Structure+and+interactions+of+the+human+programmed+cell+death+1+receptor&doi=10.1074%2Fjbc.M112.448126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and interactions of the human programmed cell death 1 receptor</span></div><div class="casAuthors">Cheng, Xiaoxiao; Veverka, Vaclav; Radhakrishnan, Anand; Waters, Lorna C.; Muskett, Frederick W.; Morgan, Sara H.; Huo, Jiandong; Yu, Chao; Evans, Edward J.; Leslie, Alasdair J.; Griffiths, Meryn; Stubberfield, Colin; Griffin, Robert; Henry, Alistair J.; Jansson, Andreas; Ladbury, John E.; Ikemizu, Shinji; Carr, Mark D.; Davis, Simon J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11771-11785</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">PD-1, a receptor expressed by T cells, B cells, and monocytes, is a potent regulator of immune responses and a promising therapeutic target.  The structure and interactions of human PD-1 are, however, incompletely characterized.  We present the soln. NMR-based structure of the human PD-1 extracellular region and detailed analyses of its interactions with its ligands, PD-L1 and PD-L2.  PD-1 has typical Ig superfamily topol. but differs at the edge of the GFCC' sheet, which is flexible and completely lacks a C'' strand.  Changes in PD-1 backbone NMR signals induced by ligand binding suggest that, whereas binding is centered on the GFCC' sheet, PD-1 is engaged by its two ligands differently and in ways incompletely explained by crystal structures of mouse PD-1·ligand complexes.  The affinities of these interactions and that of PD-L1 with the costimulatory protein B7-1, measured using surface plasmon resonance, are significantly weaker than expected.  The 3-4-fold greater affinity of PD-L2 vs. PD-L1 for human PD-1 is principally due to the 3-fold smaller dissocn. rate for PD-L2 binding.  Isothermal titrn. calorimetry revealed that the PD-1/PD-L1 interaction is entropically driven, whereas PD-1/PD-L2 binding has a large enthalpic component.  Math. simulations based on the biophys. data and quant. expression data suggest an unexpectedly limited contribution of PD-L2 to PD-1 ligation during interactions of activated T cells with antigen-presenting cells.  These findings provide a rigorous structural and biophys. framework for interpreting the important functions of PD-1 and reveal that potent inhibitory signaling can be initiated by weakly interacting receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5qIGEiutorbVg90H21EOLACvtfcHk0ljljtRpo_XaLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1OjtLo%253D&md5=b8fc26952e0562a4eaf3cbdf780fa88d</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.448126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.448126%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DVeverka%26aufirst%3DV.%26aulast%3DRadhakrishnan%26aufirst%3DA.%26aulast%3DWaters%26aufirst%3DL.%2BC.%26aulast%3DMuskett%26aufirst%3DF.%2BW.%26aulast%3DMorgan%26aufirst%3DS.%2BH.%26aulast%3DHuo%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DEvans%26aufirst%3DE.%2BJ.%26aulast%3DLeslie%26aufirst%3DA.%2BJ.%26aulast%3DGriffiths%26aufirst%3DM.%26aulast%3DStubberfield%26aufirst%3DC.%26aulast%3DGriffin%26aufirst%3DR.%26aulast%3DHenry%26aufirst%3DA.%2BJ.%26aulast%3DJansson%26aufirst%3DA.%26aulast%3DLadbury%26aufirst%3DJ.%2BE.%26aulast%3DIkemizu%26aufirst%3DS.%26aulast%3DCarr%26aufirst%3DM.%2BD.%26aulast%3DDavis%26aufirst%3DS.%2BJ.%26atitle%3DStructure%2520and%2520interactions%2520of%2520the%2520human%2520programmed%2520cell%2520death%25201%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D11771%26epage%3D11785%26doi%3D10.1074%2Fjbc.M112.448126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przetocka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Structure of the complex of human programmed death 1, PD-1, and Its ligand PD-L1</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2341</span>– <span class="NLM_lpage">2348</span>, <span class="refDoi"> DOI: 10.1016/j.str.2015.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.str.2015.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=26602187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWrsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2341-2348&author=K.+M.+Zakauthor=R.+Kitelauthor=S.+Przetockaauthor=P.+Golikauthor=K.+Guzikauthor=B.+Musielakauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Structure+of+the+complex+of+human+programmed+death+1%2C+PD-1%2C+and+Its+ligand+PD-L1&doi=10.1016%2Fj.str.2015.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1</span></div><div class="casAuthors">Zak, Krzysztof M.; Kitel, Radoslaw; Przetocka, Sara; Golik, Przemyslaw; Guzik, Katarzyna; Musielak, Bogdan; Domling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2341-2348</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Targeting the PD-1/PD-L1 immunol. checkpoint with monoclonal antibodies has recently provided breakthrough progress in the treatment of melanoma, non-small cell lung cancer, and other types of cancer.  Small-mol. drugs interfering with this pathway are highly awaited, but their development is hindered by insufficient structural information.  This study reveals the mol. details of the human PD-1/PD-L1 interaction based on an X-ray structure of the complex.  First, it is shown that the ligand binding to human PD-1 is assocd. with significant plasticity within the receptor.  Second, a detailed mol. map of the interaction surface is provided, allowing definition of the regions within both interacting partners that may likely be targeted by small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYnNEmCbOHlrVg90H21EOLACvtfcHk0ljljtRpo_XaLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWrsLzK&md5=da7dfb695e77f24d05ec4af4c586d615</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2015.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2015.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DKitel%26aufirst%3DR.%26aulast%3DPrzetocka%26aufirst%3DS.%26aulast%3DGolik%26aufirst%3DP.%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DStructure%2520of%2520the%2520complex%2520of%2520human%2520programmed%2520death%25201%252C%2520PD-1%252C%2520and%2520Its%2520ligand%2520PD-L1%26jtitle%3DStructure%26date%3D2015%26volume%3D23%26spage%3D2341%26epage%3D2348%26doi%3D10.1016%2Fj.str.2015.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo-Lopez, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czuczman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence-Bruckler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabanillas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lister, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallaire, B. K.</span></span> <span> </span><span class="NLM_article-title">Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2825</span>– <span class="NLM_lpage">2833</span>, <span class="refDoi"> DOI: 10.1200/JCO.1998.16.8.2825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1200%2FJCO.1998.16.8.2825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=9704735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADyaK1cXlsFCgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=2825-2833&author=P.+McLaughlinauthor=A.+J.+Grillo-Lopezauthor=B.+K.+Linkauthor=R.+Levyauthor=M.+S.+Czuczmanauthor=M.+E.+Williamsauthor=M.+R.+Heymanauthor=I.+Bence-Brucklerauthor=C.+A.+Whiteauthor=F.+Cabanillasauthor=V.+Jainauthor=A.+D.+Hoauthor=J.+Listerauthor=K.+Weyauthor=D.+Shenauthor=B.+K.+Dallaire&title=Rituximab+chimeric+Anti-CD20+monoclonal+antibody+therapy+for+relapsed+indolent+lymphoma%3A+half+of+patients+respond+to+a+four-dose+treatment+program&doi=10.1200%2FJCO.1998.16.8.2825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program</span></div><div class="casAuthors">McLaughlin, Peter; Grillo-Lopez, Antonio J.; Link, Brian K.; Levy, Ronald; Czuczman, Myron S.; Williams, Michael E.; Heyman, Meyer R.; Bence-Bruckler, Isabelle; White, Christine A.; Cabanillas, Fernando; Jain, Vinay; Ho, Anthony D.; Lister, John; Wey, Ken; Shen, David; Dallaire, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2825-2833</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">The CD20 antigen is expressed on more than 90% of B-cell lymphomas.  It is appealing for targeted therapy, because it does not shed or modulate.  A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies.  This was a multiinstitutional trial of the chimeric anti-CD20 antibody, IDEC-C2B8.  Patients with relapsed low grade or follicular lymphoma received an outpatient treatment course of IDEC-C2B8 375 mg/m2 i.v. weekly for four doses.  From 31 centers, 166 patients were entered.  Of this intent-to-treat group, 48% responded.  With a median follow-up duration of 11.8 mo, the projected median time to progression for responders is 13.0 mo.  Serum antibody levels were sustained longer after the fourth infusion than after the first, and were higher in responders and in patients with lower tumor burden.  The majority of adverse events occurred during the first infusion and were grade 1 or 2; fever and chills were the most common events.  Only 12% of patients had grade 3 and 3% grade 4 toxicities.  A human antichimeric antibody was detected in only one patient.  The response rate of 48% with IDECC2B8 is comparable to results with single-agent cytotoxic chemotherapy.  Toxicity was mild.  Attention needs to be paid to the rate of antibody infusion, with titrn. according to toxicity.  Further investigation of this agent is warranted, including its use in conjunction with std. chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrurijvS_ktjrVg90H21EOLACvtfcHk0ljljtRpo_XaLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlsFCgu7c%253D&md5=638b81d6fb177b32be40dc6056ced292</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1200%2FJCO.1998.16.8.2825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.1998.16.8.2825%26sid%3Dliteratum%253Aachs%26aulast%3DMcLaughlin%26aufirst%3DP.%26aulast%3DGrillo-Lopez%26aufirst%3DA.%2BJ.%26aulast%3DLink%26aufirst%3DB.%2BK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DCzuczman%26aufirst%3DM.%2BS.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DHeyman%26aufirst%3DM.%2BR.%26aulast%3DBence-Bruckler%26aufirst%3DI.%26aulast%3DWhite%26aufirst%3DC.%2BA.%26aulast%3DCabanillas%26aufirst%3DF.%26aulast%3DJain%26aufirst%3DV.%26aulast%3DHo%26aufirst%3DA.%2BD.%26aulast%3DLister%26aufirst%3DJ.%26aulast%3DWey%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DDallaire%26aufirst%3DB.%2BK.%26atitle%3DRituximab%2520chimeric%2520Anti-CD20%2520monoclonal%2520antibody%2520therapy%2520for%2520relapsed%2520indolent%2520lymphoma%253A%2520half%2520of%2520patients%2520respond%2520to%2520a%2520four-dose%2520treatment%2520program%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1998%26volume%3D16%26spage%3D2825%26epage%3D2833%26doi%3D10.1200%2FJCO.1998.16.8.2825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyland-Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajamonde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, L.</span></span> <span> </span><span class="NLM_article-title">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1056/NEJM200103153441101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJM200103153441101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=11248153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=783-792&author=D.+J.+Slamonauthor=B.+Leyland-Jonesauthor=S.+Shakauthor=H.+Fuchsauthor=V.+Patonauthor=A.+Bajamondeauthor=T.+Flemingauthor=W.+Eiermannauthor=J.+Wolterauthor=M.+Pegramauthor=J.+Baselgaauthor=L.+Norton&title=Use+of+chemotherapy+plus+a+monoclonal+antibody+against+HER2+for+metastatic+breast+cancer+that+overexpresses+HER2&doi=10.1056%2FNEJM200103153441101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span></div><div class="casAuthors">Slamon, Dennis J.; Leyland-Jones, Brian; Shak, Steven; Fuchs, Hank; Paton, Virginia; Bajamonde, Alex; Fleming, Thomas; Eiermann, Wolfgang; Wolter, Janet; Pegram, Mark; Baselga, Jose; Norton, Larry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">783-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 % of breast cancers, increasing the aggressiveness of the tumor.  We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2.  We randomly assigned 234 patients to receive std. chemotherapy plus trastuzumab.  Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide with (143 women) or without trastuzumab (138 women).  Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women).  The addn. of trastuzumab to chemotherapy was assocd. with a longer time to disease progression (median, 7.4 vs. 4.6 mo; P<0.001), a higher rate of objective response (50 % vs. 32 %, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 mo; P<0.001), a lower rate of death at 1 yr (22 % vs. 33 %, P=0.008), longer survival (median survival, 25.1 vs. 20.3 mo; P=0.046), and a 20 % redn. in the risk of death.  The most important adverse event was cardiac dysfunction, which occurred in 27 % of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 % of the group given an anthracycline and cyclophosphamide alone; 13 % of the group given paclitaxel and trastuzumab; and 1 % of the group given paclitaxel alone.  Although the cardiotoxicity was potentially severe and, in some cases, life-threatening, the symptoms generally improved with std. medical management.  Trastuzumab increases the clin. benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGK_4WWRZLKLVg90H21EOLACvtfcHk0ljOvr_j1dYV0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D&md5=81112f11ffc66fc3a898b61e104322b6</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1056%2FNEJM200103153441101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200103153441101%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DLeyland-Jones%26aufirst%3DB.%26aulast%3DShak%26aufirst%3DS.%26aulast%3DFuchs%26aufirst%3DH.%26aulast%3DPaton%26aufirst%3DV.%26aulast%3DBajamonde%26aufirst%3DA.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DWolter%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DNorton%26aufirst%3DL.%26atitle%3DUse%2520of%2520chemotherapy%2520plus%2520a%2520monoclonal%2520antibody%2520against%2520HER2%2520for%2520metastatic%2520breast%2520cancer%2520that%2520overexpresses%2520HER2%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D783%26epage%3D792%26doi%3D10.1056%2FNEJM200103153441101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levi-Schaffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">1407</span>– <span class="NLM_lpage">1424</span>, <span class="refDoi"> DOI: 10.1111/bph.13450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1111%2Fbph.13450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=26833433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC28XktV2ns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=1407-1424&author=S.+Carvalhoauthor=F.+Levi-Schafferauthor=M.+Selaauthor=Y.+Yarden&title=Immunotherapy+of+cancer%3A+from+monoclonal+to+oligoclonal+cocktails+of+anti-cancer+antibodies%3A+IUPHAR+Review+18&doi=10.1111%2Fbph.13450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18</span></div><div class="casAuthors">Carvalho, Silvia; Levi-Schaffer, Francesca; Sela, Michael; Yarden, Yosef</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1407-1424</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Antibody-based therapy of cancer employs monoclonal antibodies (mAbs) specific to sol. ligands, membrane antigens of T-lymphocytes or proteins located at the surface of cancer cells.  The latter mAbs are often combined with cytotoxic regimens, because they block survival of residual fractions of tumors that evade therapy-induced cell death.  Antibodies, along with kinase inhibitors, have become in the last decade the mainstay of oncol. pharmacol.  However, partial and transient responses, as well as emergence of tumor resistance, currently limit clin. application of mAbs.  To overcome these hurdles, oligoclonal antibody mixts. are being tested in animal models and in clin. trials.  The first homo-combination of two mAbs, each engaging a distinct site of HER2, an oncogenic receptor tyrosine kinase (RTK), has been approved for treatment of breast cancer.  Likewise, a hetero-combination of antibodies to two distinct T-cell antigens, PD1 and CTLA4, has been approved for treatment of melanoma.  In a similar vein, additive or synergistic anti-tumor effects obsd. in animal models have prompted clin. testing of hetero-combinations of antibodies simultaneously engaging distinct RTKs.  We discuss the promise of antibody cocktails reminiscent of currently used mixts. of chemotherapeutics and highlight mechanisms potentially underlying their enhanced clin. efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNGmLZo2apPbVg90H21EOLACvtfcHk0ljOvr_j1dYV0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktV2ns7w%253D&md5=176c6fa71eae9d42fc32effb347601b3</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1111%2Fbph.13450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13450%26sid%3Dliteratum%253Aachs%26aulast%3DCarvalho%26aufirst%3DS.%26aulast%3DLevi-Schaffer%26aufirst%3DF.%26aulast%3DSela%26aufirst%3DM.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DImmunotherapy%2520of%2520cancer%253A%2520from%2520monoclonal%2520to%2520oligoclonal%2520cocktails%2520of%2520anti-cancer%2520antibodies%253A%2520IUPHAR%2520Review%252018%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D1407%26epage%3D1424%26doi%3D10.1111%2Fbph.13450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span> <span> </span><span class="NLM_article-title">Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy</span>. <i>Signal Transduction Targeted Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">16029</span>, <span class="refDoi"> DOI: 10.1038/sigtrans.2016.29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fsigtrans.2016.29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=29263905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BC1MzjslKjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=16029&author=S.+Tanauthor=C.+W.+Zhangauthor=G.+F.+Gao&title=Seeing+is+believing%3A+anti-PD-1%2FPD-L1+monoclonal+antibodies+in+action+for+checkpoint+blockade+tumor+immunotherapy&doi=10.1038%2Fsigtrans.2016.29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy</span></div><div class="casAuthors">Tan Shuguang; Gao George F; Zhang Catherine W-H</div><div class="citationInfo"><span class="NLM_cas:title">Signal transduction and targeted therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16029</span>
        ISSN:<span class="NLM_cas:issn">2095-9907</span>.
    </div><div class="casAbstract">Structural immunology, focusing on structures of host immune related molecules, enables the immunologists to see what the molecules look like, and more importantly, how they work together.  Antibody-based PD-1/PD-L1 blockade therapy has achieved brilliant successes in clinical applications.  The recent breakthrough of the complex structures of checkpoint blockade antibodies with their counterparts, pembrolizumab with PD-1 and avelumab with PD-L1, have made it clear how these monoclonal antibodies compete the binding of PD-1/PD-L1 and function to blockade the receptor-ligand interaction.  Herein, we summarize the structural findings of these two reports and look into the future for how this information would facilitate the development of more efficient PD-1/PD-L1 targeting antibodies, small molecule drugs, and other protein or non-protein inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlOIoasRyqjE2yPDyEFiigfW6udTcc2eZjW1BXesEzmrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzjslKjsQ%253D%253D&md5=77c119cf3700f4d9fdb51a70a1a985cb</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fsigtrans.2016.29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsigtrans.2016.29%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%2BW.%26aulast%3DGao%26aufirst%3DG.%2BF.%26atitle%3DSeeing%2520is%2520believing%253A%2520anti-PD-1%252FPD-L1%2520monoclonal%2520antibodies%2520in%2520action%2520for%2520checkpoint%2520blockade%2520tumor%2520immunotherapy%26jtitle%3DSignal%2520Transduction%2520Targeted%2520Ther.%26date%3D2016%26volume%3D1%26spage%3D16029%26doi%3D10.1038%2Fsigtrans.2016.29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">PD-1/PD-L1 and immunotherapy for pancreatic cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>407</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.canlet.2017.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=28826722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOhu7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2017&pages=57-65&author=M.+Fengauthor=G.+Xiongauthor=Z.+Caoauthor=G.+Yangauthor=S.+Zhengauthor=X.+Songauthor=L.+Youauthor=L.+Zhengauthor=T.+Zhangauthor=Y.+Zhao&title=PD-1%2FPD-L1+and+immunotherapy+for+pancreatic+cancer&doi=10.1016%2Fj.canlet.2017.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/PD-L1 and immunotherapy for pancreatic cancer</span></div><div class="casAuthors">Feng, Mengyu; Xiong, Guangbing; Cao, Zhe; Yang, Gang; Zheng, Suli; Song, Xujun; You, Lei; Zheng, Lianfang; Zhang, Taiping; Zhao, Yupei</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-65</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Therapy that targets programmed death 1 or programmed death 1 ligand 1 (PD-1/PD-L1), which are known as immune checkpoints, has been recently rapidly developing as oncotherapy for various carcinomas.  However, this therapy has a poor effect on the treatment of pancreatic cancer with PD-1/PD-L1 blockade monotherapy.  In this review, the development and limitations of anti-PD-1/PD-L1 monotherapy in pancreatic cancer are discussed.  We then consider the underlying mechanism of anti-PD-1/PD-L1 monotherapy failure, combination strategies overcoming resistance to anti-PD-1/PD-L1 immunotherapy and the prospect of targeting PD-1/PD-L1 for the immunotherapy of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprqiZWrvMgYbVg90H21EOLACvtfcHk0li3XyDsWBkWkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOhu7fF&md5=fdf524ffb8e66ed919094486e0d34941</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DM.%26aulast%3DXiong%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DYou%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DPD-1%252FPD-L1%2520and%2520immunotherapy%2520for%2520pancreatic%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D407%26spage%3D57%26epage%3D65%26doi%3D10.1016%2Fj.canlet.2017.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacouture, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2375</span>– <span class="NLM_lpage">2391</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1093%2Fannonc%2Fmdv383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=26371282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BC283it1Khtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2375-2391&author=J.+Naidooauthor=D.+B.+Pageauthor=B.+T.+Liauthor=L.+C.+Connellauthor=K.+Schindlerauthor=M.+E.+Lacoutureauthor=M.+A.+Postowauthor=J.+D.+Wolchok&title=Toxicities+of+the+anti-PD-1+and+anti-PD-L1+immune+checkpoint+antibodies&doi=10.1093%2Fannonc%2Fmdv383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies</span></div><div class="casAuthors">Naidoo J; Page D B; Li B T; Connell L C; Schindler K; Lacouture M E; Postow M A; Wolchok J D</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2375-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained recent regulatory approval as single-agent therapy for the treatment of metastatic malignant melanoma and nonsmall-cell lung cancer.  Knowledge of toxicities associated with PD-1/PD-L1 blockade, as well as effective management algorithms for these toxicities, is pivotal in order to optimize clinical efficacy and safety.  In this article, we review selected published and presented clinical studies investigating single-agent anti-PD-1/PD-L1 therapy and trials of combination approaches with other standard anticancer therapies, in multiple tumor types.  We summarize the key adverse events reported in these studies and their management algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2aykURc4ZQMERNNga7KD-fW6udTcc2eYI1MrG_XqRQrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283it1Khtw%253D%253D&md5=fe3abfc48c19a18bcffcea7bae552844</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv383%26sid%3Dliteratum%253Aachs%26aulast%3DNaidoo%26aufirst%3DJ.%26aulast%3DPage%26aufirst%3DD.%2BB.%26aulast%3DLi%26aufirst%3DB.%2BT.%26aulast%3DConnell%26aufirst%3DL.%2BC.%26aulast%3DSchindler%26aufirst%3DK.%26aulast%3DLacouture%26aufirst%3DM.%2BE.%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DToxicities%2520of%2520the%2520anti-PD-1%2520and%2520anti-PD-L1%2520immune%2520checkpoint%2520antibodies%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26spage%3D2375%26epage%3D2391%26doi%3D10.1093%2Fannonc%2Fmdv383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of protein-protein interactions: progressing towards the dream</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1038/nrd1343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnrd1343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=15060526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1GktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=301-317&author=M.+R.+Arkinauthor=J.+A.+Wells&title=Small-molecule+inhibitors+of+protein-protein+interactions%3A+progressing+towards+the+dream&doi=10.1038%2Fnrd1343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of protein-protein interactions: progressing towards the dream</span></div><div class="casAuthors">Arkin, Michelle R.; Wells, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">301-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein-protein interactions have a key role in most biol. processes, and offer attractive opportunities for therapeutic intervention.  Developing small mols. that modulate protein-protein interactions is difficult, owing to issues such as the lack of well-defined binding pockets.  Nevertheless, there was important progress in this endeavor in recent years.  Here, the authors use illustrative examples to discuss general strategies for addressing the challenges inherent in the discovery and characterization of small-mol. inhibitors of protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7MiFDdLJu27Vg90H21EOLACvtfcHk0li3XyDsWBkWkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1GktrY%253D&md5=3e102c6207be420b4232056b4acdea12</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fnrd1343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1343%26sid%3Dliteratum%253Aachs%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520protein-protein%2520interactions%253A%2520progressing%2520towards%2520the%2520dream%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D301%26epage%3D317%26doi%3D10.1038%2Fnrd1343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skidmore, J.</span></span> <span> </span><span class="NLM_article-title">Small molecules, big targets: drug discovery faces the protein-protein interaction challenge</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnrd.2016.29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=27050677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=533-550&author=D.+E.+Scottauthor=A.+R.+Baylyauthor=C.+Abellauthor=J.+Skidmore&title=Small+molecules%2C+big+targets%3A+drug+discovery+faces+the+protein-protein+interaction+challenge&doi=10.1038%2Fnrd.2016.29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules, big targets: drug discovery faces the protein-protein interaction challenge</span></div><div class="casAuthors">Scott, Duncan E.; Bayly, Andrew R.; Abell, Chris; Skidmore, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">533-550</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein-protein interactions (PPIs) are of pivotal importance in the regulation of biol. systems and are consequently implicated in the development of disease states.  Recent work has begun to show that, with the right tools, certain classes of PPI can yield to the efforts of medicinal chemists to develop inhibitors, and the first PPI inhibitors have reached clin. development.  In this Review, we describe the research leading to these breakthroughs and highlight the existence of groups of structurally related PPIs within the PPI target class.  For each of these groups, we use examples of successful discovery efforts to illustrate the research strategies that have proved most useful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK-aGzHa9mP7Vg90H21EOLACvtfcHk0ljYALyh8JyA2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOgur4%253D&md5=9f0953567ae9338b8b36aa78b8160655</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.29%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DBayly%26aufirst%3DA.%2BR.%26aulast%3DAbell%26aufirst%3DC.%26aulast%3DSkidmore%26aufirst%3DJ.%26atitle%3DSmall%2520molecules%252C%2520big%2520targets%253A%2520drug%2520discovery%2520faces%2520the%2520protein-protein%2520interaction%2520challenge%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D533%26epage%3D550%26doi%3D10.1038%2Fnrd.2016.29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y. F.</span></span> <span> </span><span class="NLM_article-title">Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">11760</span>– <span class="NLM_lpage">11764</span>, <span class="refDoi"> DOI: 10.1002/anie.201506225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1002%2Fanie.201506225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=11760-11764&author=H.+N.+Changauthor=B.+Y.+Liuauthor=Y.+K.+Qiauthor=Y.+Zhouauthor=Y.+P.+Chenauthor=K.+M.+Panauthor=W.+W.+Liauthor=X.+M.+Zhouauthor=W.+W.+Maauthor=C.+Y.+Fuauthor=Y.+M.+Qiauthor=L.+Liuauthor=Y.+F.+Gao&title=Blocking+of+the+PD-1%2FPD-L1+interaction+by+a+D-peptide+antagonist+for+cancer+immunotherapy&doi=10.1002%2Fanie.201506225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy</span></div><div class="casAuthors">Chang, Hao-Nan; Liu, Bei-Yuan; Qi, Yun-Kun; Zhou, Yang; Chen, Yan-Ping; Pan, Kai-Mai; Li, Wen-Wen; Zhou, Xiu-Man; Ma, Wei-Wei; Fu, Cai-Yun; Qi, Yuan-Ming; Liu, Lei; Gao, Yan-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">11760-11764</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Blockade of the protein-protein interaction between the transmembrane protein programmed cell death protein 1 (PD-1) and its ligand PD-L1 has emerged as a promising immunotherapy for treating cancers.  Using the technol. of mirror-image phage display, we developed the first hydrolysis-resistant D-peptide antagonists to target the PD-1/PD-L1 pathway.  The optimized compd. DPPA-1 could bind PD-L1 at an affinity of 0.51 μΜ in vitro.  A blockade assay at the cellular level and tumor-bearing mice expts. indicated that DPPA-1 could also effectively disrupt the PD-1/PD-L1 interaction in vivo.  Thus D-peptide antagonists may provide novel low-mol.-wt. drug candidates for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHaM2oW2TzMLVg90H21EOLACvtfcHk0ljYALyh8JyA2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsbbO&md5=9861da91b177782a89c912776741f9ad</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506225%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DH.%2BN.%26aulast%3DLiu%26aufirst%3DB.%2BY.%26aulast%3DQi%26aufirst%3DY.%2BK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%2BP.%26aulast%3DPan%26aufirst%3DK.%2BM.%26aulast%3DLi%26aufirst%3DW.%2BW.%26aulast%3DZhou%26aufirst%3DX.%2BM.%26aulast%3DMa%26aufirst%3DW.%2BW.%26aulast%3DFu%26aufirst%3DC.%2BY.%26aulast%3DQi%26aufirst%3DY.%2BM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DY.%2BF.%26atitle%3DBlocking%2520of%2520the%2520PD-1%252FPD-L1%2520interaction%2520by%2520a%2520D-peptide%2520antagonist%2520for%2520cancer%2520immunotherapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D11760%26epage%3D11764%26doi%3D10.1002%2Fanie.201506225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Qi, Y.</span>; <span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">PD-L1 Affinity Peptide with Anti-Tumour Activity and Application Thereof</span>. <span class="NLM_patent">CN103304638A</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Y.+Gao&author=Y.+Chen&author=Y.+Qi&author=B.+Liu&title=PD-L1+Affinity+Peptide+with+Anti-Tumour+Activity+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26atitle%3DPD-L1%2520Affinity%2520Peptide%2520with%2520Anti-Tumour%2520Activity%2520and%2520Application%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">Peptide blocking of PD-1/PD-L1 interaction for cancer immunotherapy</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-17-0035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1158%2F2326-6066.CIR-17-0035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=29217732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=178-188&author=C.+Liauthor=N.+Zhangauthor=J.+Zhouauthor=C.+Dingauthor=Y.+Jinauthor=X.+Cuiauthor=K.+Puauthor=Y.+Zhu&title=Peptide+blocking+of+PD-1%2FPD-L1+interaction+for+cancer+immunotherapy&doi=10.1158%2F2326-6066.CIR-17-0035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy</span></div><div class="casAuthors">Li, Chunlin; Zhang, Nengpan; Zhou, Jundong; Ding, Chen; Jin, Yaqing; Cui, Xueyuan; Pu, Kefeng; Zhu, Yimin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-188</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Immunotherapy has become a promising alternative therapeutic approach for cancer patients.  Interruption of immune checkpoints, such as CTLA-4 and PD-1, has been verified to be a successful means for cancer therapy in clin. trials.  MAb targeting PD-L1 has been approved to treat urothelial carcinoma, non-small cell lung cancer, or Merkel cell carcinoma by the FDA.  However, the high cost of the antibody can limit its application.  In our study, targeting PD-L1 peptide (TPP-1), which specifically binds to PD-L1 with high affinity, was identified through bacterial surface display methods.  Using a T-cell activation assay and mixed lymphocyte reaction, TPP-1 was verified to interfere with the interaction of PD-1/PD-L1.  To examine the inhibitory effect of TPP-1 on tumor growth in vivo, a xenograft mouse model using H460 cells was established.  The growth rate of tumor masses in TPP-1 or PD-L1 antibody-treated mice was 56% or 71% lower than that in control peptide-treated mice, resp., indicating that TPP-1 inhibits, or at least retards, tumor growth.  IHC of the tumors showed that IFNγ and granzyme B expression increased in the TPP-1 or PD-L1 antibody-treated groups, indicating that TPP-1 attenuates the inhibitory effect of PD-L1 on T cells and that T cells may get reactivated.  On the basis of our data, TPP-1 peptide could work as an alternative to antibodies for tumor immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPRbtEhfQtUbVg90H21EOLACvtfcHk0ljYALyh8JyA2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWgtrc%253D&md5=df19c19b58ae966c69f9e6698a83953f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-17-0035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-17-0035%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DPu%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DPeptide%2520blocking%2520of%2520PD-1%252FPD-L1%2520interaction%2520for%2520cancer%2520immunotherapy%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2018%26volume%3D6%26spage%3D178%26epage%3D188%26doi%3D10.1158%2F2326-6066.CIR-17-0035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of peptide inhibitors targeting human programmed death 1(PD-1) receptor</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">64967</span>– <span class="NLM_lpage">64976</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.11274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.18632%2Foncotarget.11274" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=64967-64976&author=Q.+Liauthor=L.+Quanauthor=J.+Lyuauthor=Z.+Heauthor=X.+Wangauthor=J.+Mengauthor=Z.+Zhaoauthor=L.+Zhuauthor=X.+Liuauthor=H.+Li&title=Discovery+of+peptide+inhibitors+targeting+human+programmed+death+1%28PD-1%29+receptor&doi=10.18632%2Foncotarget.11274"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.11274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.11274%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DQuan%26aufirst%3DL.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520peptide%2520inhibitors%2520targeting%2520human%2520programmed%2520death%25201%2528PD-1%2529%2520receptor%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D64967%26epage%3D64976%26doi%3D10.18632%2Foncotarget.11274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Vadlamani, S. K.</span>; <span class="NLM_string-name">Vemula, K. R.</span>; <span class="NLM_string-name">Satyam, L. K.</span>; <span class="NLM_string-name">Subbarao, K.</span>; <span class="NLM_string-name">Shrimali, R. K.</span>; <span class="NLM_string-name">Kandepu, S.</span></span> <span> </span><span class="NLM_article-title">Immunosuppression Modulating Compounds</span>. <span class="NLM_patent">WO2011161699A2</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+K.+Vadlamani&author=K.+R.+Vemula&author=L.+K.+Satyam&author=K.+Subbarao&author=R.+K.+Shrimali&author=S.+Kandepu&title=Immunosuppression+Modulating+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunosuppression%2520Modulating%2520Compounds%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S.</span>; <span class="NLM_string-name">Sudarshan, S.</span></span> <span> </span><span class="NLM_article-title">Immunomodulating Peptidomimetic Derivatives</span>. <span class="NLM_patent">WO2015036927A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+Naremaddepalli&author=S.+Sudarshan&title=Immunomodulating+Peptidomimetic+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunomodulating%2520Peptidomimetic%2520Derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Sudarshan, N. S. S.</span></span> <span> </span><span class="NLM_article-title">Peptidomimetic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2013132317A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+G.+N.+Saikumar&author=M.+Ramachandra&author=N.+S.+S.+Sudarshan&title=Peptidomimetic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSaikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DPeptidomimetic%2520Compounds%2520as%2520Immunomodulators%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Vadlamani, S. K.</span>; <span class="NLM_string-name">Shrimali, K. R.</span>; <span class="NLM_string-name">Subbarao, K.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Compound for Immunomodulation</span>. <span class="NLM_patent">WO2012168944A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=P.+G.+N.+Saikumar&author=M.+Ramachandra&author=S.+K.+Vadlamani&author=K.+R.+Shrimali&author=K.+Subbarao&title=Therapeutic+Compound+for+Immunomodulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSaikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DTherapeutic%2520Compound%2520for%2520Immunomodulation%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulating Cyclic Compounds from the BC Loop of Human PD-1</span>. <span class="NLM_patent">WO2013144704A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&title=Immunomodulating+Cyclic+Compounds+from+the+BC+Loop+of+Human+PD-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunomodulating%2520Cyclic%2520Compounds%2520from%2520the%2520BC%2520Loop%2520of%2520Human%2520PD-1%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Immunomodulating Compounds</span>. <span class="NLM_patent">WO2015044900</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=Therapeutic+Immunomodulating+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DTherapeutic%2520Immunomodulating%2520Compounds%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">Cyclic Peptidomimetic Compounds as Immunomodulators Applicant</span>. <span class="NLM_patent">WO2015033303</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=Cyclic+Peptidomimetic+Compounds+as+Immunomodulators+Applicant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DCyclic%2520Peptidomimetic%2520Compounds%2520as%2520Immunomodulators%2520Applicant%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Cyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2016142835</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=Therapeutic+Cyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DTherapeutic%2520Cyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span>; <span class="NLM_string-name">Mapelli, C.</span>; <span class="NLM_string-name">Allen, M.
P.</span>; <span class="NLM_string-name">Bowsher, M. S.</span>; <span class="NLM_string-name">Boy, K. M.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Poirier, M. A.</span>; <span class="NLM_string-name">Sanghvi, N.</span>; <span class="NLM_string-name">Sun, L.</span>; <span class="NLM_string-name">Tenney, D. J.</span>; <span class="NLM_string-name">Yeung, K. S.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Reid, P. C.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions</span>. <span class="NLM_patent">WO2014151634</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=M.+M.+Miller&author=C.+Mapelli&author=M.%0AP.+Allen&author=M.+S.+Bowsher&author=K.+M.+Boy&author=E.+P.+Gillis&author=D.+R.+Langley&author=E.+Mull&author=M.+A.+Poirier&author=N.+Sanghvi&author=L.+Sun&author=D.+J.+Tenney&author=K.+S.+Yeung&author=J.+Zhu&author=P.+C.+Reid&author=P.+M.+Scola&title=Macrocyclic+Inhibitors+of+the+PD-1%2FPD-L1+and+CD80%28B7-1%29%2FPD-L1+Protein%2FProtein+Interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BM.%26atitle%3DMacrocyclic%2520Inhibitors%2520of%2520the%2520PD-1%252FPD-L1%2520and%2520CD80%2528B7-1%2529%252FPD-L1%2520Protein%252FProtein%2520Interactions%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span>; <span class="NLM_string-name">Mapelli, C.</span>; <span class="NLM_string-name">Allen, M.
P.</span>; <span class="NLM_string-name">Bowsher, M. S.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Poirier, M. A.</span>; <span class="NLM_string-name">Sanghvi, N.</span>; <span class="NLM_string-name">Sun, L.
Q.</span>; <span class="NLM_string-name">Tenney, D.
J.</span>; <span class="NLM_string-name">Yeung, K.
P.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Gillman, K. W.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Grant-Young, K. A.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-LI Protein/Protein Interactions</span>. <span class="NLM_patent">WO2016039749</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+M.+Miller&author=C.+Mapelli&author=M.%0AP.+Allen&author=M.+S.+Bowsher&author=E.+P.+Gillis&author=D.+R.+Langley&author=E.+Mull&author=M.+A.+Poirier&author=N.+Sanghvi&author=L.%0AQ.+Sun&author=D.%0AJ.+Tenney&author=K.%0AP.+Yeung&author=J.+Zhu&author=K.+W.+Gillman&author=Q.+Zhao&author=K.+A.+Grant-Young&author=P.+M.+Scola&title=Macrocyclic+Inhibitors+of+the+PD-1%2FPD-L1+and+CD80%28B7-1%29%2FPD-LI+Protein%2FProtein+Interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BM.%26atitle%3DMacrocyclic%2520Inhibitors%2520of%2520the%2520PD-1%252FPD-L1%2520and%2520CD80%2528B7-1%2529%252FPD-LI%2520Protein%252FProtein%2520Interactions%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. Q.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulators</span>. <span class="NLM_patent">WO2016057624</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Q.+Sun&author=Q.+Zhao&author=E.+Mull&author=E.+P.+Gillis&author=P.+M.+Scola&title=Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%2BQ.%26atitle%3DImmunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillman, K. W.</span>; <span class="NLM_string-name">Goodrich, J.</span>; <span class="NLM_string-name">Boy, K.
M.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Mapelli, C.</span>; <span class="NLM_string-name">Poss, M. A.</span>; <span class="NLM_string-name">Sun, L. Q.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulators</span>. <span class="NLM_patent">WO2016077518</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=K.+W.+Gillman&author=J.+Goodrich&author=K.%0AM.+Boy&author=Y.+Zhang&author=C.+Mapelli&author=M.+A.+Poss&author=L.+Q.+Sun&author=Q.+Zhao&author=E.+Mull&author=E.+P.+Gillis&author=P.+M.+Scola&title=Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGillman%26aufirst%3DK.%2BW.%26atitle%3DImmunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. Q.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Miller, M. M.</span>; <span class="NLM_string-name">Allen, M. P.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Scola, P.
M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulators</span>. <span class="NLM_patent">WO2016100608</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Q.+Sun&author=Q.+Zhao&author=E.+P.+Gillis&author=M.+M.+Miller&author=M.+P.+Allen&author=E.+Mull&author=P.%0AM.+Scola&title=Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%2BQ.%26atitle%3DImmunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span>; <span class="NLM_string-name">Allen, M. P.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Mapelli, C.</span>; <span class="NLM_string-name">Poirier, M. A.</span>; <span class="NLM_string-name">Sun, L. Q.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulators</span>. <span class="NLM_patent">WO2016126646</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+M.+Miller&author=M.+P.+Allen&author=L.+Li&author=C.+Mapelli&author=M.+A.+Poirier&author=L.+Q.+Sun&author=Q.+Zhao&author=E.+Mull&author=E.+P.+Gillis&author=P.+M.+Scola&title=Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BM.%26atitle%3DImmunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boy, K. M.</span>; <span class="NLM_string-name">Sun, L. Q.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulators</span>. <span class="NLM_patent">WO2016149351</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=K.+M.+Boy&author=L.+Q.+Sun&author=Q.+Zhao&author=E.+Mull&author=E.+P.+Gillis&author=P.+M.+Scola&title=Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoy%26aufirst%3DK.%2BM.%26atitle%3DImmunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinska-Szostak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlicki, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarganes-Tzitzikas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaabani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Bioactive macrocyclic inhibitors of the PD-1/PD-L1 immune checkpoint</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">13732</span>– <span class="NLM_lpage">13735</span>, <span class="refDoi"> DOI: 10.1002/anie.201707707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1002%2Fanie.201707707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOit7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=13732-13735&author=K.+Magiera-Mularzauthor=L.+Skalniakauthor=K.+M.+Zakauthor=B.+Musielakauthor=E.+Rudzinska-Szostakauthor=L.+Berlickiauthor=J.+Kocikauthor=P.+Grudnikauthor=D.+Salaauthor=T.+Zarganes-Tzitzikasauthor=S.+Shaabaniauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Bioactive+macrocyclic+inhibitors+of+the+PD-1%2FPD-L1+immune+checkpoint&doi=10.1002%2Fanie.201707707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint</span></div><div class="casAuthors">Magiera-Mularz, Katarzyna; Skalniak, Lukasz; Zak, Krzysztof M.; Musielak, Bogdan; Rudzinska-Szostak, Ewa; Berlicki, Lukasz; Kocik, Justyna; Grudnik, Przemyslaw; Sala, Dominik; Zarganes-Tzitzikas, Tryfon; Shaabani, Shabnam; Doemling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">13732-13735</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Blockade of the immunoinhibitory PD-1/PD-L1 pathway using monoclonal antibodies has shown impressive results with durable clin. antitumor responses.  Anti-PD-1 and anti-PD-L1 antibodies have now been approved for the treatment of a no. of tumor types, whereas the development of small mols. targeting immune checkpoints lags far behind.  We characterized two classes of macrocyclic-peptide inhibitors directed at the PD-1/PD-L1 pathway.  We show that these macrocyclic compds. act by directly binding to PD-L1 and that they are capable of antagonizing PD-L1 signaling and, similarly to antibodies, can restore the function of T-cells.  We also provide the crystal structures of two of these small-mol. inhibitors bound to PD-L1.  The structures provide a rationale for the checkpoint inhibition by these small mols., and a description of their small mol./PD-L1 interfaces provides a blueprint for the design of small-mol. inhibitors of the PD-1/PD-L1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxuarSIlQEobVg90H21EOLACvtfcHk0lhe-6eHKo4Qsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOit7%252FO&md5=b1634408007340ca0990d2607c96c1a9</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1002%2Fanie.201707707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201707707%26sid%3Dliteratum%253Aachs%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DRudzinska-Szostak%26aufirst%3DE.%26aulast%3DBerlicki%26aufirst%3DL.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DSala%26aufirst%3DD.%26aulast%3DZarganes-Tzitzikas%26aufirst%3DT.%26aulast%3DShaabani%26aufirst%3DS.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DBioactive%2520macrocyclic%2520inhibitors%2520of%2520the%2520PD-1%252FPD-L1%2520immune%2520checkpoint%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D13732%26epage%3D13735%26doi%3D10.1002%2Fanie.201707707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span>; <span class="NLM_string-name">Butte, M. J.</span>; <span class="NLM_string-name">Oyama, S.</span></span> <span> </span><span class="NLM_article-title">Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof</span>. <span class="NLM_patent">WO2011082400</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+H.+Sharpe&author=M.+J.+Butte&author=S.+Oyama&title=Modulators+of+Immunoinhibitory+Receptor+PD-1%2C+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DModulators%2520of%2520Immunoinhibitory%2520Receptor%2520PD-1%252C%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span>; <span class="NLM_string-name">Xin, T.</span>; <span class="NLM_string-name">Wen, X.</span>; <span class="NLM_string-name">Wu, Y.</span>; <span class="NLM_string-name">Yuan, H.</span></span> <span> </span><span class="NLM_article-title">2-Substituted Isonicotinic Acid Compound, Preparation Method and Application Thereof</span>. <span class="NLM_patent">CN106632021</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=H.+Sun&author=T.+Xin&author=X.+Wen&author=Y.+Wu&author=H.+Yuan&title=2-Substituted+Isonicotinic+Acid+Compound%2C+Preparation+Method+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26atitle%3D2-Substituted%2520Isonicotinic%2520Acid%2520Compound%252C%2520Preparation%2520Method%2520and%2520Application%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span>; <span class="NLM_string-name">Xiao, J.</span>; <span class="NLM_string-name">Liu, A.</span>; <span class="NLM_string-name">Wei, X.</span>; <span class="NLM_string-name">Zhong, W.</span>; <span class="NLM_string-name">Zheng, Z.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Xie, Y.</span>; <span class="NLM_string-name">Zhao, G.</span>; <span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Resorcinol Compound and Medicinal Use Thereof</span>. <span class="NLM_patent">CN107286057</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Li&author=J.+Xiao&author=A.+Liu&author=X.+Wei&author=W.+Zhong&author=Z.+Zheng&author=X.+Wang&author=Y.+Xie&author=G.+Zhao&author=H.+Li&title=Resorcinol+Compound+and+Medicinal+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26atitle%3DResorcinol%2520Compound%2520and%2520Medicinal%2520Use%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Böger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Röcken, C.</span></span> <span> </span><span class="NLM_article-title">The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?</span>. <i>OncoImmunology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e1293215</span>, <span class="refDoi"> DOI: 10.1080/2162402X.2017.1293215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1080%2F2162402X.2017.1293215" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=e1293215&author=C.+B%C3%B6gerauthor=H.+M.+Behrensauthor=S.+Kr%C3%BCgerauthor=C.+R%C3%B6cken&title=The+novel+negative+checkpoint+regulator+VISTA+is+expressed+in+gastric+carcinoma+and+associated+with+PD-L1%2FPD-1%3A+A+future+perspective+for+a+combined+gastric+cancer+therapy%3F&doi=10.1080%2F2162402X.2017.1293215"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2017.1293215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2017.1293215%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6ger%26aufirst%3DC.%26aulast%3DBehrens%26aufirst%3DH.%2BM.%26aulast%3DKr%25C3%25BCger%26aufirst%3DS.%26aulast%3DR%25C3%25B6cken%26aufirst%3DC.%26atitle%3DThe%2520novel%2520negative%2520checkpoint%2520regulator%2520VISTA%2520is%2520expressed%2520in%2520gastric%2520carcinoma%2520and%2520associated%2520with%2520PD-L1%252FPD-1%253A%2520A%2520future%2520perspective%2520for%2520a%2520combined%2520gastric%2520cancer%2520therapy%253F%26jtitle%3DOncoImmunology%26date%3D2017%26volume%3D6%26spage%3De1293215%26doi%3D10.1080%2F2162402X.2017.1293215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Prasad, A.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">3-Substituted-1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2016142886</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=A.+Prasad&author=S.+S.+S.+Naremaddepalli&title=3-Substituted-1%2C2%2C4-Oxadiazole+and+Thiadiazole+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D3-Substituted-1%252C2%252C4-Oxadiazole%2520and%2520Thiadiazole%2520Compounds%2520as%2520Immunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2016142833</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C2%2C4-Oxadiazole+and+Thiadiazole+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C2%252C4-Oxadiazole%2520and%2520Thiadiazole%2520Compounds%2520as%2520Immunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Oxadiazole Derivatives as Immunomodulators</span>. <span class="NLM_patent">WO2015033299</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C2%2C4-Oxadiazole+Derivatives+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C2%252C4-Oxadiazole%2520Derivatives%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Oxadiazole Derivatives as Immunomodulators</span>. <span class="NLM_patent">US2017101386</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C2%2C4-Oxadiazole+Derivatives+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C2%252C4-Oxadiazole%2520Derivatives%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Prasad, A.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">3-Substituted 1,3,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2016142894</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=A.+Prasad&author=S.+S.+S.+Naremaddepalli&title=3-Substituted+1%2C3%2C4-Oxadiazole+and+Thiadiazole+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D3-Substituted%25201%252C3%252C4-Oxadiazole%2520and%2520Thiadiazole%2520Compounds%2520as%2520Immunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,3,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2016142852</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C3%2C4-Oxadiazole+and+Thiadiazole+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C3%252C4-Oxadiazole%2520and%2520Thiadiazole%2520Compounds%2520as%2520Immunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,3,4-Oxadiazole and 1,3,4-Thiadiazole Derivatives as Immunomodulators</span>. <span class="NLM_patent">WO2015033301</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C3%2C4-Oxadiazole+and+1%2C3%2C4-Thiadiazole+Derivatives+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C3%252C4-Oxadiazole%2520and%25201%252C3%252C4-Thiadiazole%2520Derivatives%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">VISTA Signaling Pathway Inhibitory Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2018047143</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=VISTA+Signaling+Pathway+Inhibitory+Compounds+Useful+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DVISTA%2520Signaling%2520Pathway%2520Inhibitory%2520Compounds%2520Useful%2520as%2520Immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">Dual Inhibitors of VISTA and PD-1 Pathways</span>. <span class="NLM_patent">WO2018073754</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=Dual+Inhibitors+of+VISTA+and+PD-1+Pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DDual%2520Inhibitors%2520of%2520VISTA%2520and%2520PD-1%2520Pathways%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Prasad, A.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Cyclic Substituted-1,3,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2018051255</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+G.+N.+Sasikumar&author=A.+Prasad&author=S.+S.+S.+Naremaddepalli&author=M.+Ramachandra&title=Cyclic+Substituted-1%2C3%2C4-Oxadiazole+and+Thiadiazole+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DCyclic%2520Substituted-1%252C3%252C4-Oxadiazole%2520and%2520Thiadiazole%2520Compounds%2520as%2520Immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Prasad, A.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Cyclic Substituted-1,2,4-Oxadiazole Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2018051254</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+G.+N.+Sasikumar&author=A.+Prasad&author=S.+S.+S.+Naremaddepalli&author=M.+Ramachandra&title=Cyclic+Substituted-1%2C2%2C4-Oxadiazole+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DCyclic%2520Substituted-1%252C2%252C4-Oxadiazole%2520Compounds%2520as%2520Immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Xu, Z.</span>; <span class="NLM_string-name">Wu, T.</span>; <span class="NLM_string-name">He, M.</span>; <span class="NLM_string-name">Zhang, N.</span></span> <span> </span><span class="NLM_article-title">Aromatic Acetylene or Aromatic Ethylene Compound, Intermediate, Preparation Method, Pharmaceutical Composition and Use Thereof</span>. <span class="NLM_patent">WO2018006795</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Wang&author=Z.+Xu&author=T.+Wu&author=M.+He&author=N.+Zhang&title=Aromatic+Acetylene+or+Aromatic+Ethylene+Compound%2C+Intermediate%2C+Preparation+Method%2C+Pharmaceutical+Composition+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DAromatic%2520Acetylene%2520or%2520Aromatic%2520Ethylene%2520Compound%252C%2520Intermediate%252C%2520Preparation%2520Method%252C%2520Pharmaceutical%2520Composition%2520and%2520Use%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Yang, Y.</span>; <span class="NLM_string-name">Lai, F.</span>; <span class="NLM_string-name">Ji, M.</span>; <span class="NLM_string-name">Zhang, L.</span>; <span class="NLM_string-name">Zheng, Y.</span>; <span class="NLM_string-name">Xue, N.</span>; <span class="NLM_string-name">Wang, K.</span>; <span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Benzyl Phenyl Ether Derivative, Preparation Method Therefor, and Pharmaceutical Composition and Uses Thereof</span>. <span class="NLM_patent">WO2017202273</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Feng&author=X.+Chen&author=Y.+Yang&author=F.+Lai&author=M.+Ji&author=L.+Zhang&author=Y.+Zheng&author=N.+Xue&author=K.+Wang&author=L.+Li&title=Benzyl+Phenyl+Ether+Derivative%2C+Preparation+Method+Therefor%2C+and+Pharmaceutical+Composition+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DZ.%26atitle%3DBenzyl%2520Phenyl%2520Ether%2520Derivative%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Pharmaceutical%2520Composition%2520and%2520Uses%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Zhang, L.</span>; <span class="NLM_string-name">Yang, Y.</span>; <span class="NLM_string-name">Lai, F.</span>; <span class="NLM_string-name">Ji, M.</span>; <span class="NLM_string-name">Zhou, C.</span>; <span class="NLM_string-name">Zhen, Y.</span>; <span class="NLM_string-name">Xue, N.</span>; <span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Bromo Benzyl Ether Derivative, Preparation Method Therefor, and Pharmaceutical Composition and Uses Thereof</span>. <span class="NLM_patent">WO2017202275</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Feng&author=X.+Chen&author=L.+Zhang&author=Y.+Yang&author=F.+Lai&author=M.+Ji&author=C.+Zhou&author=Y.+Zhen&author=N.+Xue&author=L.+Li&title=Bromo+Benzyl+Ether+Derivative%2C+Preparation+Method+Therefor%2C+and+Pharmaceutical+Composition+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DZ.%26atitle%3DBromo%2520Benzyl%2520Ether%2520Derivative%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Pharmaceutical%2520Composition%2520and%2520Uses%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Yang, Y.</span>; <span class="NLM_string-name">Zhou, C.</span>; <span class="NLM_string-name">Lai, F.</span>; <span class="NLM_string-name">Ji, M.</span>; <span class="NLM_string-name">Jin, X.</span>; <span class="NLM_string-name">Xue, N.</span>; <span class="NLM_string-name">Zheng, Y.</span>; <span class="NLM_string-name">Chen, H.</span>; <span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Phenylate Derivative, Preparation Method Therefor, and Pharmaceutical Composition and Uses Thereof</span>. <span class="NLM_patent">WO2017202276</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Feng&author=X.+Chen&author=Y.+Yang&author=C.+Zhou&author=F.+Lai&author=M.+Ji&author=X.+Jin&author=N.+Xue&author=Y.+Zheng&author=H.+Chen&author=L.+Li&title=Phenylate+Derivative%2C+Preparation+Method+Therefor%2C+and+Pharmaceutical+Composition+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DZ.%26atitle%3DPhenylate%2520Derivative%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Pharmaceutical%2520Composition%2520and%2520Uses%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yu, Z.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">N-Phenyl-pyridine-2-carboxamide Derivatives and Their Use as PD-1/PD-L1 Protein/Protein Interaction Modulators</span>. <span class="NLM_patent">US2017174671</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Wu&author=Z.+Yu&author=F.+Zhang&author=W.+Yao&title=N-Phenyl-pyridine-2-carboxamide+Derivatives+and+Their+Use+as+PD-1%2FPD-L1+Protein%2FProtein+Interaction+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DN-Phenyl-pyridine-2-carboxamide%2520Derivatives%2520and%2520Their%2520Use%2520as%2520PD-1%252FPD-L1%2520Protein%252FProtein%2520Interaction%2520Modulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, K.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">US2017362253</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.+Xiao&author=F.+Zhang&author=L.+Wu&author=W.+Yao&title=Heterocyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DK.%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Shen, B.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017070089</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Wu&author=B.+Shen&author=J.+Li&author=Z.+Li&author=K.+Liu&author=F.+Zhang&author=W.+Yao&title=Heterocyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017087777</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+Li&author=L.+Wu&author=W.+Yao&title=Heterocyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lajkiewicz, N.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017112730</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=N.+Lajkiewicz&author=L.+Wu&author=W.+Yao&title=Heterocyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLajkiewicz%26aufirst%3DN.%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017192961</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Li&author=L.+Wu&author=W.+Yao&title=Heterocyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span>; <span class="NLM_string-name">Qian, D.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017205464</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Lu&author=D.+Qian&author=L.+Wu&author=W.+Yao&title=Heterocyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DL.%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupak, L. S.</span>; <span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2015034820</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+S.+Chupak&author=X.+Zheng&title=Compounds+Useful+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChupak%26aufirst%3DL.%2BS.%26atitle%3DCompounds%2520Useful%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doemling, A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the PD-1/PD-L1 Protein/Protein Interaction</span>. <span class="NLM_patent">WO2017118762</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+Doemling&title=Inhibitors+of+the+PD-1%2FPD-L1+Protein%2FProtein+Interaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDoemling%26aufirst%3DA.%26atitle%3DInhibitors%2520of%2520the%2520PD-1%252FPD-L1%2520Protein%252FProtein%2520Interaction%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zieba, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Structural basis for small molecule targeting of the programmed death ligand 1(PD-L1)</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">30323</span>– <span class="NLM_lpage">30335</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.18632%2Foncotarget.8730" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=30323-30335&author=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Guzikauthor=B.+J.+Ziebaauthor=B.+Musielakauthor=A.+D%C3%B6mlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Structural+basis+for+small+molecule+targeting+of+the+programmed+death+ligand+1%28PD-L1%29&doi=10.18632%2Foncotarget.8730"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8730%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DZieba%26aufirst%3DB.%2BJ.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DStructural%2520basis%2520for%2520small%2520molecule%2520targeting%2520of%2520the%2520programmed%2520death%2520ligand%25201%2528PD-L1%2529%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D30323%26epage%3D30335%26doi%3D10.18632%2Foncotarget.8730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5857</span>– <span class="NLM_lpage">5867</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5857-5867&author=K.+Guzikauthor=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Magieraauthor=B.+Musielakauthor=R.+Tornerauthor=L.+Skalniakauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Small-molecule+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+death-ligand+1%28PD-1%2FPD-L1%29+interaction+via+transiently+induced+protein+states+and+dimerization+of+PD-L1&doi=10.1021%2Facs.jmedchem.7b00293"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00293%26sid%3Dliteratum%253Aachs%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DTorner%26aufirst%3DR.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2528PD-1%252FPD-L1%2529%2520interaction%2520via%2520transiently%2520induced%2520protein%2520states%2520and%2520dimerization%2520of%2520PD-L1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5857%26epage%3D5867%26doi%3D10.1021%2Facs.jmedchem.7b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span>; <span class="NLM_string-name">Grant-Young, K. A.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Saulnier, M. G.</span>; <span class="NLM_string-name">Frennesson, D. B.</span>; <span class="NLM_string-name">Meng, Z.</span>; <span class="NLM_string-name">Scola, P.
M.</span></span> <span> </span><span class="NLM_article-title">1,3-Dihydroxy-phenyl Derivatives Useful as Immunomodulators</span>. <span class="NLM_patent">WO2018009505</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=K.+S.+Yeung&author=K.+A.+Grant-Young&author=J.+Zhu&author=M.+G.+Saulnier&author=D.+B.+Frennesson&author=Z.+Meng&author=P.%0AM.+Scola&title=1%2C3-Dihydroxy-phenyl+Derivatives+Useful+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.%2BS.%26atitle%3D1%252C3-Dihydroxy-phenyl%2520Derivatives%2520Useful%2520as%2520Immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span>; <span class="NLM_string-name">Connolly, T. P.</span>; <span class="NLM_string-name">Frennesson, D. B.</span>; <span class="NLM_string-name">Grant-Young, K. A.</span>; <span class="NLM_string-name">Hewawasam, P.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Meng, Z.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Parcella, K. E.</span>; <span class="NLM_string-name">Saulnier, M. G.</span>; <span class="NLM_string-name">Sun, L. Q.</span>; <span class="NLM_string-name">Wang, A. X.</span>; <span class="NLM_string-name">Xu, N.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2017066227</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.+S.+Yeung&author=T.+P.+Connolly&author=D.+B.+Frennesson&author=K.+A.+Grant-Young&author=P.+Hewawasam&author=D.+R.+Langley&author=Z.+Meng&author=E.+Mull&author=K.+E.+Parcella&author=M.+G.+Saulnier&author=L.+Q.+Sun&author=A.+X.+Wang&author=N.+Xu&author=J.+Zhu&author=P.+M.+Scola&title=Compounds+Useful+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.%2BS.%26atitle%3DCompounds%2520Useful%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupak, L. S.</span>; <span class="NLM_string-name">Ding, M.</span>; <span class="NLM_string-name">Martin, S. W.</span>; <span class="NLM_string-name">Zheng, X.</span>; <span class="NLM_string-name">Hewawasam, P.</span>; <span class="NLM_string-name">Connolly, T. P.</span>; <span class="NLM_string-name">Xu, N.</span>; <span class="NLM_string-name">Yeung, K. S.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Tenney, D. J.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2015160641</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+S.+Chupak&author=M.+Ding&author=S.+W.+Martin&author=X.+Zheng&author=P.+Hewawasam&author=T.+P.+Connolly&author=N.+Xu&author=K.+S.+Yeung&author=J.+Zhu&author=D.+R.+Langley&author=D.+J.+Tenney&author=P.+M.+Scola&title=Compounds+Useful+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChupak%26aufirst%3DL.%2BS.%26atitle%3DCompounds%2520Useful%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szelazek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzanik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyrc, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">72167</span>– <span class="NLM_lpage">72181</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.20050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.18632%2Foncotarget.20050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=29069777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ksVKhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=72167-72181&author=L.+Skalniakauthor=K.+M.+Zakauthor=K.+Guzikauthor=K.+Magieraauthor=B.+Musielakauthor=M.+Pachotaauthor=B.+Szelazekauthor=J.+Kocikauthor=P.+Grudnikauthor=M.+Tomalaauthor=S.+Krzanikauthor=K.+Pyrcauthor=A.+D%C3%B6mlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Small-molecule+inhibitors+of+PD-1%2FPD-L1+immune+checkpoint+alleviate+the+PD-L1-induced+exhaustion+of+T-cells&doi=10.18632%2Foncotarget.20050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells</span></div><div class="casAuthors">Skalniak Lukasz; Guzik Katarzyna; Magiera Katarzyna; Musielak Bogdan; Kocik Justyna; Tomala Marcin; Holak Tad A; Zak Krzysztof M; Pachota Magdalena; Szelazek Bozena; Grudnik Przemyslaw; Krzanik Sylwia; Pyrc Krzysztof; Dubin Grzegorz; Zak Krzysztof M; Pachota Magdalena; Szelazek Bozena; Grudnik Przemyslaw; Krzanik Sylwia; Pyrc Krzysztof; Dubin Grzegorz; Domling Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">72167-72181</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibodies targeting the PD-1/PD-L1 immune checkpoint achieved spectacular success in anticancer therapy in the recent years.  In contrast, no small molecules with cellular activity have been reported so far.  Here we provide evidence that small molecules are capable of alleviating the PD-1/PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes.  The two optimized small-molecule inhibitors of the PD-1/PD-L1 interaction, BMS-1001 and BMS-1166, developed by Bristol-Myers Squibb, bind to human PD-L1 and block its interaction with PD-1, when tested on isolated proteins.  The compounds present low toxicity towards tested cell lines and block the interaction of soluble PD-L1 with the cell surface-expressed PD-1.  As a result, BMS-1001 and BMS-1166 alleviate the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.  Moreover, the compounds were effective in attenuating the inhibitory effect of the cell surface-associated PD-L1.  We also determined the X-ray structures of the complexes of BMS-1001 and BMS-1166 with PD-L1, which revealed features that may be responsible for increased potency of the compounds compared to their predecessors.  Further development may lead to the design of an anticancer therapy based on the orally delivered immune checkpoint inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnxbjAjsdnFCCEBeYuoi7AfW6udTcc2eYNX6FQGVVp37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ksVKhsw%253D%253D&md5=0b70c6e7aca2f13919bfbb2a47b2e57f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.20050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.20050%26sid%3Dliteratum%253Aachs%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DPachota%26aufirst%3DM.%26aulast%3DSzelazek%26aufirst%3DB.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DTomala%26aufirst%3DM.%26aulast%3DKrzanik%26aufirst%3DS.%26aulast%3DPyrc%26aufirst%3DK.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520PD-1%252FPD-L1%2520immune%2520checkpoint%2520alleviate%2520the%2520PD-L1-induced%2520exhaustion%2520of%2520T-cells%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D72167%26epage%3D72181%26doi%3D10.18632%2Foncotarget.20050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayes, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadavilli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seestaller-Wehr, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsvetkov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smothers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, A.</span></span> <span> </span><span class="NLM_article-title">The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1651</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1158%2F1078-0432.CCR-14-2339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25589619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVahtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1639-1651&author=L.+Liuauthor=P.+A.+Mayesauthor=S.+Eastmanauthor=H.+Shiauthor=S.+Yadavilliauthor=T.+Zhangauthor=J.+Yangauthor=L.+Seestaller-Wehrauthor=S.+Y.+Zhangauthor=C.+Hopsonauthor=L.+Tsvetkovauthor=J.+Jingauthor=S.+Zhangauthor=J.+Smothersauthor=A.+Hoos&title=The+BRAF+and+MEK+inhibitors+dabrafenib+and+trametinib%3A+effects+on+immune+function+and+in+combination+with+immunomodulatory+antibodies+targeting+PD-1%2C+PD-L1%2C+and+CTLA-4&doi=10.1158%2F1078-0432.CCR-14-2339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4</span></div><div class="casAuthors">Liu, Li; Mayes, Patrick A.; Eastman, Stephen; Shi, Hong; Yadavilli, Sapna; Zhang, Tianqian; Yang, Jingsong; Seestaller-Wehr, Laura; Zhang, Shu-Yun; Hopson, Chris; Tsvetkov, Lyuben; Jing, Junping; Zhang, Shu; Smothers, James; Hoos, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1639-1651</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To assess the immunol. effects of dabrafenib and trametinib in vitro and to test whether trametinib potentiates or antagonizes the activity of immunomodulatory antibodies in vivo.  Exptl. Design: Immune effects of dabrafenib and trametinib were evaluated in human CD4+ and CD8+ T cells from healthy volunteers, a panel of human tumor cell lines, and in vivo using a CT26 mouse model.  Results: Dabrafenib enhanced pERK expression levels and did not suppress human CD4+ or CD8+ T-cell function.  Trametinib reduced pERK levels, and resulted in partial/transient inhibition of T-cell proliferation/expression of a cytokine and immunomodulatory gene subset, which is context dependent.  Trametinib effects were partially offset by adding dabrafenib.  Dabrafenib and trametinib in BRAF V600E/K, and trametinib in BRAF wild-type tumor cells induced apoptosis markers, upregulated HLA mol. expression, and downregulated certain immunosuppressive factors such as PD-L1, IL1, IL8, NT5E, and VEGFA.  PD-L1 expression in tumor cells was upregulated after acquiring resistance to BRAF inhibition in vitro.  Combinations of trametinib with immunomodulators targeting PD-1, PD-L1, or CTLA-4 in a CT26 model were more efficacious than any single agent.  The combination of trametinib with anti-PD-1 increased tumor-infiltrating CD8+ T cells in CT26 tumors.  Concurrent or phased sequential treatment, defined as trametinib lead-in followed by trametinib plus anti-PD-1 antibody, demonstrated superior efficacy compared with anti-PD-1 antibody followed by anti-PD-1 plus trametinib.  Conclusion: These findings support the potential for synergy between targeted therapies dabrafenib and trametinib and immunomodulatory antibodies.  Clin. exploration of such combination regimens is under way.  Clin Cancer Res; 21(7); 1639-51. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF6AmGUhb9dbVg90H21EOLACvtfcHk0ljxxE5Q_NAdIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVahtrw%253D&md5=855ff452d612e713fca5b41f6e302cba</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2339%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMayes%26aufirst%3DP.%2BA.%26aulast%3DEastman%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DYadavilli%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSeestaller-Wehr%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DHopson%26aufirst%3DC.%26aulast%3DTsvetkov%26aufirst%3DL.%26aulast%3DJing%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSmothers%26aufirst%3DJ.%26aulast%3DHoos%26aufirst%3DA.%26atitle%3DThe%2520BRAF%2520and%2520MEK%2520inhibitors%2520dabrafenib%2520and%2520trametinib%253A%2520effects%2520on%2520immune%2520function%2520and%2520in%2520combination%2520with%2520immunomodulatory%2520antibodies%2520targeting%2520PD-1%252C%2520PD-L1%252C%2520and%2520CTLA-4%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1639%26epage%3D1651%26doi%3D10.1158%2F1078-0432.CCR-14-2339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddupalli, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halaban, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhodapkar, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhodapkar, K. M.</span></span> <span> </span><span class="NLM_article-title">Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">950</span>– <span class="NLM_lpage">959</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1401686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.4049%2Fjimmunol.1401686" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2015&pages=950-959&author=R.+Dasauthor=R.+Vermaauthor=M.+Sznolauthor=C.+S.+Boddupalliauthor=S.+N.+Gettingerauthor=H.+Klugerauthor=M.+Callahanauthor=J.+D.+Wolchokauthor=R.+Halabanauthor=M.+V.+Dhodapkarauthor=K.+M.+Dhodapkar&title=Combination+therapy+with+anti-CTLA-4+and+anti-PD-1+leads+to+distinct+immunologic+changes+in+vivo&doi=10.4049%2Fjimmunol.1401686"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1401686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1401686%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DR.%26aulast%3DVerma%26aufirst%3DR.%26aulast%3DSznol%26aufirst%3DM.%26aulast%3DBoddupalli%26aufirst%3DC.%2BS.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DKluger%26aufirst%3DH.%26aulast%3DCallahan%26aufirst%3DM.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DHalaban%26aufirst%3DR.%26aulast%3DDhodapkar%26aufirst%3DM.%2BV.%26aulast%3DDhodapkar%26aufirst%3DK.%2BM.%26atitle%3DCombination%2520therapy%2520with%2520anti-CTLA-4%2520and%2520anti-PD-1%2520leads%2520to%2520distinct%2520immunologic%2520changes%2520in%2520vivo%26jtitle%3DJ.%2520Immunol.%26date%3D2015%26volume%3D194%26spage%3D950%26epage%3D959%26doi%3D10.4049%2Fjimmunol.1401686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 38 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Liu Liu, Zhiying Yao, Shijun Wang, Tao Xie, Guoqing Wu, Honghan Zhang, Pu Zhang, Yaojun Wu, Haoliang Yuan, <span class="NLM_string-name hlFld-ContribAuthor">Hongbin Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[c][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with In Vivo Antitumor Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8391-8409. <a href="https://doi.org/10.1021/acs.jmedchem.1c00392" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00392%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSyntheses%25252C%252BBiological%252BEvaluations%25252C%252Band%252BMechanistic%252BStudies%252Bof%252BBenzo%25255Bc%25255D%25255B1%25252C2%25252C5%25255Doxadiazole%252BDerivatives%252Bas%252BPotent%252BPD-L1%252BInhibitors%252Bwith%252BIn%252BVivo%252BAntitumor%252BActivity%26aulast%3DLiu%26aufirst%3DLiu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D04032021%26date%3D11062021%26volume%3D64%26issue%3D12%26spage%3D8391%26epage%3D8409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tianyu Wang, Shi Cai, Mingming Wang, Wanheng Zhang, Kuojun Zhang, Dong Chen, Zheng Li, <span class="NLM_string-name hlFld-ContribAuthor">Sheng Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7390-7403. <a href="https://doi.org/10.1021/acs.jmedchem.1c00010" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00010%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BBiphenyl%252BPyridines%252Bas%252BPotent%252BSmall-Molecule%252BInhibitors%252BTargeting%252Bthe%252BProgrammed%252BCell%252BDeath-1%25252FProgrammed%252BCell%252BDeath-Ligand%252B1%252BInteraction%26aulast%3DWang%26aufirst%3DTianyu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D04012021%26date%3D31052021%26volume%3D64%26issue%3D11%26spage%3D7390%26epage%3D7403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mingze Qin, Yangyang Meng, Haoshen Yang, Lei Liu, Haotian Zhang, Simeng Wang, Chunyang Liu, Xia Wu, Di Wu, Ye Tian, Yunlei Hou, Yanfang Zhao, Yajing Liu, Congjun Xu, <span class="NLM_string-name hlFld-ContribAuthor">Lihui Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 5519-5534. <a href="https://doi.org/10.1021/acs.jmedchem.0c01958" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01958</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01958%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-Arylindolines%252BContaining%252Ba%252BThiazole%252BMoiety%252Bas%252BPotential%252BAntitumor%252BAgents%252BInhibiting%252Bthe%252BProgrammed%252BCell%252BDeath-1%25252FProgrammed%252BCell%252BDeath-Ligand%252B1%252BInteraction%26aulast%3DQin%26aufirst%3DMingze%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12112020%26date%3D03052021%26volume%3D64%26issue%3D9%26spage%3D5519%26epage%3D5534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jialin Guo, Longlong Luo, Zhihong Wang, Naijing Hu, Wei Wang, Fei Xie, Erguang Liang, Xinlin Yan, Junhai Xiao, <span class="NLM_string-name hlFld-ContribAuthor">Song Li</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Linear Aliphatic Amine-Linked Triaryl Derivatives as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction with Promising Antitumor Effects In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13825-13850. <a href="https://doi.org/10.1021/acs.jmedchem.0c01329" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01329%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BLinear%252BAliphatic%252BAmine-Linked%252BTriaryl%252BDerivatives%252Bas%252BPotent%252BSmall-Molecule%252BInhibitors%252Bof%252Bthe%252BProgrammed%252BCell%252BDeath-1%25252FProgrammed%252BCell%252BDeath-Ligand%252B1%252BInteraction%252Bwith%252BPromising%252BAntitumor%252BEffects%252BIn%252BVivo%26aulast%3DGuo%26aufirst%3DJialin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06082020%26date%3D13112020%26volume%3D63%26issue%3D22%26spage%3D13825%26epage%3D13850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Fazhi Yu, Chenyu Zhu, Qiong Xie, <span class="NLM_string-name hlFld-ContribAuthor">Yonghui Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Adenosine A2A Receptor Antagonists for Cancer Immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12196-12212. <a href="https://doi.org/10.1021/acs.jmedchem.0c00237" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00237</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00237%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAdenosine%252BA2A%252BReceptor%252BAntagonists%252Bfor%252BCancer%252BImmunotherapy%26aulast%3DYu%26aufirst%3DFazhi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10022020%26date%3D30072020%26date%3D15072020%26volume%3D63%26issue%3D21%26spage%3D12196%26epage%3D12212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Haixia Sun, Daoyuan Chen, Siyue Zhan, Weijian Wu, Huiying Xu, Chunxiang Luo, Hui Su, Yanqiao Feng, Weiyan Shao, Arabella Wan, Binhua Zhou, Guohui Wan, <span class="NLM_string-name hlFld-ContribAuthor">Xianzhang Bu</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Discovery of Natural Cyclopeptide Skeleton Based Programmed Death Ligand 1 Inhibitor as Immune Modulator for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 11286-11301. <a href="https://doi.org/10.1021/acs.jmedchem.0c01262" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01262</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01262%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BDiscovery%252Bof%252BNatural%252BCyclopeptide%252BSkeleton%252BBased%252BProgrammed%252BDeath%252BLigand%252B1%252BInhibitor%252Bas%252BImmune%252BModulator%252Bfor%252BCancer%252BTherapy%26aulast%3DSun%26aufirst%3DHaixia%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D19072020%26date%3D21092020%26date%3D26082020%26volume%3D63%26issue%3D19%26spage%3D11286%26epage%3D11301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Suresh Narva, Xuqiong Xiong, Xudong Ma, Yoshimasa Tanaka, Yanling Wu, <span class="NLM_string-name hlFld-ContribAuthor">Wen Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Evaluation of Biphenyl-1,2,3-Triazol-Benzonitrile Derivatives as PD-1/PD-L1 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2020,</strong> <em>5 </em>
                                    (33)
                                     , 21181-21190. <a href="https://doi.org/10.1021/acsomega.0c02916" title="DOI URL">https://doi.org/10.1021/acsomega.0c02916</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.0c02916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.0c02916%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DSynthesis%252Band%252BEvaluation%252Bof%252BBiphenyl-1%25252C2%25252C3-Triazol-Benzonitrile%252BDerivatives%252Bas%252BPD-1%25252FPD-L1%252BInhibitors%26aulast%3DNarva%26aufirst%3DSuresh%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17062020%26date%3D28072020%26date%3D14082020%26volume%3D5%26issue%3D33%26spage%3D21181%26epage%3D21190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Binbin Cheng, Yichang Ren, Xiaoge Niu, Wei Wang, Shuanghu Wang, Yingfeng Tu, Shuwen Liu, Jin Wang, Deying Yang, Guochao Liao, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8338-8358. <a href="https://doi.org/10.1021/acs.jmedchem.0c00574" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00574</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00574%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BResorcinol%252BDibenzyl%252BEthers%252BTargeting%252Bthe%252BProgrammed%252BCell%252BDeath-1%25252FProgrammed%252BCell%252BDeath%2525E2%252580%252593Ligand%252B1%252BInteraction%252Bas%252BPotential%252BAnticancer%252BAgents%26aulast%3DCheng%26aufirst%3DBinbin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D08042020%26date%3D30072020%26date%3D15072020%26volume%3D63%26issue%3D15%26spage%3D8338%26epage%3D8358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Derek
J. Blevins, Ronan Hanley, Trevor Bolduc, David A. Powell, Michael Gignac, Kayleigh Walker, Mark D. Carr, Fraser Hof, <span class="NLM_string-name hlFld-ContribAuthor">Jeremy E. Wulff</span>. </span><span class="cited-content_cbyCitation_article-title">In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (8)
                                     , 1187-1192. <a href="https://doi.org/10.1021/acsmedchemlett.9b00221" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00221</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00221%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIn%252BVitro%252BAssessment%252Bof%252BPutative%252BPD-1%25252FPD-L1%252BInhibitors%25253A%252BSuggestions%252Bof%252Ban%252BAlternative%252BMode%252Bof%252BAction%26aulast%3DBlevins%26aufirst%3DDerek%2BJ.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15052019%26date%3D02072019%26date%3D05072019%26date%3D02072019%26volume%3D10%26issue%3D8%26spage%3D1187%26epage%3D1192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mingze Qin, Qi Cao, Shuaishuai Zheng, Ye Tian, Haotian Zhang, Jun Xie, Hongbo Xie, Yajing Liu, Yanfang Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Ping Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (9)
                                     , 4703-4715. <a href="https://doi.org/10.1021/acs.jmedchem.9b00312" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00312%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%25255B1%25252C2%25252C4%25255DTriazolo%25255B4%25252C3-a%25255Dpyridines%252Bas%252BPotent%252BInhibitors%252BTargeting%252Bthe%252BProgrammed%252BCell%252BDeath-1%25252FProgrammed%252BCell%252BDeath-Ligand%252B1%252BInteraction%26aulast%3DQin%26aufirst%3DMingze%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D17022019%26date%3D19042019%26date%3D09042019%26volume%3D62%26issue%3D9%26spage%3D4703%26epage%3D4715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yizhe  Wu</span>, <span class="hlFld-ContribAuthor ">Yu  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Guo</span>, <span class="hlFld-ContribAuthor ">Zhichao  Pan</span>, <span class="hlFld-ContribAuthor ">Shichun  Zhong</span>, <span class="hlFld-ContribAuthor ">Xinxin  Jin</span>, <span class="hlFld-ContribAuthor ">Weihao  Zhuang</span>, <span class="hlFld-ContribAuthor ">Sikang  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Gao</span>, <span class="hlFld-ContribAuthor ">Wenhai  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>, <span class="hlFld-ContribAuthor ">Jinxin  Che</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>223 </em>, 113637. <a href="https://doi.org/10.1016/j.ejmech.2021.113637" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113637</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113637%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bphenyl-linked%252Bsymmetric%252Bsmall%252Bmolecules%252Bas%252Binhibitors%252Bof%252Bthe%252Bprogrammed%252Bcell%252Bdeath-1%25252Fprogrammed%252Bcell%252Bdeath-ligand%252B1%252Binteraction%26aulast%3DWu%26aufirst%3DYizhe%26date%3D2021%26volume%3D223%26spage%3D113637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinyan  Dai</span>, <span class="hlFld-ContribAuthor ">Ke  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Xupeng  Huang</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of 1-methyl-1H-pyrazolo[4,3-b]pyridine derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105034. <a href="https://doi.org/10.1016/j.bioorg.2021.105034" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105034%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252B1-methyl-1H-pyrazolo%25255B4%25252C3-b%25255Dpyridine%252Bderivatives%252Bas%252Bnovel%252Bsmall-molecule%252Binhibitors%252Btargeting%252Bthe%252BPD-1%25252FPD-L1%252Binteraction%26aulast%3DDai%26aufirst%3DXinyan%26date%3D2021%26volume%3D114%26spage%3D105034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing‐Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Xin‐Yao  Liu</span>, <span class="hlFld-ContribAuthor ">Jiang‐Ping  Nie</span>, <span class="hlFld-ContribAuthor ">Mei‐Qi  Jia</span>, <span class="hlFld-ContribAuthor ">Yang  Yu</span>, <span class="hlFld-ContribAuthor ">Nan  Qin</span>, <span class="hlFld-ContribAuthor ">Hong‐Quan  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Antimetastatic Chiral Ionone Alkaloid Derivatives Targeting HIF‐1α/VEGF/VEGFR2 Pathway. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (13)
                                     , 2130-2145. <a href="https://doi.org/10.1002/cmdc.202100072" title="DOI URL">https://doi.org/10.1002/cmdc.202100072</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100072%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDiscovery%252Bof%252BAntimetastatic%252BChiral%252BIonone%252BAlkaloid%252BDerivatives%252BTargeting%252BHIF%2525E2%252580%2525901%2525CE%2525B1%25252FVEGF%25252FVEGFR2%252BPathway%26aulast%3DLiu%26aufirst%3DJing%25E2%2580%2590Jing%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D13%26spage%3D2130%26epage%3D2145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi  Miao</span>, <span class="hlFld-ContribAuthor ">Wanheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Kuojun  Zhang</span>, <span class="hlFld-ContribAuthor ">He  Li</span>, <span class="hlFld-ContribAuthor ">Jidong  Zhu</span>, <span class="hlFld-ContribAuthor ">Sheng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein–protein interaction. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2021,</strong> <em>11 </em>
                                    (38)
                                     , 23270-23279. <a href="https://doi.org/10.1039/D1RA03118J" title="DOI URL">https://doi.org/10.1039/D1RA03118J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1RA03118J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1RA03118J%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DRational%252Bdesign%252Bof%252Ba%252Bpotent%252Bmacrocyclic%252Bpeptide%252Binhibitor%252Btargeting%252Bthe%252BPD-1%25252FPD-L1%252Bprotein%2525E2%252580%252593protein%252Binteraction%26aulast%3DMiao%26aufirst%3DQi%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D38%26spage%3D23270%26epage%3D23279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chenglong  Liu</span>, <span class="hlFld-ContribAuthor ">Feilong  Zhou</span>, <span class="hlFld-ContribAuthor ">Ziqin  Yan</span>, <span class="hlFld-ContribAuthor ">Lian  Shen</span>, <span class="hlFld-ContribAuthor ">Xichen  Zhang</span>, <span class="hlFld-ContribAuthor ">Fenglian  He</span>, <span class="hlFld-ContribAuthor ">Heng  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaojie  Lu</span>, <span class="hlFld-ContribAuthor ">Ker  Yu</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhao</span>, <span class="hlFld-ContribAuthor ">Di  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a novel, potent and selective small‐molecule inhibitor of PD‐1/PD‐L1 interaction with robust
              in vivo
              anti‐tumour efficacy. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2021,</strong> <em>178 </em>
                                    (13)
                                     , 2651-2670. <a href="https://doi.org/10.1111/bph.15457" title="DOI URL">https://doi.org/10.1111/bph.15457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.15457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.15457%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DDiscovery%252Bof%252Ba%252Bnovel%25252C%252Bpotent%252Band%252Bselective%252Bsmall%2525E2%252580%252590molecule%252Binhibitor%252Bof%252BPD%2525E2%252580%2525901%25252FPD%2525E2%252580%252590L1%252Binteraction%252Bwith%252Brobust%252Bin%252Bvivo%252Banti%2525E2%252580%252590tumour%252Befficacy%26aulast%3DLiu%26aufirst%3DChenglong%26date%3D2021%26date%3D2021%26volume%3D178%26issue%3D13%26spage%3D2651%26epage%3D2670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Cao</span>, <span class="hlFld-ContribAuthor ">Binbin  Cheng</span>, <span class="hlFld-ContribAuthor ">Ting  Liu</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>188 </em>, 114522. <a href="https://doi.org/10.1016/j.bcp.2021.114522" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114522</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114522%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DSynthesis%252Band%252Bpharmacological%252Bevaluation%252Bof%252Bnovel%252Bresorcinol%252Bbiphenyl%252Bether%252Banalogs%252Bas%252Bsmall%252Bmolecule%252Binhibitors%252Bof%252BPD-1%25252FPD-L1%252Bwith%252Bbenign%252Btoxicity%252Bprofiles%252Bfor%252Bcancer%252Btreatment%26aulast%3DCao%26aufirst%3DHao%26date%3D2021%26volume%3D188%26spage%3D114522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mei  Liu</span>, <span class="hlFld-ContribAuthor ">Yu  Zhang</span>, <span class="hlFld-ContribAuthor ">Yu  Guo</span>, <span class="hlFld-ContribAuthor ">Jian  Gao</span>, <span class="hlFld-ContribAuthor ">Wenhai  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">A comparative study of the recent most potent small-molecule PD-L1 inhibitors: what can we learn?. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2021,</strong> <em>30 </em>
                                    (6)
                                     , 1230-1239. <a href="https://doi.org/10.1007/s00044-021-02728-3" title="DOI URL">https://doi.org/10.1007/s00044-021-02728-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-021-02728-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-021-02728-3%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DA%252Bcomparative%252Bstudy%252Bof%252Bthe%252Brecent%252Bmost%252Bpotent%252Bsmall-molecule%252BPD-L1%252Binhibitors%25253A%252Bwhat%252Bcan%252Bwe%252Blearn%25253F%26aulast%3DLiu%26aufirst%3DMei%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D6%26spage%3D1230%26epage%3D1239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Ke  Wang</span>, <span class="hlFld-ContribAuthor ">Yang  Yang</span>, <span class="hlFld-ContribAuthor ">Xupeng  Huang</span>, <span class="hlFld-ContribAuthor ">Xinyan  Dai</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>217 </em>, 113377. <a href="https://doi.org/10.1016/j.ejmech.2021.113377" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113377</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113377%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bstructure-activity%252Brelationship%252Bof%252Bprogrammed%252Bcell%252Bdeath-1%25252Fprogrammed%252Bcell%252Bdeath-ligand%252B1%252Binteraction%252Binhibitors%252Bbearing%252Ba%252Bbenzo%25255Bd%25255Disothiazole%252Bscaffold%26aulast%3DChen%26aufirst%3DHao%26date%3D2021%26volume%3D217%26spage%3D113377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew W.  Buesking</span>, <span class="hlFld-ContribAuthor ">Patrick A.  Mayes</span>, <span class="hlFld-ContribAuthor ">Andrew P.  Combs</span>. </span><span class="cited-content_cbyCitation_article-title">Immuno‐Oncology. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-30. <a href="https://doi.org/10.1002/0471266949.bmc272" title="DOI URL">https://doi.org/10.1002/0471266949.bmc272</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc272%26sid%3Dliteratum%253Aachs%26atitle%3DImmuno%2525E2%252580%252590Oncology%26aulast%3DBuesking%26aufirst%3DAndrew%2BW.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D30%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xia  Wu</span>, <span class="hlFld-ContribAuthor ">Yangyang  Meng</span>, <span class="hlFld-ContribAuthor ">Lei  Liu</span>, <span class="hlFld-ContribAuthor ">Guowei  Gong</span>, <span class="hlFld-ContribAuthor ">Haotian  Zhang</span>, <span class="hlFld-ContribAuthor ">Yunlei  Hou</span>, <span class="hlFld-ContribAuthor ">Chunyang  Liu</span>, <span class="hlFld-ContribAuthor ">Di  Wu</span>, <span class="hlFld-ContribAuthor ">Mingze  Qin</span>. </span><span class="cited-content_cbyCitation_article-title">Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>33 </em>, 116038. <a href="https://doi.org/10.1016/j.bmc.2021.116038" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116038%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DInsights%252Binto%252Bnon-peptide%252Bsmall-molecule%252Binhibitors%252Bof%252Bthe%252BPD-1%25252FPD-L1%252Binteraction%25253A%252BDevelopment%252Band%252Bperspective%26aulast%3DWu%26aufirst%3DXia%26date%3D2021%26volume%3D33%26spage%3D116038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chenghao  Pan</span>, <span class="hlFld-ContribAuthor ">Haiyan  Yang</span>, <span class="hlFld-ContribAuthor ">Yang  Lu</span>, <span class="hlFld-ContribAuthor ">Shengquan  Hu</span>, <span class="hlFld-ContribAuthor ">Yizhe  Wu</span>, <span class="hlFld-ContribAuthor ">Qiaojun  He</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113170. <a href="https://doi.org/10.1016/j.ejmech.2021.113170" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113170%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvance%252Bof%252Bpeptide-based%252Bmolecules%252Band%252Bnonpeptidic%252Bsmall-molecules%252Bmodulating%252BPD-1%25252FPD-L1%252Bprotein-protein%252Binteraction%252Bor%252Btargeting%252BPD-L1%252Bprotein%252Bdegradation%26aulast%3DPan%26aufirst%3DChenghao%26date%3D2021%26volume%3D213%26spage%3D113170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fengling  Wang</span>, <span class="hlFld-ContribAuthor ">Wenling  Ye</span>, <span class="hlFld-ContribAuthor ">Shuang  Wang</span>, <span class="hlFld-ContribAuthor ">Yongxing  He</span>, <span class="hlFld-ContribAuthor ">Haiyang  Zhong</span>, <span class="hlFld-ContribAuthor ">Yuwei  Wang</span>, <span class="hlFld-ContribAuthor ">Yongchang  Zhu</span>, <span class="hlFld-ContribAuthor ">Jianting  Han</span>, <span class="hlFld-ContribAuthor ">Zhitong  Bing</span>, <span class="hlFld-ContribAuthor ">Shaoping  Ji</span>, <span class="hlFld-ContribAuthor ">Huanxiang  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. </span><span class="cited-content_cbyCitation_journal-name">Neoplasia</span><span> <strong>2021,</strong> <em>23 </em>
                                    (3)
                                     , 281-293. <a href="https://doi.org/10.1016/j.neo.2021.01.001" title="DOI URL">https://doi.org/10.1016/j.neo.2021.01.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neo.2021.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neo.2021.01.001%26sid%3Dliteratum%253Aachs%26jtitle%3DNeoplasia%26atitle%3DDiscovery%252Bof%252Ba%252Bnew%252Binhibitor%252Btargeting%252BPD-L1%252Bfor%252Bcancer%252Bimmunotherapy%26aulast%3DWang%26aufirst%3DFengling%26date%3D2021%26volume%3D23%26issue%3D3%26spage%3D281%26epage%3D293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yosi  Gilad</span>, <span class="hlFld-ContribAuthor ">Gary  Gellerman</span>, <span class="hlFld-ContribAuthor ">David M.  Lonard</span>, <span class="hlFld-ContribAuthor ">Bert W.  O’Malley</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 669. <a href="https://doi.org/10.3390/cancers13040669" title="DOI URL">https://doi.org/10.3390/cancers13040669</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13040669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13040669%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DDrug%252BCombination%252Bin%252BCancer%252BTreatment%2525E2%252580%252594From%252BCocktails%252Bto%252BConjugated%252BCombinations%26aulast%3DGilad%26aufirst%3DYosi%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Yang</span>, <span class="hlFld-ContribAuthor ">Ke  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113001. <a href="https://doi.org/10.1016/j.ejmech.2020.113001" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113001%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bevaluation%25252C%252Band%252BSAR%252Bof%252B4-phenylindoline%252Bderivatives%25252C%252Ba%252Bnovel%252Bclass%252Bof%252Bsmall-molecule%252Binhibitors%252Bof%252Bthe%252Bprogrammed%252Bcell%252Bdeath-1%25252F%252Bprogrammed%252Bcell%252Bdeath-ligand%252B1%252B%252528PD-1%25252FPD-L1%252529%252Binteraction%26aulast%3DYang%26aufirst%3DYang%26date%3D2021%26volume%3D211%26spage%3D113001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marina A.  Dumpis</span>, <span class="hlFld-ContribAuthor ">Marija A.  Brusina</span>, <span class="hlFld-ContribAuthor ">Elena V.  Litasova</span>, <span class="hlFld-ContribAuthor ">Viktor V.  Iljin</span>, <span class="hlFld-ContribAuthor ">Dmitrii N.  Nikolayev</span>, <span class="hlFld-ContribAuthor ">Levon B.  Piotrovskiy</span>. </span><span class="cited-content_cbyCitation_article-title">How to improve the selectivity of drugs. </span><span class="cited-content_cbyCitation_journal-name">Reviews on Clinical Pharmacology and Drug Therapy</span><span> <strong>2020,</strong> <em>18 </em>
                                    (4)
                                     , 313-326. <a href="https://doi.org/10.17816/RCF184313-326" title="DOI URL">https://doi.org/10.17816/RCF184313-326</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.17816/RCF184313-326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.17816%2FRCF184313-326%26sid%3Dliteratum%253Aachs%26jtitle%3DReviews%2520on%2520Clinical%2520Pharmacology%2520and%2520Drug%2520Therapy%26atitle%3DHow%252Bto%252Bimprove%252Bthe%252Bselectivity%252Bof%252Bdrugs%26aulast%3DDumpis%26aufirst%3DMarina%2BA.%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D4%26spage%3D313%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marina A.  Dumpis</span>, <span class="hlFld-ContribAuthor ">Marija A.  Brusina</span>, <span class="hlFld-ContribAuthor ">Elena V.  Litasova</span>, <span class="hlFld-ContribAuthor ">Viktor V.  Iljin</span>, <span class="hlFld-ContribAuthor ">Dmitrii N.  Nikolayev</span>, <span class="hlFld-ContribAuthor ">Levon B.  Piotrovskiy</span>. </span><span class="cited-content_cbyCitation_article-title">How to improve the selectivity of drugs. </span><span class="cited-content_cbyCitation_journal-name">Reviews on Clinical Pharmacology and Drug Therapy</span><span> <strong>2020,</strong> <em>18 </em>
                                    (4)
                                     <a href="https://doi.org/10.17816/RCF184313_326" title="DOI URL">https://doi.org/10.17816/RCF184313_326</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.17816/RCF184313_326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.17816%2FRCF184313_326%26sid%3Dliteratum%253Aachs%26jtitle%3DReviews%2520on%2520Clinical%2520Pharmacology%2520and%2520Drug%2520Therapy%26atitle%3DHow%252Bto%252Bimprove%252Bthe%252Bselectivity%252Bof%252Bdrugs%26aulast%3DDumpis%26aufirst%3DMarina%2BA.%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiaohong  Geng</span>, <span class="hlFld-ContribAuthor ">Sagar O.  Rohondia</span>, <span class="hlFld-ContribAuthor ">Harras J.  Khan</span>, <span class="hlFld-ContribAuthor ">Peifu  Jiao</span>, <span class="hlFld-ContribAuthor ">Q. Ping  Dou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecules as antagonists of co-inhibitory pathways for cancer immunotherapy: a patent review (2018-2019). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (9)
                                     , 677-694. <a href="https://doi.org/10.1080/13543776.2020.1801640" title="DOI URL">https://doi.org/10.1080/13543776.2020.1801640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1801640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1801640%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall%252Bmolecules%252Bas%252Bantagonists%252Bof%252Bco-inhibitory%252Bpathways%252Bfor%252Bcancer%252Bimmunotherapy%25253A%252Ba%252Bpatent%252Breview%252B%2525282018-2019%252529%26aulast%3DGeng%26aufirst%3DQiaohong%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D9%26spage%3D677%26epage%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Binbin  Cheng</span>, <span class="hlFld-ContribAuthor ">Yichang  Ren</span>, <span class="hlFld-ContribAuthor ">Hao  Cao</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>199 </em>, 112377. <a href="https://doi.org/10.1016/j.ejmech.2020.112377" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112377</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112377%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bresorcinol%252Bdiphenyl%252Bether-based%252BPROTAC-like%252Bmolecules%252Bas%252Bdual%252Binhibitors%252Band%252Bdegraders%252Bof%252BPD-L1%26aulast%3DCheng%26aufirst%3DBinbin%26date%3D2020%26volume%3D199%26spage%3D112377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Megha  Aggarwal</span>, <span class="hlFld-ContribAuthor ">Richard K  Plemper</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Insight into Paramyxovirus and Pneumovirus Entry Inhibition. </span><span class="cited-content_cbyCitation_journal-name">Viruses</span><span> <strong>2020,</strong> <em>12 </em>
                                    (3)
                                     , 342. <a href="https://doi.org/10.3390/v12030342" title="DOI URL">https://doi.org/10.3390/v12030342</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/v12030342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fv12030342%26sid%3Dliteratum%253Aachs%26jtitle%3DViruses%26atitle%3DStructural%252BInsight%252Binto%252BParamyxovirus%252Band%252BPneumovirus%252BEntry%252BInhibition%26aulast%3DAggarwal%26aufirst%3DMegha%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D3%26spage%3D342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongli  Xie</span>, <span class="hlFld-ContribAuthor ">Jiwei  Ding</span>, <span class="hlFld-ContribAuthor ">Xiangling  Cui</span>, <span class="hlFld-ContribAuthor ">Meng  Wu</span>, <span class="hlFld-ContribAuthor ">Chenchao  Huang</span>, <span class="hlFld-ContribAuthor ">Rongyu  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Li</span>, <span class="hlFld-ContribAuthor ">Shan  Cen</span>, <span class="hlFld-ContribAuthor ">Jinming  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Screening of kinase inhibitors downregulating PD-L1 expression via on/in cell quantitative immunoblots.. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2020,</strong> <em>142 </em>, 105088. <a href="https://doi.org/10.1016/j.ejps.2019.105088" title="DOI URL">https://doi.org/10.1016/j.ejps.2019.105088</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2019.105088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2019.105088%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DScreening%252Bof%252Bkinase%252Binhibitors%252Bdownregulating%252BPD-L1%252Bexpression%252Bvia%252Bon%25252Fin%252Bcell%252Bquantitative%252Bimmunoblots.%26aulast%3DXie%26aufirst%3DYongli%26date%3D2020%26volume%3D142%26spage%3D105088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Catalina  Lee-Chang</span>, <span class="hlFld-ContribAuthor ">Aida  Rashidi</span>, <span class="hlFld-ContribAuthor ">Jason  Miska</span>, <span class="hlFld-ContribAuthor ">Peng  Zhang</span>, <span class="hlFld-ContribAuthor ">Katarzyna C.  Pituch</span>, <span class="hlFld-ContribAuthor ">David  Hou</span>, <span class="hlFld-ContribAuthor ">Ting  Xiao</span>, <span class="hlFld-ContribAuthor ">Mariafausta  Fischietti</span>, <span class="hlFld-ContribAuthor ">Seong Jae  Kang</span>, <span class="hlFld-ContribAuthor ">Christina L.  Appin</span>, <span class="hlFld-ContribAuthor ">Craig  Horbinski</span>, <span class="hlFld-ContribAuthor ">Leonidas C.  Platanias</span>, <span class="hlFld-ContribAuthor ">Aurora  Lopez-Rosas</span>, <span class="hlFld-ContribAuthor ">Yu  Han</span>, <span class="hlFld-ContribAuthor ">Irina V.  Balyasnikova</span>, <span class="hlFld-ContribAuthor ">Maciej S.  Lesniak</span>. </span><span class="cited-content_cbyCitation_article-title">Myeloid-Derived Suppressive Cells Promote B cell–Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma. </span><span class="cited-content_cbyCitation_journal-name">Cancer Immunology Research</span><span> <strong>2019,</strong> <em>7 </em>
                                    (12)
                                     , 1928-1943. <a href="https://doi.org/10.1158/2326-6066.CIR-19-0240" title="DOI URL">https://doi.org/10.1158/2326-6066.CIR-19-0240</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2326-6066.CIR-19-0240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2326-6066.CIR-19-0240%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Immunology%2520Research%26atitle%3DMyeloid-Derived%252BSuppressive%252BCells%252BPromote%252BB%252Bcell%2525E2%252580%252593Mediated%252BImmunosuppression%252Bvia%252BTransfer%252Bof%252BPD-L1%252Bin%252BGlioblastoma%26aulast%3DLee-Chang%26aufirst%3DCatalina%26date%3D2019%26date%3D2019%26volume%3D7%26issue%3D12%26spage%3D1928%26epage%3D1943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ran  Li</span>, <span class="hlFld-ContribAuthor ">Yu-Cheng  Gu</span>, <span class="hlFld-ContribAuthor ">Wen  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging Marine Immunomodulatory Small-molecules (2010- Present). </span><span class="cited-content_cbyCitation_journal-name">Current Chemical Biology</span><span> <strong>2019,</strong> <em>13 </em>
                                    (3)
                                     , 187-196. <a href="https://doi.org/10.2174/2212796813666190716102614" title="DOI URL">https://doi.org/10.2174/2212796813666190716102614</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/2212796813666190716102614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F2212796813666190716102614%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Chemical%2520Biology%26atitle%3DEmerging%252BMarine%252BImmunomodulatory%252BSmall-molecules%252B%2525282010-%252BPresent%252529%26aulast%3DLi%26aufirst%3DRan%26date%3D2019%26volume%3D13%26issue%3D3%26spage%3D187%26epage%3D196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunxia  Wang</span>, <span class="hlFld-ContribAuthor ">Song  Zhang</span>, <span class="hlFld-ContribAuthor ">Fengcheng  Li</span>, <span class="hlFld-ContribAuthor ">Ying  Zhou</span>, <span class="hlFld-ContribAuthor ">Ying  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhengwen  Wang</span>, <span class="hlFld-ContribAuthor ">Runyuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Yuxiang  Ren</span>, <span class="hlFld-ContribAuthor ">Ying  Tan</span>, <span class="hlFld-ContribAuthor ">Chu  Qin</span>, <span class="hlFld-ContribAuthor ">Yinghong  Li</span>, <span class="hlFld-ContribAuthor ">Xiaoxu  Li</span>, <span class="hlFld-ContribAuthor ">Yuzong  Chen</span>, <span class="hlFld-ContribAuthor ">Feng  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Nucleic Acids Research</span><span> <strong>2019,</strong> <em>16 </em><a href="https://doi.org/10.1093/nar/gkz981" title="DOI URL">https://doi.org/10.1093/nar/gkz981</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/nar/gkz981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fnar%2Fgkz981%26sid%3Dliteratum%253Aachs%26jtitle%3DNucleic%2520Acids%2520Research%26atitle%3DTherapeutic%252Btarget%252Bdatabase%252B2020%25253A%252Benriched%252Bresource%252Bfor%252Bfacilitating%252Bresearch%252Band%252Bearly%252Bdevelopment%252Bof%252Btargeted%252Btherapeutics%26aulast%3DWang%26aufirst%3DYunxia%26date%3D2019%26date%3D2019%26volume%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seiji  Kawashita</span>, <span class="hlFld-ContribAuthor ">Koichi  Aoyagi</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Yamanaka</span>, <span class="hlFld-ContribAuthor ">Rie  Hantani</span>, <span class="hlFld-ContribAuthor ">Shiori  Naruoka</span>, <span class="hlFld-ContribAuthor ">Atsuo  Tanimoto</span>, <span class="hlFld-ContribAuthor ">Yuji  Hori</span>, <span class="hlFld-ContribAuthor ">Yukiyo  Toyonaga</span>, <span class="hlFld-ContribAuthor ">Kyoko  Fukushima</span>, <span class="hlFld-ContribAuthor ">Susumu  Miyazaki</span>, <span class="hlFld-ContribAuthor ">Yoshiji  Hantani</span>. </span><span class="cited-content_cbyCitation_article-title">Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (17)
                                     , 2464-2467. <a href="https://doi.org/10.1016/j.bmcl.2019.07.027" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.07.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.07.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.07.027%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSymmetry-based%252Bligand%252Bdesign%252Band%252Bevaluation%252Bof%252Bsmall%252Bmolecule%252Binhibitors%252Bof%252Bprogrammed%252Bcell%252Bdeath-1%25252Fprogrammed%252Bdeath-ligand%252B1%252Binteraction%26aulast%3DKawashita%26aufirst%3DSeiji%26date%3D2019%26volume%3D29%26issue%3D17%26spage%3D2464%26epage%3D2467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amanda  Haymond</span>, <span class="hlFld-ContribAuthor ">Justin B.  Davis</span>, <span class="hlFld-ContribAuthor ">Virginia  Espina</span>. </span><span class="cited-content_cbyCitation_article-title">Proteomics for cancer drug design. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Proteomics</span><span> <strong>2019,</strong> <em>16 </em>
                                    (8)
                                     , 647-664. <a href="https://doi.org/10.1080/14789450.2019.1650025" title="DOI URL">https://doi.org/10.1080/14789450.2019.1650025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14789450.2019.1650025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14789450.2019.1650025%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Proteomics%26atitle%3DProteomics%252Bfor%252Bcancer%252Bdrug%252Bdesign%26aulast%3DHaymond%26aufirst%3DAmanda%26date%3D2019%26date%3D2019%26volume%3D16%26issue%3D8%26spage%3D647%26epage%3D664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katarzyna  Guzik</span>, <span class="hlFld-ContribAuthor ">Marcin  Tomala</span>, <span class="hlFld-ContribAuthor ">Damian  Muszak</span>, <span class="hlFld-ContribAuthor ">Magdalena  Konieczny</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Hec</span>, <span class="hlFld-ContribAuthor ">Urszula  Błaszkiewicz</span>, <span class="hlFld-ContribAuthor ">Marcin  Pustuła</span>, <span class="hlFld-ContribAuthor ">Roberto  Butera</span>, <span class="hlFld-ContribAuthor ">Alexander  Dömling</span>, <span class="hlFld-ContribAuthor ">Tad A.  Holak</span>. </span><span class="cited-content_cbyCitation_article-title">Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (11)
                                     , 2071. <a href="https://doi.org/10.3390/molecules24112071" title="DOI URL">https://doi.org/10.3390/molecules24112071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24112071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24112071%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDevelopment%252Bof%252Bthe%252BInhibitors%252BThat%252BTarget%252Bthe%252BPD-1%25252FPD-L1%252BInteraction%2525E2%252580%252594A%252BBrief%252BLook%252Bat%252BProgress%252Bon%252BSmall%252BMolecules%25252C%252BPeptides%252Band%252BMacrocycles%26aulast%3DGuzik%26aufirst%3DKatarzyna%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D11%26spage%3D2071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hu  Kuan</span>, <span class="hlFld-ContribAuthor ">Hanyu  Masayuki</span>, <span class="hlFld-ContribAuthor ">Lin  Xie</span>, <span class="hlFld-ContribAuthor ">Yiding  Zhang</span>, <span class="hlFld-ContribAuthor ">Nagatsu  Kotaro</span>, <span class="hlFld-ContribAuthor ">Suzuki  Hisashi</span>, <span class="hlFld-ContribAuthor ">Ming-Rong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Developing native peptide-based radiotracers for PD-L1 PET imaging and improving imaging contrast by pegylation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2019,</strong> <em>55 </em>
                                    (29)
                                     , 4162-4165. <a href="https://doi.org/10.1039/C9CC00445A" title="DOI URL">https://doi.org/10.1039/C9CC00445A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC00445A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC00445A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DDeveloping%252Bnative%252Bpeptide-based%252Bradiotracers%252Bfor%252BPD-L1%252BPET%252Bimaging%252Band%252Bimproving%252Bimaging%252Bcontrast%252Bby%252Bpegylation%26aulast%3DKuan%26aufirst%3DHu%26date%3D2019%26date%3D2019%26volume%3D55%26issue%3D29%26spage%3D4162%26epage%3D4165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shulun  Chen</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2019,</strong> <em>19 </em>
                                    (3)
                                     , 180-185. <a href="https://doi.org/10.2174/1568026619666190308131805" title="DOI URL">https://doi.org/10.2174/1568026619666190308131805</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026619666190308131805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026619666190308131805%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BImmuno-Oncology%252BTherapy%25253A%252BAdvances%25252C%252BChallenges%252Band%252BNew%252BDirections%26aulast%3DChen%26aufirst%3DShulun%26date%3D2019%26volume%3D19%26issue%3D3%26spage%3D180%26epage%3D185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Crystal structure of the extracellular domain (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2M2D">2M2D</a>) and structure-based sequence of human PD-1 (hPD-1).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Mechanism of the inhibition of the interaction between PD-1 and PD-L for cancer therapy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Crystal structure of the complex of hPD-1 (green ribbon)/hPD-L1 (blue ribbon) complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZQK">4ZQK</a>). (B) Three main hot spots (red circle) on the PD-L1 surface (gray). The first spot comprises Glu58, Arg113, and Tyr123. The second is formed by Met115 and Ala121. The third spot is composed of a shallow groove between Asp122 and Asp26. Residues interacted with PD-1 of PD-L1 are colored blue (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C3T">5C3T</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Possible structure of AUNP-12.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Small peptidomimetics developed by Aurigene.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cyclic peptidomimetic compounds developed by Aurigene. Formula <b>5</b>: L1 is selected from -CO-(CH<sub>2</sub>)<sub><i>n</i></sub>-NH-, -NH-(CH<sub>2</sub>)<sub><i>n</i></sub>-CO-, or an amide bond. Am1 and Am2 are amino acid residues. X is selected from Lys, Glu, or Ser. Y is selected from Glu, Gln, or Lys. Z is amino acid residues L2. L2: -NH-(CH<sub>2</sub>)<sub><i>n</i></sub>-CO- or absent.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Macrocyclic peptidomimetic compounds developed by Aurigene.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Macrocyclic peptidomimetic compounds developed by BMS Company.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Three macrocyclic peptides PD-1/PD-L1 antagonists reported by Holak.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Sulfonamides small-molecules inhibitors developed by Sharpe.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Isonicotinic acid derivatives reported by Sun et al. and resorcinol derivatives developed by Li et al.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. 1,2,4-Oxadiazole/thiadiazole and 1,3,4-oxadiazole/thiadiazole derivatives developed by Aurigene.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Aromatic ethylene compounds developed by the Guangzhou Maxinovel Pharmaceuticals Company.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Benzyl phenyl ether derivatives as PD-1/PD-L1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Small-molecule compounds developed by Incyte Corporation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Triaromatic compounds developed by the BMS Company. (B) Crystal structure of PD-L1 (chain A, green; chain B, blue)/<b>40</b> (yellow) complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J89">5J89</a>). Hydrogen bond is shown in yellow dashed line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. (A) Anti-PD/PD-L1 inhibitors characterized by Holak et al. (B) Crystal structure of PD-L1 (chain A, blue; chain B, green)/<b>42</b> (yellow) complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5N2F">5N2F</a>). Hydrogen bonds is shown in yellow dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/medium/jm-2018-009903_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Small-molecule inhibitors developed by the Bristol-Myers Squibb Company. The two aromatic ring system in the red cycle is the minimal fragment essential for the PD-L1 binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-4/acs.jmedchem.8b00990/20190221/images/large/jm-2018-009903_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00990&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54154" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54154" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 127 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehrlich, P.</span></span> <span> </span><span class="NLM_article-title">Ueber den jetzigen Stand der Karzinomforschung</span>. <i>Ned Tijdschr Geneeskd</i> <span class="NLM_year" style="font-weight: bold;">1909</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">290</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1909&pages=273-290&author=P.+Ehrlich&title=Ueber+den+jetzigen+Stand+der+Karzinomforschung"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEhrlich%26aufirst%3DP.%26atitle%3DUeber%2520den%2520jetzigen%2520Stand%2520der%2520Karzinomforschung%26jtitle%3DNed%2520Tijdschr%2520Geneeskd%26date%3D1909%26volume%3D5%26spage%3D273%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burnet, F. M.</span></span> <span> </span><span class="NLM_article-title">Immunological aspects of maligant disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1967</span>,  <span class="NLM_volume"><i>289</i></span>,  <span class="NLM_fpage">1171</span>– <span class="NLM_lpage">1174</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(67)92837-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2FS0140-6736%2867%2992837-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=1967&pages=1171-1174&author=F.+M.+Burnet&title=Immunological+aspects+of+maligant+disease&doi=10.1016%2FS0140-6736%2867%2992837-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2867%2992837-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252867%252992837-1%26sid%3Dliteratum%253Aachs%26aulast%3DBurnet%26aufirst%3DF.%2BM.%26atitle%3DImmunological%2520aspects%2520of%2520maligant%2520disease%26jtitle%3DLancet%26date%3D1967%26volume%3D289%26spage%3D1171%26epage%3D1174%26doi%3D10.1016%2FS0140-6736%2867%2992837-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Old, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, R. D.</span></span> <span> </span><span class="NLM_article-title">Cancer immunoediting: from immunosurveillance to tumor escape</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">998</span>, <span class="refDoi"> DOI: 10.1038/ni1102-991</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fni1102-991" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=12407406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot1Chs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=991-998&author=G.+P.+Dunnauthor=A.+T.+Bruceauthor=H.+Ikedaauthor=L.+J.+Oldauthor=R.+D.+Schreiber&title=Cancer+immunoediting%3A+from+immunosurveillance+to+tumor+escape&doi=10.1038%2Fni1102-991"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunoediting: from immunosurveillance to tumor escape</span></div><div class="casAuthors">Dunn, Gavin P.; Bruce, Allen T.; Ikeda, Hiroaki; Old, Lloyd J.; Schreiber, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">991-998</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The concept that the immune system can recognize and destroy nascent transformed cells was originally embodied in the cancer immunosurveillance hypothesis of Burnet and Thomas.  This hypothesis was abandoned shortly afterwards because of the absence of strong exptl. evidence supporting the concept.  New data, however, clearly show the existence of cancer immunosurveillance and also indicate that it may function as a component of a more general process of cancer immunoediting.  This process is responsible for both eliminating tumors and sculpting the immunogenic phenotypes of tumors that eventually form in immunocompetent hosts.  In this review, we will summarize the historical and exptl. basis of cancer immunoediting and discuss its dual roles in promoting host protection against cancer and facilitating tumor escape from immune destruction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO7C-v7QxET7Vg90H21EOLACvtfcHk0lgxjeyBwkHjHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot1Chs70%253D&md5=d9d00d443fbac9bcf5b7cbf089ff15ab</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fni1102-991&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1102-991%26sid%3Dliteratum%253Aachs%26aulast%3DDunn%26aufirst%3DG.%2BP.%26aulast%3DBruce%26aufirst%3DA.%2BT.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DOld%26aufirst%3DL.%2BJ.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DCancer%2520immunoediting%253A%2520from%2520immunosurveillance%2520to%2520tumor%2520escape%26jtitle%3DNat.%2520Immunol.%26date%3D2002%26volume%3D3%26spage%3D991%26epage%3D998%26doi%3D10.1038%2Fni1102-991" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotze, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muul, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettinghausen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matory, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skibber, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiloni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetto, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seipp, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichert, C. M.</span></span> <span> </span><span class="NLM_article-title">Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>313</i></span>,  <span class="NLM_fpage">1485</span>– <span class="NLM_lpage">1492</span>, <span class="refDoi"> DOI: 10.1056/NEJM198512053132327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJM198512053132327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=3903508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADyaL28%252FktVehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=1985&pages=1485-1492&author=S.+A.+Rosenbergauthor=M.+T.+Lotzeauthor=L.+M.+Muulauthor=S.+Leitmanauthor=A.+E.+Changauthor=S.+E.+Ettinghausenauthor=Y.+L.+Matoryauthor=J.+M.+Skibberauthor=E.+Shiloniauthor=J.+T.+Vettoauthor=C.+A.+Seippauthor=C.+Simpsonauthor=C.+M.+Reichert&title=Observations+on+the+systemic+administration+of+autologous+lymphokine-activated+killer+cells+and+recombinant+interleukin-2+to+patients+with+metastatic+cancer&doi=10.1056%2FNEJM198512053132327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer</span></div><div class="casAuthors">Rosenberg S A; Lotze M T; Muul L M; Leitman S; Chang A E; Ettinghausen S E; Matory Y L; Skibber J M; Shiloni E; Vetto J T</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1485-92</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">We describe here the preliminary results of the systemic administration of autologous lymphokine-activated killer (LAK) cells and the recombinant-derived lymphokine interleukin-2 to patients with advanced cancer.  This regimen was based on animal models in which the systemic administration of LAK cells plus interleukin-2 mediated the regression of established pulmonary and hepatic metastases from a variety of murine tumors in several strains of mice.  We treated 25 patients with metastatic cancer in whom standard therapy had failed.  Patients received both 1.8 to 18.4 X 10(10) autologous LAK cells, generated from lymphocytes obtained through multiple leukaphereses, and up to 90 doses of interleukin-2.  Objective regression of cancer (more than 50 per cent of volume) was observed in 11 of the 25 patients: complete tumor regression occurred in one patient with metastatic melanoma and has been sustained for up to 10 months after therapy, and partial responses occurred in nine patients with pulmonary or hepatic metastases from melanoma, colon cancer, or renal-cell cancer and in one patient with a primary unresectable lung adenocarcinoma.  Severe fluid retention was the major side effect of therapy, although all side effects resolved after interleukin-2 administration was stopped.  Further development of this approach and additional patient follow-up are required before conclusions about its therapeutic value can be drawn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRGpv_rFVnf-d0Q2ypr7jHkfW6udTcc2ebtGtpAfxj3Fbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL28%252FktVehug%253D%253D&md5=e2c1c071833a72770c08e72b49ad5226</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJM198512053132327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM198512053132327%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26aulast%3DLotze%26aufirst%3DM.%2BT.%26aulast%3DMuul%26aufirst%3DL.%2BM.%26aulast%3DLeitman%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DA.%2BE.%26aulast%3DEttinghausen%26aufirst%3DS.%2BE.%26aulast%3DMatory%26aufirst%3DY.%2BL.%26aulast%3DSkibber%26aufirst%3DJ.%2BM.%26aulast%3DShiloni%26aufirst%3DE.%26aulast%3DVetto%26aufirst%3DJ.%2BT.%26aulast%3DSeipp%26aufirst%3DC.%2BA.%26aulast%3DSimpson%26aufirst%3DC.%26aulast%3DReichert%26aufirst%3DC.%2BM.%26atitle%3DObservations%2520on%2520the%2520systemic%2520administration%2520of%2520autologous%2520lymphokine-activated%2520killer%2520cells%2520and%2520recombinant%2520interleukin-2%2520to%2520patients%2520with%2520metastatic%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1985%26volume%3D313%26spage%3D1485%26epage%3D1492%26doi%3D10.1056%2FNEJM198512053132327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S. M.</span></span> <span> </span><span class="NLM_article-title">Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2</span>. <i>Ann. Surg.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>228</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.1097/00000658-199809000-00004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1097%2F00000658-199809000-00004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=1998&pages=307-319&author=S.+A.+Rosenbergauthor=J.+C.+Yangauthor=D.+E.+Whiteauthor=S.+M.+Steinberg&title=Durability+of+complete+responses+in+patients+with+metastatic+cancer+treated+with+high-dose+interleukin-2&doi=10.1097%2F00000658-199809000-00004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1097%2F00000658-199809000-00004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000658-199809000-00004%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DWhite%26aufirst%3DD.%2BE.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26atitle%3DDurability%2520of%2520complete%2520responses%2520in%2520patients%2520with%2520metastatic%2520cancer%2520treated%2520with%2520high-dose%2520interleukin-2%26jtitle%3DAnn.%2520Surg.%26date%3D1998%26volume%3D228%26spage%3D307%26epage%3D319%26doi%3D10.1097%2F00000658-199809000-00004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy using checkpoint blockade</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">1350</span>– <span class="NLM_lpage">1355</span>, <span class="refDoi"> DOI: 10.1126/science.aar4060</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1126%2Fscience.aar4060" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=29567705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFehtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2018&pages=1350-1355&author=A.+Ribasauthor=J.+D.+Wolchok&title=Cancer+immunotherapy+using+checkpoint+blockade&doi=10.1126%2Fscience.aar4060"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy using checkpoint blockade</span></div><div class="casAuthors">Ribas, Antoni; Wolchok, Jedd D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">6382</span>),
    <span class="NLM_cas:pages">1350-1355</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The release of neg. regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in patients with a variety of cancers.  This can be achieved by antibodies blocking the cytotoxic T lymphocyte-assocd. protein 4 (CTLA-4) or the programmed cell death 1 (PD-1) pathway, either alone or in combination.  The main premise for inducing an immune response is the preexistence of antitumor T cells that were limited by specific immune checkpoints.  Most patients who have tumor responses maintain long-lasting disease control, yet one-third of patients relapse.  Mechanisms of acquired resistance are currently poorly understood, but evidence points to alterations that converge on the antigen presentation and interferon-γ signaling pathways.  New-generation combinatorial therapies may overcome resistance mechanisms to immune checkpoint therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHaFGKqeFnWLVg90H21EOLACvtfcHk0liHWenCqrLEGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFehtb8%253D&md5=65120662af8a2c63425212b07e423939</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.aar4060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aar4060%26sid%3Dliteratum%253Aachs%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DCancer%2520immunotherapy%2520using%2520checkpoint%2520blockade%26jtitle%3DScience%26date%3D2018%26volume%3D359%26spage%3D1350%26epage%3D1355%26doi%3D10.1126%2Fscience.aar4060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coukos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy comes of age</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>480</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1038/nature10673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnature10673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=22193102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1GksLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2011&pages=480-489&author=I.+Mellmanauthor=G.+Coukosauthor=G.+Dranoff&title=Cancer+immunotherapy+comes+of+age&doi=10.1038%2Fnature10673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy comes of age</span></div><div class="casAuthors">Mellman, Ira; Coukos, George; Dranoff, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">480</span>
        (<span class="NLM_cas:issue">7378</span>),
    <span class="NLM_cas:pages">480-489</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  An overview of the latest advances in cancer immunotherapy.  Activating the immune system for therapeutic benefit in cancer has long been a goal in immunol. and oncol.  After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clin. trials.  Most notable was the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed.  In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumor immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMJTF8Ma_xMrVg90H21EOLACvtfcHk0liHWenCqrLEGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1GksLjO&md5=c789086953e75829be713a1971901fd4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature10673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10673%26sid%3Dliteratum%253Aachs%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DCoukos%26aufirst%3DG.%26aulast%3DDranoff%26aufirst%3DG.%26atitle%3DCancer%2520immunotherapy%2520comes%2520of%2520age%26jtitle%3DNature%26date%3D2011%26volume%3D480%26spage%3D480%26epage%3D489%26doi%3D10.1038%2Fnature10673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuehn, B. M.</span></span> <span> </span><span class="NLM_article-title">The promise and challenges of CAR-T gene therapy</span>. <i>J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>318</i></span>,  <span class="NLM_fpage">2167</span>– <span class="NLM_lpage">2169</span>, <span class="refDoi"> DOI: 10.1001/jama.2017.15605</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1001%2Fjama.2017.15605" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BC1M3kt1WqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=318&publication_year=2017&pages=2167-2169&author=B.+M.+Kuehn&title=The+promise+and+challenges+of+CAR-T+gene+therapy&doi=10.1001%2Fjama.2017.15605"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Promise and Challenges of CAR-T Gene Therapy</span></div><div class="casAuthors">Kuehn Bridget M</div><div class="citationInfo"><span class="NLM_cas:title">JAMA</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">318</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2167-2169</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0f9Uo2QdIhUNHe_gFldTbfW6udTcc2eZJE9Wy_LmPnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3kt1WqtQ%253D%253D&md5=8bcd7b8acf175b94f3e208368c2c5487</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1001%2Fjama.2017.15605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2017.15605%26sid%3Dliteratum%253Aachs%26aulast%3DKuehn%26aufirst%3DB.%2BM.%26atitle%3DThe%2520promise%2520and%2520challenges%2520of%2520CAR-T%2520gene%2520therapy%26jtitle%3DJ.%2520Am.%2520Med.%2520Assoc.%26date%3D2017%26volume%3D318%26spage%3D2167%26epage%3D2169%26doi%3D10.1001%2Fjama.2017.15605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Restifo, N. P.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy: moving beyond current vaccines</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1038/nm1100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnm1100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=15340416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFSktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=909-915&author=S.+A.+Rosenbergauthor=J.+C.+Yangauthor=N.+P.+Restifo&title=Cancer+immunotherapy%3A+moving+beyond+current+vaccines&doi=10.1038%2Fnm1100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy: moving beyond current vaccines</span></div><div class="casAuthors">Rosenberg, Steven A.; Yang, James C.; Restifo, Nicholas P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">909-915</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Great progress has been made in the field of tumor immunol. in the past decade, but optimism about the clin. application of currently available cancer vaccine approaches is based more on surrogate endpoints than on clin. tumor regression.  In the authors' cancer vaccine trials of 440 patients, the objective response rate was low (2.6%), and comparable to the results obtained by others.  The authors consider here results in cancer vaccine trials and highlight alternate strategies that mediate cancer regression in preclin. and clin. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowXfcqR46cB7Vg90H21EOLACvtfcHk0lihWajD7caViA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFSktL0%253D&md5=07887dc692bb6268553e25c3fab1a32a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnm1100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1100%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26aulast%3DRestifo%26aufirst%3DN.%2BP.%26atitle%3DCancer%2520immunotherapy%253A%2520moving%2520beyond%2520current%2520vaccines%26jtitle%3DNat.%2520Med.%26date%3D2004%26volume%3D10%26spage%3D909%26epage%3D915%26doi%3D10.1038%2Fnm1100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">The blockade of immune checkpoints in cancer immunotherapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">264</span>, <span class="refDoi"> DOI: 10.1038/nrc3239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnrc3239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=22437870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVegtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=252-264&author=D.+M.+Pardoll&title=The+blockade+of+immune+checkpoints+in+cancer+immunotherapy&doi=10.1038%2Fnrc3239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The blockade of immune checkpoints in cancer immunotherapy</span></div><div class="casAuthors">Pardoll, Drew M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">252-264</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Among the most promising approaches to activating therapeutic antitumor immunity is the blockade of immune checkpoints.  Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiol. immune responses in peripheral tissues in order to minimize collateral tissue damage.  It is now clear that tumors co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumor antigens.  Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors.  Cytotoxic T-lymphocyte-assocd. antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval.  Preliminary clin. findings with blockers of addnl. immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumor immunity with the potential to produce durable clin. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosDPsOq8t6CrVg90H21EOLACvtfcHk0lihWajD7caViA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVegtrw%253D&md5=d278a058ffb1ccd3f678c1ae3ac0e55e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrc3239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3239%26sid%3Dliteratum%253Aachs%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26atitle%3DThe%2520blockade%2520of%2520immune%2520checkpoints%2520in%2520cancer%2520immunotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D252%26epage%3D264%26doi%3D10.1038%2Fnrc3239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span> <span> </span><span class="NLM_article-title">The future of immune checkpoint therapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1126/science.aaa8172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1126%2Fscience.aaa8172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25838373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXls1Wmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2015&pages=56-61&author=P.+Sharmaauthor=J.+P.+Allison&title=The+future+of+immune+checkpoint+therapy&doi=10.1126%2Fscience.aaa8172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The future of immune checkpoint therapy</span></div><div class="casAuthors">Sharma, Padmanee; Allison, James P.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">6230</span>),
    <span class="NLM_cas:pages">56-61</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clin. advances and provided a new weapon against cancer.  This therapy has elicited durable clin. responses and, in a fraction of patients, long-term remissions where patients exhibit no clin. signs of cancer for many years.  The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment.  This will provide valuable information regarding the dynamic nature of the immune response and regulation of addnl. pathways that will need to be targeted through combination therapies to provide survival benefit for greater nos. of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYdwRFIm59-7Vg90H21EOLACvtfcHk0lihWajD7caViA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXls1Wmurg%253D&md5=d63ae85b9c651ec64a3b5b002c609e35</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.aaa8172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aaa8172%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26atitle%3DThe%2520future%2520of%2520immune%2520checkpoint%2520therapy%26jtitle%3DScience%26date%3D2015%26volume%3D348%26spage%3D56%26epage%3D61%26doi%3D10.1126%2Fscience.aaa8172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">Immune checkpoint blockade: a common denominator approach to cancer therapy</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.ccell.2015.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25858804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVaku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=450-461&author=S.+L.+Topalianauthor=C.+G.+Drakeauthor=D.+M.+Pardoll&title=Immune+checkpoint+blockade%3A+a+common+denominator+approach+to+cancer+therapy&doi=10.1016%2Fj.ccell.2015.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy</span></div><div class="casAuthors">Topalian, Suzanne L.; Drake, Charles G.; Pardoll, Drew M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">450-461</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands.  These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction.  Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions.  The complex biol. of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb0YUggJYBrLVg90H21EOLACvtfcHk0liDfVJg7LWaqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVaku7k%253D&md5=e42c02d50881184b78630e5dd23f7f2e</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26atitle%3DImmune%2520checkpoint%2520blockade%253A%2520a%2520common%2520denominator%2520approach%2520to%2520cancer%2520therapy%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D450%26epage%3D461%26doi%3D10.1016%2Fj.ccell.2015.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Immune checkpoint blockade in cancer therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1974</span>– <span class="NLM_lpage">1982</span>, <span class="refDoi"> DOI: 10.1200/JCO.2014.59.4358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1200%2FJCO.2014.59.4358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25605845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKmt7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1974-1982&author=M.+A.+Postowauthor=M.+K.+Callahanauthor=J.+D.+Wolchok&title=Immune+checkpoint+blockade+in+cancer+therapy&doi=10.1200%2FJCO.2014.59.4358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Immune checkpoint blockade in cancer therapy</span></div><div class="casAuthors">Postow, Michael A.; Callahan, Margaret K.; Wolchok, Jedd D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1974-1982</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Immunol. checkpoint blockade with antibodies that target cytotoxic T lymphocyte-assocd. antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies.  Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and addnl. regulatory approvals are expected across the oncol. spectrum for a variety of other agents that target these pathways.  Treatment with both CTLA-4 and PD-1/PD-L1 blockade is assocd. with a unique pattern of adverse events called immune-related adverse events, and occasionally, unusual kinetics of tumor response are seen.  Combination approaches involving CTLA-4 and PD-1/PD-L1 blockade are being investigated to det. whether they enhance the efficacy of either approach alone.  Principles learned during the development of CTLA-4 and PD-1/PD-L1 approaches will likely be used as new immunol. checkpoint blocking antibodies begin clin. investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIUWb7xh6PgbVg90H21EOLACvtfcHk0liDfVJg7LWaqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKmt7%252FN&md5=8d79becb621a7945974641c7e3a69de7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.59.4358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.59.4358%26sid%3Dliteratum%253Aachs%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DImmune%2520checkpoint%2520blockade%2520in%2520cancer%2520therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1974%26epage%3D1982%26doi%3D10.1200%2FJCO.2014.59.4358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Couzin-Frankel, J.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>342</i></span>,  <span class="NLM_fpage">1432</span>– <span class="NLM_lpage">1433</span>, <span class="refDoi"> DOI: 10.1126/science.342.6165.1432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1126%2Fscience.342.6165.1432" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=24357284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotF2qsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=342&publication_year=2013&pages=1432-1433&author=J.+Couzin-Frankel&title=Cancer+immunotherapy&doi=10.1126%2Fscience.342.6165.1432"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy</span></div><div class="casAuthors">Couzin-Frankel, Jennifer</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">342</span>
        (<span class="NLM_cas:issue">6165</span>),
    <span class="NLM_cas:pages">1432-1433</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxASV1j-6kL7Vg90H21EOLACvtfcHk0liDfVJg7LWaqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotF2qsg%253D%253D&md5=2e0995fd567c5b59f40c46981da0bef4</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1126%2Fscience.342.6165.1432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.342.6165.1432%26sid%3Dliteratum%253Aachs%26aulast%3DCouzin-Frankel%26aufirst%3DJ.%26atitle%3DCancer%2520immunotherapy%26jtitle%3DScience%26date%3D2013%26volume%3D342%26spage%3D1432%26epage%3D1433%26doi%3D10.1126%2Fscience.342.6165.1432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Inhibitory B7-family molecules in the tumour microenvironment</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.1038/nri2326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnri2326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=18500231" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Ojt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=467-477&author=W.+Zouauthor=L.+Chen&title=Inhibitory+B7-family+molecules+in+the+tumour+microenvironment&doi=10.1038%2Fnri2326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory B7-family molecules in the tumor microenvironment</span></div><div class="casAuthors">Zou, Weiping; Chen, Lieping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">467-477</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review describes how the expression of inhibitory members of the B7 family, particularly B7-H1 and B7-H4, by cancer cells, stromal cells, and haematopoietic cells in the tumor microenvironment is regulated and acts to inhibit T-cell immunity, as well as the therapeutic implications.  The B7 family consists of activating and inhibitory co-stimulatory mols. that pos. and neg. regulate immune responses.  Recent studies have shown that human and rodent cancer cells, and stromal cells and immune cells in the cancer microenvironment upregulate expression of inhibitory B7 mols. and that these contribute to tumor immune evasion.  Here, the authors focus on the roles of these B7 mols. in the dynamic interactions between tumors and the host immune system, including their expression, regulation, and function in the tumor microenvironment.  The authors also discuss novel therapeutic strategies that target these inhibitory B7 mols. and their signaling pathways to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeeD0mme0N57Vg90H21EOLACvtfcHk0liDfVJg7LWaqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Ojt74%253D&md5=ba19bdd9603fbb1425fea3509697477a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnri2326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2326%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DInhibitory%2520B7-family%2520molecules%2520in%2520the%2520tumour%2520microenvironment%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D467%26epage%3D477%26doi%3D10.1038%2Fnri2326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">The B7 family revisited</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.23.021704.115611</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1146%2Fannurev.immunol.23.021704.115611" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=15771580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BD2M3otFKhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=515-548&author=R.+J.+Greenwaldauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=The+B7+family+revisited&doi=10.1146%2Fannurev.immunol.23.021704.115611"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The B7 family revisited</span></div><div class="casAuthors">Greenwald Rebecca J; Freeman Gordon J; Sharpe Arlene H</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">515-48</span>
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    </div><div class="casAbstract">The discovery of new functions for the original B7 family members, together with the identification of additional B7 and CD28 family members, have revealed new ways in which the B7:CD28 family regulates T cell activation and tolerance.  B7-1/B7-2:CD28 interactions not only promote initial T cell activation but also regulate self-tolerance by supporting CD4+CD25+ T regulatory cell homeostasis.  CTLA-4 can exert its inhibitory effects in both B7-1/B7-2 dependent and independent fashions.  B7-1 and B7-2 can signal bidirectionally by engaging CD28 and CTLA-4 on T cells and by delivering signals into B7-expressing cells.  The five new B7 family members, ICOS ligand, PD-L1 (B7-H1), PD-L2 (B7-DC), B7-H3, and B7-H4 (B7x/B7-S1) are expressed on professional antigen-presenting cells as well as on cells within nonlymphoid organs, providing new means for regulating T cell activation and tolerance in peripheral tissues.  The new CD28 families members, ICOS, PD-1, and BTLA, are inducibly expressed on T cells, and they have important roles in regulating previously activated T cells.  PD-1 and BTLA also are expressed on B cells and may have broader immunoregulatory functions.  The ICOS:ICOSL pathway appears to be particularly important for stimulating effector T cell responses and T cell-dependent B cell responses, but it also has an important role in regulating T cell tolerance.  In addition, the PD-1:PD-L1/PD-L2 pathway plays a critical role in regulating T cell activation and tolerance.  In this review, we revisit the roles of the B7:CD28 family members in regulating immune responses, and we discuss their therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSomh-zCjwWu6qcneEtCi92fW6udTcc2eaL75XTooqmlLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3otFKhug%253D%253D&md5=5c0d37e8233c089d731fe5bb6bac44ea</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.23.021704.115611&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.23.021704.115611%26sid%3Dliteratum%253Aachs%26aulast%3DGreenwald%26aufirst%3DR.%2BJ.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DThe%2520B7%2520family%2520revisited%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2005%26volume%3D23%26spage%3D515%26epage%3D548%26doi%3D10.1146%2Fannurev.immunol.23.021704.115611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sondak, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grippon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Ipilimumab</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1038/nrd3463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnrd3463" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=411-412&author=V.+K.+Sondakauthor=K.+S.+M.+Smalleyauthor=R.+Kudchadkarauthor=S.+Gripponauthor=P.+Kirkpatrick&title=Ipilimumab&doi=10.1038%2Fnrd3463"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrd3463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3463%26sid%3Dliteratum%253Aachs%26aulast%3DSondak%26aufirst%3DV.%2BK.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DKudchadkar%26aufirst%3DR.%26aulast%3DGrippon%26aufirst%3DS.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DIpilimumab%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D411%26epage%3D412%26doi%3D10.1038%2Fnrd3463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M.</span></span> <span> </span><span class="NLM_article-title">Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2968</span>– <span class="NLM_lpage">2971</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2013.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.ejca.2013.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=23907003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2itLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=2968-2971&author=C.+Robertauthor=J.+C.+Soriaauthor=A.+M.+Eggermont&title=Drug+of+the+year%3A+programmed+death-1+receptor%2Fprogrammed+death-1+ligand-1+receptor+monoclonal+antibodies&doi=10.1016%2Fj.ejca.2013.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies</span></div><div class="casAuthors">Robert, Caroline; Soria, Jean-Charles; Eggermont, Alexander M. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2968-2971</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Programmed death-1 receptor (PD-1)/its ligand (PD-L1) antibodies have changed the landscape in oncol. in 2013.  The most mature results have been obtained in advanced melanoma patients.  They indicate important response rates and high quality responses or prolonged duration.  Also in renal cancer and in lung cancer remarkable activity has been demonstrated.  Thus it is clear that these antibodies have a very broad potential and trials in many tumor types are being initiated.  Breaking tolerance at the tumor site is a potent phenomenon and the potential for synergy with other checkpoint inhibitors such as ipilimumab have also been demonstrated in 2013.  Long term tumor control now seems achievable and thus the concept of a clin. cure is emerging by modulation of the immune system.  These antibodies bring immunotherapy to the forefront and indicate that immune-modulation will be a key component of therapeutic strategies from now on.  Because of all these reasons PD-1/PD-L1 antibodies are considered 'drug of the year'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm0I44ghnzX7Vg90H21EOLACvtfcHk0ljMgJYvxlvaUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2itLbN&md5=0868af3f73d5ef02432b1a633bac72a2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2013.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2013.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26atitle%3DDrug%2520of%2520the%2520year%253A%2520programmed%2520death-1%2520receptor%252Fprogrammed%2520death-1%2520ligand-1%2520receptor%2520monoclonal%2520antibodies%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26spage%3D2968%26epage%3D2971%26doi%3D10.1016%2Fj.ejca.2013.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leming, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigel, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonia, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharfman, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMiller, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jure-Kunkel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollia, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wigginton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span> <span> </span><span class="NLM_article-title">Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">2443</span>– <span class="NLM_lpage">3454</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1200690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJMoa1200690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=22658127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2rs7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=2443-3454&author=S.+L.+Topalianauthor=F.+S.+Hodiauthor=J.+R.+Brahmerauthor=S.+N.+Gettingerauthor=D.+C.+Smithauthor=D.+F.+McDermottauthor=J.+D.+Powderlyauthor=R.+D.+Carvajalauthor=J.+A.+Sosmanauthor=M.+B.+Atkinsauthor=P.+D.+Lemingauthor=D.+R.+Spigelauthor=S.+J.+Antoniaauthor=L.+Hornauthor=C.+G.+Drakeauthor=D.+M.+Pardollauthor=L.+Chenauthor=W.+H.+Sharfmanauthor=R.+A.+Andersauthor=J.+M.+Taubeauthor=T.+L.+McMillerauthor=H.+Xuauthor=A.+J.+Kormanauthor=M.+Jure-Kunkelauthor=S.+Agrawalauthor=D.+McDonaldauthor=G.+D.+Kolliaauthor=A.+Guptaauthor=J.+M.+Wiggintonauthor=M.+Sznol&title=Safety%2C+activity%2C+and+immune+correlates+of+anti-PD-1+antibody+in+cancer&doi=10.1056%2FNEJMoa1200690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, activity, and immune correlates of anti-PD-1 antibody in cancer</span></div><div class="casAuthors">Topalian, Suzanne L.; Hodi, F. Stephen; Brahmer, Julie R.; Gettinger, Scott N.; Smith, David C.; McDermott, David F.; Powderly, John D.; Carvajal, Richard D.; Sosman, Jeffrey A.; Atkins, Michael B.; Leming, Philip D.; Spigel, David R.; Antonia, Scott J.; Horn, Leora; Drake, Charles G.; Pardoll, Drew M.; Chen, Lieping; Sharfman, William H.; Anders, Robert A.; Taube, Janis M.; McMiller, Tracee L.; Xu, Haiying; Korman, Alan J.; Jure-Kunkel, Maria; Agrawal, Shruti; McDonald, Daniel; Kollia, Georgia D.; Gupta, Ashok; Wigginton, Jon M.; Sznol, Mario</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2443-2454</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance.  We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1.  Methods: We enrolled patients with advanced melanoma, non-small-cell lung cancer, castration-resistant prostate cancer, or renal-cell or colorectal cancer to receive anti-PD-1 antibody at a dose of 0.1 to 10.0 mg per kg of body wt. every 2 wk.  Response was assessed after each 8-wk treatment cycle.  Patients received up to 12 cycles until disease progression or a complete response occurred.  Results: A total of 296 patients received treatment through Feb. 24, 2012.  Grade 3 or 4 drug-related adverse events occurred in 14% of patients; there were three deaths from pulmonary toxicity.  No max. tolerated dose was defined.  Adverse events consistent with immune-related causes were obsd.  Among 236 patients in whom response could be evaluated, objective responses (complete or partial responses) were obsd. in those with non-small-cell lung cancer, melanoma, or renal-cell cancer.  Cumulative response rates (all doses) were 18% among patients with non-small-cell lung cancer (14 of 76 patients), 28% among patients with melanoma (26 of 94 patients), and 27% among patients with renal-cell cancer (9 of 33 patients).  Responses were durable; 20 of 31 responses lasted 1 yr or more in patients with 1 yr or more of follow-up.  To assess the role of intratumoral PD-1 ligand (PD-L1) expression in the modulation of the PD-1-PD-L1 pathway, immunohistochem. anal. was performed on pretreatment tumor specimens obtained from 42 patients.  Of 17 patients with PD-L1-neg. tumors, none had an objective response; 9 of 25 patients (36%) with PD-L1-pos. tumors had an objective response (P = 0.006).  Conclusions: Anti-PD-1 antibody produced objective responses in approx. one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.  Preliminary data suggest a relationship between PD-L1 expression on tumor cells and objective response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLOPvHybmlvbVg90H21EOLACvtfcHk0ljMgJYvxlvaUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2rs7fN&md5=7c13f228ef92b6089982fc878d3a394b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1200690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1200690%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DSmith%26aufirst%3DD.%2BC.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DLeming%26aufirst%3DP.%2BD.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26aulast%3DAntonia%26aufirst%3DS.%2BJ.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DSharfman%26aufirst%3DW.%2BH.%26aulast%3DAnders%26aufirst%3DR.%2BA.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26aulast%3DMcMiller%26aufirst%3DT.%2BL.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DKorman%26aufirst%3DA.%2BJ.%26aulast%3DJure-Kunkel%26aufirst%3DM.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DD.%26aulast%3DKollia%26aufirst%3DG.%2BD.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DWigginton%26aufirst%3DJ.%2BM.%26aulast%3DSznol%26aufirst%3DM.%26atitle%3DSafety%252C%2520activity%252C%2520and%2520immune%2520correlates%2520of%2520anti-PD-1%2520antibody%2520in%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D2443%26epage%3D3454%26doi%3D10.1056%2FNEJMoa1200690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangadhar, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarour, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshua, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gergich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elassaiss-Schaap, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boasberg, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumeh, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebbinghaus, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Safety and tumor responses with lambrolizumab(anti-PD-1) in melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">134</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1305133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJMoa1305133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=23724846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1emsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=134-144&author=O.+Hamidauthor=C.+Robertauthor=A.+Daudauthor=F.+S.+Hodiauthor=W.+J.+Hwuauthor=R.+Keffordauthor=J.+D.+Wolchokauthor=P.+Herseyauthor=R.+W.+Josephauthor=J.+S.+Weberauthor=R.+Droncaauthor=T.+C.+Gangadharauthor=A.+Patnaikauthor=H.+Zarourauthor=A.+M.+Joshuaauthor=K.+Gergichauthor=J.+Elassaiss-Schaapauthor=A.+Algaziauthor=C.+Mateusauthor=P.+Boasbergauthor=P.+C.+Tumehauthor=B.+Chmielowskiauthor=S.+W.+Ebbinghausauthor=X.+N.+Liauthor=S.+P.+Kangauthor=A.+Ribas&title=Safety+and+tumor+responses+with+lambrolizumab%28anti-PD-1%29+in+melanoma&doi=10.1056%2FNEJMoa1305133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma</span></div><div class="casAuthors">Hamid, Omid; Robert, Caroline; Daud, Adil; Hodi, F. Stephen; Hwu, Wen-Jen; Kefford, Richard; Wolchok, Jedd D.; Mersey, Peter; Joseph, Richard W.; Weber, Jeffrey S.; Dronca, Roxana; Gangadhar, Tara C.; Patnaik, Amita; Zarour, Hassane; Joshua, Anthony M.; Gergich, Kevin; Elassaiss-Schaap, Jeroen; Algazi, Alain; Mateus, Christine; Boasberg, Peter; Tumeh, Paul C.; Chmielowski, Bartosz; Ebbinghaus, Scot W.; Li, Xiaoyun Nicole; Kang, S. Peter; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">134-144</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The programmed death 1 (PD-1) receptor is a neg. regulator of T-cell effector mechanisms that limits immune responses against cancer.  The authors tested the anti-PD-1 antibody lambrolizumab (previously known as MK-3475) in patients with advanced melanoma.  The authors administered lambrolizumab i.v. at a dose of 10 mg per kg of body wt. every 2 or 3 wk or 2 mg per kg every 3 wk in patients with advanced melanoma, both those who had received prior treatment with the immune checkpoint inhibitor ipilimumab and those who had not.  Tumor responses were assessed every 12 wk.  A total of 135 patients with advanced melanoma were treated.  Common adverse events attributed to treatment were fatigue, rash, pruritus, and diarrhea; most of the adverse events were low grade.  The confirmed response rate across all dose cohorts, evaluated by central radiol. review according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, was 38% (95% confidence interval [CI], 25 to 44), with the highest confirmed response rate obsd. in the cohort that received 10 mg per kg every 2 wk (52%; 95% CI, 38 to 66).  The response rate did not differ significantly between patients who had received prior ipilimumab treatment and those who had not (confirmed response rate, 38% [95% CI, 23 to 55] and 37% [95% CI, 26 to 49], resp.).  Responses were durable in the majority of patients (median follow-up, 11 mo among patients who had a response); 81% of the patients who had a response (42 of 52) were still receiving treatment at the time of anal. in March 2013.  The overall median progression-free survival among the 135 patients was longer than 7 mo.  In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX32-HobXKEbVg90H21EOLACvtfcHk0lhTiPWu1XmJ0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1emsbjP&md5=e325ca09569a6e2786f0523f197fd8c2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1305133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1305133%26sid%3Dliteratum%253Aachs%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DHwu%26aufirst%3DW.%2BJ.%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DJoseph%26aufirst%3DR.%2BW.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DDronca%26aufirst%3DR.%26aulast%3DGangadhar%26aufirst%3DT.%2BC.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DZarour%26aufirst%3DH.%26aulast%3DJoshua%26aufirst%3DA.%2BM.%26aulast%3DGergich%26aufirst%3DK.%26aulast%3DElassaiss-Schaap%26aufirst%3DJ.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DMateus%26aufirst%3DC.%26aulast%3DBoasberg%26aufirst%3DP.%26aulast%3DTumeh%26aufirst%3DP.%2BC.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DEbbinghaus%26aufirst%3DS.%2BW.%26aulast%3DLi%26aufirst%3DX.%2BN.%26aulast%3DKang%26aufirst%3DS.%2BP.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DSafety%2520and%2520tumor%2520responses%2520with%2520lambrolizumab%2528anti-PD-1%2529%2520in%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D134%26epage%3D144%26doi%3D10.1056%2FNEJMoa1305133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighl, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balmanoukian, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gubens, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcereny, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellmann, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolled-Filhart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutledge, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunceford, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangwala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubiniecki, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emancipator, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab for the treatment of non-small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">2018</span>– <span class="NLM_lpage">2028</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1501824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJMoa1501824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25891174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BC2MjmtVWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=2018-2028&author=E.+B.+Garonauthor=N.+A.+Rizviauthor=R.+Huiauthor=N.+Leighlauthor=A.+S.+Balmanoukianauthor=J.+P.+Ederauthor=A.+Patnaikauthor=C.+Aggarwalauthor=M.+Gubensauthor=L.+Hornauthor=E.+Carcerenyauthor=M.+J.+Ahnauthor=E.+Felipauthor=J.+S.+Leeauthor=M.+D.+Hellmannauthor=O.+Hamidauthor=J.+W.+Goldmanauthor=J.+C.+Soriaauthor=M.+Dolled-Filhartauthor=R.+Z.+Rutledgeauthor=J.+Zhangauthor=J.+K.+Luncefordauthor=R.+Rangwalaauthor=G.+M.+Lubinieckiauthor=C.+Roachauthor=K.+Emancipatorauthor=L.+Gandhi&title=Pembrolizumab+for+the+treatment+of+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1501824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab for the treatment of non-small-cell lung cancer</span></div><div class="casAuthors">Garon Edward B; Rizvi Naiyer A; Hui Rina; Leighl Natasha; Balmanoukian Ani S; Eder Joseph Paul; Patnaik Amita; Aggarwal Charu; Gubens Matthew; Horn Leora; Carcereny Enric; Ahn Myung-Ju; Felip Enriqueta; Lee Jong-Seok; Hellmann Matthew D; Hamid Omid; Goldman Jonathan W; Soria Jean-Charles; Dolled-Filhart Marisa; Rutledge Ruth Z; Zhang Jin; Lunceford Jared K; Rangwala Reshma; Lubiniecki Gregory M; Roach Charlotte; Emancipator Kenneth; Gandhi Leena</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2018-28</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study.  We also sought to define and validate an expression level of the PD-1 ligand 1 (PD-L1) that is associated with the likelihood of clinical benefit.  METHODS:  We assigned 495 patients receiving pembrolizumab (at a dose of either 2 mg or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182 patients) or a validation group (313 patients).  We assessed PD-L1 expression in tumor samples using immunohistochemical analysis, with results reported as the percentage of neoplastic cells with staining for membranous PD-L1 (proportion score).  Response was assessed every 9 weeks by central review.  RESULTS:  Common side effects that were attributed to pembrolizumab were fatigue, pruritus, and decreased appetite, with no clear difference according to dose or schedule.  Among all the patients, the objective response rate was 19.4%, and the median duration of response was 12.5 months.  The median duration of progression-free survival was 3.7 months, and the median duration of overall survival was 12.0 months.  PD-L1 expression in at least 50% of tumor cells was selected as the cutoff from the training group.  Among patients with a proportion score of at least 50% in the validation group, the response rate was 45.2%.  Among all the patients with a proportion score of at least 50%, median progression-free survival was 6.3 months; median overall survival was not reached.  CONCLUSIONS:  Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer.  PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. (Funded by Merck; KEYNOTE-001 ClinicalTrials.gov number, NCT01295827.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsaUZ3ot54zxwLZxei1HN8fW6udTcc2eYQ5phhwM70xLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjmtVWmtw%253D%253D&md5=df2eb1c37d57efb58d1863b5988b7a82</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1501824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1501824%26sid%3Dliteratum%253Aachs%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DRizvi%26aufirst%3DN.%2BA.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DLeighl%26aufirst%3DN.%26aulast%3DBalmanoukian%26aufirst%3DA.%2BS.%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DAggarwal%26aufirst%3DC.%26aulast%3DGubens%26aufirst%3DM.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DHellmann%26aufirst%3DM.%2BD.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DDolled-Filhart%26aufirst%3DM.%26aulast%3DRutledge%26aufirst%3DR.%2BZ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLunceford%26aufirst%3DJ.%2BK.%26aulast%3DRangwala%26aufirst%3DR.%26aulast%3DLubiniecki%26aufirst%3DG.%2BM.%26aulast%3DRoach%26aufirst%3DC.%26aulast%3DEmancipator%26aufirst%3DK.%26aulast%3DGandhi%26aufirst%3DL.%26atitle%3DPembrolizumab%2520for%2520the%2520treatment%2520of%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D2018%26epage%3D2028%26doi%3D10.1056%2FNEJMoa1501824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lotem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapira-Frommer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebbinghaus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Pembrolizumab versus ipilimumab in advanced melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">2521</span>– <span class="NLM_lpage">2532</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1503093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJMoa1503093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25891173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyrsbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=2521-2532&author=C.+Robertauthor=J.+Schachterauthor=G.+V.+Longauthor=A.+Aranceauthor=J.+J.+Grobauthor=L.+Mortierauthor=A.+Daudauthor=M.+S.+Carlinoauthor=C.+McNeilauthor=M.+Lotemauthor=J.+Larkinauthor=P.+Loriganauthor=B.+Neynsauthor=C.+U.+Blankauthor=O.+Hamidauthor=C.+Mateusauthor=R.+Shapira-Frommerauthor=M.+Koshauthor=H.+Zhouauthor=N.+Ibrahimauthor=S.+Ebbinghausauthor=A.+Ribas&title=Pembrolizumab+versus+ipilimumab+in+advanced+melanoma&doi=10.1056%2FNEJMoa1503093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pembrolizumab versus ipilimumab in advanced melanoma</span></div><div class="casAuthors">Robert, Caroline; Schachter, Jacob; Long, Georgina V.; Arance, Ana; Grob, Jean Jacques; Mortier, Laurent; Daud, Adil; Carlino, Matteo S.; McNeil, Catriona; Lotem, Michal; Larkin, James; Lorigan, Paul; Neyns, Bart; Blank, Christian U.; Hamid, Omid; Mateus, Christine; Shapira-Frommer, Ronnie; Kosh, Michele; Zhou, Honghong; Ibrahim, Nageatte; Ebbinghaus, Scot; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2521-2532</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The immune checkpoint inhibitor ipilimumab is the std.-of-care treatment for patients with advanced melanoma.  Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma.  Methods In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kg of body wt.) every 2 wk or every 3 wk or four doses of ipilimumab (at 3 mg per kg) every 3 wk.  Primary end points were progression-free and overall survival. results The estd. 6-mo progression-free-survival rates were 47.3% for pembrolizumab every 2 wk, 46.4% for pembrolizumab every 3 wk, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens vs. ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, resp.).  Estd. 12-mo survival rates were 74.1%, 68.4%, and 58.2%, resp. (hazard ratio for death for pembrolizumab every 2 wk, 0.63; 95% CI, 0.47 to 0.83; P = 0.0005; hazard ratio for pembrolizumab every 3 wk, 0.69; 95% CI, 0.52 to 0.90; P = 0.0036).  The response rate was improved with pembrolizumab administered every 2 wk (33.7%) and every 3 wk (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons).  Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, resp., after a median follow-up of 7.9 mo.  Efficacy was similar in the two pembrolizumab groups.  Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%).  Conclusions The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtKg2FC7SX5rVg90H21EOLACvtfcHk0lgflgd3QEt47w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyrsbrF&md5=b37f62f7aefe7d8948ff06babb9b711e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1503093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1503093%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DSchachter%26aufirst%3DJ.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DMortier%26aufirst%3DL.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DMcNeil%26aufirst%3DC.%26aulast%3DLotem%26aufirst%3DM.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DNeyns%26aufirst%3DB.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DMateus%26aufirst%3DC.%26aulast%3DShapira-Frommer%26aufirst%3DR.%26aulast%3DKosh%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DEbbinghaus%26aufirst%3DS.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DPembrolizumab%2520versus%2520ipilimumab%2520in%2520advanced%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D2521%26epage%3D2532%26doi%3D10.1056%2FNEJMoa1503093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wollner, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowy, I.</span></span> <span> </span><span class="NLM_article-title">Safety and activity of MDX-1106(ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3006</span>– <span class="NLM_lpage">3006</span>, <span class="refDoi"> DOI: 10.1200/jco.2008.26.15_suppl.3006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1200%2Fjco.2008.26.15_suppl.3006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=18458044" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=3006-3006&author=J.+R.+Brahmerauthor=S.+Topalianauthor=I.+Wollnerauthor=J.+D.+Powderlyauthor=J.+Picusauthor=C.+Drakeauthor=J.+Covinoauthor=A.+Kormanauthor=D.+Pardollauthor=I.+Lowy&title=Safety+and+activity+of+MDX-1106%28ONO-4538%29%2C+an+anti-PD-1+monoclonal+antibody%2C+in+patients+with+selected+refractory+or+relapsed+malignancies&doi=10.1200%2Fjco.2008.26.15_suppl.3006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1200%2Fjco.2008.26.15_suppl.3006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2008.26.15_suppl.3006%26sid%3Dliteratum%253Aachs%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DTopalian%26aufirst%3DS.%26aulast%3DWollner%26aufirst%3DI.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3DPicus%26aufirst%3DJ.%26aulast%3DDrake%26aufirst%3DC.%26aulast%3DCovino%26aufirst%3DJ.%26aulast%3DKorman%26aufirst%3DA.%26aulast%3DPardoll%26aufirst%3DD.%26aulast%3DLowy%26aufirst%3DI.%26atitle%3DSafety%2520and%2520activity%2520of%2520MDX-1106%2528ONO-4538%2529%252C%2520an%2520anti-PD-1%2520monoclonal%2520antibody%252C%2520in%2520patients%2520with%2520selected%2520refractory%2520or%2520relapsed%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D3006%26epage%3D3006%26doi%3D10.1200%2Fjco.2008.26.15_suppl.3006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowanetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrt, H. E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rost, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leabman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokatrin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span> <span> </span><span class="NLM_article-title">Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>515</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1038/nature14011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnature14011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25428504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFanurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=515&publication_year=2014&pages=563-567&author=R.+S.+Herbstauthor=J.+C.+Soriaauthor=M.+Kowanetzauthor=G.+D.+Fineauthor=O.+Hamidauthor=M.+S.+Gordonauthor=J.+A.+Sosmanauthor=D.+F.+McDermottauthor=J.+D.+Powderlyauthor=S.+N.+Gettingerauthor=H.+E.+K.+Kohrtauthor=L.+Hornauthor=D.+P.+Lawrenceauthor=S.+Rostauthor=M.+Leabmanauthor=Y.+Xiaoauthor=A.+Mokatrinauthor=H.+Koeppenauthor=P.+S.+Hegdeauthor=I.+Mellmanauthor=D.+S.+Chenauthor=F.+S.+Hodi&title=Predictive+correlates+of+response+to+the+anti-PD-L1+antibody+MPDL3280A+in+cancer+patients&doi=10.1038%2Fnature14011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients</span></div><div class="casAuthors">Herbst, Roy S.; Soria, Jean-Charles; Kowanetz, Marcin; Fine, Gregg D.; Hamid, Omid; Gordon, Michael S.; Sosman, Jeffery A.; McDermott, David F.; Powderly, John D.; Gettinger, Scott N.; Kohrt, Holbrook E. K.; Horn, Leora; Lawrence, Donald P.; Rost, Sandra; Leabman, Maya; Xiao, Yuanyuan; Mokatrin, Ahmad; Koeppen, Hartmut; Hegde, Priti S.; Mellman, Ira; Chen, Daniel S.; Hodi, F. Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">515</span>
        (<span class="NLM_cas:issue">7528</span>),
    <span class="NLM_cas:pages">563-567</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumor progression.  These changes distinguish cancer cells from their normal counterparts, allowing tumors to be recognized as foreign by the immune system.  However, tumors are rarely rejected spontaneously, reflecting their ability to maintain an immunosuppressive microenvironment.  Programmed death-ligand 1 (PD-L1; also called B7-H1 or CD274), which is expressed on many cancer and immune cells, plays an important part in blocking the 'cancer immunity cycle' by binding programmed death-1 (PD-1) and B7.1 (CD80), both of which are neg. regulators of T-lymphocyte activation.  Binding of PD-L1 to its receptors suppresses T-cell migration, proliferation and secretion of cytotoxic mediators, and restricts tumor cell killing.  The PD-L1-PD-1 axis protects the host from overactive T-effector cells not only in cancer but also during microbial infections.  Blocking PD-L1 should therefore enhance anticancer immunity, but little is known about predictive factors of efficacy.  This study was designed to evaluate the safety, activity and biomarkers of PD-L1 inhibition using the engineered humanized antibody MPDL3280A.  Here we show that across multiple cancer types, responses (as evaluated by Response Evaluation Criteria in Solid Tumors, version 1.1) were obsd. in patients with tumors expressing high levels of PD-L1, esp. when PD-L1 was expressed by tumor-infiltrating immune cells.  Furthermore, responses were assocd. with T-helper type 1 (TH1) gene expression, CTLA4 expression and the absence of fractalkine (CX3CL1) in baseline tumor specimens.  Together, these data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWwkJV0J8Y_bVg90H21EOLACvtfcHk0lid9ocXY82Okw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFanurbM&md5=1a5efa7b5929ca48ed17cb530e4f7916</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnature14011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14011%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DKowanetz%26aufirst%3DM.%26aulast%3DFine%26aufirst%3DG.%2BD.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DKohrt%26aufirst%3DH.%2BE.%2BK.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DLawrence%26aufirst%3DD.%2BP.%26aulast%3DRost%26aufirst%3DS.%26aulast%3DLeabman%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DMokatrin%26aufirst%3DA.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DHegde%26aufirst%3DP.%2BS.%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DD.%2BS.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26atitle%3DPredictive%2520correlates%2520of%2520response%2520to%2520the%2520anti-PD-L1%2520antibody%2520MPDL3280A%2520in%2520cancer%2520patients%26jtitle%3DNature%26date%3D2014%26volume%3D515%26spage%3D563%26epage%3D567%26doi%3D10.1038%2Fnature14011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rafii, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainberg, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curiel, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colon-Otero, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanborn, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drakaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurland, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rebelatto, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake-Haskins, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, N. H.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of durvalumab(MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3119</span>– <span class="NLM_lpage">3125</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.67.9761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1200%2FJCO.2016.67.9761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=27269937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFertrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=3119-3125&author=C.+Massardauthor=M.+S.+Gordonauthor=S.+Sharmaauthor=S.+Rafiiauthor=Z.+A.+Wainbergauthor=J.+Lukeauthor=T.+J.+Curielauthor=G.+Colon-Oteroauthor=O.+Hamidauthor=R.+E.+Sanbornauthor=P.+H.+O%E2%80%99Donnellauthor=A.+Drakakiauthor=W.+Tanauthor=J.+F.+Kurlandauthor=M.+C.+Rebelattoauthor=X.+Jinauthor=J.+A.+Blake-Haskinsauthor=A.+Guptaauthor=N.+H.+Segal&title=Safety+and+efficacy+of+durvalumab%28MEDI4736%29%2C+an+anti-programmed+cell+death+ligand-1+immune+checkpoint+inhibitor%2C+in+patients+with+advanced+urothelial+bladder+cancer&doi=10.1200%2FJCO.2016.67.9761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer</span></div><div class="casAuthors">Massard, Christophe; Gordon, Michael S.; Sharma, Sunil; Rafii, Saeed; Wainberg, Zev A.; Luke, Jason; Curiel, Tyler J.; Colon-Otero, Gerardo; Hamid, Omid; Sanborn, Rachel E.; O'Donnell, Peter H.; Drakaki, Alexandra; Tan, Winston; Kurland, John F.; Rebelatto, Marlon C.; Jin, Xiaoping; Blake-Haskins, John A.; Gupta, Ashok; Segal, Neil H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3119-3125</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose To investigate the safety and efficacy of durvalumab, a human monoclonal antibody that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1 expression on clin. response in patients with advanced urothelial bladder cancer (UBC).  Methods A phase 1/2 multicenter, open-label study is being conducted in patients with inoperable or metastatic solid tumors.  We report here the results from the UBC expansion cohort.  Durvalumab (MEDI4736, 10 mg/kg every 2 wk) was administered i.v. for up to 12 mo.  The primary end point was safety, and objective response rate (ORR, confirmed) was a key secondary end point.  An exploratory anal. of pretreatment tumor biopsies led to defining PD-L1-pos. as $ 25% of tumor cells or tumor-infiltrating immune cells expressing membrane PD-L1.  Results A total of 61 patients (40 PD-L1-pos., 21 PD-L1-neg.), 93.4% of whom received one or more prior therapies for advanced disease, were treated (median duration of follow-up, 4.3 mo).  The most common treatment-related adverse events (AEs) of any grade were fatigue (13.1%), diarrhea (9.8%), and decreased appetite (8.2%).  Grade 3 treatment-related AEs occurred in three patients (4.9%); there were no treatment-related grade 4 or 5 AEs.  One treatment-related AE (acute kidney injury) resulted in treatment discontinuation.  The ORR was 31.0% (95% CI, 17.6 to 47.1) in 42 response-evaluable patients, 46.4% (95% CI, 27.5 to 66.1) in the PD-L1-pos. subgroup, and 0% (95% CI, 0.0 to 23.2) in the PD-L1-neg. subgroup.  Responses are ongoing in 12 of 13 responding patients, withmedian duration of response not yet reached (range, 4.1+ to 49.3+ weeks).  Conclusion Durvalumab demonstrated a manageable safety profile and evidence of meaningful clin. activity in PD-L1-pos. patients with UBC, many of whom were heavily pretreated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRRzGthbTE1rVg90H21EOLACvtfcHk0lid9ocXY82Okw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFertrzP&md5=0704b7e421e36d91f953139b40890d17</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.67.9761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.67.9761%26sid%3Dliteratum%253Aachs%26aulast%3DMassard%26aufirst%3DC.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DRafii%26aufirst%3DS.%26aulast%3DWainberg%26aufirst%3DZ.%2BA.%26aulast%3DLuke%26aufirst%3DJ.%26aulast%3DCuriel%26aufirst%3DT.%2BJ.%26aulast%3DColon-Otero%26aufirst%3DG.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSanborn%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DP.%2BH.%26aulast%3DDrakaki%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DKurland%26aufirst%3DJ.%2BF.%26aulast%3DRebelatto%26aufirst%3DM.%2BC.%26aulast%3DJin%26aufirst%3DX.%26aulast%3DBlake-Haskins%26aufirst%3DJ.%2BA.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DSegal%26aufirst%3DN.%2BH.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520durvalumab%2528MEDI4736%2529%252C%2520an%2520anti-programmed%2520cell%2520death%2520ligand-1%2520immune%2520checkpoint%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520urothelial%2520bladder%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D3119%26epage%3D3125%26doi%3D10.1200%2FJCO.2016.67.9761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowey, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lao, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagstaff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrucci, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smylie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlino, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechter, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquez-Rodas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidoboni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rollin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span> <span> </span><span class="NLM_article-title">Overall survival with combined nivolumab and ipilimumab in advanced melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1709684</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJMoa1709684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=28889792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Git73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=1345-1356&author=J.+D.+Wolchokauthor=V.+Chiarion-Sileniauthor=R.+Gonzalezauthor=P.+Rutkowskiauthor=J.+J.+Grobauthor=C.+L.+Coweyauthor=C.+D.+Laoauthor=J.+Wagstaffauthor=D.+Schadendorfauthor=P.+F.+Ferrucciauthor=M.+Smylieauthor=R.+Dummerauthor=A.+Hillauthor=D.+Hoggauthor=J.+Haanenauthor=M.+S.+Carlinoauthor=O.+Bechterauthor=M.+Maioauthor=I.+Marquez-Rodasauthor=M.+Guidoboniauthor=G.+McArthurauthor=C.+Lebbeauthor=P.+A.+Asciertoauthor=G.+V.+Longauthor=J.+Cebonauthor=J.+Sosmanauthor=M.+A.+Postowauthor=M.+K.+Callahanauthor=D.+Walkerauthor=L.+Rollinauthor=R.+Bhoreauthor=F.+S.+Hodiauthor=J.+Larkin&title=Overall+survival+with+combined+nivolumab+and+ipilimumab+in+advanced+melanoma&doi=10.1056%2FNEJMoa1709684"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Overall survival with combined nivolumab and ipilimumab in advanced melanoma</span></div><div class="casAuthors">Wolchok, J. D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J.-J.; Cowey, C. L.; Lao, C. D.; Wagstaff, J.; Schadendorf, D.; Ferrucci, P. F.; Smylie, M.; Dummer, R.; Hill, A.; Hogg, D.; Haanen, J.; Carlino, M. S.; Bechter, O.; Maio, M.; Marquez-Rodas, I.; Guidoboni, M.; McArthur, G.; Lebbe, C.; Ascierto, P. A.; Long, G. V.; Cebon, J.; Sosman, J.; Postow, M. A.; Callahan, M. K.; Walker, D.; Rollin, L.; Bhore, R.; Hodi, F. S.; Larkin, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1345-1356</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma.  We now report 3-yr overall survival outcomes in this trial. methods We randomly assigned, in a 1:1:1 ratio, patients with previously untreated advanced melanoma to receive nivolumab at a dose of 1 mg per kg of body wt. plus ipilimumab at a dose of 3 mg per kg every 3 wk for four doses, followed by nivolumab at a dose of 3 mg per kg every 2 wk; nivolumab at a dose of 3 mg per kg every 2 wk plus placebo; or ipilimumab at a dose of 3 mg per kg every 3 wk for four doses plus placebo, until progression, the occurrence of unacceptable toxic effects, or withdrawal of consent.  Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and metastasis stage.  The two primary end points were progression-free survival and overall survival in the nivolumab-plus-ipilimumab group and in the nivolumab group vs. the ipilimumab group. results At a min. follow-up of 36 mo, the median overall survival had not been reached in the nivolumab-plus-ipilimumab group and was 37.6 mo in the nivolumab group, as compared with 19.9 mo in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.55 [P<0.001]; hazard ratio for death with nivolumab vs. ipilimumab, 0.65 [P<0.001]).  The overall survival rate at 3 years was 58% in the nivolumab-plus-ipilimumab group and 52% in the nivolumab group, as compared with 34% in the ipilimumab group.  The safety profile was unchanged from the initial report.  Treatment-related adverse events of grade 3 or 4 occurred in 59% of the patients in the nivolumab-plus-ipilimumab group, in 21% of those in the nivolumab group, and in 28% of those in the ipilimumab group. conclusions Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with ipilimumab alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY91ga-k7LxbVg90H21EOLACvtfcHk0lhKORzMMGAzUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Git73I&md5=bf5e5c47178631cd4485cf79dca12dd8</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1709684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1709684%26sid%3Dliteratum%253Aachs%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DCowey%26aufirst%3DC.%2BL.%26aulast%3DLao%26aufirst%3DC.%2BD.%26aulast%3DWagstaff%26aufirst%3DJ.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DFerrucci%26aufirst%3DP.%2BF.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DHill%26aufirst%3DA.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DHaanen%26aufirst%3DJ.%26aulast%3DCarlino%26aufirst%3DM.%2BS.%26aulast%3DBechter%26aufirst%3DO.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DMarquez-Rodas%26aufirst%3DI.%26aulast%3DGuidoboni%26aufirst%3DM.%26aulast%3DMcArthur%26aufirst%3DG.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DRollin%26aufirst%3DL.%26aulast%3DBhore%26aufirst%3DR.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DLarkin%26aufirst%3DJ.%26atitle%3DOverall%2520survival%2520with%2520combined%2520nivolumab%2520and%2520ipilimumab%2520in%2520advanced%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D1345%26epage%3D1356%26doi%3D10.1056%2FNEJMoa1709684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ngiow, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Scheidt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smyth, M. J.</span></span> <span> </span><span class="NLM_article-title">Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">3540</span>– <span class="NLM_lpage">3551</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-0096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1158%2F0008-5472.CAN-11-0096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3540-3551&author=S.+F.+Ngiowauthor=B.+von+Scheidtauthor=H.+Akibaauthor=H.+Yagitaauthor=M.+W.+Tengauthor=M.+J.+Smyth&title=Anti-TIM3+antibody+promotes+T+cell+IFN-gamma-mediated+antitumor+immunity+and+suppresses+established+tumors&doi=10.1158%2F0008-5472.CAN-11-0096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-0096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-0096%26sid%3Dliteratum%253Aachs%26aulast%3DNgiow%26aufirst%3DS.%2BF.%26aulast%3Dvon%2BScheidt%26aufirst%3DB.%26aulast%3DAkiba%26aufirst%3DH.%26aulast%3DYagita%26aufirst%3DH.%26aulast%3DTeng%26aufirst%3DM.%2BW.%26aulast%3DSmyth%26aufirst%3DM.%2BJ.%26atitle%3DAnti-TIM3%2520antibody%2520promotes%2520T%2520cell%2520IFN-gamma-mediated%2520antitumor%2520immunity%2520and%2520suppresses%2520established%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3540%26epage%3D3551%26doi%3D10.1158%2F0008-5472.CAN-11-0096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnis, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bankoti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selby, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirschl, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gravano, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangsombatvisit, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosso, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Netto, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeltzer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaux, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korman, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignali, D. A.</span></span> <span> </span><span class="NLM_article-title">Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">927</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1158%2F0008-5472.CAN-11-1620" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=917-927&author=S.+R.+Wooauthor=M.+E.+Turnisauthor=M.+V.+Goldbergauthor=J.+Bankotiauthor=M.+Selbyauthor=C.+J.+Nirschlauthor=M.+L.+Bettiniauthor=D.+M.+Gravanoauthor=P.+Vogelauthor=C.+L.+Liuauthor=S.+Tangsombatvisitauthor=J.+F.+Grossoauthor=G.+Nettoauthor=M.+P.+Smeltzerauthor=A.+Chauxauthor=P.+J.+Utzauthor=C.+J.+Workmanauthor=D.+M.+Pardollauthor=A.+J.+Kormanauthor=C.+G.+Drakeauthor=D.+A.+Vignali&title=Immune+inhibitory+molecules+LAG-3+and+PD-1+synergistically+regulate+T-cell+function+to+promote+tumoral+immune+escape&doi=10.1158%2F0008-5472.CAN-11-1620"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1620%26sid%3Dliteratum%253Aachs%26aulast%3DWoo%26aufirst%3DS.%2BR.%26aulast%3DTurnis%26aufirst%3DM.%2BE.%26aulast%3DGoldberg%26aufirst%3DM.%2BV.%26aulast%3DBankoti%26aufirst%3DJ.%26aulast%3DSelby%26aufirst%3DM.%26aulast%3DNirschl%26aufirst%3DC.%2BJ.%26aulast%3DBettini%26aufirst%3DM.%2BL.%26aulast%3DGravano%26aufirst%3DD.%2BM.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DC.%2BL.%26aulast%3DTangsombatvisit%26aufirst%3DS.%26aulast%3DGrosso%26aufirst%3DJ.%2BF.%26aulast%3DNetto%26aufirst%3DG.%26aulast%3DSmeltzer%26aufirst%3DM.%2BP.%26aulast%3DChaux%26aufirst%3DA.%26aulast%3DUtz%26aufirst%3DP.%2BJ.%26aulast%3DWorkman%26aufirst%3DC.%2BJ.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DKorman%26aufirst%3DA.%2BJ.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DVignali%26aufirst%3DD.%2BA.%26atitle%3DImmune%2520inhibitory%2520molecules%2520LAG-3%2520and%2520PD-1%2520synergistically%2520regulate%2520T-cell%2520function%2520to%2520promote%2520tumoral%2520immune%2520escape%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D917%26epage%3D927%26doi%3D10.1158%2F0008-5472.CAN-11-1620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarganes-Tzitzikas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinidou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzemien, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of programmed cell death 1(PD-1): a patent review (2010–2015)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">973</span>– <span class="NLM_lpage">977</span>, <span class="refDoi"> DOI: 10.1080/13543776.2016.1206527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1080%2F13543776.2016.1206527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=27367741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFaht7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=973-977&author=T.+Zarganes-Tzitzikasauthor=M.+Konstantinidouauthor=Y.+Gaoauthor=D.+Krzemienauthor=K.+Zakauthor=G.+Dubinauthor=T.+A.+Holakauthor=A.+Domling&title=Inhibitors+of+programmed+cell+death+1%28PD-1%29%3A+a+patent+review+%282010%E2%80%932015%29&doi=10.1080%2F13543776.2016.1206527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015)</span></div><div class="casAuthors">Zarganes-Tzitzikas, Tryfon; Konstantinidou, Markella; Gao, Yongzhi; Krzemien, Dobroslawa; Zak, Krzysztof; Dubin, Grzegorz; Holak, Tad A.; Doemling, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">973-977</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Inhibitors of programmed cell death 1 (PD-1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr524OBaXrAsbVg90H21EOLACvtfcHk0lhKORzMMGAzUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFaht7%252FK&md5=98f7c61ae47a48075d254454117fdfe3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1080%2F13543776.2016.1206527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2016.1206527%26sid%3Dliteratum%253Aachs%26aulast%3DZarganes-Tzitzikas%26aufirst%3DT.%26aulast%3DKonstantinidou%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DKrzemien%26aufirst%3DD.%26aulast%3DZak%26aufirst%3DK.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DDomling%26aufirst%3DA.%26atitle%3DInhibitors%2520of%2520programmed%2520cell%2520death%25201%2528PD-1%2529%253A%2520a%2520patent%2520review%2520%25282010%25E2%2580%25932015%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2016%26volume%3D26%26spage%3D973%26epage%3D977%26doi%3D10.1080%2F13543776.2016.1206527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span> <span> </span><span class="NLM_article-title">From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.drudis.2016.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=27094104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Krt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1027-1036&author=M.+M.+Zhanauthor=X.+Q.+Huauthor=X.+X.+Liuauthor=B.+F.+Ruanauthor=J.+Xuauthor=C.+Liao&title=From+monoclonal+antibodies+to+small+molecules%3A+the+development+of+inhibitors+targeting+the+PD-1%2FPD-L1+pathway&doi=10.1016%2Fj.drudis.2016.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway</span></div><div class="casAuthors">Zhan, Mei-Miao; Hu, Xue-Qin; Liu, Xiu-Xiu; Ruan, Ban-Feng; Xu, Jun; Liao, Chenzhong</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1027-1036</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cancer immunotherapy has made an extraordinary journey from bench to bedside.  Blocking the interactions between programmed cell death protein 1 (PD-1) and its ligand, PD-L1, has emerged as a promising immunotherapy for treating cancer.  Here, we review the development of drugs targeting the PD-1/PD-L1 pathway.  We discuss the monoclonal antibodies (mAbs) approved or in clin. trials, peptides and patented small mols. developed against this pathway.  Such compds. have the potential to treat cancer as well as chronic virol. diseases.  We also detail PD-1/PD-L1 interactions, an understanding of which will be useful for the rational design of small-mol. therapeutics that disrupt the PD-1/PD-L1 pathway.  It is likely that more mAbs targeting the PD-1/PD-L1 pathway will be approved for the treatment of a range of cancers.  By contrast, it is likely to be more difficult to successfully develop small mols. or peptides and for them to reach the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYsq7LUmul7bVg90H21EOLACvtfcHk0lh3_3IfRYmYig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Krt74%253D&md5=e7bfff84cb527571846c9d82a1d8accf</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DM.%2BM.%26aulast%3DHu%26aufirst%3DX.%2BQ.%26aulast%3DLiu%26aufirst%3DX.%2BX.%26aulast%3DRuan%26aufirst%3DB.%2BF.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DC.%26atitle%3DFrom%2520monoclonal%2520antibodies%2520to%2520small%2520molecules%253A%2520the%2520development%2520of%2520inhibitors%2520targeting%2520the%2520PD-1%252FPD-L1%2520pathway%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1027%26epage%3D1036%26doi%3D10.1016%2Fj.drudis.2016.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chehrazi-Raffle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span> <span> </span><span class="NLM_article-title">Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations</span>. <i>J. Immunother Cancer.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.1186/s40425-018-0316-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1186%2Fs40425-018-0316-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=29357948" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BC1MvjtFWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=8&author=J.+Gongauthor=A.+Chehrazi-Raffleauthor=S.+Reddiauthor=R.+Salgia&title=Development+of+PD-1+and+PD-L1+inhibitors+as+a+form+of+cancer+immunotherapy%3A+a+comprehensive+review+of+registration+trials+and+future+considerations&doi=10.1186%2Fs40425-018-0316-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations</span></div><div class="casAuthors">Gong Jun; Chehrazi-Raffle Alexander; Reddi Srikanth; Salgia Ravi</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy given that activation of the PD-1/PD-L1 axis putatively served as a mechanism for tumor evasion of host tumor antigen-specific T-cell immunity.  Early-phase studies investigating several humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in advanced solid tumors paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by the Food and Drug Administration (FDA) in 2014.  The number of FDA-approved agents of this class is rapidly enlarging with indications for treatment spanning across a spectrum of malignancies.  The purpose of this review is to highlight the clinical development of PD-1 and PD-L1 inhibitors in cancer therapy to date.  In particular, we focus on detailing the registration trials that have led to FDA-approved indications of anti-PD-1 and anti-PD-L1 therapies in cancer.  As the number of PD-1/PD-L1 inhibitors continues to grow, predictive biomarkers, mechanisms of resistance, hyperprogressors, treatment duration and treatment beyond progression, immune-related toxicities, and clinical trial design are key concepts in need of further consideration to optimize the anticancer potential of this class of immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ9ioF2w_a5-bGbPKh4T9eAfW6udTcc2eZyACcZ_bVZS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvjtFWnsg%253D%253D&md5=4b6b86e0539b18080af0bd30c562620e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2Fs40425-018-0316-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-018-0316-z%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DChehrazi-Raffle%26aufirst%3DA.%26aulast%3DReddi%26aufirst%3DS.%26aulast%3DSalgia%26aufirst%3DR.%26atitle%3DDevelopment%2520of%2520PD-1%2520and%2520PD-L1%2520inhibitors%2520as%2520a%2520form%2520of%2520cancer%2520immunotherapy%253A%2520a%2520comprehensive%2520review%2520of%2520registration%2520trials%2520and%2520future%2520considerations%26jtitle%3DJ.%2520Immunother%2520Cancer.%26date%3D2018%26volume%3D6%26spage%3D8%26doi%3D10.1186%2Fs40425-018-0316-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huck, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kötzner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbahns, K.</span></span> <span> </span><span class="NLM_article-title">Small molecules drive big improvements in immuno-oncology therapies</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4412</span>– <span class="NLM_lpage">4428</span>, <span class="refDoi"> DOI: 10.1002/anie.201707816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1002%2Fanie.201707816" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlWqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=4412-4428&author=B.+R.+Huckauthor=L.+K%C3%B6tznerauthor=K.+Urbahns&title=Small+molecules+drive+big+improvements+in+immuno-oncology+therapies&doi=10.1002%2Fanie.201707816"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecules Drive Big Improvements in Immuno-Oncology Therapies</span></div><div class="casAuthors">Huck, Bayard R.; Koetzner, Lisa; Urbahns, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4412-4428</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Immunooncol. therapies have the potential to revolutionize the armamentarium of available cancer treatments.  To further improve clin. response rates, researchers are looking for novel combination regimens, with checkpoint blockade being used as a backbone of the treatment.  This Review highlights the significance of small mols. in this approach, which holds promise to provide increased benefit to cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobJKXxvd05sLVg90H21EOLACvtfcHk0lh3_3IfRYmYig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlWqsbo%253D&md5=bef3a381977686b5bdb432a76364b066</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fanie.201707816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201707816%26sid%3Dliteratum%253Aachs%26aulast%3DHuck%26aufirst%3DB.%2BR.%26aulast%3DK%25C3%25B6tzner%26aufirst%3DL.%26aulast%3DUrbahns%26aufirst%3DK.%26atitle%3DSmall%2520molecules%2520drive%2520big%2520improvements%2520in%2520immuno-oncology%2520therapies%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D4412%26epage%3D4428%26doi%3D10.1002%2Fanie.201707816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinidou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarganes-Tzitzikas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span> <span> </span><span class="NLM_article-title">Immune checkpoint PD-1/PD-L1: is there life beyond antibodies?</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4840</span>– <span class="NLM_lpage">4848</span>, <span class="refDoi"> DOI: 10.1002/anie.201710407</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1002%2Fanie.201710407" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjtlajtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=4840-4848&author=M.+Konstantinidouauthor=T.+Zarganes-Tzitzikasauthor=K.+Magiera-Mularzauthor=T.+A.+Holakauthor=A.+Domling&title=Immune+checkpoint+PD-1%2FPD-L1%3A+is+there+life+beyond+antibodies%3F&doi=10.1002%2Fanie.201710407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?</span></div><div class="casAuthors">Konstantinidou, Markella; Zarganes-Tzitzikas, Tryfon; Magiera-Mularz, Katarzyna; Holak, Tad A.; Doemling, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4840-4848</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The PD-1/PD-L1 interaction has emerged as a significant target in cancer immunotherapy.  Current medications include monoclonal antibodies, which have shown impressive clin. results in the treatment of several types of tumors.  The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small mols., and macrocycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptGmK21i2_fLVg90H21EOLACvtfcHk0lhWa6MxP13ouw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjtlajtrk%253D&md5=b95fda31d16a4847bb6eb4eabdd1d84e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fanie.201710407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201710407%26sid%3Dliteratum%253Aachs%26aulast%3DKonstantinidou%26aufirst%3DM.%26aulast%3DZarganes-Tzitzikas%26aufirst%3DT.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DDomling%26aufirst%3DA.%26atitle%3DImmune%2520checkpoint%2520PD-1%252FPD-L1%253A%2520is%2520there%2520life%2520beyond%2520antibodies%253F%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D4840%26epage%3D4848%26doi%3D10.1002%2Fanie.201710407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bojadzic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, P.</span></span> <span> </span><span class="NLM_article-title">Toward small-molecule inhibition of protein-protein interactions: general aspects and recent progress in targeting costimulatory and coinhibitory(immune checkpoint) interactions</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">699</span>, <span class="refDoi"> DOI: 10.2174/1568026618666180531092503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.2174%2F1568026618666180531092503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=29848279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVekurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=674-699&author=D.+Bojadzicauthor=P.+Buchwald&title=Toward+small-molecule+inhibition+of+protein-protein+interactions%3A+general+aspects+and+recent+progress+in+targeting+costimulatory+and+coinhibitory%28immune+checkpoint%29+interactions&doi=10.2174%2F1568026618666180531092503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions</span></div><div class="casAuthors">Bojadzic, Damir; Buchwald, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">674-699</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein-Protein Interactions (PPIs) that are part of the costimulatory and coinhibitory (immune checkpoint) signaling are crit. for adequate T cell response and are important therapeutic targets for immunomodulation.  Biologics targeting them have already achieved considerable clin. success in the treatment of autoimmune diseases or transplant recipients (e.g., abatacept, belatacept, and belimumab) as well as cancer (e.g., ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab).  In view of such progress, there have been only relatively limited efforts toward developing small-mol. PPI inhibitors (SMPPIIs) targeting these cosignaling interactions, possibly because they, as all other PPIs, are difficult to target by small mols. and were not considered druggable.  Nevertheless, substantial progress has been achieved during the last decade.  SMPPIIs proving the feasibility of such approaches have been identified through various strategies for a no. of cosignaling interactions including CD40-CD40L, OX40-OX40L, BAFFR-BAFF, CD80-CD28, and PD-1-PD-L1s.  Here, after an overview of the general aspects and challenges of SMPPII-focused drug discovery, we review them briefly together with relevant structural, immune-signaling, physicochem., and medicinal chem. aspects.  While so far only a few of these SMPPIIs have shown activity in animal models (DRI-C21045 for CD40-D40L, KR33426 for BAFFR-BAFF) or reached clin. development (RhuDex for CD80-CD28, CA-170 for PD-1-PD-L1), there is proof-of-principle evidence for the feasibility of such approaches in immunomodulation.  They can result in products that are easier to develop/ manuf. and are less likely to be immunogenic or encounter postmarket safety events than corresponding biologics, and, contrary to them, can even become orally bioavailable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxFgcfDDFwirVg90H21EOLACvtfcHk0lhWa6MxP13ouw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVekurbM&md5=0c3c3adbf37198bf3db786209abb5892</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F1568026618666180531092503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026618666180531092503%26sid%3Dliteratum%253Aachs%26aulast%3DBojadzic%26aufirst%3DD.%26aulast%3DBuchwald%26aufirst%3DP.%26atitle%3DToward%2520small-molecule%2520inhibition%2520of%2520protein-protein%2520interactions%253A%2520general%2520aspects%2520and%2520recent%2520progress%2520in%2520targeting%2520costimulatory%2520and%2520coinhibitory%2528immune%2520checkpoint%2529%2520interactions%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2018%26volume%3D18%26spage%3D674%26epage%3D699%26doi%3D10.2174%2F1568026618666180531092503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geng, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, G. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span> <span> </span><span class="NLM_article-title">PD-1/PD-L1 inhibitors for immuno-oncology: from antibodies to small molecules</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6033</span>– <span class="NLM_lpage">6041</span>, <span class="refDoi"> DOI: 10.2174/1381612823666171004120152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.2174%2F1381612823666171004120152" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=6033-6041&author=Q.+H.+Gengauthor=P.+F.+Jiaoauthor=P.+Jinauthor=G.+X.+Suauthor=J.+L.+Dongauthor=B.+Yan&title=PD-1%2FPD-L1+inhibitors+for+immuno-oncology%3A+from+antibodies+to+small+molecules&doi=10.2174%2F1381612823666171004120152"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2174%2F1381612823666171004120152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612823666171004120152%26sid%3Dliteratum%253Aachs%26aulast%3DGeng%26aufirst%3DQ.%2BH.%26aulast%3DJiao%26aufirst%3DP.%2BF.%26aulast%3DJin%26aufirst%3DP.%26aulast%3DSu%26aufirst%3DG.%2BX.%26aulast%3DDong%26aufirst%3DJ.%2BL.%26aulast%3DYan%26aufirst%3DB.%26atitle%3DPD-1%252FPD-L1%2520inhibitors%2520for%2520immuno-oncology%253A%2520from%2520antibodies%2520to%2520small%2520molecules%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2017%26volume%3D23%26spage%3D6033%26epage%3D6041%26doi%3D10.2174%2F1381612823666171004120152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibahara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3887</span>– <span class="NLM_lpage">3895</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1992.tb05481.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1002%2Fj.1460-2075.1992.tb05481.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1396582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADyaK3sXkslShtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1992&pages=3887-3895&author=Y.+Ishidaauthor=Y.+Agataauthor=K.+Shibaharaauthor=T.+Honjo&title=Induced+expression+of+PD-1%2C+a+novel+member+of+the+immunoglobulin+gene+superfamily%2C+upon+programmed+cell+death&doi=10.1002%2Fj.1460-2075.1992.tb05481.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death</span></div><div class="casAuthors">Ishida, Yasumasa; Agata, Yasutoshi; Shibahara, Keiichi; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3887-95</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    </div><div class="casAbstract">The classical type of programmed cell death is characterized by its dependence on de novo RNA and protein synthesis and morphol. features of apoptosis.  It was confirmed that stimulated 2B4.11 (a murine T-cell hybridoma) and interleukin-3 (IL-3)-deprived LyD9 (a murine hematopoietic progenitor cell line) died by the classical type of programmed cell death.  Assuming that common biochem. pathways might be involved in the deaths of 2B4.11 and LyD9, the authors isolated the PD-1 gene, a novel member of the Ig gene superfamily, by using subtractive hybridization technique.  The predicted PD-1 protein has a variant form of the consensus sequence found in cytoplasmic tails of signal transducing polypeptides assocd. with immune recognition receptors.  The PD-1 gene was activated in both stimulated 2B4.11 and IL-3-deprived LyD9 cells, but not in other death-induced cell lines that did not show the characteristic features of the classical programmed cell death.  Expression of the PD-1 mRNA in mouse was restricted to the thymus and increased when thymocyte death was augmented by in vivo injection of anti-CD3 antibody.  These results suggest that activation of the PD-1 gene may be involved in the classical type of programmed cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbDcD6IecsO7Vg90H21EOLACvtfcHk0lgKhO3DE843WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXkslShtbs%253D&md5=7e677e5da5923a9f27cd5166de394243</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1992.tb05481.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1992.tb05481.x%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DY.%26aulast%3DAgata%26aufirst%3DY.%26aulast%3DShibahara%26aufirst%3DK.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DInduced%2520expression%2520of%2520PD-1%252C%2520a%2520novel%2520member%2520of%2520the%2520immunoglobulin%2520gene%2520superfamily%252C%2520upon%2520programmed%2520cell%2520death%26jtitle%3DEMBO%2520J.%26date%3D1992%26volume%3D11%26spage%3D3887%26epage%3D3895%26doi%3D10.1002%2Fj.1460-2075.1992.tb05481.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shinohara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniwaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaichi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Structure and chromosomal localization of the human PD-1 gene(PDCD1)</span>. <i>Genomics</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">704</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1006/geno.1994.1562</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1006%2Fgeno.1994.1562" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=7851902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADyaK2MXhvFWmt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1994&pages=704-706&author=T.+Shinoharaauthor=M.+Taniwakiauthor=Y.+Ishidaauthor=M.+Kawaichiauthor=T.+Honjo&title=Structure+and+chromosomal+localization+of+the+human+PD-1+gene%28PDCD1%29&doi=10.1006%2Fgeno.1994.1562"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and chromosomal localization of the human PD-1 gene (PDCD1)</span></div><div class="casAuthors">Shinohara, Takashi; Taniwaki, Masafumi; Ishida, Yasumasa; Kawaichi, Masashi; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Genomics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">704-6</span>CODEN:
                <span class="NLM_cas:coden">GNMCEP</span>;
        ISSN:<span class="NLM_cas:issn">0888-7543</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A cDNA encoding mouse PD-1, a member of the Ig superfamily was previously isolated from apoptosis-induced cells by subtractive hybridization.  To det. the structure and chromosomal location of the human PD-1 gene, the authors screened a human T cell cDNA library by mouse PD-1 probe and isolated a cDNA coding for the human PD-1 protein.  The deduced amino acid sequence of human PD-1 was 60% identical to the mouse counterpart, and a putative tyrosine kinase-assocn. motif was well conserved.  The human PD-1 gene was mapped to 2q37.3 by chromosomal in situ hybridization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSAAD8AW1bfbVg90H21EOLACvtfcHk0lgKhO3DE843WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXhvFWmt7o%253D&md5=82fa9ea9123891c54f089e7ee50ee0a9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1006%2Fgeno.1994.1562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fgeno.1994.1562%26sid%3Dliteratum%253Aachs%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DTaniwaki%26aufirst%3DM.%26aulast%3DIshida%26aufirst%3DY.%26aulast%3DKawaichi%26aufirst%3DM.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DStructure%2520and%2520chromosomal%2520localization%2520of%2520the%2520human%2520PD-1%2520gene%2528PDCD1%2529%26jtitle%3DGenomics%26date%3D1994%26volume%3D23%26spage%3D704%26epage%3D706%26doi%3D10.1006%2Fgeno.1994.1562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, J. C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edidin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathenson, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almo, S. C.</span></span> <span> </span><span class="NLM_article-title">Structural and functional analysis of the costimulatory receptor programmed death-1</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">337</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1016/S1074-7613(04)00051-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2FS1074-7613%2804%2900051-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=15030777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Kht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2004&pages=337-347&author=X.+Zhangauthor=J.+C.+D.+Schwartzauthor=X.+Guoauthor=S.+Bhatiaauthor=E.+Caoauthor=L.+Chenauthor=Z.+Y.+Zhangauthor=M.+A.+Edidinauthor=S.+G.+Nathensonauthor=S.+C.+Almo&title=Structural+and+functional+analysis+of+the+costimulatory+receptor+programmed+death-1&doi=10.1016%2FS1074-7613%2804%2900051-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and functional analysis of the costimulatory receptor programmed death-1</span></div><div class="casAuthors">Zhang, Xuewu; Schwartz, Jean-Claude D.; Guo, Xiaoling; Bhatia, Sumeena; Cao, Erhu; Chen, Lieping; Zhang, Zhong-Yin; Edidin, Michael A.; Nathenson, Stanley G.; Almo, Steven C.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">337-347</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PD-1, a member of the CD28/CTLA-4/ICOS costimulatory receptor family, delivers neg. signals that have profound effects on T and B cell immunity.  The 2.0 Å crystal structure of the extracellular domain of murine PD-1 reveals an Ig V-type topol. with overall similarity to the CTLA-4 monomer; however, there are notable differences in regions relevant to function.  Structural and biophys. data show that PD-1 is monomeric both in soln. as well as on cell surface, in contrast to CTLA-4 and other family members that are all disulfide-linked homodimers.  Furthermore, the authors' structure-based mutagenesis studies identify the ligand binding surface of PD-1, which displays significant differences compared to those present in the other members of the family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo63-pm8vX3trVg90H21EOLACvtfcHk0lgTeGQuYMc-iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Kht70%253D&md5=6690369dc08ae119677a9c602c110508</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2804%2900051-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252804%252900051-2%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSchwartz%26aufirst%3DJ.%2BC.%2BD.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DBhatia%26aufirst%3DS.%26aulast%3DCao%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%2BY.%26aulast%3DEdidin%26aufirst%3DM.%2BA.%26aulast%3DNathenson%26aufirst%3DS.%2BG.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26atitle%3DStructural%2520and%2520functional%2520analysis%2520of%2520the%2520costimulatory%2520receptor%2520programmed%2520death-1%26jtitle%3DImmunity%26date%3D2004%26volume%3D20%26spage%3D337%26epage%3D347%26doi%3D10.1016%2FS1074-7613%2804%2900051-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubat, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">765</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1093/intimm/8.5.765</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1093%2Fintimm%2F8.5.765" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=8671665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADyaK28Xjt1Kmurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1996&pages=765-772&author=Y.+Agataauthor=A.+Kawasakiauthor=H.+Nishimuraauthor=Y.+Ishidaauthor=T.+Tsubatauthor=H.+Yagitaauthor=T.+Honjo&title=Expression+of+the+PD-1+antigen+on+the+surface+of+stimulated+mouse+T+and+B+lymphocytes&doi=10.1093%2Fintimm%2F8.5.765"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes</span></div><div class="casAuthors">Agata, Yasutoshi; Kawasaki, Akemi; Nishimura, Hiroyuki; Ishida, Yasumasa; Tsubata, Takeshi; Yagita, Hideo; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">765-772</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A mAb J43 has been produced against the product of the mouse PD-1 gene, a member of the Ig gene superfamily, which was previously isolated from an apoptosis-induced T cell hybridoma (2B4.11) by using subtractive hybridization.  Analyses by flow cytometry and immunopptn. using the J43 mAb revealed that the PD-1 gene product is a 50-55 kDa membrane protein expressed on the cell surface of several PD-1 cDNA transfectants and 2B4.11 cells.  Since the mol. wt. calcd. from the amino acid sequence is 29,310, the PD-1 protein appears to be heavily glycosylated.  Normal murine lymphoid tissues such as thymus, spleen, lymph node and bone marrow contained very small nos. of PD-1+ cells.  However, a significant PD-1+ population appeared in the thymocytes as well as T cells in spleen and lymph nodes by the in vivo anti-CD3 mAb treatment.  Furthermore, the PD-1 antigen expression was strongly induced in distinct subsets of thymocytes and spleen T cells by in vitro stimulation with either anti-CD3 mAb or Con A (Con A) which could lead T cells to both activation and cell death.  Similarly, PD-1 expression was induced on spleen B cells by in vitro stimulation with anti-IgM antibody.  By contrast, PD-1 was not significantly expressed on lymphocytes by treatment with growth factor deprivation, dexamethasone or lipopolysaccharide.  These results suggest that the expression of the PD-1 antigen is tightly regulated and induced by signal transduction through the antigen receptor and do not exclude the possibility that the PD-1 antigen may play a role in clonal selection of lymphocytes although PD-1 expression is not required for the common pathway of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkUdMmfGmC3rVg90H21EOLACvtfcHk0lgTeGQuYMc-iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjt1Kmurw%253D&md5=af84123a1dd38ee82c3c72877db76761</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2F8.5.765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252F8.5.765%26sid%3Dliteratum%253Aachs%26aulast%3DAgata%26aufirst%3DY.%26aulast%3DKawasaki%26aufirst%3DA.%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DY.%26aulast%3DTsubat%26aufirst%3DT.%26aulast%3DYagita%26aufirst%3DH.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DExpression%2520of%2520the%2520PD-1%2520antigen%2520on%2520the%2520surface%2520of%2520stimulated%2520mouse%2520T%2520and%2520B%2520lymphocytes%26jtitle%3DInt.%2520Immunol.%26date%3D1996%26volume%3D8%26spage%3D765%26epage%3D772%26doi%3D10.1093%2Fintimm%2F8.5.765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Developmentally regulated expression of the PD-1 protein on the surface of double-negative(CD4(-)CD8(-)) thymocytes</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1093/intimm/8.5.773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1093%2Fintimm%2F8.5.773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=8671666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADyaK28Xjt1Kmuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1996&pages=773-780&author=H.+Nishimuraauthor=Y.+Agataauthor=A.+Kawasakiauthor=M.+Satoauthor=S.+Imamuraauthor=N.+Minatoauthor=H.+Yagitaauthor=T.+Nakanoauthor=T.+Honjo&title=Developmentally+regulated+expression+of+the+PD-1+protein+on+the+surface+of+double-negative%28CD4%28-%29CD8%28-%29%29+thymocytes&doi=10.1093%2Fintimm%2F8.5.773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes</span></div><div class="casAuthors">Nishimura, Hiroyuki; Agata, Yasutoshi; Kawasaki, Akemi; Sato, Masaki; Imamura, Sadao; Minato, Nagahiro; Yagita, Hideo; Nakano, Toru; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">773-780</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">PD-1, a member of the Ig superfamily, was previously isolated from an apoptosis-induced T cell hybridoma 2B4.11 by subtractive hybridization.  Expression of the PD-1 mRNA is restricted to thymus in adult mice.  Using an anti-PD-1 mAb (J43), we examd. expression of the PD-1 protein during differentiation of thymocytes in normal adult, fetal and RAG-2-l-mice with or without anti-CD3 mAb stimulation.  While PD-1 was expressed only on 3-5% of total normal thymocytes, ∼34% of the CD4-CD8- double-neg. (DN) fraction are PD-1+ cells with two distinct expression levels (low and high).  PD-1high thymocytes belonged to TCR γδ lineage cells.  In the DN compartment of the TCR αβ lineage, PD-1 expression started at the low level from the CD44+CD25+ stage and the majority of thymocytes expressed PD-1 at the CD44-CD25- stage in which thymocytes express TCR β chains.  The anti-CD3ε antibody administration augmented the PD-1 expression as well as the differentiation of the CD44-CD25+ DN cells into the CD44-CD25- DN stage, not only in normal mice but also in RAG-2-deficient mice.  The fraction of the PD-1low cells in the CD4+CD8+ double-pos. (DP) compartment was very small (<5%) but increased by stimulation with the anti-CD3 antibody, although the total no. of DP cells was drastically reduced.  The results show that PD-1 expression is specifically induced at the stages preceding clonal selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPO38YNwp-nbVg90H21EOLACvtfcHk0lgTeGQuYMc-iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjt1Kmuro%253D&md5=be831e803a7805df30fc72c84eea77be</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2F8.5.773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252F8.5.773%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DAgata%26aufirst%3DY.%26aulast%3DKawasaki%26aufirst%3DA.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DImamura%26aufirst%3DS.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DYagita%26aufirst%3DH.%26aulast%3DNakano%26aufirst%3DT.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DDevelopmentally%2520regulated%2520expression%2520of%2520the%2520PD-1%2520protein%2520on%2520the%2520surface%2520of%2520double-negative%2528CD4%2528-%2529CD8%2528-%2529%2529%2520thymocytes%26jtitle%3DInt.%2520Immunol.%26date%3D1996%26volume%3D8%26spage%3D773%26epage%3D780%26doi%3D10.1093%2Fintimm%2F8.5.773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakatani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1126/science.291.5502.319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1126%2Fscience.291.5502.319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=11209085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD3MXktlKlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2001&pages=319-322&author=H.+Nishimuraauthor=T.+Okazakiauthor=Y.+Tanakaauthor=K.+Nakataniauthor=M.+Haraauthor=A.+Matsumoriauthor=S.+Sasayamaauthor=A.+Mizoguchiauthor=H.+Hiaiauthor=N.+Minatoauthor=T.+Honjo&title=Autoimmune+dilated+cardiomyopathy+in+PD-1+receptor-deficient+mice&doi=10.1126%2Fscience.291.5502.319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice</span></div><div class="casAuthors">Nishimura, Hiroyuki; Okazaki, Taku; Tanaka, Yoshimasa; Nakatani, Kazuki; Hara, Masatake; Matsumori, Akira; Sasayama, Shigetake; Mizoguchi, Akira; Hiai, Hiroshi; Minato, Nagahiro; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">5502</span>),
    <span class="NLM_cas:pages">319-322</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Dilated cardiomyopathy is a severe pathol. of the heart with poorly understood etiol.  Disruption of the gene encoding the neg. immunoregulatory receptor PD-1 in BALB/c mice, but not in BALB/c RAG-2-/- mice, cause dilated cardiomyopathy with severely impaired contraction and sudden death by congestive heart failure.  Affected hearts showed diffuse deposition of IgG on the surface of cardiomyocytes.  All of the affected PD-1-/- mice exhibited high-titer circulating IgG autoantibodies reactive to a 33-kDa protein expressed specifically on the surface of cardiomyocytes.  These results indicate that PD-1 may be an important factor contributing to the prevention of autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAkP6AbmRol7Vg90H21EOLACvtfcHk0lj7ijJDJzrl9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXktlKlsw%253D%253D&md5=eaf356d0fdef363b003be973ade36d84</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1126%2Fscience.291.5502.319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.291.5502.319%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DNakatani%26aufirst%3DK.%26aulast%3DHara%26aufirst%3DM.%26aulast%3DMatsumori%26aufirst%3DA.%26aulast%3DSasayama%26aufirst%3DS.%26aulast%3DMizoguchi%26aufirst%3DA.%26aulast%3DHiai%26aufirst%3DH.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DAutoimmune%2520dilated%2520cardiomyopathy%2520in%2520PD-1%2520receptor-deficient%2520mice%26jtitle%3DScience%26date%3D2001%26volume%3D291%26spage%3D319%26epage%3D322%26doi%3D10.1126%2Fscience.291.5502.319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nose, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1016/S1074-7613(00)80089-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2FS1074-7613%2800%2980089-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10485649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADyaK1MXlvVShsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1999&pages=141-151&author=H.+Nishimuraauthor=M.+Noseauthor=H.+Hiaiauthor=N.+Minatoauthor=T.+Honjo&title=Development+of+lupus-like+autoimmune+diseases+by+disruption+of+the+PD-1+gene+encoding+an+ITIM+motif-carrying+immunoreceptor&doi=10.1016%2FS1074-7613%2800%2980089-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor</span></div><div class="casAuthors">Nishimura, Hiroyuki; Nose, Masato; Hiai, Hiroshi; Minato, Nagahiro; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-151</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">PD-1, a 55 kDa transmembrane protein contg. an immunoreceptor tyrosine-based inhibitory motif, is induced in lymphocytes and monocytes following activation.  Aged C57BL/6(B6)-PD-1-/- congenic mice spontaneously developed characteristic lupus-like proliferative arthritis and glomerulonephritis with predominant IgG3 deposition, which were markedly accelerated by introduction of a Fas mutation (lpr).  Introduction of a PD-1 null mutation into the 2C-TCR (anti-H-2Ld) transgenic mice of the H-2b/d background resulted in the chronic and systemic graft-vs.- host-like disease.  Furthermore, CD8+2C-TCR+PD-1-/- T cells exhibited markedly augmented proliferation in vitro in response to H-2d allogeneic cells.  Collectively, it is suggested that PD-1 is involved in the maintenance of peripheral self-tolerance by serving as a neg. regulator of immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHFuMDDfhG3bVg90H21EOLACvtfcHk0lj7ijJDJzrl9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvVShsb8%253D&md5=f627767082377fb523671a1635cb0a8f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2FS1074-7613%2800%2980089-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1074-7613%252800%252980089-8%26sid%3Dliteratum%253Aachs%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DNose%26aufirst%3DM.%26aulast%3DHiai%26aufirst%3DH.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DDevelopment%2520of%2520lupus-like%2520autoimmune%2520diseases%2520by%2520disruption%2520of%2520the%2520PD-1%2520gene%2520encoding%2520an%2520ITIM%2520motif-carrying%2520immunoreceptor%26jtitle%3DImmunity%26date%3D1999%26volume%3D11%26spage%3D141%26epage%3D151%26doi%3D10.1016%2FS1074-7613%2800%2980089-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labarriere, N.</span></span> <span> </span><span class="NLM_article-title">PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">e1364828</span>, <span class="refDoi"> DOI: 10.1080/2162402X.2017.1364828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1080%2F2162402X.2017.1364828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFajtrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=e1364828&author=S.+Simonauthor=N.+Labarriere&title=PD-1+expression+on+tumor-specific+T+cells%3A+Friend+or+foe+for+immunotherapy%3F&doi=10.1080%2F2162402X.2017.1364828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?</span></div><div class="casAuthors">Simon, Sylvain; Labarriere, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e1364828/1-e1364828/7</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">Inhibitory properties of PD-1 receptor engagement on activated T cells are well established in physiol. and pathol. contexts.  In cancer, the use of checkpoint blockade, such as anti-PD-1 antibodies, becomes progressively a ref. treatment of a growing no. of tumors.  Nonetheless, it is also established that PD-1 expression on antigen-specific T cells reflects the functional avidity and anti-tumor reactivity of these T cells.  We will discuss this dual significance of PD-1 expression on tumor-specific T cells, due to a complex regulation and the opportunity to exploit this expression to define, monitor and exploit tumor-reactive T cells for immunotherapy purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzOU6-AtgPlbVg90H21EOLACvtfcHk0lhkyE3o_Elz9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFajtrnF&md5=f2b520772c0462f652888e45fe2cd4f6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2017.1364828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2017.1364828%26sid%3Dliteratum%253Aachs%26aulast%3DSimon%26aufirst%3DS.%26aulast%3DLabarriere%26aufirst%3DN.%26atitle%3DPD-1%2520expression%2520on%2520tumor-specific%2520T%2520cells%253A%2520Friend%2520or%2520foe%2520for%2520immunotherapy%253F%26jtitle%3DOncoimmunology%26date%3D2018%26volume%3D7%26spage%3De1364828%26doi%3D10.1080%2F2162402X.2017.1364828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiba, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span> <span> </span><span class="NLM_article-title">Expression of programmed death 1 ligands by murine T cells and APC</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">5538</span>– <span class="NLM_lpage">5545</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.169.10.5538</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.4049%2Fjimmunol.169.10.5538" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2002&pages=5538-5545&author=T.+Yamazakiauthor=H.+Akibaauthor=H.+Iwaiauthor=H.+Matsudaauthor=M.+Aokiauthor=Y.+Tannoauthor=T.+Shinauthor=H.+Tsuchiyaauthor=D.+M.+Pardollauthor=K.+Okumuraauthor=M.+Azumaauthor=H.+Yagita&title=Expression+of+programmed+death+1+ligands+by+murine+T+cells+and+APC&doi=10.4049%2Fjimmunol.169.10.5538"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.169.10.5538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.169.10.5538%26sid%3Dliteratum%253Aachs%26aulast%3DYamazaki%26aufirst%3DT.%26aulast%3DAkiba%26aufirst%3DH.%26aulast%3DIwai%26aufirst%3DH.%26aulast%3DMatsuda%26aufirst%3DH.%26aulast%3DAoki%26aufirst%3DM.%26aulast%3DTanno%26aufirst%3DY.%26aulast%3DShin%26aufirst%3DT.%26aulast%3DTsuchiya%26aufirst%3DH.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DOkumura%26aufirst%3DK.%26aulast%3DAzuma%26aufirst%3DM.%26aulast%3DYagita%26aufirst%3DH.%26atitle%3DExpression%2520of%2520programmed%2520death%25201%2520ligands%2520by%2520murine%2520T%2520cells%2520and%2520APC%26jtitle%3DJ.%2520Immunol.%26date%3D2002%26volume%3D169%26spage%3D5538%26epage%3D5545%26doi%3D10.4049%2Fjimmunol.169.10.5538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keir, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">PD-1 and its ligands in tolerance and immunity</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1146/annurev.immunol.26.021607.090331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1146%2Fannurev.immunol.26.021607.090331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=18173375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlWktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=677-704&author=M.+E.+Keirauthor=M.+J.+Butteauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=PD-1+and+its+ligands+in+tolerance+and+immunity&doi=10.1146%2Fannurev.immunol.26.021607.090331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 and its ligands in tolerance and immunity</span></div><div class="casAuthors">Keir, Mary E.; Butte, Manish J.; Freeman, Gordon J.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">677-704</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathol.  Immune responses to foreign and self-antigens require specific and balanced responses to clear pathogens and tumors and yet maintain tolerance.  Induction and maintenance of T cell tolerance requires PD-1, and its ligand PD-L1 on nonhematopoietic cells can limit effector T cell responses and protect tissues from immune-mediated tissue damage.  The PD-1:PD-L pathway also has been usurped by microorganisms and tumors to attenuate antimicrobial or tumor immunity and facilitate chronic infection and tumor survival.  The identification of B7-1 as an addnl. binding partner for PD-L1, together with the discovery of an inhibitory bidirectional interaction between PD-L1 and B7-1, reveals new ways the B7:CD28 family regulates T cell activation and tolerance.  In this review, we discuss current understanding of the immunoregulatory functions of PD-1 and its ligands and their therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTbTIs2Ruos7Vg90H21EOLACvtfcHk0lhkyE3o_Elz9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlWktrY%253D&md5=4b9b36a8716b8b1b47b7953f134448cf</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1146%2Fannurev.immunol.26.021607.090331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.immunol.26.021607.090331%26sid%3Dliteratum%253Aachs%26aulast%3DKeir%26aufirst%3DM.%2BE.%26aulast%3DButte%26aufirst%3DM.%2BJ.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DPD-1%2520and%2520its%2520ligands%2520in%2520tolerance%2520and%2520immunity%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D26%26spage%3D677%26epage%3D704%26doi%3D10.1146%2Fannurev.immunol.26.021607.090331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourque, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitz, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenkovich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrne, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouser, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">1027</span>– <span class="NLM_lpage">1034</span>, <span class="refDoi"> DOI: 10.1084/jem.192.7.1027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1084%2Fjem.192.7.1027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=11015443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFSlt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2000&pages=1027-1034&author=G.+J.+Freemanauthor=A.+J.+Longauthor=Y.+Iwaiauthor=K.+Bourqueauthor=T.+Chernovaauthor=H.+Nishimuraauthor=L.+J.+Fitzauthor=N.+Malenkovichauthor=T.+Okazakiauthor=M.+C.+Byrneauthor=H.+F.+Hortonauthor=L.+Fouserauthor=L.+Carterauthor=V.+Lingauthor=M.+R.+Bowmanauthor=B.+M.+Carrenoauthor=M.+Collinsauthor=C.+R.+Woodauthor=T.+Honjo&title=Engagement+of+the+PD-1+immunoinhibitory+receptor+by+a+novel+B7+family+member+leads+to+negative+regulation+of+lymphocyte+activation&doi=10.1084%2Fjem.192.7.1027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation</span></div><div class="casAuthors">Freeman, Gordon J.; Long, Andrew J.; Iwai, Yoshiko; Bourque, Karen; Chernova, Tatyana; Nishimura, Hiroyuki; Fitz, Lori J.; Malenkovich, Nelly; Okazaki, Taku; Byrne, Michael C.; Horton, Heidi F.; Fouser, Lynette; Carter, Laura; Ling, Vincent; Bowman, Michael R.; Carreno, Beatriz M.; Collins, Mary; Wood, Clive R.; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1027-1034</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">PD-1 is an immunoinhibitory receptor expressed by activated T cells, B cells, and myeloid cells.  Mice deficient in PD-1 exhibit a breakdown of peripheral tolerance and demonstrate multiple autoimmune features.  The authors report here that the ligand of PD-1 (PD-L1) is a member of the B7 gene family.  Engagement of PD-1 by PD-L1 leads to the inhibition of T cell receptor-mediated lymphocyte proliferation and cytokine secretion.  In addn., PD-1 signaling can inhibit at least suboptimal levels of CD28-mediated costimulation.  PD-L1 is expressed by antigen-presenting cells, including human peripheral blood monocytes stimulated with interferon γ, and activated human and murine dendritic cells.  In addn., PD-L1 is expressed in nonlymphoid tissues such as heart and lung.  The relative levels of inhibitory PD-L1 and costimulatory B7-1/B7-2 signals on antigen-presenting cells may det. the extent of T cell activation and consequently the threshold between tolerance and autoimmunity.  PD-L1 expression on nonlymphoid tissues and its potential interaction with PD-1 may subsequently det. the extent of immune responses at sites of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZIeEjiecqBbVg90H21EOLACvtfcHk0lhQPiMrnJxUJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFSlt7o%253D&md5=bc1499033282cd9dbfa396a4e2697f6e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1084%2Fjem.192.7.1027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.192.7.1027%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DBourque%26aufirst%3DK.%26aulast%3DChernova%26aufirst%3DT.%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DFitz%26aufirst%3DL.%2BJ.%26aulast%3DMalenkovich%26aufirst%3DN.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DByrne%26aufirst%3DM.%2BC.%26aulast%3DHorton%26aufirst%3DH.%2BF.%26aulast%3DFouser%26aufirst%3DL.%26aulast%3DCarter%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DV.%26aulast%3DBowman%26aufirst%3DM.%2BR.%26aulast%3DCarreno%26aufirst%3DB.%2BM.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DC.%2BR.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DEngagement%2520of%2520the%2520PD-1%2520immunoinhibitory%2520receptor%2520by%2520a%2520novel%2520B7%2520family%2520member%2520leads%2520to%2520negative%2520regulation%2520of%2520lymphocyte%2520activation%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2000%26volume%3D192%26spage%3D1027%26epage%3D1034%26doi%3D10.1084%2Fjem.192.7.1027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span> <span> </span><span class="NLM_article-title">PD-1 and PD-1 ligands: from discovery to clinical application</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">824</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxm057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1093%2Fintimm%2Fdxm057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=17606980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtValtbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=813-824&author=T.+Okazakiauthor=T.+Honjo&title=PD-1+and+PD-1+ligands%3A+from+discovery+to+clinical+application&doi=10.1093%2Fintimm%2Fdxm057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 and PD-1 ligands: from discovery to clinical application</span></div><div class="casAuthors">Okazaki, Taku; Honjo, Tasuku</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">813-824</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family neg. regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2.  Because of the wide range of ligand distribution in the body, its biol. significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunol. privilege.  In this review, the authors would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clin. application of PD-1 agonists and antagonists to various human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1eGKswQHDqbVg90H21EOLACvtfcHk0lhQPiMrnJxUJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtValtbbO&md5=aca4a61a3d4bf65e0abb620510eb7f38</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxm057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxm057%26sid%3Dliteratum%253Aachs%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DHonjo%26aufirst%3DT.%26atitle%3DPD-1%2520and%2520PD-1%2520ligands%253A%2520from%2520discovery%2520to%2520clinical%2520application%26jtitle%3DInt.%2520Immunol.%26date%3D2007%26volume%3D19%26spage%3D813%26epage%3D824%26doi%3D10.1093%2Fintimm%2Fdxm057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Latchman, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chernova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourque, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boussiotis, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenkovich, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span> <span> </span><span class="NLM_article-title">PD-L2 is a second ligand for PD-1 and inhibits T cell activation</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1038/85330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2F85330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=11224527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhvVaksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=261-268&author=Y.+Latchmanauthor=C.+R.+Woodauthor=T.+Chernovaauthor=D.+Chaudharyauthor=M.+Bordeauthor=I.+Chernovaauthor=Y.+Iwaiauthor=A.+J.+Longauthor=J.+A.+Brownauthor=R.+Nunesauthor=E.+A.+Greenfieldauthor=K.+Bourqueauthor=V.+A.+Boussiotisauthor=L.+L.+Carterauthor=B.+M.+Carrenoauthor=N.+Malenkovichauthor=H.+Nishimuraauthor=T.+Okazakiauthor=T.+Honjoauthor=A.+H.+Sharpeauthor=G.+J.+Freeman&title=PD-L2+is+a+second+ligand+for+PD-1+and+inhibits+T+cell+activation&doi=10.1038%2F85330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L2 is a second ligand for PD-1 and inhibits T cell activation</span></div><div class="casAuthors">Latchman, Yvette; Wood, Clive R.; Chernova, Tatyana; Chaudhary, Divya; Borde, Madhuri; Chernova, Irene; Iwai, Yoshiko; Long, Andrew J.; Brown, Julia A.; Nunes, Raquel; Greenfield, Edward A.; Borque, Karen; Boussiotis, Vassiliki A.; Carter, Laura L.; Carreno, Beatriz M.; Malenkovich, Nelly; Nishimura, Hiroyuki; Okazaki, Taku; Honjo, Tasuku; Sharpe, Arlene H.; Freeman, Gordon J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">261-268</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">Programmed death 1 (PD-1)-deficient mice develop a variety of autoimmune-like diseases, which suggests that this immunoinhibitory receptor plays an important role in tolerance.  The authors identify here PD-1 ligand 2 (PD-L2) as a second ligand for PD-1 and compare the function and expression of PD-L I and PD-L2.  Engagement of PD-I by PD-L2 dramatically inhibits T cell receptor (TCR)-mediated proliferation and cytokine prodn. by CD4+ T cells.  At low antigen concns., PD-L2-PD-1 interactions inhibit strong B7-CD28 signals.  In contrast, at high antigen concns., PD-L2-PD-I interactions reduce cytokine prodn. but do not inhibit T cell proliferation.  PD-L-PD-1 interactions lead to cell cycle arrest in G0/G1 but do not increase cell death.  In addn., ligation of PD-1 + TCR leads to rapid phosphorylation of SHP-2, as compared to TCR ligation alone.  PD-L expression was up-regulated on antigen-presenting cells by interferon γ treatment and was also present on some normal tissues and tumor cell lines.  Taken together, these studies show overlapping functions of PD-L1 and PD-L2 and indicate a key role for the PD-L-PD-1 pathway in regulating T cell responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqUwK7ud9M77Vg90H21EOLACvtfcHk0lg44ryM6TizWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhvVaksrc%253D&md5=5f22eb9ddfa496a760c07e235e9e2c8e</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2F85330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F85330%26sid%3Dliteratum%253Aachs%26aulast%3DLatchman%26aufirst%3DY.%26aulast%3DWood%26aufirst%3DC.%2BR.%26aulast%3DChernova%26aufirst%3DT.%26aulast%3DChaudhary%26aufirst%3DD.%26aulast%3DBorde%26aufirst%3DM.%26aulast%3DChernova%26aufirst%3DI.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26aulast%3DBrown%26aufirst%3DJ.%2BA.%26aulast%3DNunes%26aufirst%3DR.%26aulast%3DGreenfield%26aufirst%3DE.%2BA.%26aulast%3DBourque%26aufirst%3DK.%26aulast%3DBoussiotis%26aufirst%3DV.%2BA.%26aulast%3DCarter%26aufirst%3DL.%2BL.%26aulast%3DCarreno%26aufirst%3DB.%2BM.%26aulast%3DMalenkovich%26aufirst%3DN.%26aulast%3DNishimura%26aufirst%3DH.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DHonjo%26aufirst%3DT.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26atitle%3DPD-L2%2520is%2520a%2520second%2520ligand%2520for%2520PD-1%2520and%2520inhibits%2520T%2520cell%2520activation%26jtitle%3DNat.%2520Immunol.%26date%3D2001%26volume%3D2%26spage%3D261%26epage%3D268%26doi%3D10.1038%2F85330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fouser, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jussif, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carreno, B. M.</span></span> <span> </span><span class="NLM_article-title">PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">634</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1002%2F1521-4141%28200203%2932%3A3%3C634%3A%3AAID-IMMU634%3E3.0.CO%3B2-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2002&pages=634-643&author=L.+L.+Carterauthor=L.+A.+Fouserauthor=J.+Jussifauthor=L.+Fitzauthor=B.+Dengauthor=C.+R.+Woodauthor=M.+Collinsauthor=T.+Honjoauthor=G.+J.+Freemanauthor=B.+M.+Carreno&title=PD-1%3APD-L+inhibitory+pathway+affects+both+CD4%2B+and+CD8%2B+T+cells+and+is+overcome+by+IL-2&doi=10.1002%2F1521-4141%28200203%2932%3A3%3C634%3A%3AAID-IMMU634%3E3.0.CO%3B2-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1002%2F1521-4141%28200203%2932%3A3%3C634%3A%3AAID-IMMU634%3E3.0.CO%3B2-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-4141%2528200203%252932%253A3%253C634%253A%253AAID-IMMU634%253E3.0.CO%253B2-9%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DL.%2BL.%26aulast%3DFouser%26aufirst%3DL.%2BA.%26aulast%3DJussif%26aufirst%3DJ.%26aulast%3DFitz%26aufirst%3DL.%26aulast%3DDeng%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DC.%2BR.%26aulast%3DCollins%26aufirst%3DM.%26aulast%3DHonjo%26aufirst%3DT.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DCarreno%26aufirst%3DB.%2BM.%26atitle%3DPD-1%253APD-L%2520inhibitory%2520pathway%2520affects%2520both%2520CD4%252B%2520and%2520CD8%252B%2520T%2520cells%2520and%2520is%2520overcome%2520by%2520IL-2%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D2002%26volume%3D32%26spage%3D634%26epage%3D643%26doi%3D10.1002%2F1521-4141%28200203%2932%3A3%3C634%3A%3AAID-IMMU634%3E3.0.CO%3B2-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Youngnak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otsuki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagita, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, M.</span></span> <span> </span><span class="NLM_article-title">Differential binding properties of B7-H1 and B7-DC to programmed death-1</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">672</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/S0006-291X(03)01257-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2FS0006-291X%2803%2901257-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2003&pages=672-677&author=P.+Youngnakauthor=Y.+Kozonoauthor=H.+Kozonoauthor=H.+Iwaiauthor=N.+Otsukiauthor=H.+Jinauthor=K.+Omuraauthor=H.+Yagitaauthor=D.+M.+Pardollauthor=L.+Chenauthor=M.+Azuma&title=Differential+binding+properties+of+B7-H1+and+B7-DC+to+programmed+death-1&doi=10.1016%2FS0006-291X%2803%2901257-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2803%2901257-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252803%252901257-9%26sid%3Dliteratum%253Aachs%26aulast%3DYoungnak%26aufirst%3DP.%26aulast%3DKozono%26aufirst%3DY.%26aulast%3DKozono%26aufirst%3DH.%26aulast%3DIwai%26aufirst%3DH.%26aulast%3DOtsuki%26aufirst%3DN.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DOmura%26aufirst%3DK.%26aulast%3DYagita%26aufirst%3DH.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DAzuma%26aufirst%3DM.%26atitle%3DDifferential%2520binding%2520properties%2520of%2520B7-H1%2520and%2520B7-DC%2520to%2520programmed%2520death-1%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2003%26volume%3D307%26spage%3D672%26epage%3D677%26doi%3D10.1016%2FS0006-291X%2803%2901257-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghiotto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serriari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truneh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunes, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olive, D.</span></span> <span> </span><span class="NLM_article-title">PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxq049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1093%2Fintimm%2Fdxq049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=20587542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1Oit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2010&pages=651-660&author=M.+Ghiottoauthor=L.+Gauthierauthor=N.+Serriariauthor=S.+Pastorauthor=A.+Trunehauthor=J.+A.+Nunesauthor=D.+Olive&title=PD-L1+and+PD-L2+differ+in+their+molecular+mechanisms+of+interaction+with+PD-1&doi=10.1093%2Fintimm%2Fdxq049"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1</span></div><div class="casAuthors">Ghiotto, Marguerite; Gauthier, Laurent; Serriari, Nacer; Pastor, Sonia; Truneh, Alemseged; Nunes, Jacques A.; Olive, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">651-660</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The programmed death-1 (PD-1) mol. is involved in peripheral tolerance and in the immune escape mechanisms during chronic viral infections and cancer.  PD-1 interacts with two ligands, PD-L1 and PD-L2.  We have investigated the mol. mechanisms of PD-1 interactions with its ligands by surface plasmon resonance and cell surface binding as well as the ability of the two ligands to compete for PD-1 binding.  PD-L1 and PD-L2 bound PD-1 with comparable affinities, but striking differences were obsd. at the level of the assocn. and dissocn. characteristics.  PD-L1, but not PD-L2, had a delayed interaction reminiscent of a phenomenon of conformational transition.  These mechanisms were confirmed by using PD-L1 mAbs that delayed the dissocn. of PD-L1 from PD-1.  This mechanism was not restricted to PD-1 binding since PD-L1 behaved in a similar manner with its second ligand, CD80.  Finally, we could demonstrate that PD-L1 and PD-L2 competed for PD-1 binding and conversely, an antagonist PD-1 mAb blocked both PD-L1 and PD-L2 binding to PD-1 and strongly enhanced T-cell proliferation.  These data further emphasize the differential mol. mechanisms of interaction of PD-L1 and PD-L2 with PD-1, and suggest possible new approach for the therapy of chronic infection, cancer and transplantation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0NI_hTjJfRrVg90H21EOLACvtfcHk0lhsCUTMAWKzcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1Oit74%253D&md5=ea53e559075444f0827d98fd1ccc1768</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxq049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxq049%26sid%3Dliteratum%253Aachs%26aulast%3DGhiotto%26aufirst%3DM.%26aulast%3DGauthier%26aufirst%3DL.%26aulast%3DSerriari%26aufirst%3DN.%26aulast%3DPastor%26aufirst%3DS.%26aulast%3DTruneh%26aufirst%3DA.%26aulast%3DNunes%26aufirst%3DJ.%2BA.%26aulast%3DOlive%26aufirst%3DD.%26atitle%3DPD-L1%2520and%2520PD-L2%2520differ%2520in%2520their%2520molecular%2520mechanisms%2520of%2520interaction%2520with%2520PD-1%26jtitle%3DInt.%2520Immunol.%26date%3D2010%26volume%3D22%26spage%3D651%26epage%3D660%26doi%3D10.1093%2Fintimm%2Fdxq049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamanishi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yagi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takakura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, S.</span></span> <span> </span><span class="NLM_article-title">Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">3360</span>– <span class="NLM_lpage">3365</span>, <span class="refDoi"> DOI: 10.1073/pnas.0611533104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1073%2Fpnas.0611533104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=17360651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtVWlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=3360-3365&author=J.+Hamanishiauthor=M.+Mandaiauthor=M.+Iwasakiauthor=T.+Okazakiauthor=Y.+Tanakaauthor=K.+Yamaguchiauthor=T.+Higuchiauthor=H.+Yagiauthor=K.+Takakuraauthor=N.+Minatoauthor=T.+Honjoauthor=S.+Fujii&title=Programmed+cell+death+1+ligand+1+and+tumor-infiltrating+CD8%2B+T+lymphocytes+are+prognostic+factors+of+human+ovarian+cancer&doi=10.1073%2Fpnas.0611533104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer</span></div><div class="casAuthors">Hamanishi, Junzo; Mandai, Masaki; Iwasaki, Masashi; Okazaki, Taku; Tanaka, Yoshimasa; Yamaguchi, Ken; Higuchi, Toshihiro; Yagi, Haruhiko; Takakura, Kenji; Minato, Nagahiro; Honjo, Tasuku; Fujii, Shingo</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3360-3365</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The ligands for programmed cell death 1 (PD-1), an immunoinhibitory receptor belonging to CD28/cytotoxic T lymphocyte antigen 4 family, are PD-1 ligand 1 and 2 (PD-Ls).  Recent reports suggest that the aberrant expression of PD-Ls on tumor cells impairs antitumor immunity, resulting in the immune evasion of the tumor cells.  Although an inverse correlation between the expression level of PD-Ls and patients' prognosis has been reported for several malignant tumors, the follow-up period was limited because of the lack of the antibody (Ab) applicable to paraffin-embedded specimens.  Here the authors generated a new Ab against PD-1 ligand 1 (PD-L1) and analyzed the expression level of PD-Ls in human ovarian cancer using paraffin-embedded specimens.  Patients with higher expression of PD-L1 had a significantly poorer prognosis than patients with lower expression.  Although patients with higher expression of PD-1 ligand 2 also had a poorer prognosis, the difference was not statistically significant.  A significant inverse correlation was obsd. between PD-L1 expression and the intraepithelial CD8+ T lymphocyte count, suggesting that PD-L1 on tumor cells directly suppresses antitumor CD8+ T cells.  Multivariate anal. showed the expression of PD-L1 on tumor cells and intraepithelial CD8+ T lymphocyte count are independent prognostic factors.  The PD-1/PD-L pathway can be a good target for restoring antitumor immunity in ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8qybSgtrVmLVg90H21EOLACvtfcHk0lhsCUTMAWKzcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtVWlt7s%253D&md5=0be1fefec8110b344e8279b2d16da88a</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0611533104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0611533104%26sid%3Dliteratum%253Aachs%26aulast%3DHamanishi%26aufirst%3DJ.%26aulast%3DMandai%26aufirst%3DM.%26aulast%3DIwasaki%26aufirst%3DM.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DHiguchi%26aufirst%3DT.%26aulast%3DYagi%26aufirst%3DH.%26aulast%3DTakakura%26aufirst%3DK.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DHonjo%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DS.%26atitle%3DProgrammed%2520cell%2520death%25201%2520ligand%25201%2520and%2520tumor-infiltrating%2520CD8%252B%2520T%2520lymphocytes%2520are%2520prognostic%2520factors%2520of%2520human%2520ovarian%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D3360%26epage%3D3365%26doi%3D10.1073%2Fpnas.0611533104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parsa, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crane, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parney, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cachola, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tihan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mischel, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieper, R. O.</span></span> <span> </span><span class="NLM_article-title">Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1038/nm1517</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnm1517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=17159987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FhtFOkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=84-88&author=A.+T.+Parsaauthor=J.+S.+Waldronauthor=A.+Pannerauthor=C.+A.+Craneauthor=I.+F.+Parneyauthor=J.+J.+Barryauthor=K.+E.+Cacholaauthor=J.+C.+Murrayauthor=T.+Tihanauthor=M.+C.+Jensenauthor=P.+S.+Mischelauthor=D.+Stokoeauthor=R.+O.+Pieper&title=Loss+of+tumor+suppressor+PTEN+function+increases+B7-H1+expression+and+immunoresistance+in+glioma&doi=10.1038%2Fnm1517"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma</span></div><div class="casAuthors">Parsa Andrew T; Waldron James S; Panner Amith; Crane Courtney A; Parney Ian F; Barry Jeffrey J; Cachola Kristine E; Murray Joseph C; Tihan Tarik; Jensen Michael C; Mischel Paul S; Stokoe David; Pieper Russell O</div><div class="citationInfo"><span class="NLM_cas:title">Nature medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">84-8</span>
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    </div><div class="casAbstract">Cancer immunoresistance and immune escape may play important roles in tumor progression and pose obstacles for immunotherapy.  Expression of the immunosuppressive protein B7 homolog 1 (B7-H1), also known as programmed death ligand-1 (PD-L1), is increased in many pathological conditions, including cancer.  Here we show that expression of the gene encoding B7-H1 increases post transcriptionally in human glioma after loss of phosphatase and tensin homolog (PTEN) and activation of the phosphatidylinositol-3-OH kinase (PI(3)K) pathway.  Tumor specimens from individuals with glioblastoma multiforme (GBM) had levels of B7-H1 protein that correlated with PTEN loss, and tumor-specific T cells lysed human glioma targets expressing wild-type PTEN more effectively than those expressing mutant PTEN.  These data identify a previously unrecognized mechanism linking loss of the tumor suppressor PTEN with immunoresistance, mediated in part by B7-H1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbpgtPeBjOUT69zv1FsJFMfW6udTcc2ebz0R0iM12Q_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FhtFOkuw%253D%253D&md5=5e270877e35126e5433af850053ce480</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnm1517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm1517%26sid%3Dliteratum%253Aachs%26aulast%3DParsa%26aufirst%3DA.%2BT.%26aulast%3DWaldron%26aufirst%3DJ.%2BS.%26aulast%3DPanner%26aufirst%3DA.%26aulast%3DCrane%26aufirst%3DC.%2BA.%26aulast%3DParney%26aufirst%3DI.%2BF.%26aulast%3DBarry%26aufirst%3DJ.%2BJ.%26aulast%3DCachola%26aufirst%3DK.%2BE.%26aulast%3DMurray%26aufirst%3DJ.%2BC.%26aulast%3DTihan%26aufirst%3DT.%26aulast%3DJensen%26aufirst%3DM.%2BC.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DPieper%26aufirst%3DR.%2BO.%26atitle%3DLoss%2520of%2520tumor%2520suppressor%2520PTEN%2520function%2520increases%2520B7-H1%2520expression%2520and%2520immunoresistance%2520in%2520glioma%26jtitle%3DNat.%2520Med.%26date%3D2007%26volume%3D13%26spage%3D84%26epage%3D88%26doi%3D10.1038%2Fnm1517" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marzec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goradia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raghunath, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paessler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wysocka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasik, M. A.</span></span> <span> </span><span class="NLM_article-title">Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274(PD-L1, B7-H1)</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">20852</span>– <span class="NLM_lpage">20857</span>, <span class="refDoi"> DOI: 10.1073/pnas.0810958105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1073%2Fpnas.0810958105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=20852-20857&author=M.+Marzecauthor=Q.+Zhangauthor=A.+Goradiaauthor=P.+N.+Raghunathauthor=X.+B.+Liuauthor=M.+Paesslerauthor=H.+Y.+Wangauthor=M.+Wysockaauthor=M.+G.+Chengauthor=B.+A.+Ruggeriauthor=M.+A.+Wasik&title=Oncogenic+kinase+NPM%2FALK+induces+through+STAT3+expression+of+immunosuppressive+protein+CD274%28PD-L1%2C+B7-H1%29&doi=10.1073%2Fpnas.0810958105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0810958105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0810958105%26sid%3Dliteratum%253Aachs%26aulast%3DMarzec%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGoradia%26aufirst%3DA.%26aulast%3DRaghunath%26aufirst%3DP.%2BN.%26aulast%3DLiu%26aufirst%3DX.%2BB.%26aulast%3DPaessler%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DWysocka%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DM.%2BG.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DWasik%26aufirst%3DM.%2BA.%26atitle%3DOncogenic%2520kinase%2520NPM%252FALK%2520induces%2520through%2520STAT3%2520expression%2520of%2520immunosuppressive%2520protein%2520CD274%2528PD-L1%252C%2520B7-H1%2529%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D20852%26epage%3D20857%26doi%3D10.1073%2Fpnas.0810958105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeng, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. S.</span></span> <span> </span><span class="NLM_article-title">IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells</span>. <i>J. Dermatol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1016/j.jdermsci.2005.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.jdermsci.2005.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=16085391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFSmtrzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2005&pages=95-103&author=S.+K.+Leeauthor=S.+H.+Seoauthor=B.+S.+Kimauthor=C.+D.+Kimauthor=J.+H.+Leeauthor=J.+S.+Kangauthor=P.+J.+Maengauthor=J.+S.+Lim&title=IFN-gamma+regulates+the+expression+of+B7-H1+in+dermal+fibroblast+cells&doi=10.1016%2Fj.jdermsci.2005.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells</span></div><div class="casAuthors">Lee, Sang-Keun; Seo, Sam-Hwa; Kim, Byoung-Soo; Kim, Chang-Deok; Lee, Jeung-Hoon; Kang, Jung-Soo; Maeng, Pil Jae; Lim, Jong-Soon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Dermatological Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-103</span>CODEN:
                <span class="NLM_cas:coden">JDSCEI</span>;
        ISSN:<span class="NLM_cas:issn">0923-1811</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Programmed cell death ligand 1 (B7-H1) was recently cloned in antigen presenting cells (APCs) and represents a third member of the B7 family.  Thus, B7-H1 may be a novel target for clin. intervention in human inflammatory disease.  The aim of this study is to investigate the signal transduction mechanism and transcriptional regulation of B7-H1 expression in human dermal fibroblasts.  We performed reverse transcription PCR (RT-PCR) for the detection of mRNA expression, luciferase reporter assays with B7-H1 promoter constructs, and Western blot anal.  From RT-PCR anal., IFN-γ can induce the expression of B7-H1 mRNA in dermal fibroblast.  This expression is similar to the results of luciferase reporter assay with B7-H1 promoter.  Western blot anal. and EMSA revealed that NF-κB transcription factors mediate the induction of B7-H1 expression via the transient phosphorylation of ERK1/2 and PI3K when cells are stimulated by IFN-γ.  Also, Specific destruction of the NF-κB binding site abolished the induction of the promoter activity by IFN-γ.  Our data not only provides the first evidence to demonstrate that dermal fibroblast express the B7-H1 mRNA in the process of skin inflammation, but also suggests the involvement of NF-κB and MAPK and PI3K, that may play some important roles in inflammation process in human skin diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvsU0FiZBZ2bVg90H21EOLACvtfcHk0lggUQU6H5hsxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFSmtrzE&md5=7a614c95c8aa3f2d9e7dc37f57c96608</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.jdermsci.2005.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jdermsci.2005.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DSeo%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DB.%2BS.%26aulast%3DKim%26aufirst%3DC.%2BD.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DMaeng%26aufirst%3DP.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%2BS.%26atitle%3DIFN-gamma%2520regulates%2520the%2520expression%2520of%2520B7-H1%2520in%2520dermal%2520fibroblast%2520cells%26jtitle%3DJ.%2520Dermatol.%2520Sci.%26date%3D2005%26volume%3D40%26spage%3D95%26epage%3D103%26doi%3D10.1016%2Fj.jdermsci.2005.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keir, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phamduy, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span> <span> </span><span class="NLM_article-title">Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2007.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.immuni.2007.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=17629517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFeqtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=111-122&author=M.+J.+Butteauthor=M.+E.+Keirauthor=T.+B.+Phamduyauthor=A.+H.+Sharpeauthor=G.+J.+Freeman&title=Programmed+death-1+ligand+1+interacts+specifically+with+the+B7-1+costimulatory+molecule+to+inhibit+T+cell+responses&doi=10.1016%2Fj.immuni.2007.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed Death-1 Ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses</span></div><div class="casAuthors">Butte, Manish J.; Keir, Mary E.; Phamduy, Theresa B.; Sharpe, Arlene H.; Freeman, Gordon J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-122</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Pathways in the B7:CD28 family of costimulatory mols. regulate T cell activation and tolerance.  B7-dependent responses in Cd28-/- Ctla4-/- T cells together with reports of stimulatory and inhibitory functions for Programmed Death-1 Ligand 1 or 2 mols. (PD-L1 or PD-L2) have suggested addnl. receptors for these B7 family members.  The authors show that B7-1 and PD-L1 interacted with affinity intermediate to that of B7-1:CD28 and B7-1:CTLA-4.  The PD-L1:B7-1 interface overlapped with the B7-1:CTLA-4 and PD-L1:PD-1 (Programmed Death-1) interfaces.  T cell activation and cytokine prodn. were inhibited by the interaction of B7-1 with PD-L1.  The responses of PD-1-deficient vs. PD-1,B7-1 double-deficient T cells to PD-L1 and of CD28,CTLA-4 double-deficient vs. CD28,CTLA-4,PD-L1 triple-deficient T cells to B7-1 demonstrated that PD-L1 and B7-1 interact specifically to inhibit T cell activation.  The authors' findings point to a substantial bidirectional inhibitory interaction between B7-1 and PD-L1 and add an addnl. dimension to immunoregulatory functions of the B7:CD28 family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMR5dpv_Vr5LVg90H21EOLACvtfcHk0lggUQU6H5hsxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFeqtrk%253D&md5=8fabef0e1244a1d356378867d92a248e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2007.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2007.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DButte%26aufirst%3DM.%2BJ.%26aulast%3DKeir%26aufirst%3DM.%2BE.%26aulast%3DPhamduy%26aufirst%3DT.%2BB.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26atitle%3DProgrammed%2520death-1%2520ligand%25201%2520interacts%2520specifically%2520with%2520the%2520B7-1%2520costimulatory%2520molecule%2520to%2520inhibit%2520T%2520cell%2520responses%26jtitle%3DImmunity%26date%3D2007%26volume%3D27%26spage%3D111%26epage%3D122%26doi%3D10.1016%2Fj.immuni.2007.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tumeh, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harview, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yearley, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shintaku, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spasic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciobanu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivork, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seja, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grogan, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomasic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaspy, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerson, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elashoff, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">PD-1 blockade induces responses by inhibiting adaptive immune resistance</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>515</i></span>,  <span class="NLM_fpage">568</span>– <span class="NLM_lpage">571</span>, <span class="refDoi"> DOI: 10.1038/nature13954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnature13954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25428505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFanu7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=515&publication_year=2014&pages=568-571&author=P.+C.+Tumehauthor=C.+L.+Harviewauthor=J.+H.+Yearleyauthor=I.+P.+Shintakuauthor=E.+J.+Taylorauthor=L.+Robertauthor=B.+Chmielowskiauthor=M.+Spasicauthor=G.+Henryauthor=V.+Ciobanuauthor=A.+N.+Westauthor=M.+Carmonaauthor=C.+Kivorkauthor=E.+Sejaauthor=G.+Cherryauthor=A.+J.+Gutierrezauthor=T.+R.+Groganauthor=C.+Mateusauthor=G.+Tomasicauthor=J.+A.+Glaspyauthor=R.+O.+Emersonauthor=H.+Robinsauthor=R.+H.+Pierceauthor=D.+A.+Elashoffauthor=C.+Robertauthor=A.+Ribas&title=PD-1+blockade+induces+responses+by+inhibiting+adaptive+immune+resistance&doi=10.1038%2Fnature13954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1 blockade induces responses by inhibiting adaptive immune resistance</span></div><div class="casAuthors">Tumeh, Paul C.; Harview, Christina L.; Yearley, Jennifer H.; Shintaku, I. Peter; Taylor, Emma J. M.; Robert, Lidia; Chmielowski, Bartosz; Spasic, Marko; Henry, Gina; Ciobanu, Voicu; West, Alisha N.; Carmona, Manuel; Kivork, Christine; Seja, Elizabeth; Cherry, Grace; Gutierrez, Antonio J.; Grogan, Tristan R.; Mateus, Christine; Tomasic, Gorana; Glaspy, John A.; Emerson, Ryan O.; Robins, Harlan; Pierce, Robert H.; Elashoff, David A.; Robert, Caroline; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">515</span>
        (<span class="NLM_cas:issue">7528</span>),
    <span class="NLM_cas:pages">568-571</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented rates of durable clin. responses in patients with various cancer types.  One mechanism by which cancer tissues limit the host immune response is via upregulation of PD-1 ligand (PD-L1) and its ligation to PD-1 on antigen-specific CD8+ T cells (termed adaptive immune resistance).  Here we show that pre-existing CD8+ T cells distinctly located at the invasive tumor margin are assocd. with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy.  We analyzed samples from 46 patients with metastatic melanoma obtained before and during anti-PD-1 therapy (pembrolizumab) using quant. immunohistochem., quant. multiplex immunofluorescence, and next-generation sequencing for T-cell antigen receptors (TCRs).  In serially sampled tumors, patients responding to treatment showed proliferation of intratumoral CD8+ T cells that directly correlated with radiog. redn. in tumor size.  Pre-treatment samples obtained from responding patients showed higher nos. of CD8-, PD-1- and PD-L1-expressing cells at the invasive tumor margin and inside tumors, with close proximity between PD-1 and PD-L1, and a more clonal TCR repertoire.  Using multivariate anal., we established a predictive model based on CD8 expression at the invasive margin and validated the model in an independent cohort of 15 patients.  Our findings indicate that tumor regression after therapeutic PD-1 blockade requires pre-existing CD8+ T cells that are neg. regulated by PD-1/PD-L1-mediated adaptive immune resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHvr5NAB5kD7Vg90H21EOLACvtfcHk0lh1WevNbYFSMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFanu7jL&md5=df43fa2237e9e66d99ad230159e0fe9e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnature13954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13954%26sid%3Dliteratum%253Aachs%26aulast%3DTumeh%26aufirst%3DP.%2BC.%26aulast%3DHarview%26aufirst%3DC.%2BL.%26aulast%3DYearley%26aufirst%3DJ.%2BH.%26aulast%3DShintaku%26aufirst%3DI.%2BP.%26aulast%3DTaylor%26aufirst%3DE.%2BJ.%26aulast%3DRobert%26aufirst%3DL.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DSpasic%26aufirst%3DM.%26aulast%3DHenry%26aufirst%3DG.%26aulast%3DCiobanu%26aufirst%3DV.%26aulast%3DWest%26aufirst%3DA.%2BN.%26aulast%3DCarmona%26aufirst%3DM.%26aulast%3DKivork%26aufirst%3DC.%26aulast%3DSeja%26aufirst%3DE.%26aulast%3DCherry%26aufirst%3DG.%26aulast%3DGutierrez%26aufirst%3DA.%2BJ.%26aulast%3DGrogan%26aufirst%3DT.%2BR.%26aulast%3DMateus%26aufirst%3DC.%26aulast%3DTomasic%26aufirst%3DG.%26aulast%3DGlaspy%26aufirst%3DJ.%2BA.%26aulast%3DEmerson%26aufirst%3DR.%2BO.%26aulast%3DRobins%26aufirst%3DH.%26aulast%3DPierce%26aufirst%3DR.%2BH.%26aulast%3DElashoff%26aufirst%3DD.%2BA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DPD-1%2520blockade%2520induces%2520responses%2520by%2520inhibiting%2520adaptive%2520immune%2520resistance%26jtitle%3DNature%26date%3D2014%26volume%3D515%26spage%3D568%26epage%3D571%26doi%3D10.1038%2Fnature13954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span> <span> </span><span class="NLM_article-title">Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">12293</span>– <span class="NLM_lpage">12297</span>, <span class="refDoi"> DOI: 10.1073/pnas.192461099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1073%2Fpnas.192461099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=12218188" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD38XntlCksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=12293-12297&author=Y.+Iwaiauthor=M.+Ishidaauthor=Y.+Tanakaauthor=T.+Okazakiauthor=T.+Honjoauthor=N.+Minato&title=Involvement+of+PD-L1+on+tumor+cells+in+the+escape+from+host+immune+system+and+tumor+immunotherapy+by+PD-L1+blockade&doi=10.1073%2Fpnas.192461099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade</span></div><div class="casAuthors">Iwai, Yoshiko; Ishida, Masayoshi; Tanaka, Yoshimasa; Okazaki, Taku; Honjo, Tasuku; Minato, Nagahiro</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">12293-12297</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">PD-1 is a receptor of the Ig superfamily that neg. regulates T cell antigen receptor signaling by interacting with the specific ligands (PD-L) and is suggested to play a role in the maintenance of self-tolerance.  In the present study, we examd. possible roles of the PD-1/PD-L system in tumor immunity.  Transgenic expression of PD-L1, one of the PD-L, in P815 tumor cells rendered them less susceptible to the specific T cell antigen receptor-mediated lysis by cytotoxic T cells in vitro, and markedly enhanced their tumorigenesis and invasiveness in vivo in the syngeneic hosts as compared with the parental tumor cells that lacked endogenous PD-L.  Both effects could be reversed by anti-PD-L1 Ab.  Survey of murine tumor lines revealed that all of the myeloma cell lines examd. naturally expressed PD-L1.  Growth of the myeloma cells in normal syngeneic mice was inhibited significantly albeit transiently by the administration of anti-PD-L1 Ab in vivo and was suppressed completely in the syngeneic PD-1-deficient mice.  These results suggest that the expression of PD-L1 can serve as a potent mechanism for potentially immunogenic tumors to escape from host immune responses and that blockade of interaction between PD-1 and PD-L may provide a promising strategy for specific tumor immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMFtH51vQ-YbVg90H21EOLACvtfcHk0lh1WevNbYFSMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntlCksL8%253D&md5=d6fda8be518526bf50e89fd9a44a8060</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1073%2Fpnas.192461099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.192461099%26sid%3Dliteratum%253Aachs%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DIshida%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DHonjo%26aufirst%3DT.%26aulast%3DMinato%26aufirst%3DN.%26atitle%3DInvolvement%2520of%2520PD-L1%2520on%2520tumor%2520cells%2520in%2520the%2520escape%2520from%2520host%2520immune%2520system%2520and%2520tumor%2520immunotherapy%2520by%2520PD-L1%2520blockade%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D12293%26epage%3D12297%26doi%3D10.1073%2Fpnas.192461099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strome, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salomao, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flies, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennon, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span> <span> </span><span class="NLM_article-title">Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">800</span>, <span class="refDoi"> DOI: 10.1038/nm730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnm730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=12091876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls12msLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=793-800&author=H.+Dongauthor=S.+E.+Stromeauthor=D.+R.+Salomaoauthor=H.+Tamuraauthor=F.+Hiranoauthor=D.+B.+Fliesauthor=P.+C.+Rocheauthor=J.+Luauthor=G.+Zhuauthor=K.+Tamadaauthor=V.+A.+Lennonauthor=E.+Celisauthor=L.+Chen&title=Tumor-associated+B7-H1+promotes+T-cell+apoptosis%3A+A+potential+mechanism+of+immune+evasion&doi=10.1038%2Fnm730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion</span></div><div class="casAuthors">Dong, Haidong; Strome, Scott E.; Salomao, Diva R.; Tamura, Hideto; Hirano, Fumiya; Flies, Dallas B.; Roche, Patrick C.; Lu, Jun; Zhu, Gefeng; Tamada, Koji; Lennon, Vanda A.; Celis, Esteban; Chen, Lieping</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">793-800</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B7-H1, a recently described member of the B7 family of costimulatory mols., is thought to be involved in the regulation of cellular and humoral immune responses through the PD-1 receptor on activated T and B cells.  We report here that, except for cells of the macrophage lineage, normal human tissues do not express B7-H1.  In contrast, B7-H1 is abundant in human carcinomas of lung, ovary and colon and in melanomas.  The pro-inflammatory cytokine interferon-γ upregulates B7-H1 on the surface of tumor cell lines.  Cancer cell-assocd. B7-H1 increases apoptosis of antigen-specific human T-cell clones in vitro, and the apoptotic effect of B7-H1 is mediated largely by one or more receptors other than PD-1.  In addn., expression of B7-H1 on mouse P815 tumor increases apoptosis of activated tumor-reactive T cells and promotes the growth of highly immunogenic B7-1+ tumors in vivo.  These findings have implications for the design of T cell-based cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo8Nj_X-lk-7Vg90H21EOLACvtfcHk0liyPwABQevysg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls12msLo%253D&md5=a5a1fae0101d6b100eb456c4e4b4d5dc</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fnm730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm730%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DH.%26aulast%3DStrome%26aufirst%3DS.%2BE.%26aulast%3DSalomao%26aufirst%3DD.%2BR.%26aulast%3DTamura%26aufirst%3DH.%26aulast%3DHirano%26aufirst%3DF.%26aulast%3DFlies%26aufirst%3DD.%2BB.%26aulast%3DRoche%26aufirst%3DP.%2BC.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DG.%26aulast%3DTamada%26aufirst%3DK.%26aulast%3DLennon%26aufirst%3DV.%2BA.%26aulast%3DCelis%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DL.%26atitle%3DTumor-associated%2520B7-H1%2520promotes%2520T-cell%2520apoptosis%253A%2520A%2520potential%2520mechanism%2520of%2520immune%2520evasion%26jtitle%3DNat.%2520Med.%26date%3D2002%26volume%3D8%26spage%3D793%26epage%3D800%26doi%3D10.1038%2Fnm730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yearley, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juco, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunceford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chow, L. Q. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seiwert, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomassini, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McClanahan, T.</span></span> <span> </span><span class="NLM_article-title">PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3158</span>– <span class="NLM_lpage">3167</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-1761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1158%2F1078-0432.CCR-16-1761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=28619999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVSqurbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=3158-3167&author=J.+H.+Yearleyauthor=C.+Gibsonauthor=N.+Yuauthor=C.+Moonauthor=E.+Murphyauthor=J.+Jucoauthor=J.+Luncefordauthor=J.+Chengauthor=L.+Q.+M.+Chowauthor=T.+Y.+Seiwertauthor=M.+Handaauthor=J.+E.+Tomassiniauthor=T.+McClanahan&title=PD-L2+expression+in+human+tumors%3A+relevance+to+anti-PD-1+therapy+in+cancer&doi=10.1158%2F1078-0432.CCR-16-1761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer</span></div><div class="casAuthors">Yearley, Jennifer H.; Gibson, Christopher; Yu, Ni; Moon, Christina; Murphy, Erin; Juco, Jonathan; Lunceford, Jared; Cheng, Jonathan; Chow, Laura Q. M.; Seiwert, Tanguy Y.; Handa, Masahisa; Tomassini, Joanne E.; McClanahan, Terrill</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3158-3167</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Tumor-assocd. PD-L1 expression is predictive of clin. response to PD-1-directed immunotherapy.  However, PD-L1-neg. patients may also respond to PD-1 checkpoint blockade, suggesting that other PD-1 ligands may be relevant to the clin. activity of these therapies.  The prevalence of PD-L2, the other known ligand of PD-1, and its relationship to response to anti-PD-1 therapy were evaluated.  Exptl. Design: PD-L2 expression was assessed in archival tumor tissue from seven indications using a novel immunohistochem. assay.  In addn., relationships between clin. response and PD-L2 status were evaluated in tumor tissues from patients with head and neck squamous cell carcinoma (HNSCC) with recurrent or metastatic disease, treated with pembrolizumab.  Results: PD-L2 expression was obsd. in all tumor types and present in stromal, tumor, and endothelial cells.  The prevalence and distribution of PD-L2 correlated significantly with PD-L1 (P = 0.0012-<0.0001); however, PD-L2 was detected in the absence of PD-L1 in some tumor types.  Both PD-L1 and PD-L2 positivity significantly predicted clin. response to pembrolizumab on combined tumor, stromal and immune cells, with PD-L2 predictive independent of PD-L1.  Response was greater in patients pos. for both PD-L1 and PD-L2 (27.5%) than those pos. only for PD-L1 (11.4%).  PD-L2 status was also a significant predictor of progression-free survival (PFS) with pembrolizumab independent of PD-L1 status.  Longer median times for PFS and overall survival were obsd. for PD-L2-pos. than PD-L2-neg. patients.  Conclusions: Clin. response to pembrolizumab in patients with HNSCC may be related partly to blockade of PD-1/PD-L2 interactions.  Therapy targeting both PD-1 ligands may provide clin. benefit in these patients.  Clin Cancer Res; 23(12); 3158-67. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvguMmZLnrNbVg90H21EOLACvtfcHk0liyPwABQevysg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVSqurbL&md5=3d66a39c89e87561ff0fec1a752bfd55</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-1761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-1761%26sid%3Dliteratum%253Aachs%26aulast%3DYearley%26aufirst%3DJ.%2BH.%26aulast%3DGibson%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DMoon%26aufirst%3DC.%26aulast%3DMurphy%26aufirst%3DE.%26aulast%3DJuco%26aufirst%3DJ.%26aulast%3DLunceford%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DChow%26aufirst%3DL.%2BQ.%2BM.%26aulast%3DSeiwert%26aufirst%3DT.%2BY.%26aulast%3DHanda%26aufirst%3DM.%26aulast%3DTomassini%26aufirst%3DJ.%2BE.%26aulast%3DMcClanahan%26aufirst%3DT.%26atitle%3DPD-L2%2520expression%2520in%2520human%2520tumors%253A%2520relevance%2520to%2520anti-PD-1%2520therapy%2520in%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D3158%26epage%3D3167%26doi%3D10.1158%2F1078-0432.CCR-16-1761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazar-Molnar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramagopal, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathenson, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almo, S. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the complex between programmed death-1(PD-1) and its ligand PD-L2</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">10483</span>– <span class="NLM_lpage">10488</span>, <span class="refDoi"> DOI: 10.1073/pnas.0804453105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1073%2Fpnas.0804453105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=10483-10488&author=E.+Lazar-Molnarauthor=Q.+Yanauthor=E.+Caoauthor=U.+Ramagopalauthor=S.+G.+Nathensonauthor=S.+C.+Almo&title=Crystal+structure+of+the+complex+between+programmed+death-1%28PD-1%29+and+its+ligand+PD-L2&doi=10.1073%2Fpnas.0804453105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0804453105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0804453105%26sid%3Dliteratum%253Aachs%26aulast%3DLazar-Molnar%26aufirst%3DE.%26aulast%3DYan%26aufirst%3DQ.%26aulast%3DCao%26aufirst%3DE.%26aulast%3DRamagopal%26aufirst%3DU.%26aulast%3DNathenson%26aufirst%3DS.%2BG.%26aulast%3DAlmo%26aufirst%3DS.%2BC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520complex%2520between%2520programmed%2520death-1%2528PD-1%2529%2520and%2520its%2520ligand%2520PD-L2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D10483%26epage%3D10488%26doi%3D10.1073%2Fpnas.0804453105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veverka, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radhakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waters, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muskett, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stubberfield, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladbury, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikemizu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. J.</span></span> <span> </span><span class="NLM_article-title">Structure and interactions of the human programmed cell death 1 receptor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">11771</span>– <span class="NLM_lpage">11785</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.448126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1074%2Fjbc.M112.448126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=23417675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1OjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=11771-11785&author=X.+Chengauthor=V.+Veverkaauthor=A.+Radhakrishnanauthor=L.+C.+Watersauthor=F.+W.+Muskettauthor=S.+H.+Morganauthor=J.+Huoauthor=C.+Yuauthor=E.+J.+Evansauthor=A.+J.+Leslieauthor=M.+Griffithsauthor=C.+Stubberfieldauthor=R.+Griffinauthor=A.+J.+Henryauthor=A.+Janssonauthor=J.+E.+Ladburyauthor=S.+Ikemizuauthor=M.+D.+Carrauthor=S.+J.+Davis&title=Structure+and+interactions+of+the+human+programmed+cell+death+1+receptor&doi=10.1074%2Fjbc.M112.448126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and interactions of the human programmed cell death 1 receptor</span></div><div class="casAuthors">Cheng, Xiaoxiao; Veverka, Vaclav; Radhakrishnan, Anand; Waters, Lorna C.; Muskett, Frederick W.; Morgan, Sara H.; Huo, Jiandong; Yu, Chao; Evans, Edward J.; Leslie, Alasdair J.; Griffiths, Meryn; Stubberfield, Colin; Griffin, Robert; Henry, Alistair J.; Jansson, Andreas; Ladbury, John E.; Ikemizu, Shinji; Carr, Mark D.; Davis, Simon J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11771-11785</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">PD-1, a receptor expressed by T cells, B cells, and monocytes, is a potent regulator of immune responses and a promising therapeutic target.  The structure and interactions of human PD-1 are, however, incompletely characterized.  We present the soln. NMR-based structure of the human PD-1 extracellular region and detailed analyses of its interactions with its ligands, PD-L1 and PD-L2.  PD-1 has typical Ig superfamily topol. but differs at the edge of the GFCC' sheet, which is flexible and completely lacks a C'' strand.  Changes in PD-1 backbone NMR signals induced by ligand binding suggest that, whereas binding is centered on the GFCC' sheet, PD-1 is engaged by its two ligands differently and in ways incompletely explained by crystal structures of mouse PD-1·ligand complexes.  The affinities of these interactions and that of PD-L1 with the costimulatory protein B7-1, measured using surface plasmon resonance, are significantly weaker than expected.  The 3-4-fold greater affinity of PD-L2 vs. PD-L1 for human PD-1 is principally due to the 3-fold smaller dissocn. rate for PD-L2 binding.  Isothermal titrn. calorimetry revealed that the PD-1/PD-L1 interaction is entropically driven, whereas PD-1/PD-L2 binding has a large enthalpic component.  Math. simulations based on the biophys. data and quant. expression data suggest an unexpectedly limited contribution of PD-L2 to PD-1 ligation during interactions of activated T cells with antigen-presenting cells.  These findings provide a rigorous structural and biophys. framework for interpreting the important functions of PD-1 and reveal that potent inhibitory signaling can be initiated by weakly interacting receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5qIGEiutorbVg90H21EOLACvtfcHk0ljUXUghbAi_QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1OjtLo%253D&md5=b8fc26952e0562a4eaf3cbdf780fa88d</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.448126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.448126%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DVeverka%26aufirst%3DV.%26aulast%3DRadhakrishnan%26aufirst%3DA.%26aulast%3DWaters%26aufirst%3DL.%2BC.%26aulast%3DMuskett%26aufirst%3DF.%2BW.%26aulast%3DMorgan%26aufirst%3DS.%2BH.%26aulast%3DHuo%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DEvans%26aufirst%3DE.%2BJ.%26aulast%3DLeslie%26aufirst%3DA.%2BJ.%26aulast%3DGriffiths%26aufirst%3DM.%26aulast%3DStubberfield%26aufirst%3DC.%26aulast%3DGriffin%26aufirst%3DR.%26aulast%3DHenry%26aufirst%3DA.%2BJ.%26aulast%3DJansson%26aufirst%3DA.%26aulast%3DLadbury%26aufirst%3DJ.%2BE.%26aulast%3DIkemizu%26aufirst%3DS.%26aulast%3DCarr%26aufirst%3DM.%2BD.%26aulast%3DDavis%26aufirst%3DS.%2BJ.%26atitle%3DStructure%2520and%2520interactions%2520of%2520the%2520human%2520programmed%2520cell%2520death%25201%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D11771%26epage%3D11785%26doi%3D10.1074%2Fjbc.M112.448126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przetocka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Structure of the complex of human programmed death 1, PD-1, and Its ligand PD-L1</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2341</span>– <span class="NLM_lpage">2348</span>, <span class="refDoi"> DOI: 10.1016/j.str.2015.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.str.2015.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=26602187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslWrsLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=2341-2348&author=K.+M.+Zakauthor=R.+Kitelauthor=S.+Przetockaauthor=P.+Golikauthor=K.+Guzikauthor=B.+Musielakauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Structure+of+the+complex+of+human+programmed+death+1%2C+PD-1%2C+and+Its+ligand+PD-L1&doi=10.1016%2Fj.str.2015.09.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1</span></div><div class="casAuthors">Zak, Krzysztof M.; Kitel, Radoslaw; Przetocka, Sara; Golik, Przemyslaw; Guzik, Katarzyna; Musielak, Bogdan; Domling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2341-2348</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Targeting the PD-1/PD-L1 immunol. checkpoint with monoclonal antibodies has recently provided breakthrough progress in the treatment of melanoma, non-small cell lung cancer, and other types of cancer.  Small-mol. drugs interfering with this pathway are highly awaited, but their development is hindered by insufficient structural information.  This study reveals the mol. details of the human PD-1/PD-L1 interaction based on an X-ray structure of the complex.  First, it is shown that the ligand binding to human PD-1 is assocd. with significant plasticity within the receptor.  Second, a detailed mol. map of the interaction surface is provided, allowing definition of the regions within both interacting partners that may likely be targeted by small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYnNEmCbOHlrVg90H21EOLACvtfcHk0ljUXUghbAi_QQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslWrsLzK&md5=da7dfb695e77f24d05ec4af4c586d615</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2015.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2015.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DKitel%26aufirst%3DR.%26aulast%3DPrzetocka%26aufirst%3DS.%26aulast%3DGolik%26aufirst%3DP.%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DStructure%2520of%2520the%2520complex%2520of%2520human%2520programmed%2520death%25201%252C%2520PD-1%252C%2520and%2520Its%2520ligand%2520PD-L1%26jtitle%3DStructure%26date%3D2015%26volume%3D23%26spage%3D2341%26epage%3D2348%26doi%3D10.1016%2Fj.str.2015.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo-Lopez, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czuczman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bence-Bruckler, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabanillas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lister, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallaire, B. K.</span></span> <span> </span><span class="NLM_article-title">Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2825</span>– <span class="NLM_lpage">2833</span>, <span class="refDoi"> DOI: 10.1200/JCO.1998.16.8.2825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1200%2FJCO.1998.16.8.2825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=9704735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADyaK1cXlsFCgu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=2825-2833&author=P.+McLaughlinauthor=A.+J.+Grillo-Lopezauthor=B.+K.+Linkauthor=R.+Levyauthor=M.+S.+Czuczmanauthor=M.+E.+Williamsauthor=M.+R.+Heymanauthor=I.+Bence-Brucklerauthor=C.+A.+Whiteauthor=F.+Cabanillasauthor=V.+Jainauthor=A.+D.+Hoauthor=J.+Listerauthor=K.+Weyauthor=D.+Shenauthor=B.+K.+Dallaire&title=Rituximab+chimeric+Anti-CD20+monoclonal+antibody+therapy+for+relapsed+indolent+lymphoma%3A+half+of+patients+respond+to+a+four-dose+treatment+program&doi=10.1200%2FJCO.1998.16.8.2825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program</span></div><div class="casAuthors">McLaughlin, Peter; Grillo-Lopez, Antonio J.; Link, Brian K.; Levy, Ronald; Czuczman, Myron S.; Williams, Michael E.; Heyman, Meyer R.; Bence-Bruckler, Isabelle; White, Christine A.; Cabanillas, Fernando; Jain, Vinay; Ho, Anthony D.; Lister, John; Wey, Ken; Shen, David; Dallaire, Brian K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2825-2833</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">The CD20 antigen is expressed on more than 90% of B-cell lymphomas.  It is appealing for targeted therapy, because it does not shed or modulate.  A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies.  This was a multiinstitutional trial of the chimeric anti-CD20 antibody, IDEC-C2B8.  Patients with relapsed low grade or follicular lymphoma received an outpatient treatment course of IDEC-C2B8 375 mg/m2 i.v. weekly for four doses.  From 31 centers, 166 patients were entered.  Of this intent-to-treat group, 48% responded.  With a median follow-up duration of 11.8 mo, the projected median time to progression for responders is 13.0 mo.  Serum antibody levels were sustained longer after the fourth infusion than after the first, and were higher in responders and in patients with lower tumor burden.  The majority of adverse events occurred during the first infusion and were grade 1 or 2; fever and chills were the most common events.  Only 12% of patients had grade 3 and 3% grade 4 toxicities.  A human antichimeric antibody was detected in only one patient.  The response rate of 48% with IDECC2B8 is comparable to results with single-agent cytotoxic chemotherapy.  Toxicity was mild.  Attention needs to be paid to the rate of antibody infusion, with titrn. according to toxicity.  Further investigation of this agent is warranted, including its use in conjunction with std. chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrurijvS_ktjrVg90H21EOLACvtfcHk0litC60_8jRkeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlsFCgu7c%253D&md5=638b81d6fb177b32be40dc6056ced292</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1200%2FJCO.1998.16.8.2825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.1998.16.8.2825%26sid%3Dliteratum%253Aachs%26aulast%3DMcLaughlin%26aufirst%3DP.%26aulast%3DGrillo-Lopez%26aufirst%3DA.%2BJ.%26aulast%3DLink%26aufirst%3DB.%2BK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DCzuczman%26aufirst%3DM.%2BS.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DHeyman%26aufirst%3DM.%2BR.%26aulast%3DBence-Bruckler%26aufirst%3DI.%26aulast%3DWhite%26aufirst%3DC.%2BA.%26aulast%3DCabanillas%26aufirst%3DF.%26aulast%3DJain%26aufirst%3DV.%26aulast%3DHo%26aufirst%3DA.%2BD.%26aulast%3DLister%26aufirst%3DJ.%26aulast%3DWey%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DDallaire%26aufirst%3DB.%2BK.%26atitle%3DRituximab%2520chimeric%2520Anti-CD20%2520monoclonal%2520antibody%2520therapy%2520for%2520relapsed%2520indolent%2520lymphoma%253A%2520half%2520of%2520patients%2520respond%2520to%2520a%2520four-dose%2520treatment%2520program%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1998%26volume%3D16%26spage%3D2825%26epage%3D2833%26doi%3D10.1200%2FJCO.1998.16.8.2825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyland-Jones, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajamonde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eiermann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, L.</span></span> <span> </span><span class="NLM_article-title">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">792</span>, <span class="refDoi"> DOI: 10.1056/NEJM200103153441101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1056%2FNEJM200103153441101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=11248153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=783-792&author=D.+J.+Slamonauthor=B.+Leyland-Jonesauthor=S.+Shakauthor=H.+Fuchsauthor=V.+Patonauthor=A.+Bajamondeauthor=T.+Flemingauthor=W.+Eiermannauthor=J.+Wolterauthor=M.+Pegramauthor=J.+Baselgaauthor=L.+Norton&title=Use+of+chemotherapy+plus+a+monoclonal+antibody+against+HER2+for+metastatic+breast+cancer+that+overexpresses+HER2&doi=10.1056%2FNEJM200103153441101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span></div><div class="casAuthors">Slamon, Dennis J.; Leyland-Jones, Brian; Shak, Steven; Fuchs, Hank; Paton, Virginia; Bajamonde, Alex; Fleming, Thomas; Eiermann, Wolfgang; Wolter, Janet; Pegram, Mark; Baselga, Jose; Norton, Larry</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">783-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 % of breast cancers, increasing the aggressiveness of the tumor.  We evaluated the efficacy and safety of trastuzumab, a recombinant monoclonal antibody against HER2, in women with metastatic breast cancer that overexpressed HER2.  We randomly assigned 234 patients to receive std. chemotherapy plus trastuzumab.  Patients who had not previously received adjuvant (postoperative) therapy with an anthracycline were treated with doxorubicin (or epirubicin in the case of 36 women) and cyclophosphamide with (143 women) or without trastuzumab (138 women).  Patients who had previously received adjuvant anthracycline were treated with paclitaxel alone (96 women) or paclitaxel with trastuzumab (92 women).  The addn. of trastuzumab to chemotherapy was assocd. with a longer time to disease progression (median, 7.4 vs. 4.6 mo; P<0.001), a higher rate of objective response (50 % vs. 32 %, P<0.001), a longer duration of response (median, 9.1 vs. 6.1 mo; P<0.001), a lower rate of death at 1 yr (22 % vs. 33 %, P=0.008), longer survival (median survival, 25.1 vs. 20.3 mo; P=0.046), and a 20 % redn. in the risk of death.  The most important adverse event was cardiac dysfunction, which occurred in 27 % of the group given an anthracycline, cyclophosphamide, and trastuzumab; 8 % of the group given an anthracycline and cyclophosphamide alone; 13 % of the group given paclitaxel and trastuzumab; and 1 % of the group given paclitaxel alone.  Although the cardiotoxicity was potentially severe and, in some cases, life-threatening, the symptoms generally improved with std. medical management.  Trastuzumab increases the clin. benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGK_4WWRZLKLVg90H21EOLACvtfcHk0ljXGRmgvCDIFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXisVGktrc%253D&md5=81112f11ffc66fc3a898b61e104322b6</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1056%2FNEJM200103153441101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200103153441101%26sid%3Dliteratum%253Aachs%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DLeyland-Jones%26aufirst%3DB.%26aulast%3DShak%26aufirst%3DS.%26aulast%3DFuchs%26aufirst%3DH.%26aulast%3DPaton%26aufirst%3DV.%26aulast%3DBajamonde%26aufirst%3DA.%26aulast%3DFleming%26aufirst%3DT.%26aulast%3DEiermann%26aufirst%3DW.%26aulast%3DWolter%26aufirst%3DJ.%26aulast%3DPegram%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DNorton%26aufirst%3DL.%26atitle%3DUse%2520of%2520chemotherapy%2520plus%2520a%2520monoclonal%2520antibody%2520against%2520HER2%2520for%2520metastatic%2520breast%2520cancer%2520that%2520overexpresses%2520HER2%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D783%26epage%3D792%26doi%3D10.1056%2FNEJM200103153441101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levi-Schaffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sela, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">1407</span>– <span class="NLM_lpage">1424</span>, <span class="refDoi"> DOI: 10.1111/bph.13450</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1111%2Fbph.13450" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=26833433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC28XktV2ns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=1407-1424&author=S.+Carvalhoauthor=F.+Levi-Schafferauthor=M.+Selaauthor=Y.+Yarden&title=Immunotherapy+of+cancer%3A+from+monoclonal+to+oligoclonal+cocktails+of+anti-cancer+antibodies%3A+IUPHAR+Review+18&doi=10.1111%2Fbph.13450"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18</span></div><div class="casAuthors">Carvalho, Silvia; Levi-Schaffer, Francesca; Sela, Michael; Yarden, Yosef</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1407-1424</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Antibody-based therapy of cancer employs monoclonal antibodies (mAbs) specific to sol. ligands, membrane antigens of T-lymphocytes or proteins located at the surface of cancer cells.  The latter mAbs are often combined with cytotoxic regimens, because they block survival of residual fractions of tumors that evade therapy-induced cell death.  Antibodies, along with kinase inhibitors, have become in the last decade the mainstay of oncol. pharmacol.  However, partial and transient responses, as well as emergence of tumor resistance, currently limit clin. application of mAbs.  To overcome these hurdles, oligoclonal antibody mixts. are being tested in animal models and in clin. trials.  The first homo-combination of two mAbs, each engaging a distinct site of HER2, an oncogenic receptor tyrosine kinase (RTK), has been approved for treatment of breast cancer.  Likewise, a hetero-combination of antibodies to two distinct T-cell antigens, PD1 and CTLA4, has been approved for treatment of melanoma.  In a similar vein, additive or synergistic anti-tumor effects obsd. in animal models have prompted clin. testing of hetero-combinations of antibodies simultaneously engaging distinct RTKs.  We discuss the promise of antibody cocktails reminiscent of currently used mixts. of chemotherapeutics and highlight mechanisms potentially underlying their enhanced clin. efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNGmLZo2apPbVg90H21EOLACvtfcHk0ljXGRmgvCDIFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktV2ns7w%253D&md5=176c6fa71eae9d42fc32effb347601b3</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1111%2Fbph.13450&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13450%26sid%3Dliteratum%253Aachs%26aulast%3DCarvalho%26aufirst%3DS.%26aulast%3DLevi-Schaffer%26aufirst%3DF.%26aulast%3DSela%26aufirst%3DM.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DImmunotherapy%2520of%2520cancer%253A%2520from%2520monoclonal%2520to%2520oligoclonal%2520cocktails%2520of%2520anti-cancer%2520antibodies%253A%2520IUPHAR%2520Review%252018%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D1407%26epage%3D1424%26doi%3D10.1111%2Fbph.13450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span> <span> </span><span class="NLM_article-title">Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy</span>. <i>Signal Transduction Targeted Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">16029</span>, <span class="refDoi"> DOI: 10.1038/sigtrans.2016.29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fsigtrans.2016.29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=29263905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BC1MzjslKjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=16029&author=S.+Tanauthor=C.+W.+Zhangauthor=G.+F.+Gao&title=Seeing+is+believing%3A+anti-PD-1%2FPD-L1+monoclonal+antibodies+in+action+for+checkpoint+blockade+tumor+immunotherapy&doi=10.1038%2Fsigtrans.2016.29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy</span></div><div class="casAuthors">Tan Shuguang; Gao George F; Zhang Catherine W-H</div><div class="citationInfo"><span class="NLM_cas:title">Signal transduction and targeted therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16029</span>
        ISSN:<span class="NLM_cas:issn">2095-9907</span>.
    </div><div class="casAbstract">Structural immunology, focusing on structures of host immune related molecules, enables the immunologists to see what the molecules look like, and more importantly, how they work together.  Antibody-based PD-1/PD-L1 blockade therapy has achieved brilliant successes in clinical applications.  The recent breakthrough of the complex structures of checkpoint blockade antibodies with their counterparts, pembrolizumab with PD-1 and avelumab with PD-L1, have made it clear how these monoclonal antibodies compete the binding of PD-1/PD-L1 and function to blockade the receptor-ligand interaction.  Herein, we summarize the structural findings of these two reports and look into the future for how this information would facilitate the development of more efficient PD-1/PD-L1 targeting antibodies, small molecule drugs, and other protein or non-protein inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlOIoasRyqjE2yPDyEFiigfW6udTcc2ebjRbyqPbpRirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MzjslKjsQ%253D%253D&md5=77c119cf3700f4d9fdb51a70a1a985cb</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fsigtrans.2016.29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsigtrans.2016.29%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DC.%2BW.%26aulast%3DGao%26aufirst%3DG.%2BF.%26atitle%3DSeeing%2520is%2520believing%253A%2520anti-PD-1%252FPD-L1%2520monoclonal%2520antibodies%2520in%2520action%2520for%2520checkpoint%2520blockade%2520tumor%2520immunotherapy%26jtitle%3DSignal%2520Transduction%2520Targeted%2520Ther.%26date%3D2016%26volume%3D1%26spage%3D16029%26doi%3D10.1038%2Fsigtrans.2016.29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">PD-1/PD-L1 and immunotherapy for pancreatic cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>407</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1016%2Fj.canlet.2017.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=28826722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOhu7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=407&publication_year=2017&pages=57-65&author=M.+Fengauthor=G.+Xiongauthor=Z.+Caoauthor=G.+Yangauthor=S.+Zhengauthor=X.+Songauthor=L.+Youauthor=L.+Zhengauthor=T.+Zhangauthor=Y.+Zhao&title=PD-1%2FPD-L1+and+immunotherapy+for+pancreatic+cancer&doi=10.1016%2Fj.canlet.2017.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/PD-L1 and immunotherapy for pancreatic cancer</span></div><div class="casAuthors">Feng, Mengyu; Xiong, Guangbing; Cao, Zhe; Yang, Gang; Zheng, Suli; Song, Xujun; You, Lei; Zheng, Lianfang; Zhang, Taiping; Zhao, Yupei</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">407</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-65</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Therapy that targets programmed death 1 or programmed death 1 ligand 1 (PD-1/PD-L1), which are known as immune checkpoints, has been recently rapidly developing as oncotherapy for various carcinomas.  However, this therapy has a poor effect on the treatment of pancreatic cancer with PD-1/PD-L1 blockade monotherapy.  In this review, the development and limitations of anti-PD-1/PD-L1 monotherapy in pancreatic cancer are discussed.  We then consider the underlying mechanism of anti-PD-1/PD-L1 monotherapy failure, combination strategies overcoming resistance to anti-PD-1/PD-L1 immunotherapy and the prospect of targeting PD-1/PD-L1 for the immunotherapy of pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprqiZWrvMgYbVg90H21EOLACvtfcHk0ljgEyituCZlkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOhu7fF&md5=fdf524ffb8e66ed919094486e0d34941</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DM.%26aulast%3DXiong%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DYou%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DPD-1%252FPD-L1%2520and%2520immunotherapy%2520for%2520pancreatic%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D407%26spage%3D57%26epage%3D65%26doi%3D10.1016%2Fj.canlet.2017.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naidoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connell, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schindler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacouture, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span> <span> </span><span class="NLM_article-title">Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">2375</span>– <span class="NLM_lpage">2391</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv383</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1093%2Fannonc%2Fmdv383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=26371282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BC283it1Khtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=2375-2391&author=J.+Naidooauthor=D.+B.+Pageauthor=B.+T.+Liauthor=L.+C.+Connellauthor=K.+Schindlerauthor=M.+E.+Lacoutureauthor=M.+A.+Postowauthor=J.+D.+Wolchok&title=Toxicities+of+the+anti-PD-1+and+anti-PD-L1+immune+checkpoint+antibodies&doi=10.1093%2Fannonc%2Fmdv383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies</span></div><div class="casAuthors">Naidoo J; Page D B; Li B T; Connell L C; Schindler K; Lacouture M E; Postow M A; Wolchok J D</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2375-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Immune checkpoint antibodies that augment the programmed cell death protein 1 (PD-1)/PD-L1 pathway have demonstrated antitumor activity across multiple malignancies, and gained recent regulatory approval as single-agent therapy for the treatment of metastatic malignant melanoma and nonsmall-cell lung cancer.  Knowledge of toxicities associated with PD-1/PD-L1 blockade, as well as effective management algorithms for these toxicities, is pivotal in order to optimize clinical efficacy and safety.  In this article, we review selected published and presented clinical studies investigating single-agent anti-PD-1/PD-L1 therapy and trials of combination approaches with other standard anticancer therapies, in multiple tumor types.  We summarize the key adverse events reported in these studies and their management algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT2aykURc4ZQMERNNga7KD-fW6udTcc2ebjRbyqPbpRirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283it1Khtw%253D%253D&md5=fe3abfc48c19a18bcffcea7bae552844</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv383%26sid%3Dliteratum%253Aachs%26aulast%3DNaidoo%26aufirst%3DJ.%26aulast%3DPage%26aufirst%3DD.%2BB.%26aulast%3DLi%26aufirst%3DB.%2BT.%26aulast%3DConnell%26aufirst%3DL.%2BC.%26aulast%3DSchindler%26aufirst%3DK.%26aulast%3DLacouture%26aufirst%3DM.%2BE.%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26atitle%3DToxicities%2520of%2520the%2520anti-PD-1%2520and%2520anti-PD-L1%2520immune%2520checkpoint%2520antibodies%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26spage%3D2375%26epage%3D2391%26doi%3D10.1093%2Fannonc%2Fmdv383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arkin, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of protein-protein interactions: progressing towards the dream</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1038/nrd1343</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnrd1343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=15060526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1GktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=301-317&author=M.+R.+Arkinauthor=J.+A.+Wells&title=Small-molecule+inhibitors+of+protein-protein+interactions%3A+progressing+towards+the+dream&doi=10.1038%2Fnrd1343"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of protein-protein interactions: progressing towards the dream</span></div><div class="casAuthors">Arkin, Michelle R.; Wells, James A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">301-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein-protein interactions have a key role in most biol. processes, and offer attractive opportunities for therapeutic intervention.  Developing small mols. that modulate protein-protein interactions is difficult, owing to issues such as the lack of well-defined binding pockets.  Nevertheless, there was important progress in this endeavor in recent years.  Here, the authors use illustrative examples to discuss general strategies for addressing the challenges inherent in the discovery and characterization of small-mol. inhibitors of protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7MiFDdLJu27Vg90H21EOLACvtfcHk0lhE7kqz5BtCoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1GktrY%253D&md5=3e102c6207be420b4232056b4acdea12</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fnrd1343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1343%26sid%3Dliteratum%253Aachs%26aulast%3DArkin%26aufirst%3DM.%2BR.%26aulast%3DWells%26aufirst%3DJ.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520protein-protein%2520interactions%253A%2520progressing%2520towards%2520the%2520dream%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D301%26epage%3D317%26doi%3D10.1038%2Fnrd1343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skidmore, J.</span></span> <span> </span><span class="NLM_article-title">Small molecules, big targets: drug discovery faces the protein-protein interaction challenge</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">533</span>– <span class="NLM_lpage">550</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1038%2Fnrd.2016.29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=27050677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOgur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=533-550&author=D.+E.+Scottauthor=A.+R.+Baylyauthor=C.+Abellauthor=J.+Skidmore&title=Small+molecules%2C+big+targets%3A+drug+discovery+faces+the+protein-protein+interaction+challenge&doi=10.1038%2Fnrd.2016.29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules, big targets: drug discovery faces the protein-protein interaction challenge</span></div><div class="casAuthors">Scott, Duncan E.; Bayly, Andrew R.; Abell, Chris; Skidmore, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">533-550</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Protein-protein interactions (PPIs) are of pivotal importance in the regulation of biol. systems and are consequently implicated in the development of disease states.  Recent work has begun to show that, with the right tools, certain classes of PPI can yield to the efforts of medicinal chemists to develop inhibitors, and the first PPI inhibitors have reached clin. development.  In this Review, we describe the research leading to these breakthroughs and highlight the existence of groups of structurally related PPIs within the PPI target class.  For each of these groups, we use examples of successful discovery efforts to illustrate the research strategies that have proved most useful.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK-aGzHa9mP7Vg90H21EOLACvtfcHk0lhE7kqz5BtCoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOgur4%253D&md5=9f0953567ae9338b8b36aa78b8160655</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.29%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DD.%2BE.%26aulast%3DBayly%26aufirst%3DA.%2BR.%26aulast%3DAbell%26aufirst%3DC.%26aulast%3DSkidmore%26aufirst%3DJ.%26atitle%3DSmall%2520molecules%252C%2520big%2520targets%253A%2520drug%2520discovery%2520faces%2520the%2520protein-protein%2520interaction%2520challenge%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D533%26epage%3D550%26doi%3D10.1038%2Fnrd.2016.29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y. F.</span></span> <span> </span><span class="NLM_article-title">Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">11760</span>– <span class="NLM_lpage">11764</span>, <span class="refDoi"> DOI: 10.1002/anie.201506225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1002%2Fanie.201506225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=11760-11764&author=H.+N.+Changauthor=B.+Y.+Liuauthor=Y.+K.+Qiauthor=Y.+Zhouauthor=Y.+P.+Chenauthor=K.+M.+Panauthor=W.+W.+Liauthor=X.+M.+Zhouauthor=W.+W.+Maauthor=C.+Y.+Fuauthor=Y.+M.+Qiauthor=L.+Liuauthor=Y.+F.+Gao&title=Blocking+of+the+PD-1%2FPD-L1+interaction+by+a+D-peptide+antagonist+for+cancer+immunotherapy&doi=10.1002%2Fanie.201506225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy</span></div><div class="casAuthors">Chang, Hao-Nan; Liu, Bei-Yuan; Qi, Yun-Kun; Zhou, Yang; Chen, Yan-Ping; Pan, Kai-Mai; Li, Wen-Wen; Zhou, Xiu-Man; Ma, Wei-Wei; Fu, Cai-Yun; Qi, Yuan-Ming; Liu, Lei; Gao, Yan-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">11760-11764</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Blockade of the protein-protein interaction between the transmembrane protein programmed cell death protein 1 (PD-1) and its ligand PD-L1 has emerged as a promising immunotherapy for treating cancers.  Using the technol. of mirror-image phage display, we developed the first hydrolysis-resistant D-peptide antagonists to target the PD-1/PD-L1 pathway.  The optimized compd. DPPA-1 could bind PD-L1 at an affinity of 0.51 μΜ in vitro.  A blockade assay at the cellular level and tumor-bearing mice expts. indicated that DPPA-1 could also effectively disrupt the PD-1/PD-L1 interaction in vivo.  Thus D-peptide antagonists may provide novel low-mol.-wt. drug candidates for cancer immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHaM2oW2TzMLVg90H21EOLACvtfcHk0lgs14yeco6XLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSlsbbO&md5=9861da91b177782a89c912776741f9ad</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506225%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DH.%2BN.%26aulast%3DLiu%26aufirst%3DB.%2BY.%26aulast%3DQi%26aufirst%3DY.%2BK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DY.%2BP.%26aulast%3DPan%26aufirst%3DK.%2BM.%26aulast%3DLi%26aufirst%3DW.%2BW.%26aulast%3DZhou%26aufirst%3DX.%2BM.%26aulast%3DMa%26aufirst%3DW.%2BW.%26aulast%3DFu%26aufirst%3DC.%2BY.%26aulast%3DQi%26aufirst%3DY.%2BM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DY.%2BF.%26atitle%3DBlocking%2520of%2520the%2520PD-1%252FPD-L1%2520interaction%2520by%2520a%2520D-peptide%2520antagonist%2520for%2520cancer%2520immunotherapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2015%26volume%3D54%26spage%3D11760%26epage%3D11764%26doi%3D10.1002%2Fanie.201506225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span>; <span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Qi, Y.</span>; <span class="NLM_string-name">Liu, B.</span></span> <span> </span><span class="NLM_article-title">PD-L1 Affinity Peptide with Anti-Tumour Activity and Application Thereof</span>. <span class="NLM_patent">CN103304638A</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=Y.+Gao&author=Y.+Chen&author=Y.+Qi&author=B.+Liu&title=PD-L1+Affinity+Peptide+with+Anti-Tumour+Activity+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26atitle%3DPD-L1%2520Affinity%2520Peptide%2520with%2520Anti-Tumour%2520Activity%2520and%2520Application%2520Thereof%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">Peptide blocking of PD-1/PD-L1 interaction for cancer immunotherapy</span>. <i>Cancer Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">188</span>, <span class="refDoi"> DOI: 10.1158/2326-6066.CIR-17-0035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1158%2F2326-6066.CIR-17-0035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=29217732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=178-188&author=C.+Liauthor=N.+Zhangauthor=J.+Zhouauthor=C.+Dingauthor=Y.+Jinauthor=X.+Cuiauthor=K.+Puauthor=Y.+Zhu&title=Peptide+blocking+of+PD-1%2FPD-L1+interaction+for+cancer+immunotherapy&doi=10.1158%2F2326-6066.CIR-17-0035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy</span></div><div class="casAuthors">Li, Chunlin; Zhang, Nengpan; Zhou, Jundong; Ding, Chen; Jin, Yaqing; Cui, Xueyuan; Pu, Kefeng; Zhu, Yimin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-188</span>CODEN:
                <span class="NLM_cas:coden">CIRACV</span>;
        ISSN:<span class="NLM_cas:issn">2326-6066</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Immunotherapy has become a promising alternative therapeutic approach for cancer patients.  Interruption of immune checkpoints, such as CTLA-4 and PD-1, has been verified to be a successful means for cancer therapy in clin. trials.  MAb targeting PD-L1 has been approved to treat urothelial carcinoma, non-small cell lung cancer, or Merkel cell carcinoma by the FDA.  However, the high cost of the antibody can limit its application.  In our study, targeting PD-L1 peptide (TPP-1), which specifically binds to PD-L1 with high affinity, was identified through bacterial surface display methods.  Using a T-cell activation assay and mixed lymphocyte reaction, TPP-1 was verified to interfere with the interaction of PD-1/PD-L1.  To examine the inhibitory effect of TPP-1 on tumor growth in vivo, a xenograft mouse model using H460 cells was established.  The growth rate of tumor masses in TPP-1 or PD-L1 antibody-treated mice was 56% or 71% lower than that in control peptide-treated mice, resp., indicating that TPP-1 inhibits, or at least retards, tumor growth.  IHC of the tumors showed that IFNγ and granzyme B expression increased in the TPP-1 or PD-L1 antibody-treated groups, indicating that TPP-1 attenuates the inhibitory effect of PD-L1 on T cells and that T cells may get reactivated.  On the basis of our data, TPP-1 peptide could work as an alternative to antibodies for tumor immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPRbtEhfQtUbVg90H21EOLACvtfcHk0lgs14yeco6XLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWgtrc%253D&md5=df19c19b58ae966c69f9e6698a83953f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1158%2F2326-6066.CIR-17-0035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2326-6066.CIR-17-0035%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DPu%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DPeptide%2520blocking%2520of%2520PD-1%252FPD-L1%2520interaction%2520for%2520cancer%2520immunotherapy%26jtitle%3DCancer%2520Immunol.%2520Res.%26date%3D2018%26volume%3D6%26spage%3D178%26epage%3D188%26doi%3D10.1158%2F2326-6066.CIR-17-0035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of peptide inhibitors targeting human programmed death 1(PD-1) receptor</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">64967</span>– <span class="NLM_lpage">64976</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.11274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.18632%2Foncotarget.11274" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=64967-64976&author=Q.+Liauthor=L.+Quanauthor=J.+Lyuauthor=Z.+Heauthor=X.+Wangauthor=J.+Mengauthor=Z.+Zhaoauthor=L.+Zhuauthor=X.+Liuauthor=H.+Li&title=Discovery+of+peptide+inhibitors+targeting+human+programmed+death+1%28PD-1%29+receptor&doi=10.18632%2Foncotarget.11274"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.11274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.11274%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DQuan%26aufirst%3DL.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520peptide%2520inhibitors%2520targeting%2520human%2520programmed%2520death%25201%2528PD-1%2529%2520receptor%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D64967%26epage%3D64976%26doi%3D10.18632%2Foncotarget.11274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Vadlamani, S. K.</span>; <span class="NLM_string-name">Vemula, K. R.</span>; <span class="NLM_string-name">Satyam, L. K.</span>; <span class="NLM_string-name">Subbarao, K.</span>; <span class="NLM_string-name">Shrimali, R. K.</span>; <span class="NLM_string-name">Kandepu, S.</span></span> <span> </span><span class="NLM_article-title">Immunosuppression Modulating Compounds</span>. <span class="NLM_patent">WO2011161699A2</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+K.+Vadlamani&author=K.+R.+Vemula&author=L.+K.+Satyam&author=K.+Subbarao&author=R.+K.+Shrimali&author=S.+Kandepu&title=Immunosuppression+Modulating+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunosuppression%2520Modulating%2520Compounds%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S.</span>; <span class="NLM_string-name">Sudarshan, S.</span></span> <span> </span><span class="NLM_article-title">Immunomodulating Peptidomimetic Derivatives</span>. <span class="NLM_patent">WO2015036927A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+Naremaddepalli&author=S.+Sudarshan&title=Immunomodulating+Peptidomimetic+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunomodulating%2520Peptidomimetic%2520Derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Sudarshan, N. S. S.</span></span> <span> </span><span class="NLM_article-title">Peptidomimetic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2013132317A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+G.+N.+Saikumar&author=M.+Ramachandra&author=N.+S.+S.+Sudarshan&title=Peptidomimetic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSaikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DPeptidomimetic%2520Compounds%2520as%2520Immunomodulators%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Vadlamani, S. K.</span>; <span class="NLM_string-name">Shrimali, K. R.</span>; <span class="NLM_string-name">Subbarao, K.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Compound for Immunomodulation</span>. <span class="NLM_patent">WO2012168944A1</span>, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=P.+G.+N.+Saikumar&author=M.+Ramachandra&author=S.+K.+Vadlamani&author=K.+R.+Shrimali&author=K.+Subbarao&title=Therapeutic+Compound+for+Immunomodulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSaikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DTherapeutic%2520Compound%2520for%2520Immunomodulation%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulating Cyclic Compounds from the BC Loop of Human PD-1</span>. <span class="NLM_patent">WO2013144704A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&title=Immunomodulating+Cyclic+Compounds+from+the+BC+Loop+of+Human+PD-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunomodulating%2520Cyclic%2520Compounds%2520from%2520the%2520BC%2520Loop%2520of%2520Human%2520PD-1%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Immunomodulating Compounds</span>. <span class="NLM_patent">WO2015044900</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=Therapeutic+Immunomodulating+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DTherapeutic%2520Immunomodulating%2520Compounds%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">Cyclic Peptidomimetic Compounds as Immunomodulators Applicant</span>. <span class="NLM_patent">WO2015033303</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=Cyclic+Peptidomimetic+Compounds+as+Immunomodulators+Applicant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DCyclic%2520Peptidomimetic%2520Compounds%2520as%2520Immunomodulators%2520Applicant%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Cyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2016142835</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=Therapeutic+Cyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DTherapeutic%2520Cyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span>; <span class="NLM_string-name">Mapelli, C.</span>; <span class="NLM_string-name">Allen, M.
P.</span>; <span class="NLM_string-name">Bowsher, M. S.</span>; <span class="NLM_string-name">Boy, K. M.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Poirier, M. A.</span>; <span class="NLM_string-name">Sanghvi, N.</span>; <span class="NLM_string-name">Sun, L.</span>; <span class="NLM_string-name">Tenney, D. J.</span>; <span class="NLM_string-name">Yeung, K. S.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Reid, P. C.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 Protein/Protein Interactions</span>. <span class="NLM_patent">WO2014151634</span>, <span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=M.+M.+Miller&author=C.+Mapelli&author=M.%0AP.+Allen&author=M.+S.+Bowsher&author=K.+M.+Boy&author=E.+P.+Gillis&author=D.+R.+Langley&author=E.+Mull&author=M.+A.+Poirier&author=N.+Sanghvi&author=L.+Sun&author=D.+J.+Tenney&author=K.+S.+Yeung&author=J.+Zhu&author=P.+C.+Reid&author=P.+M.+Scola&title=Macrocyclic+Inhibitors+of+the+PD-1%2FPD-L1+and+CD80%28B7-1%29%2FPD-L1+Protein%2FProtein+Interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BM.%26atitle%3DMacrocyclic%2520Inhibitors%2520of%2520the%2520PD-1%252FPD-L1%2520and%2520CD80%2528B7-1%2529%252FPD-L1%2520Protein%252FProtein%2520Interactions%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span>; <span class="NLM_string-name">Mapelli, C.</span>; <span class="NLM_string-name">Allen, M.
P.</span>; <span class="NLM_string-name">Bowsher, M. S.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Poirier, M. A.</span>; <span class="NLM_string-name">Sanghvi, N.</span>; <span class="NLM_string-name">Sun, L.
Q.</span>; <span class="NLM_string-name">Tenney, D.
J.</span>; <span class="NLM_string-name">Yeung, K.
P.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Gillman, K. W.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Grant-Young, K. A.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Macrocyclic Inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-LI Protein/Protein Interactions</span>. <span class="NLM_patent">WO2016039749</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+M.+Miller&author=C.+Mapelli&author=M.%0AP.+Allen&author=M.+S.+Bowsher&author=E.+P.+Gillis&author=D.+R.+Langley&author=E.+Mull&author=M.+A.+Poirier&author=N.+Sanghvi&author=L.%0AQ.+Sun&author=D.%0AJ.+Tenney&author=K.%0AP.+Yeung&author=J.+Zhu&author=K.+W.+Gillman&author=Q.+Zhao&author=K.+A.+Grant-Young&author=P.+M.+Scola&title=Macrocyclic+Inhibitors+of+the+PD-1%2FPD-L1+and+CD80%28B7-1%29%2FPD-LI+Protein%2FProtein+Interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BM.%26atitle%3DMacrocyclic%2520Inhibitors%2520of%2520the%2520PD-1%252FPD-L1%2520and%2520CD80%2528B7-1%2529%252FPD-LI%2520Protein%252FProtein%2520Interactions%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. Q.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulators</span>. <span class="NLM_patent">WO2016057624</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Q.+Sun&author=Q.+Zhao&author=E.+Mull&author=E.+P.+Gillis&author=P.+M.+Scola&title=Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%2BQ.%26atitle%3DImmunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillman, K. W.</span>; <span class="NLM_string-name">Goodrich, J.</span>; <span class="NLM_string-name">Boy, K.
M.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Mapelli, C.</span>; <span class="NLM_string-name">Poss, M. A.</span>; <span class="NLM_string-name">Sun, L. Q.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulators</span>. <span class="NLM_patent">WO2016077518</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=K.+W.+Gillman&author=J.+Goodrich&author=K.%0AM.+Boy&author=Y.+Zhang&author=C.+Mapelli&author=M.+A.+Poss&author=L.+Q.+Sun&author=Q.+Zhao&author=E.+Mull&author=E.+P.+Gillis&author=P.+M.+Scola&title=Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGillman%26aufirst%3DK.%2BW.%26atitle%3DImmunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L. Q.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Miller, M. M.</span>; <span class="NLM_string-name">Allen, M. P.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Scola, P.
M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulators</span>. <span class="NLM_patent">WO2016100608</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Q.+Sun&author=Q.+Zhao&author=E.+P.+Gillis&author=M.+M.+Miller&author=M.+P.+Allen&author=E.+Mull&author=P.%0AM.+Scola&title=Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%2BQ.%26atitle%3DImmunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. M.</span>; <span class="NLM_string-name">Allen, M. P.</span>; <span class="NLM_string-name">Li, L.</span>; <span class="NLM_string-name">Mapelli, C.</span>; <span class="NLM_string-name">Poirier, M. A.</span>; <span class="NLM_string-name">Sun, L. Q.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulators</span>. <span class="NLM_patent">WO2016126646</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+M.+Miller&author=M.+P.+Allen&author=L.+Li&author=C.+Mapelli&author=M.+A.+Poirier&author=L.+Q.+Sun&author=Q.+Zhao&author=E.+Mull&author=E.+P.+Gillis&author=P.+M.+Scola&title=Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BM.%26atitle%3DImmunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boy, K. M.</span>; <span class="NLM_string-name">Sun, L. Q.</span>; <span class="NLM_string-name">Zhao, Q.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Gillis, E. P.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Immunomodulators</span>. <span class="NLM_patent">WO2016149351</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=K.+M.+Boy&author=L.+Q.+Sun&author=Q.+Zhao&author=E.+Mull&author=E.+P.+Gillis&author=P.+M.+Scola&title=Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBoy%26aufirst%3DK.%2BM.%26atitle%3DImmunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudzinska-Szostak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlicki, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarganes-Tzitzikas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaabani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Bioactive macrocyclic inhibitors of the PD-1/PD-L1 immune checkpoint</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">13732</span>– <span class="NLM_lpage">13735</span>, <span class="refDoi"> DOI: 10.1002/anie.201707707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1002%2Fanie.201707707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOit7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=13732-13735&author=K.+Magiera-Mularzauthor=L.+Skalniakauthor=K.+M.+Zakauthor=B.+Musielakauthor=E.+Rudzinska-Szostakauthor=L.+Berlickiauthor=J.+Kocikauthor=P.+Grudnikauthor=D.+Salaauthor=T.+Zarganes-Tzitzikasauthor=S.+Shaabaniauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Bioactive+macrocyclic+inhibitors+of+the+PD-1%2FPD-L1+immune+checkpoint&doi=10.1002%2Fanie.201707707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint</span></div><div class="casAuthors">Magiera-Mularz, Katarzyna; Skalniak, Lukasz; Zak, Krzysztof M.; Musielak, Bogdan; Rudzinska-Szostak, Ewa; Berlicki, Lukasz; Kocik, Justyna; Grudnik, Przemyslaw; Sala, Dominik; Zarganes-Tzitzikas, Tryfon; Shaabani, Shabnam; Doemling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">13732-13735</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Blockade of the immunoinhibitory PD-1/PD-L1 pathway using monoclonal antibodies has shown impressive results with durable clin. antitumor responses.  Anti-PD-1 and anti-PD-L1 antibodies have now been approved for the treatment of a no. of tumor types, whereas the development of small mols. targeting immune checkpoints lags far behind.  We characterized two classes of macrocyclic-peptide inhibitors directed at the PD-1/PD-L1 pathway.  We show that these macrocyclic compds. act by directly binding to PD-L1 and that they are capable of antagonizing PD-L1 signaling and, similarly to antibodies, can restore the function of T-cells.  We also provide the crystal structures of two of these small-mol. inhibitors bound to PD-L1.  The structures provide a rationale for the checkpoint inhibition by these small mols., and a description of their small mol./PD-L1 interfaces provides a blueprint for the design of small-mol. inhibitors of the PD-1/PD-L1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxuarSIlQEobVg90H21EOLACvtfcHk0lgpBRyxwCWqbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOit7%252FO&md5=b1634408007340ca0990d2607c96c1a9</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1002%2Fanie.201707707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201707707%26sid%3Dliteratum%253Aachs%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DRudzinska-Szostak%26aufirst%3DE.%26aulast%3DBerlicki%26aufirst%3DL.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DSala%26aufirst%3DD.%26aulast%3DZarganes-Tzitzikas%26aufirst%3DT.%26aulast%3DShaabani%26aufirst%3DS.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DBioactive%2520macrocyclic%2520inhibitors%2520of%2520the%2520PD-1%252FPD-L1%2520immune%2520checkpoint%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D13732%26epage%3D13735%26doi%3D10.1002%2Fanie.201707707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span>; <span class="NLM_string-name">Butte, M. J.</span>; <span class="NLM_string-name">Oyama, S.</span></span> <span> </span><span class="NLM_article-title">Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof</span>. <span class="NLM_patent">WO2011082400</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+H.+Sharpe&author=M.+J.+Butte&author=S.+Oyama&title=Modulators+of+Immunoinhibitory+Receptor+PD-1%2C+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DModulators%2520of%2520Immunoinhibitory%2520Receptor%2520PD-1%252C%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span>; <span class="NLM_string-name">Xin, T.</span>; <span class="NLM_string-name">Wen, X.</span>; <span class="NLM_string-name">Wu, Y.</span>; <span class="NLM_string-name">Yuan, H.</span></span> <span> </span><span class="NLM_article-title">2-Substituted Isonicotinic Acid Compound, Preparation Method and Application Thereof</span>. <span class="NLM_patent">CN106632021</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=H.+Sun&author=T.+Xin&author=X.+Wen&author=Y.+Wu&author=H.+Yuan&title=2-Substituted+Isonicotinic+Acid+Compound%2C+Preparation+Method+and+Application+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DH.%26atitle%3D2-Substituted%2520Isonicotinic%2520Acid%2520Compound%252C%2520Preparation%2520Method%2520and%2520Application%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span>; <span class="NLM_string-name">Xiao, J.</span>; <span class="NLM_string-name">Liu, A.</span>; <span class="NLM_string-name">Wei, X.</span>; <span class="NLM_string-name">Zhong, W.</span>; <span class="NLM_string-name">Zheng, Z.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Xie, Y.</span>; <span class="NLM_string-name">Zhao, G.</span>; <span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Resorcinol Compound and Medicinal Use Thereof</span>. <span class="NLM_patent">CN107286057</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Li&author=J.+Xiao&author=A.+Liu&author=X.+Wei&author=W.+Zhong&author=Z.+Zheng&author=X.+Wang&author=Y.+Xie&author=G.+Zhao&author=H.+Li&title=Resorcinol+Compound+and+Medicinal+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26atitle%3DResorcinol%2520Compound%2520and%2520Medicinal%2520Use%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Böger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krüger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Röcken, C.</span></span> <span> </span><span class="NLM_article-title">The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?</span>. <i>OncoImmunology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e1293215</span>, <span class="refDoi"> DOI: 10.1080/2162402X.2017.1293215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1080%2F2162402X.2017.1293215" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=e1293215&author=C.+B%C3%B6gerauthor=H.+M.+Behrensauthor=S.+Kr%C3%BCgerauthor=C.+R%C3%B6cken&title=The+novel+negative+checkpoint+regulator+VISTA+is+expressed+in+gastric+carcinoma+and+associated+with+PD-L1%2FPD-1%3A+A+future+perspective+for+a+combined+gastric+cancer+therapy%3F&doi=10.1080%2F2162402X.2017.1293215"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2017.1293215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2017.1293215%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25B6ger%26aufirst%3DC.%26aulast%3DBehrens%26aufirst%3DH.%2BM.%26aulast%3DKr%25C3%25BCger%26aufirst%3DS.%26aulast%3DR%25C3%25B6cken%26aufirst%3DC.%26atitle%3DThe%2520novel%2520negative%2520checkpoint%2520regulator%2520VISTA%2520is%2520expressed%2520in%2520gastric%2520carcinoma%2520and%2520associated%2520with%2520PD-L1%252FPD-1%253A%2520A%2520future%2520perspective%2520for%2520a%2520combined%2520gastric%2520cancer%2520therapy%253F%26jtitle%3DOncoImmunology%26date%3D2017%26volume%3D6%26spage%3De1293215%26doi%3D10.1080%2F2162402X.2017.1293215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Prasad, A.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">3-Substituted-1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2016142886</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=A.+Prasad&author=S.+S.+S.+Naremaddepalli&title=3-Substituted-1%2C2%2C4-Oxadiazole+and+Thiadiazole+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D3-Substituted-1%252C2%252C4-Oxadiazole%2520and%2520Thiadiazole%2520Compounds%2520as%2520Immunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2016142833</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C2%2C4-Oxadiazole+and+Thiadiazole+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C2%252C4-Oxadiazole%2520and%2520Thiadiazole%2520Compounds%2520as%2520Immunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Oxadiazole Derivatives as Immunomodulators</span>. <span class="NLM_patent">WO2015033299</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C2%2C4-Oxadiazole+Derivatives+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C2%252C4-Oxadiazole%2520Derivatives%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,2,4-Oxadiazole Derivatives as Immunomodulators</span>. <span class="NLM_patent">US2017101386</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C2%2C4-Oxadiazole+Derivatives+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C2%252C4-Oxadiazole%2520Derivatives%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Prasad, A.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">3-Substituted 1,3,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2016142894</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=A.+Prasad&author=S.+S.+S.+Naremaddepalli&title=3-Substituted+1%2C3%2C4-Oxadiazole+and+Thiadiazole+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D3-Substituted%25201%252C3%252C4-Oxadiazole%2520and%2520Thiadiazole%2520Compounds%2520as%2520Immunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,3,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2016142852</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C3%2C4-Oxadiazole+and+Thiadiazole+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C3%252C4-Oxadiazole%2520and%2520Thiadiazole%2520Compounds%2520as%2520Immunomodulators%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">1,3,4-Oxadiazole and 1,3,4-Thiadiazole Derivatives as Immunomodulators</span>. <span class="NLM_patent">WO2015033301</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=1%2C3%2C4-Oxadiazole+and+1%2C3%2C4-Thiadiazole+Derivatives+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3D1%252C3%252C4-Oxadiazole%2520and%25201%252C3%252C4-Thiadiazole%2520Derivatives%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">VISTA Signaling Pathway Inhibitory Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2018047143</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=VISTA+Signaling+Pathway+Inhibitory+Compounds+Useful+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DVISTA%2520Signaling%2520Pathway%2520Inhibitory%2520Compounds%2520Useful%2520as%2520Immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">Dual Inhibitors of VISTA and PD-1 Pathways</span>. <span class="NLM_patent">WO2018073754</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=Dual+Inhibitors+of+VISTA+and+PD-1+Pathways"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DDual%2520Inhibitors%2520of%2520VISTA%2520and%2520PD-1%2520Pathways%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Prasad, A.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Cyclic Substituted-1,3,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2018051255</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+G.+N.+Sasikumar&author=A.+Prasad&author=S.+S.+S.+Naremaddepalli&author=M.+Ramachandra&title=Cyclic+Substituted-1%2C3%2C4-Oxadiazole+and+Thiadiazole+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DCyclic%2520Substituted-1%252C3%252C4-Oxadiazole%2520and%2520Thiadiazole%2520Compounds%2520as%2520Immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Prasad, A.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Cyclic Substituted-1,2,4-Oxadiazole Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2018051254</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+G.+N.+Sasikumar&author=A.+Prasad&author=S.+S.+S.+Naremaddepalli&author=M.+Ramachandra&title=Cyclic+Substituted-1%2C2%2C4-Oxadiazole+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DCyclic%2520Substituted-1%252C2%252C4-Oxadiazole%2520Compounds%2520as%2520Immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Xu, Z.</span>; <span class="NLM_string-name">Wu, T.</span>; <span class="NLM_string-name">He, M.</span>; <span class="NLM_string-name">Zhang, N.</span></span> <span> </span><span class="NLM_article-title">Aromatic Acetylene or Aromatic Ethylene Compound, Intermediate, Preparation Method, Pharmaceutical Composition and Use Thereof</span>. <span class="NLM_patent">WO2018006795</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Wang&author=Z.+Xu&author=T.+Wu&author=M.+He&author=N.+Zhang&title=Aromatic+Acetylene+or+Aromatic+Ethylene+Compound%2C+Intermediate%2C+Preparation+Method%2C+Pharmaceutical+Composition+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26atitle%3DAromatic%2520Acetylene%2520or%2520Aromatic%2520Ethylene%2520Compound%252C%2520Intermediate%252C%2520Preparation%2520Method%252C%2520Pharmaceutical%2520Composition%2520and%2520Use%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Yang, Y.</span>; <span class="NLM_string-name">Lai, F.</span>; <span class="NLM_string-name">Ji, M.</span>; <span class="NLM_string-name">Zhang, L.</span>; <span class="NLM_string-name">Zheng, Y.</span>; <span class="NLM_string-name">Xue, N.</span>; <span class="NLM_string-name">Wang, K.</span>; <span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Benzyl Phenyl Ether Derivative, Preparation Method Therefor, and Pharmaceutical Composition and Uses Thereof</span>. <span class="NLM_patent">WO2017202273</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Feng&author=X.+Chen&author=Y.+Yang&author=F.+Lai&author=M.+Ji&author=L.+Zhang&author=Y.+Zheng&author=N.+Xue&author=K.+Wang&author=L.+Li&title=Benzyl+Phenyl+Ether+Derivative%2C+Preparation+Method+Therefor%2C+and+Pharmaceutical+Composition+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DZ.%26atitle%3DBenzyl%2520Phenyl%2520Ether%2520Derivative%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Pharmaceutical%2520Composition%2520and%2520Uses%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Zhang, L.</span>; <span class="NLM_string-name">Yang, Y.</span>; <span class="NLM_string-name">Lai, F.</span>; <span class="NLM_string-name">Ji, M.</span>; <span class="NLM_string-name">Zhou, C.</span>; <span class="NLM_string-name">Zhen, Y.</span>; <span class="NLM_string-name">Xue, N.</span>; <span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Bromo Benzyl Ether Derivative, Preparation Method Therefor, and Pharmaceutical Composition and Uses Thereof</span>. <span class="NLM_patent">WO2017202275</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Feng&author=X.+Chen&author=L.+Zhang&author=Y.+Yang&author=F.+Lai&author=M.+Ji&author=C.+Zhou&author=Y.+Zhen&author=N.+Xue&author=L.+Li&title=Bromo+Benzyl+Ether+Derivative%2C+Preparation+Method+Therefor%2C+and+Pharmaceutical+Composition+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DZ.%26atitle%3DBromo%2520Benzyl%2520Ether%2520Derivative%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Pharmaceutical%2520Composition%2520and%2520Uses%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span>; <span class="NLM_string-name">Chen, X.</span>; <span class="NLM_string-name">Yang, Y.</span>; <span class="NLM_string-name">Zhou, C.</span>; <span class="NLM_string-name">Lai, F.</span>; <span class="NLM_string-name">Ji, M.</span>; <span class="NLM_string-name">Jin, X.</span>; <span class="NLM_string-name">Xue, N.</span>; <span class="NLM_string-name">Zheng, Y.</span>; <span class="NLM_string-name">Chen, H.</span>; <span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Phenylate Derivative, Preparation Method Therefor, and Pharmaceutical Composition and Uses Thereof</span>. <span class="NLM_patent">WO2017202276</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Feng&author=X.+Chen&author=Y.+Yang&author=C.+Zhou&author=F.+Lai&author=M.+Ji&author=X.+Jin&author=N.+Xue&author=Y.+Zheng&author=H.+Chen&author=L.+Li&title=Phenylate+Derivative%2C+Preparation+Method+Therefor%2C+and+Pharmaceutical+Composition+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DZ.%26atitle%3DPhenylate%2520Derivative%252C%2520Preparation%2520Method%2520Therefor%252C%2520and%2520Pharmaceutical%2520Composition%2520and%2520Uses%2520Thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yu, Z.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">N-Phenyl-pyridine-2-carboxamide Derivatives and Their Use as PD-1/PD-L1 Protein/Protein Interaction Modulators</span>. <span class="NLM_patent">US2017174671</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Wu&author=Z.+Yu&author=F.+Zhang&author=W.+Yao&title=N-Phenyl-pyridine-2-carboxamide+Derivatives+and+Their+Use+as+PD-1%2FPD-L1+Protein%2FProtein+Interaction+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DN-Phenyl-pyridine-2-carboxamide%2520Derivatives%2520and%2520Their%2520Use%2520as%2520PD-1%252FPD-L1%2520Protein%252FProtein%2520Interaction%2520Modulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, K.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">US2017362253</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.+Xiao&author=F.+Zhang&author=L.+Wu&author=W.+Yao&title=Heterocyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DK.%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Shen, B.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017070089</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Wu&author=B.+Shen&author=J.+Li&author=Z.+Li&author=K.+Liu&author=F.+Zhang&author=W.+Yao&title=Heterocyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017087777</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+Li&author=L.+Wu&author=W.+Yao&title=Heterocyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lajkiewicz, N.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017112730</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=N.+Lajkiewicz&author=L.+Wu&author=W.+Yao&title=Heterocyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLajkiewicz%26aufirst%3DN.%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017192961</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Z.+Li&author=L.+Wu&author=W.+Yao&title=Heterocyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span>; <span class="NLM_string-name">Qian, D.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic Compounds as Immunomodulators</span>. <span class="NLM_patent">WO2017205464</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Lu&author=D.+Qian&author=L.+Wu&author=W.+Yao&title=Heterocyclic+Compounds+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DL.%26atitle%3DHeterocyclic%2520Compounds%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupak, L. S.</span>; <span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2015034820</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+S.+Chupak&author=X.+Zheng&title=Compounds+Useful+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChupak%26aufirst%3DL.%2BS.%26atitle%3DCompounds%2520Useful%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doemling, A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the PD-1/PD-L1 Protein/Protein Interaction</span>. <span class="NLM_patent">WO2017118762</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+Doemling&title=Inhibitors+of+the+PD-1%2FPD-L1+Protein%2FProtein+Interaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDoemling%26aufirst%3DA.%26atitle%3DInhibitors%2520of%2520the%2520PD-1%252FPD-L1%2520Protein%252FProtein%2520Interaction%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zieba, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Structural basis for small molecule targeting of the programmed death ligand 1(PD-L1)</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">30323</span>– <span class="NLM_lpage">30335</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.8730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.18632%2Foncotarget.8730" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=30323-30335&author=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Guzikauthor=B.+J.+Ziebaauthor=B.+Musielakauthor=A.+D%C3%B6mlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Structural+basis+for+small+molecule+targeting+of+the+programmed+death+ligand+1%28PD-L1%29&doi=10.18632%2Foncotarget.8730"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.8730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.8730%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DZieba%26aufirst%3DB.%2BJ.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DStructural%2520basis%2520for%2520small%2520molecule%2520targeting%2520of%2520the%2520programmed%2520death%2520ligand%25201%2528PD-L1%2529%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D30323%26epage%3D30335%26doi%3D10.18632%2Foncotarget.8730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5857</span>– <span class="NLM_lpage">5867</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5857-5867&author=K.+Guzikauthor=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Magieraauthor=B.+Musielakauthor=R.+Tornerauthor=L.+Skalniakauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Small-molecule+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+death-ligand+1%28PD-1%2FPD-L1%29+interaction+via+transiently+induced+protein+states+and+dimerization+of+PD-L1&doi=10.1021%2Facs.jmedchem.7b00293"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00293%26sid%3Dliteratum%253Aachs%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DTorner%26aufirst%3DR.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2528PD-1%252FPD-L1%2529%2520interaction%2520via%2520transiently%2520induced%2520protein%2520states%2520and%2520dimerization%2520of%2520PD-L1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5857%26epage%3D5867%26doi%3D10.1021%2Facs.jmedchem.7b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span>; <span class="NLM_string-name">Grant-Young, K. A.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Saulnier, M. G.</span>; <span class="NLM_string-name">Frennesson, D. B.</span>; <span class="NLM_string-name">Meng, Z.</span>; <span class="NLM_string-name">Scola, P.
M.</span></span> <span> </span><span class="NLM_article-title">1,3-Dihydroxy-phenyl Derivatives Useful as Immunomodulators</span>. <span class="NLM_patent">WO2018009505</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=K.+S.+Yeung&author=K.+A.+Grant-Young&author=J.+Zhu&author=M.+G.+Saulnier&author=D.+B.+Frennesson&author=Z.+Meng&author=P.%0AM.+Scola&title=1%2C3-Dihydroxy-phenyl+Derivatives+Useful+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.%2BS.%26atitle%3D1%252C3-Dihydroxy-phenyl%2520Derivatives%2520Useful%2520as%2520Immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span>; <span class="NLM_string-name">Connolly, T. P.</span>; <span class="NLM_string-name">Frennesson, D. B.</span>; <span class="NLM_string-name">Grant-Young, K. A.</span>; <span class="NLM_string-name">Hewawasam, P.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Meng, Z.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Parcella, K. E.</span>; <span class="NLM_string-name">Saulnier, M. G.</span>; <span class="NLM_string-name">Sun, L. Q.</span>; <span class="NLM_string-name">Wang, A. X.</span>; <span class="NLM_string-name">Xu, N.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2017066227</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.+S.+Yeung&author=T.+P.+Connolly&author=D.+B.+Frennesson&author=K.+A.+Grant-Young&author=P.+Hewawasam&author=D.+R.+Langley&author=Z.+Meng&author=E.+Mull&author=K.+E.+Parcella&author=M.+G.+Saulnier&author=L.+Q.+Sun&author=A.+X.+Wang&author=N.+Xu&author=J.+Zhu&author=P.+M.+Scola&title=Compounds+Useful+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.%2BS.%26atitle%3DCompounds%2520Useful%2520as%2520Immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupak, L. S.</span>; <span class="NLM_string-name">Ding, M.</span>; <span class="NLM_string-name">Martin, S. W.</span>; <span class="NLM_string-name">Zheng, X.</span>; <span class="NLM_string-name">Hewawasam, P.</span>; <span class="NLM_string-name">Connolly, T. P.</span>; <span class="NLM_string-name">Xu, N.</span>; <span class="NLM_string-name">Yeung, K. S.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Tenney, D. J.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Compounds Useful as Immunomodulators</span>. <span class="NLM_patent">WO2015160641</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+S.+Chupak&author=M.+Ding&author=S.+W.+Martin&author=X.+Zheng&author=P.+Hewawasam&author=T.+P.+Connolly&author=N.+Xu&author=K.+S.+Yeung&author=J.+Zhu&author=D.+R.+Langley&author=D.+J.+Tenney&author=P.+M.+Scola&title=Compounds+Useful+as+Immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChupak%26aufirst%3DL.%2BS.%26atitle%3DCompounds%2520Useful%2520as%2520Immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachota, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szelazek, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krzanik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyrc, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">72167</span>– <span class="NLM_lpage">72181</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.20050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.18632%2Foncotarget.20050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=29069777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ksVKhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=72167-72181&author=L.+Skalniakauthor=K.+M.+Zakauthor=K.+Guzikauthor=K.+Magieraauthor=B.+Musielakauthor=M.+Pachotaauthor=B.+Szelazekauthor=J.+Kocikauthor=P.+Grudnikauthor=M.+Tomalaauthor=S.+Krzanikauthor=K.+Pyrcauthor=A.+D%C3%B6mlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Small-molecule+inhibitors+of+PD-1%2FPD-L1+immune+checkpoint+alleviate+the+PD-L1-induced+exhaustion+of+T-cells&doi=10.18632%2Foncotarget.20050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells</span></div><div class="casAuthors">Skalniak Lukasz; Guzik Katarzyna; Magiera Katarzyna; Musielak Bogdan; Kocik Justyna; Tomala Marcin; Holak Tad A; Zak Krzysztof M; Pachota Magdalena; Szelazek Bozena; Grudnik Przemyslaw; Krzanik Sylwia; Pyrc Krzysztof; Dubin Grzegorz; Zak Krzysztof M; Pachota Magdalena; Szelazek Bozena; Grudnik Przemyslaw; Krzanik Sylwia; Pyrc Krzysztof; Dubin Grzegorz; Domling Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">72167-72181</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Antibodies targeting the PD-1/PD-L1 immune checkpoint achieved spectacular success in anticancer therapy in the recent years.  In contrast, no small molecules with cellular activity have been reported so far.  Here we provide evidence that small molecules are capable of alleviating the PD-1/PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes.  The two optimized small-molecule inhibitors of the PD-1/PD-L1 interaction, BMS-1001 and BMS-1166, developed by Bristol-Myers Squibb, bind to human PD-L1 and block its interaction with PD-1, when tested on isolated proteins.  The compounds present low toxicity towards tested cell lines and block the interaction of soluble PD-L1 with the cell surface-expressed PD-1.  As a result, BMS-1001 and BMS-1166 alleviate the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.  Moreover, the compounds were effective in attenuating the inhibitory effect of the cell surface-associated PD-L1.  We also determined the X-ray structures of the complexes of BMS-1001 and BMS-1166 with PD-L1, which revealed features that may be responsible for increased potency of the compounds compared to their predecessors.  Further development may lead to the design of an anticancer therapy based on the orally delivered immune checkpoint inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnxbjAjsdnFCCEBeYuoi7AfW6udTcc2eYEdDBXrJG1r7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ksVKhsw%253D%253D&md5=0b70c6e7aca2f13919bfbb2a47b2e57f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.20050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.20050%26sid%3Dliteratum%253Aachs%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DPachota%26aufirst%3DM.%26aulast%3DSzelazek%26aufirst%3DB.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DTomala%26aufirst%3DM.%26aulast%3DKrzanik%26aufirst%3DS.%26aulast%3DPyrc%26aufirst%3DK.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520PD-1%252FPD-L1%2520immune%2520checkpoint%2520alleviate%2520the%2520PD-L1-induced%2520exhaustion%2520of%2520T-cells%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D72167%26epage%3D72181%26doi%3D10.18632%2Foncotarget.20050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayes, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadavilli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seestaller-Wehr, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsvetkov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smothers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, A.</span></span> <span> </span><span class="NLM_article-title">The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1651</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.1158%2F1078-0432.CCR-14-2339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=25589619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVahtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1639-1651&author=L.+Liuauthor=P.+A.+Mayesauthor=S.+Eastmanauthor=H.+Shiauthor=S.+Yadavilliauthor=T.+Zhangauthor=J.+Yangauthor=L.+Seestaller-Wehrauthor=S.+Y.+Zhangauthor=C.+Hopsonauthor=L.+Tsvetkovauthor=J.+Jingauthor=S.+Zhangauthor=J.+Smothersauthor=A.+Hoos&title=The+BRAF+and+MEK+inhibitors+dabrafenib+and+trametinib%3A+effects+on+immune+function+and+in+combination+with+immunomodulatory+antibodies+targeting+PD-1%2C+PD-L1%2C+and+CTLA-4&doi=10.1158%2F1078-0432.CCR-14-2339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4</span></div><div class="casAuthors">Liu, Li; Mayes, Patrick A.; Eastman, Stephen; Shi, Hong; Yadavilli, Sapna; Zhang, Tianqian; Yang, Jingsong; Seestaller-Wehr, Laura; Zhang, Shu-Yun; Hopson, Chris; Tsvetkov, Lyuben; Jing, Junping; Zhang, Shu; Smothers, James; Hoos, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1639-1651</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To assess the immunol. effects of dabrafenib and trametinib in vitro and to test whether trametinib potentiates or antagonizes the activity of immunomodulatory antibodies in vivo.  Exptl. Design: Immune effects of dabrafenib and trametinib were evaluated in human CD4+ and CD8+ T cells from healthy volunteers, a panel of human tumor cell lines, and in vivo using a CT26 mouse model.  Results: Dabrafenib enhanced pERK expression levels and did not suppress human CD4+ or CD8+ T-cell function.  Trametinib reduced pERK levels, and resulted in partial/transient inhibition of T-cell proliferation/expression of a cytokine and immunomodulatory gene subset, which is context dependent.  Trametinib effects were partially offset by adding dabrafenib.  Dabrafenib and trametinib in BRAF V600E/K, and trametinib in BRAF wild-type tumor cells induced apoptosis markers, upregulated HLA mol. expression, and downregulated certain immunosuppressive factors such as PD-L1, IL1, IL8, NT5E, and VEGFA.  PD-L1 expression in tumor cells was upregulated after acquiring resistance to BRAF inhibition in vitro.  Combinations of trametinib with immunomodulators targeting PD-1, PD-L1, or CTLA-4 in a CT26 model were more efficacious than any single agent.  The combination of trametinib with anti-PD-1 increased tumor-infiltrating CD8+ T cells in CT26 tumors.  Concurrent or phased sequential treatment, defined as trametinib lead-in followed by trametinib plus anti-PD-1 antibody, demonstrated superior efficacy compared with anti-PD-1 antibody followed by anti-PD-1 plus trametinib.  Conclusion: These findings support the potential for synergy between targeted therapies dabrafenib and trametinib and immunomodulatory antibodies.  Clin. exploration of such combination regimens is under way.  Clin Cancer Res; 21(7); 1639-51. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF6AmGUhb9dbVg90H21EOLACvtfcHk0lgCS5a6MwoEsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVahtrw%253D&md5=855ff452d612e713fca5b41f6e302cba</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2339%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DMayes%26aufirst%3DP.%2BA.%26aulast%3DEastman%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DYadavilli%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSeestaller-Wehr%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DHopson%26aufirst%3DC.%26aulast%3DTsvetkov%26aufirst%3DL.%26aulast%3DJing%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSmothers%26aufirst%3DJ.%26aulast%3DHoos%26aufirst%3DA.%26atitle%3DThe%2520BRAF%2520and%2520MEK%2520inhibitors%2520dabrafenib%2520and%2520trametinib%253A%2520effects%2520on%2520immune%2520function%2520and%2520in%2520combination%2520with%2520immunomodulatory%2520antibodies%2520targeting%2520PD-1%252C%2520PD-L1%252C%2520and%2520CTLA-4%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1639%26epage%3D1651%26doi%3D10.1158%2F1078-0432.CCR-14-2339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Das, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddupalli, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halaban, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhodapkar, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhodapkar, K. M.</span></span> <span> </span><span class="NLM_article-title">Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>194</i></span>,  <span class="NLM_fpage">950</span>– <span class="NLM_lpage">959</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1401686</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;key=10.4049%2Fjimmunol.1401686" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=194&publication_year=2015&pages=950-959&author=R.+Dasauthor=R.+Vermaauthor=M.+Sznolauthor=C.+S.+Boddupalliauthor=S.+N.+Gettingerauthor=H.+Klugerauthor=M.+Callahanauthor=J.+D.+Wolchokauthor=R.+Halabanauthor=M.+V.+Dhodapkarauthor=K.+M.+Dhodapkar&title=Combination+therapy+with+anti-CTLA-4+and+anti-PD-1+leads+to+distinct+immunologic+changes+in+vivo&doi=10.4049%2Fjimmunol.1401686"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1401686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1401686%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DR.%26aulast%3DVerma%26aufirst%3DR.%26aulast%3DSznol%26aufirst%3DM.%26aulast%3DBoddupalli%26aufirst%3DC.%2BS.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DKluger%26aufirst%3DH.%26aulast%3DCallahan%26aufirst%3DM.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DHalaban%26aufirst%3DR.%26aulast%3DDhodapkar%26aufirst%3DM.%2BV.%26aulast%3DDhodapkar%26aufirst%3DK.%2BM.%26atitle%3DCombination%2520therapy%2520with%2520anti-CTLA-4%2520and%2520anti-PD-1%2520leads%2520to%2520distinct%2520immunologic%2520changes%2520in%2520vivo%26jtitle%3DJ.%2520Immunol.%26date%3D2015%26volume%3D194%26spage%3D950%26epage%3D959%26doi%3D10.4049%2Fjimmunol.1401686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2M2D" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2M2D','PDB','2M2D'); return false;">PDB: 2M2D</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZQK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZQK','PDB','4ZQK'); return false;">PDB: 4ZQK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C3T" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C3T','PDB','5C3T'); return false;">PDB: 5C3T</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J89" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J89','PDB','5J89'); return false;">PDB: 5J89</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5N2F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5N2F','PDB','5N2F'); return false;">PDB: 5N2F</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-4%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00990" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00990" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679937472d9b3c6a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
